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Lower urinary tract symptoms (LUTS) cumulate a multitude of syndromes and 
urinary tract infections (UTI). This thesis focuses principally on recurrent UTIs 
(rUTIs) in renal transplant recipients and overactive bladder (OAB).  In many cases, 
the cause of OAB is unknown. Recent studies in bladder microbial investigation have 
proposed that low-level bacteriuria or alterations in the bladder microbiome may be 
a cause for the symptoms of this syndrome. This thesis sets out to investigate the 
types of bacteria in the bladder of women with OAB and renal transplant recipients 
compared to asymptomatic controls by culturing urine samples and using 16s rRNA 
gene sequencing to identify exact species in each sample. The data is analysed 
alongside clinical data to determine better biomarkers for both rUTI and OAB. The 
results highlight that current hospital tests for infection are underreporting low-level 
infection and many of the biomarkers for infection do not correlate with incidence of 
infection. Here, the use of clue cells as a biomarker for rUTI is investigated for the first 
time with optimistic results. Furthermore, the alterations of the bladder microbiome 
over time post-renal transplant highlight consistently reduced incidence of particular 
species indicating shifts in the bladder microbiome in these patients. Using similar 
methods to explore the microbiome of women with OAB, it was found that there is a 
significant reduction of Lactobacillus, a crucial probiotic in the urogenitary tract that 
may be key to shifts in the bladder microbiome in OAB. The final section attempts to 
explore the physiology behind the symptoms of OAB in light of recent findings 
associating bacteria to OAB by looking at pericytes (a peri-vascular cell type found on 
capillaries). Pericytes are capable of transdifferentiating into myofibroblasts, a 
fibrotic cell which may increase spontaneous contraction in the bladder. This section 
investigates pericytes behaviour in the bladder in response to ATP, angiotensin, 
lipopolysaccharide and pro-inflammatory cytokines in a series of DIC imaging and 
immunohistochemistry experiments. The data supports this theory since pericytes 
constrict vessels upon acute stimulation and pericyte numbers dwindle with 
prolonged exposure. In conclusion, this thesis highlights the importance of correct 
testing for bladder infections and suggests that shifts in the bladder microbiome may 
be a cause for some lower urinary tract symptoms and this could be caused by 
pericyte responses to ATP and downstream cytokines. 
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TLR Toll-like receptor 
TRPV Transient receptor potential (vanilloid) 
UPEC Uropathogenic Eschericia coli 
UTI Urinary tract infection 
UUI Urge urinary incontinence 
vSMC Vascular smooth muscle cell 
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CHAPTER 1 - 
GENERAL INTRODUCTION 
1.1 OVERVIEW OF THE BLADDER 
 The bladder is a spherical organ that functions to store urine produced by the 
kidneys and subsequently eliminate it from the body. It is situated in the abdomino-
pelvic cavity and is connected to the kidneys via ureters that enter the bladder in the 
trigone area. Once the bladder reaches a volume of approximately 300–400 ml, a 
sense of fullness begins, however the voluntary signal to begin voiding can be 
withheld until a suitable time and place when urine is then voided in a process known 
as micturition, via the urethra.   
   The function of the bladder is strictly regulated by molecular signalling, receptors, 
nerves and muscles. In many lower urinary tract symptoms, such as overactive 
bladder (OAB), this function has become disrupted leading to spontaneous 
uncontrolled activity. Currently, the exact cause of many cases of OAB is unknown, 
however many investigations have highlighted a possible role for specific cells found 
within the bladder such as interstitial cells of Cajal (ICC) (1), myofibroblasts (2), and 
pericytes (3). Furthermore, recent investigations into low-level infection within the bladder have resulted in the identification of a Ǯcoreǯ bladder microbiome (4), which 
may also play a valuable role in healthy bladder function. This introductory chapter 
shall discuss i) the structure of the bladder with highlights on the fore mentioned 
cells of interest, ii) the normal function of the bladder and how it is controlled, iii) 
various symptoms of bladder dysfunction with a highlight on OAB, iv) urinary tract 
infections and the role of the bacteria in OAB, and v) the bladder microbiome and its 
role in bladder dysfunction.  
1.2 THE STRUCTURE OF THE BLADDER  
 The bladder is formed of multiple notably unique layers of different cells with 
differing functions, consisting of the innermost urothelium, followed by the basal 
membrane, the lamina propria, the detrusor muscle, a perivesicle fat layer, and finally 
the peritoneum (figure 1.1). Since the fat and peritoneum have little reported 
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importance in the function of the bladder, these shall not be discussed further. The 
urothelium comprises of superficial or umbrella cells, intermediate and basal cells. 
The umbrella cells are in the closest proximity to the bladder contents and as they are 
exfoliated, are replaced by those in the intermediate layer below. Urothelial cells have 
a half-life of approximately 3 to 6 months (5), however this is often reduced when the 
bladder is put under stress e.g. during infection, when they are shed more rapidly. 
The basal membrane attaches the urothelium to the lamina propria; a complexity of 
connective tissue containing collagen and elastin as well as a microvasculature 
network, sensory afferent nerves, fibroblasts, and myofibroblasts (6). The muscle 
layer or detrusor follows, which is innervated with somatic, sympathetic and 
parasympathetic nerves. The layers work in association with each other to control 
bladder filling and voiding via complex interactions between activator signalling 
molecules, receptors and nerves in both the bladder and the central nervous system 
(CNS). The structure and expression of markers and receptors in each layer as well as 
individual cells of interest in each, such as ICCs, myofibroblasts and pericytes shall be 
discussed first, followed by the physiological regulation of the bladder by activator 
signalling and the role of the CNS.  
 
Figure 1.1: Cross section of bladder wall. The urothelial layer consisting of superficial umbrella cells, 
intermediate cells and basal cells. The basal membrane attaches the urothelium to the lamina propria, which 
consists of microvasculature, efferent nerves, myofibroblasts, suburothelial interstitial cells of Cajal (ICC), and 
microvasculature including pericytes. Below this a muscularis mucosa layer; a thin layer of muscle followed by the 
extracellular matrix and the detrusor; a thick layer of smooth muscle. The detrusor contains detrusor ICCs and is 




1.2.1 THE UROTHELIUM  
 The urothelium is the innermost layer of the bladder consisting of umbrella 
cells, intermediate cells and basal cells creating a urothelial layer. In humans there 
are up to 5 layers of intermediate cells however only one in mice (6). The 
replacement of umbrella cells occurs by fusion of basal cells into intermediate cells 
followed by fusion of intermediate cells into umbrella cells (5). Old umbrella cells are 
shed into the urine and discarded during micturition. Umbrella cells are so called due 
their shape and ability to open out and spread across the urothelial surface as the 
bladder stretches. The urothelium was historically known as a passive barrier and 
was generally renowned as the most impenetrable barrier in the body (7). This is due 
to the presence of hexagonal plaques on the umbrella cells called uroplakins, which 
are made up of crystalline proteins (8, 9). Tight junctions between the umbrella cells 
further prevents ion exchange between the urine and blood (10), and a 
glycosaminoglycan (GAG) layer on the outside of the umbrella cells prevents bacteria 
coming in too close contact with the vulnerable cell membrane (11) (figure 1.1). More 
recent investigations have discovered that the bladder urothelium is much more 
selective and sensory than previously thought. Various studies on the sensitivity of 
the bladder urothelium to stretch, temperature, capsaicin, pH, and various signalling molecules such as adenosine ͷǯ-triphospahe (ATP), acetylcholine (ACh), and 
bradykinin, as well as infectious components such as pathogen associated molecular 
patterns (PAMPs e.g. lipopolysaccharide) and cytokines have highlighted the 
importance of the urothelium in sensing changes in the bladder environment during 
regular bladder function and disease states. Each of these individual sensory 
components shall be discussed in more detail in sections 1.3 Physiological regulation 
of the bladder and 1.5 Bladder Infections. 
1.2.2 THE LAMINA PROPRIA 
 The lamina propria consists of an extracellular matrix containing multiple cell 
types such as adipocytes, myofibroblasts and ICC, as well as a wealth of 
microvasculature and nerves. The specialised cells in this region of the bladder have 
been shown to be vital for supporting and propagating the sensory mechanism 
required for healthy bladder function, therefore this section will discuss nerves, ICC 
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and myofibroblasts, their specific markers and how they have been associated to 
bladder dysfunction, particularly OAB.  
1.2.2.1 SENSORY AFFERENT NERVES 
 Afferent nerves found in the lamina propria are most crucial for bladder 
function (12), and consist of myelinated fibres ȋAɁ) and unmyelinated fibres (C-
fibres), which originate from neural cell bodies of the dorsal root ganglion. AɁ fibres 
are most important for sensing bladder filling (12), whereas C-fibres do not respond 
to increased bladder volume but are stimulated by high mechanical threshold and 
respond to noxious chemicals (13), and cooling by temperature or menthol (14). The 
sensory afferents are predominant in the trigone area of the bladder and less dense in 
the upper dome (15). Afferent nerves express receptors for chemical stimuli e.g. ATP 
of ACh originating from the urothelium or from proximal cells such as ICC or 
myofibroblasts and signal to the CNS to initiate the sensation of bladder fullness (3, 
16). It is hypothesised by various research teams that in some forms of OAB these 
nerves are either being over stimulated by increased production of ATP or ACh (17, 
18), or by the increased presence of interstitial cells in proximity to nerves 
(2)(discussed in sections 1.2.2.2 Interstitial cells of Cajal and 1.2.2.3 Myofibroblasts). 
Another theory suggests that increased production of NGF by mast cells, which has 
shown to be increased in individuals with OAB, may be leading to alterations in the 
autonomic innervation (19, 20)(discussed in sections 1.5.5.2 Mast cell infiltration and 
activation and 1.5.5.3 Nerve growth factor and other biomarkers).  
1.2.2.2 INTERSTITIAL CELLS OF CAJAL (ICC) 
   ICC are found in organs innervated by peripheral nerves, in particular the 
intestinal tract (21) and bladder. Most ICC, but not all, are receptor tyrosine kinase (c-
Kit) positive, which is the ligand for stem cell factor, and this marker is generally used 
to identify ICC. Staining for c-Kit positive cells in the bladder has identified ICC in the 
smooth muscle layers and the lamina propria, where they are named detrusor ICCs 
(dICC) and suburothelial ICCs (sICC), respectively (22).  
  In the intestine, ICCs act as a pacemaker stimulating autonomic rhythmical 
peristalsis by spontaneously generating Ca2+ transients, which produce depolarizing 
currents to initiate smooth muscle contraction (23). Interestingly, similar 
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spontaneous activity occurs in the bladder to adjust the smooth muscle during filling 
to accommodate for increased volume (24). There is much interest in spontaneous 
bladder activity as this movement can become overactive, termed detrusor 
overactivity (DO) and is, in some cases, the cause for OAB, a syndrome that can lead to 
urinary incontinence (25). Therefore, many studies have tried to identify the origin of 
spontaneous bladder activity with various conclusions, however one of particular 
solidity is the role of ICC (1, 3, 23, 26-28). The exact contribution of ICC to 
spontaneous activity is still debated as to whether they directly generate action 
potentials (26), or if they merely accentuate them (3), but it is certain that these are 
not contractile cells (26). An exciting contribution by Biers et al (1) found that 
numbers of dICCs are increased in individuals with OAB suggesting that if ICC are 
indeed the origin of spontaneous activity, then accentuation of this mechanism may 
be the cause of some cases of OAB (16). ICC have therefore been targeted by use of 
Glivec, an inhibitor of c-Kit, a marker for ICCs (27, 28) with positive results, further 
supporting the role of ICC in bladder dysfunction. Due to the location of sICCs, it is 
more likely that these cells act as signal transductors between urothelial cells and 
sensory nerves providing a sensory role rather than acting upon smooth muscle cells 
in the case of dICCs (29). The term sICCs is often used interchangeably with 
myofibroblasts due to the similarities of both the function and cell marker expression 
on these two cell types. However, the presence of certain cell markers on myofibroblasts, such as alpha smooth muscle actin ȋȽ-SMA), the multiple cell origins, 
and contractile properties of myofibroblasts does make these cells unique (discussed 
next). For that reason, myofibroblasts shall be taken as a separate cell type, unique to 
sICCs, and the focus shall be on this cell type rather than sICCs.  
1.2.2.3 MYOFIBROBLASTS  
Myofibroblasts are the principal cell form responsible for fibrosis in tissues; 
forming extracellular fibrotic matrices consisting of collagen, fibronectin and 
glycosaminoglycans in the surrounding tissue (30). Fibrosis is a physiological change 
that occurs after chronic injury or exposure to injury stimuli resulting in damaged 
endothelium/epithelium, cytokine production (predominantly tumour growth factor-
beta 1 (TGF-ȾͳȌ) (31), inflammatory cell infiltration (32), activation of 
myofibroblasts, and subsequent production of extracellular matrices (for a review see 
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Tomasek et al, (30)). The result is the thickening of tissue, scarring and, in extreme 
cases, organ malfunction (33). Myofibroblasts are usually derived from resident 
fibroblasts activated by various factors during inflammation and/or damage. 
Fibroblasts differentiate into proto-myofibroblasts after exposure to mechanical 
stress (34), and platelet derived growth factor (PDGF), which, as the name suggests, is 
released from activated platelets (30). These proto-myofibroblasts require TGF-Ⱦͳ to 
become active myofibroblasts, which is released from various cell types including white blood cells and platelets, and induces Ƚ-SMA production and collagen type 1 
(35, 36), making myofibroblasts phenotypically unique from fibroblasts (37). They 
also have actin bundles within their structure, which adhere to the fibronexus of the 
cell, allowing the internal structure of the myofibroblasts to be strongly attached to 
the extracellular fibronectin (38). 
Identifying myofibroblasts in any organ is difficult due the absence of a unique 
marker for this cell type (table 1.1) (39). As discussed, myofibroblasts are distinctive from fibroblasts in that they express Ƚ-SMA. Unfortunately, expression of Ƚ-SMA is 
not unique to myofibroblasts; it is also expressed by smooth muscle cells (SMC) (40). 
C-Kit can be used to distinguish myofibroblasts from fibroblasts and SMCs as they are 
generally c-Kit negative and this marker has been widely used as a marker for 
myofibroblasts in mice. However, c-Kit is not expressed on all subtypes of 
myofibroblasts and not always in humans (41). Fortunately, myofibroblasts can be 
identified by other means. By using transmission electron microscopy (TEM) to 
identify the fibronexus, unique to this cell type, myofibroblasts have been identified 
in human bladder biopsies and their ultrastructure and exact location within the 
lamina propria determined. The images generated by Wiseman et al in 2003 show 
that myofibroblasts exist underneath the urothelial layer, in the lamina propria (42). 
Also noted is the proximity of these cells to nerve varicosities giving rise to 
speculation of the exact role of these cells in bladder function. It could be suggested 
that these cells, like sICC, may accentuate responses from exogenous ATP and other 
purines to act as an intermediary between the urothelium and afferent nerves (16, 42, 
43). That is, myofibroblasts may act as an amplification step in the sensory process 
between the urothelium and nerves and thus may also be involved in contraction. 
This is further supported by the fact that increased numbers of myofibroblasts is 
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associated to increased spontaneous contraction (2). In respect to OAB, it has also 
been reported that thickening of the bladder wall is increased in individuals with OAB 
compared with asymptomatic individuals (44, 45), which may be due to fibrosis. 
Therefore, it could be suggested that increased numbers of myofibroblasts could be a 
cause for some cases of OAB. Recently, there has been interest in pericytes as a 
potential progenitor cell for myofibroblasts development alongside fibroblasts (46). 
As such, these cells are of equal interest but firstly however, it is important to discuss 
the role of pericytes more broadly, which will be discussed in the following section on 
microvasculature. 
Cell type c-Kit Ƚ-SMA PDGFRȾ NG2 
Preferred method of 
identification 
ICC + - - +/- c-Kit 
Fibroblasts - +/- + - Vimentin 
Myofibroblasts +/- ++ ++ +/- Fibronexus by TEM 
SMC - ++ - - Ƚ-SMA 
Pericytes +/- +/- + + NG2 
Table 1.1: Expression of receptors used to identify myofibroblasts and pericytes in the bladder. C-Kit is not 
unique to myofibroblasts as it is also expressed on interstitial cells of Cajal (ICC) and some pericytes (41). Alpha smooth muscle actin ȋȽSMAȌ is also found on smooth muscle cells ȋSMCȌ, some pericytes and fibroblasts (40). 
Neuro-glial 2 (NG2), the principal marker for pericytes, is also found on some myofibroblasts and fibroblasts (47). 
Platelet derived growth factor receptor (PDGFRB) is found on fibroblasts and pericytes and binding of PDGF 
assists in the activation of these cells to differentiate into myofibroblasts (47). Therefore, it is difficult to 
differentiate between these cells types, the preferred method is therefore suggested in the final column. 
1.2.3 BLADDER MICROVASCULATURE 
The microvasculature of the bladder supplies oxygen and nutrients to the 
bladder as well as removing metabolites and waste products. The bladder blood 
supply arrives via the iliac artery into the lower peritoneum and branches into the 
dorsal and ventral sides of the bladder and leaves by the iliac vein (48). The 
vasculature is predominantly found in the lamina propria but also has capillary 
extensions into the urothelium and detrusor muscle. The capillary arrangement in the 
bladder is winding so that bladder stretch during filling does not affect blood 
pressure or blood flow (49). The arterioles in the bladder are supported by smooth 
muscle cells and surrounded by nerve cells and fibroblasts. Capillaries and venules on 
the other hand have a thinner endothelial layer but are supported by pericytes, which 





   Pericytes are peri-endothelial cells, which support the vasculature network and can 
be found throughout the body principally dotted along the microvessels such as 
capillaries, post-capillary venules and terminal arterioles (47). They are believed to 
play a valuable role in i) vasoconstriction and vasodilation in response to vasoactive 
compounds, ii) control of vascular permeability to both cells and molecules, iii) 
pluripotency, and iv) angiogenesis (each of these shall be discussed in more depth 
later in this section). Pericytes are derived from the mesenchymal stem cell lineage, 
the progenitor cell line for osteoblasts (bone cells), chondrocytes (cartilage cells), 
adipocytes (fat cells), and are closely related to vascular smooth muscle cells (vSMC) in that they both express ȽSMA, CDͳ͵, PDGFRȾ, neuro-glial 2 chondroitin sulphate 
proteoglycan 4 (NG2), a marker for oligodendrocyte cells, and other various markers 
requiring further validation (47) (table 1.1). The similarity between pericytes and 
myofibroblasts is also evident by the shared markers ȽSMA and PDGFRȾ. It is 
therefore difficult to stain for pericytes in tissue. The most effective marker is 
therefore, is NG2 since the structure of pericytes is significantly different from that of 
vSMCs so that they can be distinguished (figure 1.2A). Crawford et al used NG2 and 
isolectin B4 (IB4) to stain for pericytes and vasculature respectively in the medulla of 
rat kidney (52). Images from their 2012 publication highlight how pericytes can be 
identified along the vasculature based on their slightly bulbous morphology (figure 
1.2B). 
 
Figure 1.2: Staining of vascular smooth muscle and pericytes with neuro-glial 2 antibody and vasculature 
by isolectin B-4, A) (Adapted from Murfee, Skalek and Peirce (53)). Smooth muscle cells in both arterioles (A) 
and venules (V) express NG2 (green), the bulbous structures of pericytes can be seen in the capillaries B) 
(Adapted from Crawford et al (52)). Pericytes (NG2, red) are dotted along the microvessels and differ from 
endothelial smooth muscle in that they express a bulbous structure, which make them easy to identify on the 
vasculature (IB4, Green). They also have projections, which extend along the and around the vessel.  
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   Vasoactive compounds can act directly at pericytes to alter the flow of blood 
through the vasculature by causing vasodilation or vasoconstriction. The control of 
blood flow can also have an effect on the permeability of the vascular bed to 
molecules and cells, which is essential during the inflammatory process. Perhaps the 
most relevant is by Crawford et al who used an array of vasoactive compounds in a 
live rat kidney slice model to investigate the function of pericytes on regulation of 
medullary blood flow. Pericytes responded to various vasoconstrictive agents such as 
angiotensin II, noradrenaline, endothelin, indomethacin, and ATP by constricting the 
vasa recta more significantly than at non-pericyte sites (52). The reverse was true for 
vasodilatory agents such as prostaglandin E2, NO, bradykinin, and carbachol which 
caused vasodilation.  By facilitating vasodilation, pericytes are able to increase 
vascular permeability. They can also upregulate certain adhesion molecules such as 
intercellular adhesion molecule 1 (ICAM-1) in response to pro-inflammatory 
cytokines in vivo (54, 55). ICAM-1 binds to leukocyte integins such as LFA-1 and 
assists in leukocyte extravasation from the blood to tissues (56), which is the main 
cause of inflammation.  
   Pericytes are also pluripotent; that is, they can differentiate into other cell types 
under specific conditions. Pericytes appear to share pluripotency features with 
mesenchymal stem cells (from which they originate) in that they have been shown to 
differentiate into osteoblasts, chondrocytes, adipocytes, vSMCs and skeletal muscle 
cells in vitro (57, 58). The pericyte marker PDGFRȾ has been used in a variety of 
studies to confirm if the exact origin of vascular pluripotent cells is indeed pericytes 
by using techniques such as fate mapping and constitutive activation (59, 60). The problem in these experiments however is that PDGFRȾ is also expressed by other 
cells of mesenchymal origin such as fibroblasts and some smooth muscle cells (table 
1.1). Fate mapping (discussed in more detail in section 6.5.4 - Tracking pericyte 
transdifferentiation in the bladder) using NG2 is also inconclusive for the same reason 
(59), nevertheless, there is still open debate as to whether pericytes contribute to a 
vascular niche of pluripotent cells. 
   Hashitani et al have described the morphological features of pericytes in the bladder 
by performing TEM and scanning electron microscopy (SEM) and immunohistochemistry using Ƚ-SMA, c-kit and NG2 in the suburothelial venules, 
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capillaries and arterioles of rat bladders (50). EM revealed pericytes adjacent to 
endothelial cells in the venules whereas arterioles had fewer pericytes and more 
arteriolar smooth muscle cells surrounded by nerve bundles.  Pericytes were positive for Ƚ-SMA but negative for NG2 and c-Kit in the venules, however in the capillaries 
and suburothelial arterioles, both pericytes and smooth muscle cells were positive for NGʹ and PDGFRȾ.  Therefore, the exact location of pericytes within the bladder 
structure has been identified, however the function of pericytes has not been as well 
characterised in the bladder as in other organs such as the kidney, lung and brain. 
Studies in other organs can inform us of the possible role that they might play in the 
bladder and highlight methods by which the function can be investigated. As 
mentioned in the section on myofibroblasts, pericytes have been associated to the 
development of fibrosis through their ability to differentiate into myofibroblasts. Fate 
mapping in mice has been performed to observe pericyte contribution to fibrosis in 
the kidney (59), CNS (61), lung (62), skin (63), and liver (64). Taking the results of 
these studies together, it can be summarised that in the presence of increased PDGF-
B, VEGF-A and TGF-Ⱦͳ, pericytes increase expression of ȽSMA and regulators of G 
protein signalling (e.g. RGS5) and can transdifferentiate into fibroblasts and 
myofibroblasts (47). If this also occurred tin the bladder it may in turn lead to the 
increased spontaneous bladder contractions and fibrosis often seen in certain cases 
of OAB. Due to the importance of pericytes in regulating blood flow and the fact that 
they can differentiate into myofibroblasts, which have been associated to increased 
spontaneous contraction particularly in OAB (16), pericytes are therefore of much 
interests in the bladder and their function is investigated in Chapter 6 – The role of 
pericytes in bladder infection. This concludes the section on the urothelium and the 
lamina propria and the cells within it. The next section discusses the final layer of the 
bladder, the detrusor muscle.   
1.2.4 THE DETRUSOR MUSCLE 
 The detrusor muscle is made up of smooth muscle cells whose contractions 
allow for urine to be stored safely by adjusting to increasing volume, and later 
allowing for controlled urine voidance. The smooth muscle cells in the detrusor are 
morphologically similar to that of other smooth muscle cells, containing actin and 
myofilaments attached to dense bodies under the cell membrane. These cells are 
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arranged in two unique orientations, longitudinally in the outer and inner layer of 
detrusor, and circularly in the central muscle layer (65). The detrusor is highly 
innervated with autonomic (parasympathetic and sympathetic) and somatic efferent 
nerves, predominantly parasympathetic nerves which are involved in the neural 
control of detrusor contraction and overall bladder function (discussed in more detail 
in the section 1.3 - Physiological control of the bladder).  
      As discussed earlier, dICC appear to contribute to spontaneous bladder activity 
(1), which are small contractions of the smooth muscle that allow muscle to adjust 
during bladder filling. The strength and frequency of these contractions increases in 
the later phases of filling and may contribute to the sensation of bladder fullness (66, 
67). The strongest detrusor contractions occur during voiding and are controlled by the CNS rather than local stimuli. The bladder has first to Ǯinstructǯ the CNS of bladder 
fullness, which involves complex physiological interactions between the urothelium, 
lamina propria, nerves and detrusor discussed in the following section. 
1.3 PHYSIOLOGICAL REGULATION OF THE BLADDER 
 The urothelium comprises of specialised umbrella cells, which open out to 
accommodate increasing volumes of urine (68), and act as sensors to both chemical 
and mechanical changes in the bladder (for a review see Birder and Andersson (69)). 
As mentioned previously in section 1.2.1 The Urothelium, urothelial cells express a 
variety of signalling receptors including i) muscarinic and nicotinic receptors for ACh, 
ii) purinergic receptors for ATP and other purines, iii) adrenergic receptors for 
adrenaline and noradrenaline (NA) and iv) transient receptor potential channels 
(TRP channels), of which there are multiple groups of differing functions; the most 
abundant in the bladder is the vanilloid receptor (TRPV). This allows the urothelium 
to detect changes in the bladder environment and signal to other cells (e.g. ICC, 
myofibroblasts, nerves and muscle cells) to respond in particular ways controlling 
bladder regulation for storing and voiding urine. This section shall focus on the types 
of signalling receptors that are expressed in the bladder, the cells that express these 
receptors and the cells which are able to release other signalling molecules in 
response to these stimuli.  
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 The principal function of TRPV channels is to detect changes in heat (TRPV-1, 2, 4), 
capsaicin, found in chilli peppers (TRPV-1), osmolality and stretch (TRPV-4), and pH 
via H+ protons (TRPV-1). Increases in H+ (lowered pH), increased temperature, 
presence of capsaicin, and stretch induce TRPV channel activation in the bladder, 
which in turn may lead to an increase in intracellular calcium leading to release of 
ATP, ACh, nitric oxide (NO), neurokinin A (NKA), and nerve growth factor (NGF), all of 
which act upon other cells and structures within the bladder (70), and in a paracrine 
manner to urothelial cells (figure 1.3). The activation of TRPV channels in the 
urothelium initiates signalling to the lamina propria via these transmitters and 
cytokines to inform the brain that the bladder is filling up. The receptors for ACh, NO, 
ATP, the ATP by-products, bradykinin and NKA are expressed on a variety of cells 
including ICC, myofibroblasts, nerves and SMCs (table 1.2).   
   ATP is released from urothelial cells by exocytosis or ATP-binding cassettes (ABC) 
(71) when the cells are put under pressure from increased volume in the bladder 
(72), or as a response to other signalling molecules. This is thought to be controlled 
by intracellular Ca2+ mediated by carbochol (73). Released ATP and its by-products 
i.e. ADP, AMP and Adenosine, bind to P2 receptors (P2R) and P1 receptors (P1R) 
respectively. There are two kinds of P2R; - P2XR (ligand-gated ion channels - 
ionotropic) and P2YR (coupled to G protein - metabotropic). Both types of receptors 
can be homomeric or heteromeric and have various agonists and antagonists. The 
P2XRs most associated with bladder function are P2X1 (expressed on dSMCs), P2X2 
and P2X3 (expressed of myofibroblasts) (42). P2X1 has been shown to induce an 
inward current of Ca2+ and Na+ contracting the detrusor muscle. In the detrusor, ATP 
is released by efferent nerves to directly stimulate the smooth muscle cells (table 1.2). 
P2X3 on myofibroblasts could directly affect afferent nerves due to their proximity to 
each other; myofibroblasts also release ATP and therefore may be an intermediary 
cell accentuating ATP responses to afferent nerves (74). P2YR stimulation by ATP has 
been suggested to cause the release of IL-8, a pro-inflammatory cytokine, and 
increases spontaneous contractions (75).  
   Nicotinic (Nm and Nn) and muscarinic (M1-3) cholinergic receptors are highly 
responsive to nicotine and muscarine, respectively, but all bind ACh. In the bladder, 
the muscarinic receptor M2 is expressed throughout, however it is the M3 receptor 
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that is responsible for contractions (table 1.2) (76). Another neurotransmitter released in the bladder, noradrenaline ȋNAȌ, binds to Ⱦ3 adrenergic receptors 
expressed on all responder cells other than efferent nerves in the bladder. Other 
receptors do exist in the bladder for other stimulants; tachykinin receptors are 
stimulated by nerve growth factor (NGF) and bradykinin binds to B1 and B2 
receptors.  
 
Table 1.2: Table of signalling receptors and their expression on various cell types in the bladder. ATP is 
released by urothelial cells, myofibroblasts and efferent nerve cells and can stimulate all cells in the bladder via 
purinergic receptors P2X1 in the urothelial cells, P2Y2, 4 and 6 on myofibroblasts and ICCs and P2X3 on afferent 
nerves. SMCs respond to ATP from efferent nerves via P2X1. All cells express cholinergic receptors M2 and M3 
however only receptor M3 stimulates contractions. All cells express and respond to noradrenaline via the Ⱦ͵-AR 
receptor except efferent nerves. The majority of TRP receptors are expressed in the urothelium to respond to heat, 
pH and stretch however other cells (bar efferent nerves) also express TRPV1 which responds to temperature and 
capsaicin. 
 
    Once the volume of urine in the adult bladder reaches 300 – 400 ml, the urothelium 
begins to stretch stimulating TRPV receptors and releasing ATP and ACh. Stimulation 
of TRP receptors increases intracellular calcium which can further stimulate release 
of ATP, ACh and NO in response to this. ATP and ACh are also released as a response 
to bladder stretch (reviewed by Lori Birder and Karl-Erik Andersson (69)). These 
signalling molecules are able to stimulate the various cells in the lamina propria e.g. )CCs, myofibroblasts and afferent nerves via M͵ receptors, Ⱦ3-AR receptors and 
various P2X and P2Y receptors, respectively (table 1.2 and figure 1.3). Myofibroblasts 
may be able to influence/accentuate close proximity lamina propria sensory nerves in 
response to ATP, ACh and NO released from urothelial cells by releasing further ATP 
acting collectively as a stretch-receptor organ (42, 77).   Work by Wu, Sui and Fry has 
developed a better understanding of the role of myofibroblasts in the bladder by 
looking at purinergic signalling. A study in 2004 showed that addition of ATP leads to 

















Urothelial cells P2X1, P2Y M2, M3 Ⱦ3-AR TRPA, 
TRPV1, 2 & 4, TRMP8 
ATP, ACh, NO, 
NKA, NGF, 
ICCs P2Y2, 4 & 6 M2, M3 Ⱦ3-AR TRPV1  
Myofibroblasts P2Y2, 4 & 6, P2X3 M2, M3 Ⱦ3-AR TRPV1 ATP 
Afferent nerve P2X3 M2, M3 Ⱦ3-AR TRPV1 NKA 
Efferent nerve P2X M2, M3   ATP, ACh 
SMCs P2X1 M2, M3 Ⱦ3-AR TRPV1  
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oscillation using various purine compounds and blockers gives insight into the types 
of purinoceptors expressed on bladder myofibroblasts (43). Authors suggest P2Y2 as 
a most likely receptor, however this is inconclusive due to the difficulties in 
constructing pharmacologically unique profiles for receptors based on their agonists. 
A later study in 2008 by the same group further investigating the response of 
myofibroblasts to sensory triggers, highlighted that these cells can also respond to 
low pH in a similar manner to which they do ATP (16). Interestingly, these responses 
were attenuated with addition of capsaicin (a TRPV agonist) and the NO donor SNP 
suggesting the presence of sensory modulation mechanisms in this cell type. 
Furthermore, the proximity of myofibroblasts to each other in these stimulatory 
experiments (cell pairs compared with single cells) showed augmented responses 
suggesting a role for gap junctions and adherins in enhancing responses to stimuli. 
The stimulation of afferent nerves (potentially enhanced by myofibroblasts) signals 
to the CNS to instruct the individual of a need to void, which relays back to the 
efferent nerves to release ACh and NA to stimulate smooth muscle contraction and 
sphincter relaxation, respectively (figure 1.3). The mechanism for this is discussed in 




Figure 1.3: Schematic of physiological regulation of normal bladder function. A) Stretch, pH change, 
temperature change, vanilloid, capsaicin activate TRP receptors on urothelial cells as well as stretch induced 
ATP release by exocytosis, B) Urothelial cells release ATP, ACh and NO in response to stretch, C) ATP, ACh 
and NO can act in a paracrine manner to further stimulate urothelial cells via P2Y2,4 and 6, P2X1 for ATP; M3, Mʹ and Mͷ for Ach; and Ⱦ͵-AR for NO, D) ATP binds to P2Y receptors on myofibroblasts and P2X3 on afferent nerves. ACh binds to M͵ on myofibroblasts and M͵, Mʹ/Ͷ on afferent nerves. NO binds to Ⱦ͵-AR on both 
myofibroblasts and afferent nerves, E) Afferent nerves responding to ACh and NO signal to the CNS to induce 
a conscious desire to void, F) Once a suitable place to void has been found the pontine micturition centre 
sends a signal via the somatic nervous system to override the sympathetic nervous system (noradrenaline, 
NA) and stimulate the parasympathetic nervous system (ACh). NA relaxes the sphincters and ACh causes 
constriction of the detrusor. 
1.3.1 NEURAL CONTROL OF BLADDER FUNCTION 
 So far, local bladder sensitisation has been discussed, however these 
sensations and the way they affect bladder function are regulated by the CNS. Bladder 
filling and voiding is controlled by both the autonomic and somatic pathways of the 
nervous system. The autonomic nervous system is involuntary and controls smooth 
muscles in the body. This branch of the nervous system can be divided into the 
parasympathetic system which promotes active bodily function such as digestion, 
salivation, defecation and urination, and the sympathetic system which redirects 
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away from the parasympathetic system, in many cases stopping active bodily 
function, particularly during stressful or adrenaline induced reactions. During storage 
and filling of the bladder the hypogastric nerve (sympathetic) functions by release of 
noradrenaline to activate Ⱦ3 adrenergic receptors relaxing the detrusor muscle and Ƚ1 
adrenergic receptors to contract the urethral smooth muscles (table 1.3), and inhibit 
the parasympathetic nerve presynaptically. During micturition, the pelvic nerve 
(parasympathetic) functions by release of ACh to activate M3 muscarinic receptors on 
the bladder smooth muscle. The pudendal nerve (somatic) functions by release of 
acetylcholine to relax the external urethral sphincter by stimulating nicotinic 
receptors (70, 78, 79) (table 1.3).  
 
Nerve System Innervation Neuro-
transmitter 














NA Ⱦ͵ receptor 
(detrusor) Ƚͳ receptor 
(urethra) 
Relaxation of the 
detrusor and 







Pudendal nerve ACh Nicotinic receptor 
(external sphincter) 
Urethral sphincter 
and pelvic floor 
Micturition 
Table 1.3: Neural control of the bladder. During bladder storage the detrusor is relaxed and the bladder neck 
and sphincters are contracted as a result of noradrenaline release via the sympathetic nervous system. The noradrenaline binds to Ⱦ͵ receptor in the detrusor and Ƚͳ receptor in the urethra to keep urine stored until a 
suitable time and place to void is found. Once a decision to void has been made, the somatic nervous system 
signals via the pudendal nerve to relax the external sphincter. At the same time the sympathetic nervous system is 
overridden by the parasympathetic nervous system. During voiding, acetylcholine contracts the detrusor muscle 
and relaxes the sphincters via binding to M3 and nicotinic receptors, respectively, to induce micturition.   
 
   When the bladder fills up with urine from the kidneys, constant pressure is 
maintained in the bladder with a higher pressure in the urethra. As the bladder fills, 
the stimulus of stretching stimulates TRPV receptors as well as releasing ATP from 
urothelial cells triggering low frequency afferent ACh signalling along the pelvic 
nerves to the sacral region of the spinal cord, which in turn stimulates the 
parasympathetic preganglionic neurons that control the detrusor muscle. At the same 
time, increasing afferent signalling of the sensory neurons ascend up to the pontine 
micturition centre in the periaqueductal grey matter of the cerebellum which results 
in a conscious desire to urinate. Here the information is integrated and transferred to 
two sets of neurons. If an appropriate time and place to urinate is not found signals 
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are transferred back down the spinal cord to inhibit the parasympathetic 
preganglionic neurons controlling the detrusor and the somatic motor neurons 
(pudendal nerve) controlling the external urinary sphincter. Once a voluntary 
decision to void has started the somatic motor neurons inhibit the external sphincter 
relaxing it and the detrusor muscle contracts as discussed in the following section 
(65, 79).  
  The pelvic floor muscle also plays a valuable role in bladder function. Although not 
part of the bladder itself, the pelvic floor muscle supports the organs directly above it 
which includes the bladder and can be consciously controlled and therefore trained. 
During later stages of filling and storage, when the bladder is under the most 
pressure, the pelvic flood muscles can consciously support the bladder until voiding. 
Furthermore, by contracting the pelvic floor muscles in the opposite way, micturition 
can be forced, expelling urine at an increased rate (80). 
1.3.2 BLADDER CONTRACTION MECHANISM 
 The function of contraction of the detrusor muscle depends upon release of 
stored Ca2+. ACh released from afferent neural cells bind to receptors in the 
sarcoplasmic reticulum, which depolarises the membrane of the muscle fibre 
releasing calcium from calcium stores in the sarcoplasmic reticulum. The calcium 
binds to troponin on actin filaments altering the shape of troponin and rotates the 
actin fibre towards the myosin fibre. Hydrolysis of ATP to ADP and inorganic 
phosphate (Pi) on the myosin head extends it upwards to attach to binding sites on 
the actin filament to form a cross-bridge. Cross-bridge formation triggers a power 
stroke, which pulls the actin filament along the myosin and releases ADP and Pi. A 
new ATP molecule attaches to release the myosin and actin. This cycle is repeated and 
the myosin and actin filaments slide across each other contracting the muscle (81). 
Increased pressure in the bladder due to detrusor contraction opens the internal 
sphincter. The pressure in the urethra is then reduced and the pelvic floor muscle 
relaxes forming a funnel in the bladder neck as urine is voided (65, 78, 79). 
   Both the physiological and neurological control of the bladder can become impaired 
through infection, disease, injury, or unknown means, leading to bladder dysfunction. 
The following sections discuss how dysregulation can affect the normal function of 
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the bladder and with OAB as a particular focus for this thesis since in many cases the 
exact cause of this common bladder disorder is unknown. 
1.4 BLADDER DYSFUNCTION 
 In many cases of bladder dysfunction, the cause lies in the CNS rather than the 
bladder itself. For example, bladder dysregulation can occur in autonomic 
neuropathological diseases where control of muscles is impaired such as in Parkinsonǯs, multiple sclerosis, brain tumours or syphilis. Uncontrolled firing along 
parasympathetic nerves or a lack of firing along sympathetic nerves can lead to 
incontinence. Bladder dysfunction can also occur when the CNS has been damaged, in 
particular, by injury to the spinal cord. In these cases, the sense of fullness of the 
bladder may not signal to the brain, and/or the conscious somatic control may not be 
communicated back to the bladder. For the sake of this thesis however, the focus shall 
remain on the physiological dysfunction of the bladder rather than dysregulation by 
the CNS. For a good review article on CNS-related bladder dysfunction see a review by 
Kennelly and DeVoe (82). 
    Lower urinary tract symptoms (LUTS) is a term given to difficulties in filling, 
storing or voiding urine (as opposed to upper urinary tract symptoms which refers to 
disorders of the kidneys and ureters). LUTS include urinary tract infections (UTI), 
interstitial cystitis (IC), stress urinary incontinence (SUI) and urge urinary 
incontinence (UUI). This section will differentiate between these common disorders, 
their symptoms and the causes of each, and explain how OAB is, in itself, a separate 
and unique syndrome. 
1.4.1 STRESS URINARY INCONTINENCE (SUI) 
 Stress urinary incontinence (SUI) is a form of incontinence that mainly affects 
post-natal or post-menopausal women. They find it difficult to hold in urine when 
stress or pressure is applied to the bladder during strenuous exercise or when 
coughing, laughing or sneezing for example. It is easily diagnosed with a stress-test, where the patientǯs bladder is filled up with fluid and then they are asked to cough. )n 
women with SUI the pelvic floor muscles are not strong enough to control the bladder 
properly which may be due to muscle rupturing during delivery of a baby, 
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hypermobility of the urethra, or lowered detrusor pressure or lowered oestrogen 
levels post-menopause for examples. SUI patients show predominantly physical 
changes due to weak or damaged pelvic floor and sphincter muscles (rather than 
physiological changes such as increased ATP release or inflammation as seen in other 
LUTS), and therefore the symptoms can commonly be rectified with pelvic floor 
exercises, structural pessaries, vaginal cones or surgical insertion of a tension-free 
transvaginal support (communication with Dr Aswini Balachandran at Medway 
Maritime Hospital). 
1.4.2 BLADDER PAIN SYNDROME/INTERSTITIAL CYSTITIS 
 Patients with bladder pain syndrome, or interstitial cystitis (IC) as it is better 
known, present with symptoms similar to bacterial cystitis e.g. dysuria, increased 
frequency of urination and urgency, however IC is typically characterised by 
inflammation in the absence of infection (83). If a patientǯs microbiology results are 
negative (that is they have less than 105 colony forming units per millilitre (CFU/ml) 
of a single species of bacterium in their urine when plating midstream urine), IC is 
diagnosed following a cystoscopy, whereby areas of inflammation, broken skin, glomerulations and (unnerǯs ulcers within the bladder are observed (83). Causes of 
IC are multiple and could include autoimmunity, mast cell infiltration, viral infection, 
or production of toxins in the urine (84). The symptoms of IC cannot be treated with 
antibiotics due to a lack of an apparent infection. Instead pentosan polysulfate sodium 
is the only prescribed treatment for IC however a restricted diet, anti-depressants 
and anti-histamines have been reported to relieve symptoms (85). 
1.4.3 OAB AND DETRUSOR OVERACTIVITY 
 OAB is a syndrome characterised by an array of symptoms such as urinary 
urgency, urge incontinence, increased frequency whereby the patient feels the need 
to urinate more than seven or eight times per day, and nocturia (increased need to 
urinate at night), in the absence of a bacterial infection (86). The symptoms of this 
syndrome are similar to that of IC however in there is an absence of inflammation in 
OAB (observed through cystoscopy) and it is often pain free which informs a 
diagnosis away from IC (83). There are various suggested causes for OAB but in some 
cases the cause is unknown and is termed idiopathic detrusor activity (IDO). OAB is 
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extremely common, affecting up to 41.9% of men and 31.3% of women over 75 (87), 
and given that many cases of OAB are idiopathic, there is much research interest into 
other possible causes in order to find prospective new treatments for this particular 
LUTS. This section shall discuss i) the epidemiology of OAB, ii) how IDO is diagnosed 
by ruling out other possible causes for the symptoms, and iii) current and prospective 
treatment of OAB. 
1.4.3.1 EPIDEMIOLOGY AND ECONOMIC BURDEN OF OAB 
 OAB affects both men and women of all ages and prevalence increases with 
age. There have been various studies investigating the demographics of OAB based on 
age, gender, body mass index, smoking and other health related issues however there 
are discrepancies in each of the studies. A study based on a population-based study of 
5 European countries (including the UK) by Milsom et al in 2001 reported a clear 
increase in incidence of OAB with increased age, which has been widely supported 
(87), however whether OAB is more predominant in women than in men has since 
been debated (88, 89). Milsomǯs study was however the largest ȋn=ͳ͸,͹͹͸Ȍ reporting 
OAB to be more common in women (17.4%) than men (15.6%) and increases with 
age up to 41.9% in men and 31.3% (87).  
   It is estimated that around 16.6% of the total population of the UK suffer with OAB 
(87), however this is likely to be a significant underestimate due to the nature of the 
condition which means people are embarrassed to talk about it, and it goes 
undiagnosed and untreated (90). Patients with OAB tend to feel trapped, unwilling to 
go out in case of an accident, leading to depression and loneliness, which can, in older 
patients, lead to admission into nursing homes (91, 92). When the urge to urinate 
occurs, sufferers are more likely to rush to the toilet increasing risk of accidents, trips, 
falls and fractures (92). Along with the cost of treatment of OAB, these accidents and 
nursing home admission cost the health service around £1 billion per year in the UK 
alone (93). 
1.4.3.2 DIAGNOSIS OF OAB 
OAB is usually diagnosed by excluding other LUTS first; for example, OAB is 
not a UTI based on microbiological results nor is it IC based on cystoscopy and a lack 
of pain (table 1.4). Certain additional tests can help diagnose whether a particular 
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patientǯs symptoms are caused by an infection, neurological disease, bladder outlet 
obstruction, or IDO. Knowing the cause enables the consultant to prescribe the 
correct treatment for each case e.g. antibiotics, surgery, or pharmaceuticals. 
 
Table 1.4: Summary of the symptoms and causes of various lower urinary tract symptoms and their 
respective treatments. Urinary tract infections (UTI) are diagnosed when a patient has >105 CFU/ml of a single 
species of bacteria in a midstream sample of urine. This results in symptoms such as urgency and increased 
frequency and is treated with antibiotics. Interstitial cystitis (IC) is diagnosed when an individual does not have an 
infection (<105 CFU/ml) and has observed inflammation by means of a cystoscopy. Certain dietary restrictions and 
pentosane polysulfate sodium can be used to treat IC symptoms which often include urgency, pain and increased 
frequency. Stress urinary incontinence (SUI) is caused by weakened muscles and diagnosed with a stress test. 
Bladder training is the initial treatment followed by pessaries and tapes to support the muscles. OAB is diagnosed 
when an individual has no infection (<105 CFU/ml), no inflammation and positive responses to the international 
continence questionnaire (ICIQ) and may be caused by neurological disease such as multiple sclerosis or Parkinsonǯs, blockages in the urethra, low-level infection (<105 CFU/ml) or detrusor overactivity. Idiopathic OAB 
is diagnosed when an individual has detrusor overactivity and the cause is unknown (IDO). For both OAB and IDO, 
the treatments include antimuscarinics and Botox (BTX-A). 
 
    In the case of male patients with OAB, the cause can often be benign prostatic 
hyperplasia, which is a enlargement of the prostate, which increases with age, putting 
pressure on the bladder (reviewed by Roehrborn (94)). However, since this thesis 
shall focus on female patients with OAB only, the possible causes in women only shall 
be discussed here forth. Patients suffering with neurological diseases such as 
neuropathy, dementia, spinal cord injury, multiple sclerosis or Parkinsonǯs disease 
can also experience OAB symptoms due to loss of muscle control as discussed in the 
previous section on bladder dysfunction (95). Specific tests on a patientǯs 
neurological status will diagnose one of these as a potential cause for OAB. 
Background medical checks and routine urinalysis testing for infection, diabetes, and 
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blood or protein in the urine, which could be a sign of a kidney problem, can exclude 
infection and diabetes as possible causes for overactivity (96). This is often then 
followed by fitting a specific description dictated by international validated questions 
from the International Consultation on Incontinence Modular Questionnaire (ICIQ) 
(see Appendix 1.3). By obtaining a score of 1 or above on certain questions such as ǲDo you suffer with a sudden need to urinate?ǳ a patient is then diagnosed with OAB 
(communication with Dr Balachandran, Medway Maritime Hospital). It is then 
essential to look at post-void residual volume to see if the bladder is emptying 
properly which might indicate a blockage in the urethra. A final test is urodynamics, 
which involves filling the bladder with fluid and measuring pressure over time. If the 
pressure fluctuates involuntarily this indicates detrusor overactivity (DO), which can 
either be due to a neurological condition, or in many cases, cannot be explained at all 
in which case it is diagnosed as IDO (96). Current treatment of OAB can range from 
lifestyle changes, to pharmacological intervention and in severe cases, botox 
injections or insertion of a small device that generates electrical stimulation of the 
post-tibial or sacral nerve (discussed in more detail in the next section). 
1.4.3.3 CURRENT AND PROSPECTIVE TREATMENTS OF OAB 
 There are a numerous lines of management for OAB depending upon the severity of an individualǯs symptoms and their responsiveness to treatment. For the 
first line of treatment, consultants will usually encourage the patient to adapt their 
lifestyle and partake in bladder control exercises (97). If these are not successful in 
curbing symptoms, medical intervention is the next line of treatment, however 
bladder exercises are always recommended in conjunction with this. Alternative 
therapies have recently been introduced which are more invasive such as botox 
injections, however these are reserved for severe refractory OAB, that is, individuals 
who have failed to respond to all other treatments (98). In this section, each of these 
treatments is discussed in more detail. 
  Lifestyle changes involve adaptations to an individualǯs diet and pelvic floor 
exercises. The symptoms of OAB can be exacerbated by increased consumption of 
diuretics such as alcohol, coffee, tea and fizzy drinks, therefore patients with OAB are 
encouraged to reduce their intake of these drinks as well as reducing the quantity of 
liquid consumed in the evenings in order to moderate nocturia. Much of the time, like 
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with SUI, pelvic floor exercises can be used to reduce the symptoms of OAB (99). 
Bladder training is always advised as a first line of treatment (communication with Dr 
Aswini Balachandran at Medway Maritime Hospital). These involve the patient trying 
to retain urine for as long as possible when the urge to urinate occurs. Another 
method is stop-start training where the patient starts to void and then attempts to 
stop and hold the urine in the bladder for as long as possible (97). Over time 
increasing the interval between voiding can significantly reduce the urge to urinate in 
patients with OAB but this does not work with DO. 
   If pelvic floor exercises are not found to be helpful, consultants will follow the next 
line of treatment; prescription of antimuscarinic drugs, which block the muscarinic 
acetylcholine receptors preventing smooth muscle contraction. There are 7 
antimuscarinic drugs currently on the market in the UK for OAB and they all have 
slightly different effects on patient symptoms dependent on responsiveness to the 
drug (98). Since antimuscarinics are not specifically designed to target solely the 
detrusor muscle there are a multitude of unwanted side effects associated with these 
types of drugs including: - inhibition of salivation, reduced intestinal mobility, 
cognitive dysfunction, and memory impairment (100). In many cases the side effects 
cause the patient more distress than the OAB symptoms themselves and the 
medication is stopped by patient or changed by the consultant. Another setback is 
that responsiveness to the drug often subsides after a matter of weeks and thus the 
patient may be prescribed a new type of antimuscarinic. When multiple drugs have been unsuccessful, the patientǯs syndrome is termed refractory and alternative 
therapies may be considered. 
   The neurotoxin botulinum A (BTX-A) produced by the bacterium Clostridium 
botulinum has recently been introduced as a treatment for OAB and has proven to be 
fairly successful (101). BTX-A is injected directly into the wall of the bladder wall at 
multiple points where it blocks the local vesicular release of neurotransmitters (98). 
Unfortunately, in some cases patients find they cannot urinate at all after treatment 
and may need to self-catheterise until the BTX-A has subsided after approximately 3-
7 days allowing the patient to regain control again (102). Furthermore, this line of 
treatment requires repeat administration every 6 - 12 months initially, increasing in 
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frequency as treatment progresses, which will also carry further financial 
implications (103). 
   As previously mentioned, patients with OAB, by definition, do not present with 
detectable bacteria during routine microbiology assessment. However, in 2011 James 
Malone-Lee of University College London presented an abstract at the International 
Continence Society reporting results of an antibiotic treatment trial for patients with 
OAB symptoms (104). Group one (n=147) presented with OAB and pyuria and was 
prescribed antibiotics straight away, group two (n=212) presented with OAB and no 
pyuria and was not treated, and the third group (n=81) had OAB and late onset of 
pyuria at which point they were prescribed antibiotics. There was clear evidence of 
antibiotic efficacy demonstrated by the clearance of all symptoms in all groups 
prescribed the antibiotics. Those who started antibiotics later in the study period 
took significantly longer to recover than those who started antibiotics straight away. 
The results of this study have not yet been published beyond the abstract and the 
numbers of patients included are relatively low, however they do suggest that 
infection is being missed in a large number of these patients (the reasons for this are 
discussed in the next section) and that antibiotics could be a valuable treatment for 
some types of OAB in the near future but this study needs expanding upon in order to 





1.5 URINARY TRACT INFECTIONS 
 A UTI is a bacterial infection occurring anywhere along the urinary tract from 
the urethra to the kidneys. The main symptoms of a lower UTI (acute bacterial 
cystitis) include increased frequency of urination, urinary urgency, dysuria (painful 
urination), and discoloured or foul-smelling urine (105). When an infection reaches 
the kidneys, symptoms may also comprise of pain or pressure in the back and a fever. 
UTIs are generally diagnosed by the NHS when a patient has greater than 105 CFU/ml 
of a single species of bacterium in their urine when plating midstream urine (105, 
106). Most UTIs are caused by uropathogenic Escherichia coli (UPEC; 85%) but also 
by bacterium such as Enterococcus faecalis, Proteus mirabilis, Klebsiella pneumoniae, 
Pseudomonas aerogenosa, and Serritia marcenscens (107, 108). UTIs are treated with 
oral antibiotics such as nitrofurantoin or trimethoprim, taking into consideration the 
local antibiotic resistance patterns (109). 
   UTIs are defined as recurrent UTIs (rUTI) when a patient has a UTI three to 
four time within a 12-month period (105). The reasons for rUTI occurrence could be 
due to genetic predisposition (110), the patient being immunocompromised, 
antibiotic resistance or intracellular capabilities of particular bacterial species 
allowing them to be protected from antibiotic targeting and immune responses 
(111)(discussed in section 1.5.2.4 - Intracellular bacterial communities in OAB). In 
cases of rUTI, alternative antibiotics are prescribed and often for longer-term, which 
can further develop multi-drug resistant strains and increase risk of rUTI. Recurrent 
UTIs are of particular interest when caring for individuals who have received a renal 
transplant as they are particularly predisposed to rUTIs due to the 
immunosuppressant and antibiotic medications they are required to take post-
transplant. These drugs predispose renal transplant recipients (RTR) to rUTI since 
they reduce the effect of the immune system in order to prevent organ rejection. 
Furthermore, these patients also receive antibiotics as a prophylactic for infections, 





1.5.1 RECURRENT UTI IN RENAL TRANSPLANTATION 
Renal transplantation is the surgical removal of a healthy kidney from a living 
or deceased individual and implanting it into a patient with significantly reduced 
kidney function. Chronic kidney disease is measured by the estimated glomerular 
filtration rate ȋeGFRȌ which indicates how well an individualǯs kidneys are 
functioning to filter the waste from the bloodstream.  When a patient has low eGFR, 
dialysis is often required to perform blood filtration, however in more severe cases, 
renal transplantation is a real alternative to renal dialysis. This is usually a required 
surgical procedure for patients suffering with end-stage renal disease, which can be 
brought on by a number of factors including diabetes, hypertension, pyelonephritis 
(upper urinary tract infection), or autoimmune diseases such as autoimmune 
glomerular nephritis (112). Finding an appropriate organ donor is more complex 
than finding an appropriate blood donor since cells within the organ express major 
histocompatibility complexes (MHC) for which there are thousands of haplotype 
variants across the population (56). Foreign MHC is a target for immune cells, 
therefore it is essential to try to match the MHC haplotypes of the donor and the 
recipient as closely as possible, and is the reason why family members are often the 
best option for organ transplantation. Difficulty in finding a good match also means 
that when a kidney donor match is found and the kidney is transplanted it is essential 
to maintain the health of the kidney and the recipient, and monitor their health for 
many years post-operation. Success rates are very good in the UK for renal-
transplantation with approximately 93% kidney survival and 96% patient survival 
within the first year, and 86% kidney survival and 89% patient survival after 5 years 
(113). The post-operative care costs approximately £17,000 for the first year and 
approximately £5,000 for every subsequent year, whereas dialysis costs an estimated £͵Ͳ,ͺͲͲ per year per patient ȋN(S Standard Contract ǮFor adult kidney transplant 
service (114). Therefore, if a kidney donor match can be found, a renal transplant is 
the preferred method as it offers enhanced quality of life, enhanced survival rates and 
reduced cost implications.  
During the procedure, neither of the two kidneys within the recipient are 
removed, but rather the new kidney is connected to the external iliac artery and 
external iliac vein in the extra-peritoneal left or right iliac fossa. The donor ureter is 
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connected to the bladder and is lined with a stent to offer support and good urine 
flow as the graft establishes. Immunosuppressants and antibiotics are prescribed 
immediately to suppress immune responses and act as a prophylactic against 
infection, respectively (discussed in more detail in the following sections). 
1.5.1.1 POST-OPERATIVE CARE FOR RENAL TRANSPLANT RECIPIENTS 
As mentioned, finding a good match that will reduce graft-versus-host disease 
and graft rejection is difficult and therefore maintaining kidney health is absolutely 
essential post-transplant. There are 19 transplant centres in the UK where 
transplants are performed, however patients are required to attend local hospital 
renal outpatients for check-ups and medication to monitor, prevent and treat graft 
rejection and infection. Immunosuppressants and antibiotics are continually 
prescribed for 3-12 months depending upon the stability of the graft and the patient 
(115). The first few weeks are intensely monitored since acute-graft rejection is the 
most common form of rejection and can occur within the first week to three months, 
but if caught early can be treated. Routine monitoring is performed weekly within the 
first 3 months and then monthly for the remaining year. Monitoring strategies 
includes blood tests, electrolyte and glucose measurements, liver function tests and 
blood pressure measurements, to ascertain general health (116). Further tests for 
inflammation, infection, rejection and renal failure may be performed via blood tests, 
scans and in some cases, a kidney biopsy (116). Rejection can subsequently be 
treated if caught early enough. The stent is usually removed six to ten weeks post-
transplant to reduce risk of infection (116). 
   Immunosuppression is essential to graft success as it reduces the systemic immune 
responses and allows the graft to become established quickly with reduced risk of 
rejection. Initially, basiliximab is prescribed for the first few weeks to prevent acute 
graft rejection during the induction period. Basiliximab is an IL-2 receptor 
monoclonal antibody that blocks the IL-2 receptor and prevents maturation and 
activation of T-cells and B-cells, which are able to recognise foreign MHC (117). 
Immunosuppression is acheived thereafter by use of a calcineurin inhibitor. 
Calcineurin is essential for signalling in T-cells and when blocked prevents T-cell 
proliferation. Two particular calcineurin inhibitors are used post-renal 
transplantation; tacrolimus and cyclosporine (used in rare cases e.g. diabtetes), which 
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have similar side effects, however the choice of drug depends upon the side-effects of 
the patient. Side effects can include hypertension, renal dysfunction and 
nephrotoxicity, and risk of infection, due to the inability of the weakened immune 
system to fight opportunistic pathogens (118). 
   Since patients must be prescribed immunosuppressants for life post-transplant, this 
renders individuals at high risk from opportunistic infections, notably bacterial 
infections such as pneumonia, MRSA, UTIs and pyelonephritis; viral infections such as 
herpes, hepatitis, cytomegalovirus, and Epstein-Barr virus; and yeast infections such 
as candiditis (119). For this reason a cocktail of antibiotics is prescribed as a 
prophylactic for 3-6 months usually consisting of co-trimaxazole, a combination of 
sulfmethoxazole and trimethoprim, which are particularly effective at protecting 
against Pneumonocystis jirovaci pneumonia (116). Oral anti-fungals are advised to 
prevent oral, vaginal and urinary candiditis. Unfortunately, UTIs are still common in 
RTR and are therefore of particular interest as they can significantly reduce graft 
function (120).  
1.5.1.2 INCIDENCE OF RUTI IN RENAL TRANSPLANT RECIPIENTS  
 Reported prevalence of UTI incidence in RTR varies greatly between 23% and 
75% depending on the study.  The most prevalent species which are found to cause 
UTI in RTR is E.coli in 34.5% of cases, followed by Enterococcus (19.5%) and 
Pseudomonas aeruginosa (12.5%). Strong correlations have been recorded between 
incidence of rUTI and intensity of immunotherapy suggesting that most infections are 
opportunistic (121). 
1.5.1.3 CONSEQUENCES OF UTI POST-RENAL TRANSPLANT 
The correlation with incidence of rUTI and graft rejection has been widely 
accepted. A study by Pelle et al comparing 255 patients with chronic rejection and 
351 patients with no rejection showed a strong correlation between UTI and chronic rejection. Furthermore, Pelleǯs investigations have confirmed that UT) increases the 
risk of acute pyelonephritis (APN) detected by increased numbers of infiltrating 
immune cells, which decreases risk of survival (122). Increased acute rejection 
episodes carry high risk of developing complicated chronic rejection which is harder 
to control and often results in graft and host morbidity (122). Kamath et al suggested 
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a theory that pro-inflammatory cytokines produced during a UTI could lead to 
inflammation in the graft that promote and support graft-versus-host reactions (123), 
which has since been supported by a report showing that TNF-Ƚ and )L-ͳȾ 
significantly reduce graft acceptance (124).  
   Furthermore, increased use of antibiotics, both as a prophylactic and as a treatment 
carry high risk of developing antibiotic resistance. El Amari at al found that antibiotic 
resistance develops in 78% of treated E.coli and E.faecalis infections in RTR (125). 
Another investigation using co-trimoxazole as a prophylactic for women with rUTI 
found that 100% of women treated with this antibiotic cocktail developed resistant 
forms of UPEC (126). Although this study was not performed in immunosuppressed 
RTRs, it highlights the high probability of antibiotic resistance development in 
vulnerable patients with this particular antibiotic cocktail. As resistant strains are 
able to colonise the urinary tract, treatment becomes harder in the individual and it 
causes further risk to hospital and community health. It is therefore essential to be 
able to diagnose UTIs early before they develop into chronic or recurrent infections, 
which can increase the risk of rejection and morbidity or the need for further 
treatment with antibiotics. Unfortunately, current routine urinalysis techniques do 
not always pick up low-level opportunistic infections until they are deeply manifested 
(127). 
1.5.2 DIAGNOSIS OF UTIS  
 UTIs are diagnosed when a patient has 104 colony forming units (CFU) or more 
when plating midstream urine (Public Health England (128)). Anything less than this 
and patients are considered negative for infection by most diagnostic laboratories 
(105, 129). )n the late ͳͻͷͲǯs a (arvard nephrologist, Dr Edward (. Kass, derived this 
traditional diagnostic criterion as a threshold to define UTI (106). According to the 
study, 95% of patients had >105 CFU/ml of a single species in voided urine. A major flaw with this with Kassǯs findings was that his study was only based on patients with 
severe infections of the kidney (pyelonephritis) therefore the CFU count in the 
bladder was undoubtedly higher than in patients with a lower tract UTI. In 1964, 
Gallagher et al conducted a study that showed that approximately one-third of 
women with an acute UTI had bacterial counts between 102 and 104 CFU/ml of a single species discrediting Kassǯs diagnostic assumption (130). Later in 1984, Stamm 
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et al concluded that urine culture with more than 102 CFU/ml of one species among 
acutely symptomatic women is the best criterion to be used to establish diagnosis of 
UTI (127). Since then, the Infectious Diseases Society of America (IDSA) (131), and 
the European Association of Urology (EAU) (132), have revised the guidelines to 
include a cut off of 103 CFU/ml for the diagnosis of bacterial cystitis. However, most 
diagnostic laboratories still follow Kassǯs criterion interpreting urine culture with 
<105 CFU/ml as probable absence of infection (129). This could arguably be in order 
to reduce prescription of antibiotics in order to prevent antibiotic resistance and for 
financial consideration. For this reason, many low-level infections could be being 
missed in many cases of LUTS. Even at low level, certain species could potentially lead 
to the symptoms of UTIs; increased frequency, nocturia and urgency, which are 
similar symptoms to OAB. As such, reduced bacterial threshold and low-count 
bacteriuria has been of recent interest to a number of research groups who believe 
that OAB may be caused by a low-level infection missed by diagnostic laboratories 
due to the high threshold of 105 CFU/ml. 
1.5.3 BACTERIURIA IN OVERACTIVE BLADDER 
1.5.3.2 ǮLOW COUNTǯ BACTERIURIA IN LOWER URINARY TRACT SYMPTOMS 
 In the past 5 years, a handful of research groups including those headed by 
Professor Kate Moore (University of New South Wales, Australia), Professor James 
Malone-Lee (University College London, UK) and Professor Vik Khuller (Imperial 
College London, UK) have reported bacterial cystitis (bacteriuria with or without 
pyuria) in approximately one third of patients with refractory OAB, that is patients 
who do not respond to treatment (129). Malone-Lee and collaborators published the first indication that Ǯlow countǯ bacteriuria may be relevant in OAB in ʹͲͲͺ (133). 
When culturing midstream urine (MSU) samples from patients with OAB they 
discovered that by reducing the threshold to 102 CFU/ml more than 30% of patients 
had bacteriuria compared to 12% with a threshold of 105 CFU/ml. A later study by 
Moore and collaborators supported these findings and further reported 39% 
bacteriuria with 102 CFU/ml versus 6% in individuals with no OAB symptoms (134). 
They also revealed the predominant species found to cause low-level bacteriuria in 
OAB to include E.coli, Streptococci, Klebsiella, Pseudomonas and Enterococci. Both of 
these studies used MSU samples, which have since been argued to be highly 
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contaminated with perineal organisms (129), as such catheter specimens of urine 
(CSU) are regarded as more accurate in providing insight into the species within the 
bladder itself (129). Due to the invasive nature of the collection method, CSU 
sampling is harder to recruit for and limits obtainable sample numbers. However, a 
study by Walsh et al, again led by Moore, performed similar experiments in 2011 
using CSU samples from women with OAB and asymptomatic women (135). Their 
work revealed two thirds of women with OAB to have low count bacteriuria, which is 
higher than reported with MSU (30-39%) (133, 136), however the comparison with 
the control group was insignificant.  
   In 2013, Malone-Lee et al set out to fully investigate the diversity of urinary species 
in OAB using the 16s rRNA gene sequencing technique, which provides more accurate 
species identification than biochemical techniques used in previous studies (137). 
Their work showed a hugely diverse range of bacterial species found in both MSU and 
CSU sample urine with the most predominant species from CSUs identified as 
Staphylococcus, Streptococcus, Lactobacillus, Escherichia coli and Enterococcus. Their 
results however showed a larger diversity of bacteria from CSU than MSU 
contradicting the well-accepted notion that MSU samples contain more contaminants 
that CSU samples.  This was however an excellent bridging publication between previous work on Ǯlow countǯ bacteriuria and the most up to date report on the range 
of bacteria residing within the bladder published a year later by Pearce et al (138) 
(discussed in more detail in the introduction to Chapter 5 - Improved methodology for 
urine culture). 
1.5.3.2 UPEC AND A POSSIBLE ROLE IN THE PATHOPHYSIOLOGY OF OAB  
 Most UTIs are caused by UPEC (85%), but also by bacterium such as 
Enterococcus faecalis, Proteus mirabilis, Klebsiella pneumoniae, Pseudomonas 
aerogenosa, and Serritia marcenscens (107, 108), all of which have also been isolated 
from patients with OAB (136-138). Many research studies looking at the pathogenesis 
of bacteria in UTIs have been performed with UPEC. The findings from these studies could be applied to OAB considering recent evidence on the importance of Ǯlow countǯ 
bacteriuria in some individuals with OAB. UPEC enter the bladder via the urethra and 
establish themselves by invading the urothelium, which induces immune responses 
such as antimicrobial factors and activation of mast cells and macrophages. The 
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ability of UPEC to do this relies heavily on lipopolysaccharide (LPS) in the cell wall, as 
well as pili and fimbrae, which are used for attachment to host cells (139, 140). UPEC 
and many other Gram-negative bacteria are capable of forming biofilms (strongly 
adhered groups of cells in an extracellular polymeric matrix) through LPS binding 
and quorum sensing (reviewed by Flores-Mireles (141)). Furthermore, UPEC release 
toxins and metabolites that can severely affect the function of host cell. For example, 
the production of the toxin cytotoxic necrotizing factor 1 (CNF1) provokes actin 
filamentation in the host cells by acting upon GTPases (142), and Ƚ-haemolysin 
triggers pore-formation in target cells and disrupts cell adhesion (143). Altered 
structural integrity of the bladder urothelium as a consequence of UPEC adhesion and 
invasion will understandably have repercussions on the functionality of the bladder 
as a whole.  
1.5.3.3 INTRACELLULAR BACTERIAL COMMUNITIES IN OAB  
 FimH on the type 1 pilus found on E.coli can induce intracellular targeting 
allowing this bacterium to live inside host epithelial cells in intracellular bacterial 
communities (IBC) (139, 142, 144-148). Despite inducing immune responses, both 
biofilms and IBCs are resistant to targeting by host immune defences and water-
soluble antibiotics (142, 149-152), providing a reservoir of bacteria, which can lead 
to reinvasion and rUTIs. Incidence of IBCs prompts exfoliation of infected superficial 
cells exposing naïve transitional cells underneath. IBCs have been observed in 
patients with OAB (137, 152-154) and could therefore be implemented in triggering 
symptoms of urgency in OAB.  
   The field of IBCs in the bladder has been particularly well investigated by Professor Scott (ultgrenǯs and collaborators at Washington University, St Louis, USA, however 
their focus is mainly on IBCs in UTIs and research is often performed in mice rather than humans. (ultgrenǯs resrach has shown that adhesion of UPEC to the host cell 
membrane is led by the binding of FimH adhesion to mannosylated uroplakins on the 
bladder epithelium (145, 147). Three main post-invasion stages have been described 
in the acute lifecycle of intracellular UPEC (in murine models) using SEM, TEM and 
immunohistochemistry (144, 145). Early IBC; - individual bacilli divide within 
lysosomes of the host urothelial cell, Middle IBC; - coccoid bacterium form tightly 
packed biofilm-like pods (144), Late IBC; - peripheral bacteria regain bacillus 
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formation and efflux from the host cell to re-infect adjacent cells (145, 149).  Fluxed 
bacteria often take the form of filamentous bacilli, which allows them to evade 
phagocytosis by neutrophils (149). A later study by the same group using similar 
techniques on samples of urine from women with cystitis and rUTI, but not OAB, 
showed the presence of biofilm-like pods and filamentous bacteria in human 
urothelial cells also (111). They identified other bacteria in IBCs including 
Enterobacter aerogenes, Klebsiella pneumoniae and Proteus mirabilis, and expectedly 
patients with infections caused by Gram-positive bacteria (LPS and FimH negative) 
did not present with IBCs. They concluded that the presence of filamentous bacteria 
indicates presence of IBCs in the epithelium and could be useful in predicting rUTIs.  
   The work by Hultgren et al focuses on UTIs and cystitis but not OAB, however most 
of the fore mentioned groups working on bacteriuria in OAB have also demonstrated 
a presence of intracellular bacteria in their findings on OAB. Cheng et al, led by Moore, 
noted IBCs in 56% of samples that were negative for routine microbiology by 
observing cells with confocal microscopy (154)-cited in (129). Malone-Lee et al have 
also shown that by performing an antibiotic protection assay on MSU samples and 
then lysing urothelial cells with Triton X-100, there are more colony forming units 
post-lysis than pre-treatment suggesting a reservoir of intracellular bacteria within 
host cells of species E.coli, Enterococcus faecalis, Streptococcus anginosus and Proteus 
mirabilis (137). Taken together these studies suggest that intracellular bacteria may 
be important in OAB however only the latter study compared CFU numbers from 
patients with LUTS with asymptomatic individuals. The differences between IBC 
CFU/ml were not significantly different between OAB and asymptomatic adults (137) 
suggesting that IBCs may occur in healthy individuals as well, but it is the 
pathogenicity of the bacterium in these reservoirs that is the cause for LUTS.  
   In a separate publication in the same year, Malone-Lee and collaborators 
investigated the invasiveness of bacteria by confocal microscopy and showed that 
Enterococcus faecalis are more invasive than E.coli by performing confocal analysis of 
cultured cells infected by either Enterococcus or E.coli. (152). This introduces an 
interesting alternative to the heavy focus on UPEC and highlights the importance of 
investigating other uropathogenic bacterium. 
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   Of course due to the proposed lifecycle process of intracellular bacteria there is 
likely a transient production of filaments, therefore it is essential to sample urine 
more often in order to increase the likelihood of detecting them. It also implies that 
antibiotic treatment ought to be prolonged to ensure efficacy. Hultgren et al has 
publicised results on an exciting alternative to antibiotics. They showed that by 
treating mice burdened with multidrug resistant UPEC with a single oral dose of a 
FimH agonists bacterial load was reduced by >1000-fold (155, 156). Taken together 
these studies suggest that the species of intracellular bacteria are of more relevance 
than the presence of IBC themselves, however they may be a potential means of 
detecting low-level bacteriuria, explaining rUTI and a possible cause for OAB in some 
patients. Furthermore, in cases where IBCs are present, alternatives to antibiotics 
could be used which are more effective at targeting pathogenic intracellular species, 
thus preventing development of antibiotic resistance with over use of antibiotics. . 
1.5.4 IMMUNE RESPONSES TO BACTERIA IN THE BLADDER 
 Despite the bladder being at risk of colonization, it has numerous innate 
immune defences that prevent UTI. For example, as urine is voided, the force of the 
fluid passing through the narrow urethra removes many bacteria from within it. 
Hence, midstream samples of urine are less sterile than catheter samples. 
Furthermore, the GAG layer (figure 1.1) prevents bacteria from reaching the exposed 
surface of the urothelial cells. Other innate defences consist of secretory 
immunoglobulin A (sIgA) production (157), antimicrobials and defensins produced in 
the kidney and the vagina. Finally, innate immune cells, again similar to those found 
in the gut, can also be found within the urothelial walls of the bladder. Such cells 
include of macrophages, dendritic cells (158, 159) and ɀɁ T cells (160). ɀɁ T cells are so called as their T cell receptor is composed of different glycoproteins ȋa ɀ chain and a Ɂ chainȌ compared to the standard glycoproteins found on ȽȾ T cells such as helper 
T cells, cytotoxic T cells and Treg cells (161). The exact role of these unique cells is 
generally unknown, however they are associated with innate functions, and since 
they do not require major histocompatibility complex II for activation, they 
presumably act as danger sensors in mucosal areas and skin. 
    As previously mentioned, many of the bacterial species found in patients with OAB 
express LPS in their cell wall, which is extremely potent activator of immune 
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responses. The pathophysiology of UPEC in UTIs has been extensively studied in 
relation to how they initiate immune responses in the bladder. Considering the recent 
findings in regards to colony count, this information could be extrapolated to OAB. 
Furthermore, there are increased populations of mast cells in patients with OAB and 
IC compared with controls indicating a possible role for these immune cells in 
exacerbating symptoms in these syndromes (162).  
1.5.4.1 LIPOPOLYSACCHARIDE AND TOLL-LIKE RECEPTORS  
    In 1993 a study by Svanborg et al showed that epithelial cell lines grown in 
culture with UPEC have increased intracellular IL-ͳȽ, )L-8 and IL-6 concentrations 
which may in turn be involved in the recruitment of polymorphonuclear cells (PMNs) 
(163). A later study revealed exposure of renal epithelial cells to the exotoxin Ƚ-
haemolysin of UPEC increased intracellular Ca2+, which correlated with increased IL-6 
and IL-8 production from these cells (164). As previously mentioned, E.coli express 
LPS and type 1 pili in their cell wall which are extremely potent activators of innate 
immune responses acting via binding to receptors such as toll-like receptor 4 (TLR4), 
CD14, sCD14 and LPS-binding protein (LBP) (159). Bladder cell lines (e.g. 5637 
epithelial cells, T24 epithelial cells, J82 epithelial cells, and A498 epithelial cells, all 
derived from bladder carcinoma) express CD14 and TLR4 and TLR2 and activation of 
bladder cells is dependent on TLR signalling, p38 MAP kinase, and the transcription 
factor NF-κB which transcribes the afore mentioned pro-inflammatory cytokines IL-6 
and IL-8 (159).  A later study by Song et al revealed that another distinct pathway 
involving Ca2+ and cyclic adenosine monophosphate (cAMP) exists in bladder 
epithelial cells, which can also trigger IL-6 production (165). Taken together these 
studies illustrate that UPEC bind to CD14 and TLRs in the bladder urothelium via LPS 
to activate p38 MAP kinase, Ca2+ and cAMP signalling which in turn triggers IL-6 and 
IL-8 production (figure 1.3). IL-6 is associated with activation of the acute phase 
response, which increases production of C-reactive protein from the liver and IL-8 
acts as a chemotactic factor for neutrophils. Interestingly, mast cell and neutrophil 
infiltration, C-reactive protein, IL-6, and IL-8, have all been shown to be increased in 




1.5.4.2 MAST CELL INFILTRATION AND ACTIVATION 
 Neutrophils, mast cells and macrophages are all increased in the bladder of 
patients with OAB compared with asymptomatic individuals (162, 169, 170). These 
cell types are associated with innate immune responses. Neutrophils are the first cells 
to reach a site of infection by chemo-attraction to IL-8 released by activated 
macrophages. Mast cells are often recruited during parasitic infections and allergic 
reactions and release nerve growth factor (NGF), prostaglandins, histamine, and 
tyrosine, which can in turn provoke smooth muscle contraction (figure 1.4) (171-
173). A study by Liu et al showed that mast cells are increased in both OAB and IC 
however the tight junction protein, zonula occluden-1 (ZO-1), and adherence protein, 
E-cadherin, are only decreased in IC indicating a breakdown of urothelial integrity 
associated with mast cell infiltration occurs in IC but not in OAB (162). Interestingly, 
antihistamines can be used to ease the symptoms of IC (85), however have not been 
trialled for treatment of OAB symptoms despite the similarities in these two LUTS 
disorders in regards to mast cell infiltration and prostaglandin increase. 
1.5.4.3 NERVE GROWTH FACTOR AND OTHER BIOMARKERS 
 Many studies have associated NGF with OAB, and proposed it to be a 
biomarker of OAB (174-176). NGF is a molecule that promotes differentiation, 
maintenance and repair of sensory and sympathetic neurons (20). Within the 
bladder, it is produced from the urothelium and smooth muscle cells, however it has 
also been shown that mast cells produce NGF. It has been widely publicised that NGF 
is higher in urine from in patients with OAB compared to asymptomatic controls 
(n=51 maximum) (174-176)However increased NGF is not restricted to OAB and has 
been indicated other LUTS including IC (177) and mixed urinary incontinence (175). 
NGF is however reduced post anti-muscarinic and BTX-A treatment (178) but also 
post antibiotic treatment (179), therefore it could be worthwhile investigating the 
correlation between urinary NGF and presence of pathogenic and/or intracellular 
bacteria to better understand the potential effects of low-level infection and how OAB 
may manifest as a result. 
   Of course a vast array of other cytokines have been analysed in the urine of patients with OAB using EL)SAǯs and Luminex™ technology. The results of these tend to show 
increased macrophage inflammatory protein (MIP-1B), monocyte chemotactic 
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protein-1 (MCP-1), IL-10, soluble IL-2 receptor-Ƚ, tumour necrosis factor ȋTNF) and 
epidermal growth factor (EGF) in samples of urine from individuals with OAB 
compared to asymptomatic individuals suggesting a possible inflammatory role (166-
168). Interestingly MCP-1 is known to provoke mast cell activation (180), which 
correlates with increased mast cell numbers in these patients. However the results of 
these studies looking at cytokines in urine have all been very contradictory indicating 
that samples size may be an issue (n=20 maximum) or perhaps that cytokine 
variation between individuals is too varied to make conclusions at this stage. Testing 
the same individual at various times on a wider number of patients would clarify this.  
1.5.5 ACTIVATOR SIGNALLING AND BACTERIURIA  
Another potential biomarker for OAB is ATP. Increased ATP in urine has been 
well documented in individuals with OAB and IC compared to asymptomatic 
individuals (75, 181-183). Furthermore, a study by Conterez et al investigating ATP 
release from biopsies taken from individuals with OAB with pyuria (n=15), OAB 
without pyuria (n=33) and asymptomatic individuals (n=9) showed that biopsies 
with pyuria have a higher basal level ATP than the other groups, suggesting that 
infection leads to increased ATP release (182). It was also been shown that P2Y 
receptor expression is increased in patients with OAB with pyuria and ATP acts in a 
paracrine/autocrine manner. The authors concluded this research hypothesising 
intracellular bacteria as a cause for the observed increase in ATP and receptor 
expression. This investigation does however lack accompanying culture, which would 
have given more support to the idea that bacteria are at the centre of this hypothesis. 
A study by Save et al has shown that bladder urothelial cells infected with 
intracellular UPEC in culture increase ATP levels in the supernatant of cells (75), 
however UPEC themselves contributed to this increase which was investigated by 
comparing ATP levels in bacterial, cell culture and co-culture medium. Studies by the 
same group have also shown that ATP release by cells infected with UPEC induces IL-
8 release via P2 receptor signalling (75, 184, 185). Furthermore, ATP activation of P2 
receptors directly affects neutrophil migration to the source of IL-8, acting in a 
chemokine manner (186). Taken together these findings highlights the importance of 
extracellular ATP and P2 receptor signalling in bladder bacterial infection and their 
combined role in generating immune responses. Additionally, since sensory nerves 
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and myofibroblasts express P2 receptors it is hypothesised that ATP released during 
infection can directly affect the afferent nerves inducing contractions of the detrusor 
muscle as part of the micturition reflex (43, 71) (figure 1.4).  
 
 
Figure 1.4: Schematic of how bacteria can alter the physiological function of the bladder A) ATP is released 
from stress-induced urothelial cells which may occur due to invasion by urothelial bacterium such as UPEC (75). 
ATP is also released by the bacteria themselves, B) ATP release binds to P2Y receptors on urothelial & 
suburothelial cells and myofibroblasts (42). Myofibroblasts may in turn induce signalling of suburothelial sensory 
nerves (16, 42, 43). Excess ATP presence can activate cytokine production and directly induce neutrophil 
infiltration (75, 184, 185), C) LPS on Gram-negative bacteria induce activation on Calcium, cyclic AMP and NF-kB 
pathways to release cytokines including IL-6, IL-8 and TNF (159, 164, 165), D) Cytokines lead to infiltration of 
mast cells and neutrophils (186), E) Mast cells release NGF which stimulates nerve development, maintenance 
and repair . They also release histamine, prostaglandins and tryptase which can cause smooth muscle contraction 
(171-173) F) Immune cell infiltration leads to production of more cytokines including NGF (162, 178) and PDGF 
which can lead to altered innervation and pericytes transdifferentiation, respectively, G) Stimulation of pericytes 
by TGFB1 and PDGF stimulates pericytes to differentiate into myofibroblasts (47). H) Increased myofibroblasts 
presence in turn increases the signal strength received by afferent nerves, which will in turn instruct the CNS of a 




1.6 THE BLADDER MICROBIOME 
 The work on low count bacteriuria in OAB by Moore and Malone-Lee 
discussed in Section ͷ.5.͹.͸ ǮLow countǯ bacteriuria in lower urinary tract symptoms 
suggests a possible role for pathogenic bacteria in the pathology of OAB. Interestingly, 
all of these studies made comparisons to asymptomatic individuals and in all cases 
the reports show presence of bacteria in asymptomatic individuals as well as in OAB 
(134, 136, 137). This supports the notion that urine is not sterile and that the bladder 
is normally colonised with bacteria. Furthermore, advanced methods comprising of enhanced culturing techniques and mass spectrometry have described a Ǯmicrobiomeǯ 
present in bladders of asymptomatic individuals. The term microbiome refers to a 
niche of bacteria and their genes present in a particular environment.  There is a well-
described microbiome in the human gut which is tolerated by the immune system 
and the metabolites of which can prevent gut infection. Alterations in the gut 
microbiome have been associated with some gut diseases such as Crohnǯs disease and 
inflammatory bowel disease, where there is no obvious bacterial infection but the lack of some key Ǯgood bacteriaǯ or probiotics has led to dysfunction of the immune 
system (187). The notion of a potential bladder microbiome lends itself to the 
hypothesis that alteration may be a cause for some LUTS in much the same way. The 
following section discusses key bacterial species in the microbiome of the healthy 
bladder and the role that these bacteria play in regulating the immune system and 
protecting against pathogens. Alterations in the bladder microbiome can be caused by 
a number of factors, which will also be discussed, as well as the evidence to date 
about the potential effects this may have on LUTS. 
1.6.1 A ǮCOREǯ BLADDER MICROBIOME 
 Microbes isolated from the bladder were not included in the Human 
Microbiome Project based on the theory that urine is sterile (188). Research 
published in the last 6 years has rectified this misconception in both the scientific and 
general community.  Many bacterial species are noncultivatable, that is, they cannot 
be cultured by routine microbiological techniques. Various alternative techniques 
have been adopted for identifying species including culture independent molecular 
PCR on the 16s rRNA gene and expanded quantitative urinary culture (EQUC). 
Multiple investigations led by Fortenberry et al (189-191), Jakobsen et al (192, 193), 
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and Wolfe et al (138, 194-197), have employed the former of these methods to 
identify bacterial species in the urine of healthy men and women. They each collected 
clean catch urine and extracted bacterial genomic DNA directly from the samples 
followed by next generation sequencing and bioinformatics which provides 
quantitative information on all species present within each sample.  Taken together 
these studies have identified notable taxa which could make up the core bladder 
microbiome including: Actinobaculum, Aerococcus, Anaerococcus, Atopobium, 
Bifidobacterium, Burkholderium, Corynebacterium, Finegoldia, Fusobacterium, 
Gardnerella, Lactobacillus, Jonquetella, Megasphera, Prevotella, Proteobacterium, 
Ralstonia, Sneathia, Staphylococcus, Streptococcus and Veillonella. Hilt et al, led by 
Professor Wolfe, used EQUC which involved culture of CSU samples from OAB and 
asymptomatic individuals on blood agar, chocolate and colistin agar, and nalidixic 
acid agars in the following conditions: - aerobic at 35oC, aerobic at 30oC, 5% CO2 at 
35oC, anaerobic at 35oC and in campygas (6% O2, 10% CO2) at 35oC followed by 
species identification by matrix-assisted laser desorption ionization-time of flight 
mass spectrometry (MALDI-TOF MS) (195). They identified and tabulated all the 
species that were cultured in each of these conditions affirming the most prevalent as 
Lactobacillus (15%), Corynebacterium (14.2%), Streptococcus (11.9%), Actinomyces 
(6.9%), and Staphylococcus (6.9%). Pearce et al, again led by Wolfe, recognised that 
even with EQUC some species were still missed when comparing to the spectrum of 
species found by high-throughput sequencing. Therefore they combined the results 
from high-throughput sequencing of the 16s rRNA gene with those from EQUC as well 
as MALDI-TOF MS to obtain the most complete description of bladder bacterial 
species to date (138). In this same study they observed the differences between the 
normal bladder and that of women with urinary incontinence. They concluded that 
there may not be key distinct differences between the two groups but rather that 
each individuals microbiome is unique and dysbiosis in the individual is a more likely 
cause of urinary symptoms. By understanding how the bladder microbiome serves to 
protect the bladder, it can be better understood how dysbiosis can possibly lead to 
dysfunction.   
1.6.2 THE PROTECTIVE ROLE OF THE MICROBIOME 
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 The bladder, much like the gut, is a mucosal tissue and is exposed to the 
exterior environment especially in women who have a shorter urethra than men, and 
therefore it is prone to colonisation by microorganisms. Many species of bacteria that colonise the mucosal tissues are tolerated by the hostǯs immune system and live in 
symbiosis providing protection against pathogens and preventing overactivity of the 
immune system. The immune systemǯs principal role is to protect against infection by 
recognition of foreign antigen within the body. The cells of the immune system 
undergo a selection check before they enter the peripheral body so that they 
recognise and tolerate self-antigen; this is known as central tolerance (for a review 
see Hogguist et al (198)). Since humans are obligate symbionts, that is, they rely on 
commensal microorganisms for survival, another level of tolerance is required to 
prevent elimination of necessary microbes which is known as peripheral tolerance 
(for a review see Mueller (199)). As microorganisms begin to colonise the host, which 
occurs straight after birth, the peripheral immune system begins to recognise commensal bacteria and develops tolerance towards them. )n part, an individualǯs 
microbiome and their peripheral tolerance develop together.  In the gut, where the 
biomass of microorganisms can reach up to 3% of total body mass, a unique mucosal 
immune system consisting of specialised cells such as microfold (M) cells, regulatory 
T (Treg) cells and tolerant antigen presenting cells (APC) help to develop tolerance to 
the commensal species. M cells obtain antigen from commensal bacteria in the gut 
lumen and transport it to other immune cells and Treg cells inhibit immune 
responses through the production of particular suppressive cytokines such as TGF-Ⱦ 
and Interleukin 10 (IL-10). Activation of these cells by commensal bacteria helps to 
prevent autoimmunity and immune overactivity. Interestingly, in some autoimmune diseases such as Crohnǯs disease dysregulation of the immune system has been 
associated to alterations in the numbers of M cells and regulatory T cells (200). 
Therefore, commensal bacteria play a vital role in shaping, maturing and maintaining 
a balanced immune system, at least in the context of the gut. 
   As in the gut, constitutively secreted IgA (SIgA) is produced in the bladder (157), 
which acts to constantly inhibit bacteria for which it has a high affinity. IgA does not 
only act to eliminate pathogenic bacteria but can control signals generated by 
commensal bacteria for which it has a lower affinity. )n the gut, dendritic cells Ǯtasteǯ 
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the exposed environment and present commensal bacterial antigen to B cells which 
undergo class switching of the immunoglobulin genes to produce IgA in the presence 
of suppressive cytokines such as TGF-Ⱦ (201). Notably, germ free mice have 
significantly reduced SIgA in their gut, therefore the presence of commensal bacteria 
is essential for the production of IgA (202). Although the same has not been proven in 
the bladder the presence of dendritic cells and SIgA suggests a similar mechanism 
may exist.  
    Many probiotic species are able to protect against pathogens directly, by producing 
metabolites and proteins such as lactic acid and various bacteriocins by Lactobacillus 
species. These species are also acid tolerant so they cannot be affected by their own 
production of lactic acid. Lactobacillus crispatus has been identified as the species that 
produces the highest concentrations of hydrogen peroxide of all Lactobacillus species 
in the bladder followed by L.jensenii (203). Other species have been shown to produce 
hydrogen peroxide; L. delbrueckii, L. acidophilus, L. johnsonii and L. gasseri (204).  
Together, this taxa contributes highly to the antimicrobial proteins and organic acids 
found in the body which can keep pathogenic bacteria at bay. Furthermore, 
Lactobacillus is of particular interest in the gut and vagina, where they have not only 
been shown to prevent infection in various clinical trials but have also been shown to 
modulate homeostasis and support a healthy nervous system and emotions (205), the 
circadian cycle (206), and prevention of bacterial vaginosis during pregnancy (207). 
   The commensal bacteria of the microbiome are therefore essential for preventing 
autoimmunity and maintaining production of antimicrobials and IgA by manipulating 
the host immune system. Also, key species appear to be able to contribute to the 
production of antimicrobials and can themselves directly affect bodily functions. This 
gives a strong foundation to advocate that dysbiosis of the bladder microbiome would 
be detrimental and inevitably lead to dysfunction. 
1.6.3 ALTERATIONS IN THE BLADDER MICROBIOME 
 As with any microbiome, the symbiotic balance between microbes and host, 
and other microbes is ever changing and evolving as the environment changes. 
Certain bacteria will not be able to survive with alterations in temperature, pH, 
salinity and substrates allowing those that can to thrive and become more populous 
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by natural selection (208). Since the bladder functions as a storage for urine prior to 
voiding, the unwanted metabolites from kidney filtration will be present in the urine. 
Variations in diet can alter these metabolites and in the gut have been shown to 
reduce the diversity of the microbiome (209, 210). Drugs, both medicinal and 
recreational, can have a profound effect on the gut microbiome (210, 211), and this is 
likely to include the bladder microbiome too since both the gut and the bladder are 
exposed to downstream metabolites. 
   As previously mentioned, each individualǯs microbiome is unique. Ones exposure to 
microbes will evidently have an effect on the diversity of their microbiome. As an 
individual develops their hormones change, i.e. during puberty, pregnancy and 
menopause. Changes in hormones have in fact been shown to have an effect on the 
microbiome of the vagina, particularly in reducing Lactobacillus incidence in 
postmenopausal women (212). Furthermore, sexual exposure can have a profound 
effect on the urogenital microbiome (190, 191). Since each individualǯs microbiome is 
unique, unprotected sex can introduce new species, especially with oral and anal sex. 
Due to the proximity of the bladder to the vagina in women, changes in the vaginal 
microbiome will evidently lead to alterations in the bladder also. A most significant 
cause of alteration of the microbiome is the use of antibiotics, which can in some 
cases only target specific taxa leaving room for other species to grow. Furthermore, 
use of antibiotics can allow survival of bacteria with beneficial genetic mutations 
inferring antibiotic resistant leading to the development of antibiotic resistant niches 
within individuals and populations. Therefore it is inevitable that the microbiome will 
change as one is exposed to various factors. 
1.6.4 MICROBIOME ROLE IN LUTS  
  Many of the aforementioned researchers who employed new methods to 
identify the core microbiome, furthered their studies by comparing samples from 
asymptomatic individuals with samples from individuals with LUTS, including IC 
(n=8) (192), OAB (n=41, 60, 11) (138, 194, 195), exposure to STIs (n=10, 10) (190, 
191), and post renal transplant (n=60) (213). Of these that investigated the 
differences between the microbiota in asymptomatic individuals and women with 
OAB, increased incidence of Gardnerella, Actinobaculum, Actinomyces, Aerococcus, 
Arthrobacter, Cornybacterium, and Oligella, and reduced incidence of Lactobacillus, 
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Streptococcus, and Bifidobacterium were observed.  Interestingly, Siddiqui et al noted 
a reduction in microbiome diversity in women with IC with increased incidence of 
Lactobacillus and reduced Bacteriodes, Bifidobacterium and Clostridium (192). These 
differences not only demonstrate that the microbiota from patients with OAB and IC 
both differ from asymptomatic individuals but that they are also unique from each 
other, suggesting that these syndromes are perhaps more distinct from each other 
than previously thought. 
   One particular study of interest observed changes in individual microbiomes of 
patients post renal transplant (213). These patients were treated with 
sulfmethoxazole-trimethoprim as a prophylactic antibiotic. The key species that 
decreased in prevalence between 1 and 6 months post renal transplant were 
Proteobacteria, Escherichia and Porphyromonas, likely due to the use of antibiotics.   
These studies indicate a significant alteration in the microbiome of the bladder with 
LUTS suggesting that bacteria may indeed play a role in development of bladder 
dysfunction however this is not proven. There could be numerous other factors 
affecting changes in the microbiome observed between comparable groups.  
1.7 CURRENT RESEARCH QUESTIONS 
 There is an irrefutable amount of evidence that supports the fact that urine is 
not sterile, and rather that there is a bladder microbiome, which is unique to 
individuals and populations, and can be altered through lifestyle changes and disease. 
What is still unknown however, is whether alterations in the bladder microbiome are 
a direct cause of bladder dysfunction, and if so, how this alters the physiological 
function of the bladder. There are various research questions that have arisen from 
the discussions in the introduction. The research in this thesis will aim to determine if 
changes in the bladder microbiome may; i) be a cause for rUTI in renal transplant 
recipients in the first results chapter; ii) be a cause for some idiopathic cases of OAB 
in the second results chapter; and iii) lead to bladder dysfunction by investigating the 
role of pericytes during bladder infection in the final results chapter. 
    The first results chapter tries to determine whether changes in the bladder 
microbiome may be a cause for rUTI in RTRs. Alterations in the microbiome can be 
due to a variety of factors but one of the most devastating of these is the use of 
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antibiotics. The use of antibiotics is often acute and temporary as one to two weeks of 
treatment is sufficient to control infections. However, in the case of recurrent 
infections of the mucosal areas it is necessary to repeat antibiotic use and change the 
types of antibiotics prescribed as antibiotic resistance develops. Another example of 
extended antibiotic use is as a prophylactic during organ transplantation to 
counteract the use of immunosuppressants, which are essential for foreign organ 
tolerance.  Recurrent infection as a result of antibiotic and immunosuppressants use 
is no more relevant to organ survival than in kidney transplantation, where patients 
are highly susceptible to rUTI post-transplantation. It is essential therefore to 
determine how use of prophylactic antibiotics and immunosuppressants alters the 
bladder microbiome post-renal transplant and if changes can indicate predisposition 
to rUTI and thus prevent infection before it manifests. The first results chapter takes a 
closer look at the exact species found in the bladder of renal transplant recipients 
over time to determine if the bladder microbiome does indeed change over time in 
these patients and whether it correlates with any clinical changes which can be used 
to predict UTIs and rUTIs.  
   The second results chapter tries to determine whether changes in the bladder 
microbiome may be a cause for OAB. OAB is an incredibly common syndrome costing 
millions to health services across the globe on treatments, many of which are 
unsuccessful due to the existence of idiopathic forms of OAB. The cause of IDO has 
recently been associated to low level bacteriuria however no real conclusions have 
been formed as to how this could lead to the symptoms of OAB. Many of the 
pathogenic bacteria associated with UTI, and more recently OAB, are able to invade 
host cells to form IBCs capable of avoiding antibiotics and immune responses, in turn 
leading to recurrent infections. A handful of studies have proposed that there may be 
an intracellular component to OAB, however a detailed description of both 
extracellular and intracellular bacterial species found in OAB and asymptomatic 
individuals does not yet exist. The second results chapter aims to confirm if there is 
indeed a role for IBC in OAB by performing an established isolation technique 
followed by genetic identification of bacteria. Furthermore, by determining if 
presence of IBC or particular pathogens correlates with any alterations in clinical 
characteristics it would be possible to understand exactly how infection could affect 
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the function of the bladder in OAB. In particular by looking at cytokines, ATP, and 
white blood cell count in order to link the observed increase in these biomarkers in 
OAB with infection. Additionally, any significant biological and clinical differences 
between OAB and asymptomatic individuals could potentially be developed further 
with an aim to better diagnosing this syndrome.  
   The third results chapter tries to determine whether changes in the bladder 
microbiome can be more easily detected.  If changes in the bladder microbiome are 
significant to rUTI in post-renal transplant, or OAB, it would be essential to develop a 
more cost effective means of determining low-level infection than is currently 
employed by many diagnostic laboratories. In most laboratories, the criterion for 
infection is 104 – 105 CFU/ml of a single species to determine infection, however it is 
clear that low-levels of bacteria are also capable of causing bladder dysfunction. Many 
of the methods used to determine exact species are costly and time consuming; 
therefore with the results from the clinical studies, we would like to develop a means 
of finding a more effective method of investigating the bladder microbiome in 
individuals. 
   The final results chapter tries to determine how changes in the bladder microbiome 
may lead to the physiological symptoms observed in OAB. Many studies have 
confirmed that significant differences in the microbiome exist between asymptomatic 
individuals and various LUTS, but it is not clear how alterations in the microbiome 
could lead to dysfunction.  Increased numbers of pathogenic bacteria, even at less 
than 105 CFU, may interfere with the complex physiological and neurological control 
of normal bladder function by cytokine and ATP signalling for example. Many 
pathogenic bacteria found in UTI and OAB are Gram negative and therefore have LPS 
in their cell walls which is a potent activator of immune responses. Downstream 
cytokines of these responses can directly affect vascular permeability increasing 
immune cell infiltration, inflammation, ATP release and fibrosis. Furthermore, 
bacteria and infected/stressed cells release ATP, which cannot directly affect the 
afferent nerves and the detrusor but can diffuse to the lamina propria and stimulate 
P2 receptor expressing cells such as myofibroblasts and pericytes. Since pericytes in the bladder are already Ƚ-SMA positive and express PDGFRȾ it suggests that these 
cells have the potential to develop into myofibroblasts in the presence of PDGF. The 
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research by (ashitani was concluded by suggesting ǲthe pluripotency of pericytes 
may contribute to the remodelling of the bladder suburothelium that is commonly seen in an overactive bladderǳ (50). With this in mind, and the role that 
myofibroblasts play in bladder function as potential intermediary cells in the sensory 
process, the research in this thesis will aim to determine if infection could lead to 





1. The use of antibiotics and immunosuppressants for renal transplant recipients 
leads to changes in the microbiome which predisposes these patients to rUTI. 
2. The microbiome of women with OAB is different to that of asymptomatic women, 
potentially caused by increased age, predisposing older women to OAB. 
3. Intracellular bacteria may be a reservoir in both renal transplant recipients and 
women with OAB leading to rUTIs and induced smooth muscle contraction in each 
case, respectively. 
4. A cost effective, quick method for determining low-level infection needs to be 
developed which can be adapted by diagnostic laboratories in order to better 
identify potential causes for LUTS. 
5. Bacteria in the bladder can lead to loss or differentiation of pericytes, altered 
activity of pericytes, remodelling of the suburothelium and accentuated sensory 







1.8.1 AIMS AND OBJECTIVES 
In order to begin to test these hypotheses the following objectives will be carried 
out:- 
1.  • Determine how the bladder microbiome changes over the course of 6 
months post-renal transplant. • Compare microbiome changes with clinical and biological observations to 
determine if there are any potential biomarkers for predisposition to rUTI 
in renal transplant. 
2.  • Investigate the differences in the microbiota in the urine between patients 
with OAB and asymptomatic individuals in various age groups. • Analyse and compare all clinical and biological information from patients 
with OAB and asymptomatic individuals to determine if there are any 
potential biomarkers for OAB. 
3.  • Determine if there is an intracellular component to renal transplantation 
and OAB and which species are most prevalent in each case.  • Can presence of IBC be a predictor for rUTI post-renal transplantation? 
4.  • Investigate various methodologies for identifying urinary species of 
bacteria and their adaptabilities for diagnostic laboratories. • Determine how these methodologies can be used in conjunction with other 
diagnostic tests to potentially better diagnose OAB. 
5.  • Observe pericytes in the urinary bladder of mice. • Investigate the function of bladder pericytes by observing the responses to 





CHAPTER 2 –  
GENERAL METHODOLOGY 
2.1 COLLECTION AND PROCESSING OF HUMAN SAMPLES 
Collection of samples was individual for each project and is described in detail in the 
methods for each results chapter; sections 3.3 and 4.3 – Project specific methodology.  
2.1.1 PATIENT RECRUITMENT AND ETHICAL APPROVAL 
 Patients visiting renal outpatients clinic at Kent and Canterbury Hospital for 
renal donor and recipient check-ups provided midstream sample urine (MSU) 
samples for the renal transplant prospective cohort study (chapter 3). All recipients 
were prescribed co-trimoxazole 80/400 mg tablets (80 mg Trimethoprim and 400 mg 
Sulfamethoxazole) for 12 months post-transplant as a prophylactic for pneumonia. 
Upon being consented, patients were invited to provide an MSU at 1 month, 3 months 
and 6 months post-transplantation. On each visit they also fill in in a questionnaire 
designed by East Kent Hospital University Foundation Trust to determine symptoms 
and impact on life (see Appendix 1.1 – Diagnosing urine infection in kidney transplant 
patients, EKHUFT, 2015). Also, 2 MSU samples were taken from the renal donor 
patients before removal of the donor kidney, and acted as the asymptomatic control 
group. These were taken during donor check at approximately 1 month and 2 weeks 
pre-transplant and are therefore here forth named the Ǯdonor baselineǯ group. 
   For the OAB study (chapter 4), MSU and CSU samples were collected from patients 
who fitted a specific description of OAB dictated by International Validated Questions 
from the International Consultation on Incontinence Modular Questionnaire – Female 
Lower Urinary Tract Symptoms Long Form (ICIQ-FLUTS-LF) (see Appendix 1.3 - ICIQ-
FLUTS-LF).  Patients were all women clinically diagnosed with OAB after an 
assessment of their history, cystoscopy, urinalysis, and urodynamics. All patients also 
indicated a positive response to Question 3a of the ICIQ-FLUTS-LF (Do you have a 
sudden need to rush to a toilet to urinate?). All patients were female aged 18 and over 
and suffered moderate to severe OAB with urgency, frequency and nocturia. Any 
patients with symptomatic UTI, IC, predominant SUI symptoms, or previous pelvic 
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radiation were excluded from the cohort. Asymptomatic control samples were also all 
from females, taken from women who had scored 0 on the ICIQ-FLUTS short form to 
ensure that they did not suffer with any OAB symptoms. All sampling methods met 
the ethical approval and each patient gave consent on every occasion before 
providing a sample. MSU samples were obtained from patients attending outpatient 
clinics at Medway Maritime Hospital, Gillingham, Kent. For CSU samples, patients 
with OAB partaking in a cystodistension clinical trial (214) at the Sunderland Day 
Case Clinic at Medway Maritime Hospital were requested to provide a CSU sample 
and bladder biopsies on the day of their surgery. The biopsies were taken via a 
cystoscopy (telescopic examination of the inside of the bladder) and were placed in 
sterile saline to be processed as according to the protocols for microbial culturing, 
electron microscopy or ATP assay (described later in this chapter). Asymptomatic 
control samples of catheter specimen urine were obtained from patients attending 
the same day surgery for non-bladder surgeries such as hysterectomy, myomectomy 
and laparoscopy. All samples were collected under general anaesthetic in a sterile 
operating theatre prior to the scheduled operation. 
2.1.2 ROUTINE URINALYSIS AND NHS MICROBIOLOGY   
 Samples were immediately analysed with a urinalysis dipstick (Multistix, 
Seimens) for leukocytes, nitrites, protein, pH, blood, specific gravity, ketones and 
glucose (128, 215). Dipstick analysis is used as a rapid test for possible infection 
whereas traditional cell counting methods must be performed within 2 hours of 
sample collection and repeated three times for accuracy. Leukocyte esterase is 
released from leukocytes, usually present in urine during an infection. Nitrites are 
another sign of infection. Protein and glucose in the urine signifies kidney failure and 
diabetes, respectively. A small sample of urine was also mixed with Sternheimer-
Malbin stain (Fisher Scientific, Loughborough, UK) in a ratio of 1:1 and loaded onto a 
standard haemocytometer (216). Shed urothelial cells, white blood cells and red 
blood cells (figure 2.1) were counted per μl and multiplied by a dilution factor of ʹ 




Figure 2.1: Image of Sternheimer-malbin stained urine.  A) Urothelial cells are identifiable as large squamous 
cells with a dark pink central nucleus B) white blood cells are identifiable as small, compact, dark pink cells with a 
minimal cytoplasm, C) red blood cells are identifiable as nucleus-free, concave cells with a lighter colouration. 
 
  Urine samples were sent to hospital pathology for routine culturing and biochemical 
testing of cultures. Each hospital had its own protocol for culturing samples. Medway 
hospital was not able to provide a protocol for their urine culture however the 
protocol lfor East Kent Health Trust can be found in the appendix (appendix 1.2 - MSU 
and CSU culture interpretation, EKHU NHS Foundation Trust, 2015). Results of these 
were compared with our own (chapters 3 and 4). 
2.1.3 PROCESSING OF FRESH URINE SAMPLES 
 Urine was kept on ice or in the fridge until processing, which was performed 
within a 4 hour window post-collection in order to reduce cell death, particularly of 
white blood cells (215). The following tests were performed on all samples and are 
discussed below; - i) urine was stained with DAPI (4',6-diamidino-2-phenylindole) to 
determine the presence of possible intracellular bacteria in urothelial cells (217), ii) 
any samples with prospective intracellular bacteria are then stained with acridine 
orange and crystal violet to determine if the bacteria are indeed intracellular (218), 
iii) urine was plated to culture microbes which were then identified using 16s rRNA 
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gene sequencing (137)(discussed in section 2.1.3.5 Identification of isolates by 16s 
rRNA gene sequencing). 
2.1.3.1 DAPI & ACRIDINE ORANGE/CRYSTAL VIOLET STAINING OF CYTOSPUN URINE 
    Both MSU and CSU samples were stained with DAPI, which binds to DNA (figure 
2.2B). This allowed the identification of urothelial cells with associated bacteria (clue 
cells), which may or may not be intracellular. Fresh samples were diluted with 4% 
v/w paraformaldehyde (PFA) in 0.4M phosphate buffered saline (PBS), in a ratio of ͳ:ͳ to fix them, then ͳͲͲ μl was loaded into a Cytospin™ funnel attached to a standard microscope slide. The Cytospin™ centrifuge was run at ͺͲͲ RPM for ͷ mins depositing 
a thin-layer cell preparation on the microscope slide (figure 2.2A). The slides where 
then mounted with a small droplet of Vectasheild mounting medium with DAPI 
(Vector Laboratories, Peterborough, UK) and imaged with an x40 air objective on a 
Nikon eclipse 50i fluorescent microscope (217). DAPI was excited by a mercury bulb 
at 350 nm and emission was visualised via a DAPI emission filter at 470 nm (blue). 
Presence of urothelial cells with closely associated bacteria indicated that bacteria 
could be intracellular (figure 2.2B). Since DAPI can penetrate both eukaryotic and 
prokaryotic cells it was necessary to conduct a separate test to determine if the 





Figure 2.2: Image of cytospin setup and images of urothelial cells stained with DAPI and Acridine orange 
and crystal violet. A) Cytospin setup consisting of the metal holder, microscope slide, filter and funnel. Urine is 
pipetted into the top of the funnel and spun in a cytospin centrifuge. Cells are deposited through the filter holes on 
to the microscope slide. Excess liquid by the filter, which is discarded after use. B) DAPI stained urothelial cell 
with associated bacteria, which could be intracellular or extracellular. C) Acridine orange and crystal violet 
stained urothelial cell with intracellular bacteria indicated inside the red circle. 
 
    The subsequent procedure for staining urine was with acridine orange and crystal 
violet. Acridine orange binds to DNA and is able to penetrate eukaryotic cells and 
stain urothelial cell nuclei and all bacteria. Crystal violet however is not able to 
penetrate eukaryotes therefore would only stain extracellular bacteria by quenching 
the colour of the acridine orange from these particular cells (218).  Cytospin™ funnels 
were loaded with fresh urine without PFA and run at 800 RPM for 5 mins depositing a 
thin-layer of urothelial cells on the microscope slide (figure 2.2AȌ. Small DAKO™ pen 
circles were made around the cell preparations to allow the fluids to stay 
 





concentrated during the staining process. The slides were washed 3 times with Hanks 
balanced salt solution (Sigma Aldrich, Gillingham, UK) on a rocker for 5 mins each time. Acridine orange ȋͲ.ͷ%Ȍ ȋSigma Aldrich, Gillingham, UKȌ was prepared in Geyǯs 
balanced salt solution (Sigma Aldrich, Gillingham, UK). This stain was added to the 
slides and kept covered to protect from light for 25 mins on the rocker at room 
temperature. The slides were then washed 3 times for 5 mins with Hanks balanced 
salt solution to remove excess acridine orange. The final stain was 0.1% crystal violet 
(Sigma Aldrich, Gillingham, UK) in 0.15 M NaCl. This solution was left for 25 mins on 
the rocker followed by a final 3x 5 min washes with Hanks. The slides were mounted 
with Citifluor AF1 (Agar Scientific) and analysed with an x40 air objective on a Nikon 
eclipse 50i fluorescent microscope. Acridine orange bound to DNA was excited by a 
mercury bulb at 502nm and emission was visualised via a FITC emission filter at 
526nm (orange). One slide was prepared per patient and the presence or absence of 
intracellular bacteria was noted (qualitative) (figure 2.2C).  
2.1.3.2 STREAK PLATING AND ANTIBIOTIC PROTECTION ASSAY 
 Fresh urine (5 ml, if available), was centrifuged in a 15 ml falcon tube at 800 
RPM for 5 mins. The sediment was resuspended in ͳͲͲ μl Ͳ.ͳM PBS and ͷ μl was 
streak plated on 2 chocolate agar plates per patient sample (E&O Labs) with a sterile 
single-use plastic ͷ μl inoculation loop ȋBetter Equipped, Wrenbury, UK) as shown in 
figure 2.3.  
 
Figure 2.3:  Diagram of method used for streaking urine on agar plates. Centrifuged urine (5 μl) was 
transferred to the chocolate plate in section 1, this was streaked back and forth in section 1, and a new inoculation 
loop was used to streak from section 1 across into section 2 and repeated through to section 4. In each section the 
bacterial concentration is reduced allowing for individual colonies to be isolated from sections 3 and 4. 
70 
 
  One plate was placed in 5% CO2 at 37oC for 48 h and one was placed in a 2.5 l 
anaerobic jar with anaerogen (Fisher Scientific, Loughborough, UK) and anaerobic 
indicator, resazurin (Fisher Scientific, Loughborough, UK) and kept at 37oC for 7 days 
(figure 2.4). Anaerobic bacterial growth is slower than in bacterial growth in 5% CO2 
therefore the plates in anaerobic jars were left for longer to ensure growth was 
optimised.  
 For samples taken from Medway Maritime Hospital, Gillingham, Kent, UK an 
antibiotic protection assay protocol was designed in order to identify bacteria that 
were antibiotic resistant and intracellular. This protocol was adapted from Khasriya 
et al (137). In cases where an antibiotic protection assay was performed, the remaining resuspension was treated with ͹ͲͲ μl Minimum Essential Medium Eagle 
(Sigma Aldrich, Gillingham, UK) containing L-glutamine, 5% filtered fetal bovine 
serum (Life Technologies, Paisley, UK), 200 ng/ml Amoxicillin, 200 ng/ml Gentamicin 
and 200 ng/ml Linezolid (all Sigma Aldrich, Gillingham, UK) overnight in order to kill 
any extracellular bacteria (figure 2.4). (These antibiotics were chosen specifically 
since they have poor intracellular penetration would therefore be less likely to affect 
intracellular bacteria. The concentrations were optimised by Khashriya in his PhD 
thesis, University College London, UK (219). After 16 hours, this was spun down at 
800 RPM for 5 mins, the supernatant discarded and the pellet resuspended in the 
small amount of fluid remaining after centrifugation ȋapprox. ͳͲͲ μlȌ and from this 5 μl was streaked onto ʹ chocolate agar plates each using a sterile ͷ μl inoculation loop 
(figure 2.4). The antibiotics were then washed off by adding 5 ml 0.1M PBS to the 
falcon tube and centrifuging again. By performing a wash step, the antibiotics are 
removed and prevent any intracellular bacteria released in the following step from 
being killed by the antibiotics. The resuspended pellet was plated on 2 chocolate agar plates. Finally, ͳͷͲ μl Ͳ.Ͳͳ% Triton X-100 was added to the falcon and left for 5 mins 
at room temperature to lyse any urothelial cells and release intracellular bacteria. 
This was plated on 2 chocolate agar plates as detailed previously (figure 2.4). For 
each step, 1 plate was placed in 5% CO2 at 37oC for 48 hours and 1 was placed in a 2.5 
L anaerobic jar with anaeogen (Fisher Scientific, Loughborough, UK) and anaerobic 
indicator, resazurin (Fisher Scientific, Loughborough, UK) and kept at 37OC for 7 days. 
The number of intracellular bacterial CFU can be identified from the antibiotic 
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resistant ones by deducting the number of CFU from the third plating from the final 
plating (figure 2.4). 
 
Figure 2.4: Illustration of antibiotic protection assay protocol, adapted from Khasriya et al (137). 5 ml of 
urine is centrifuged and the sediment plated on 2 plates to culture planktonic bacteria. The remaining sediment 
has an antibiotic cocktail added consisting of 700 μl Modified essential medium eagle containing L-glutamine, 5% 
filtered fetal bovine serum, 200 ng/ml Amoxicillin, 200 ng/ml Gentamicin and 200 ng/ml Linezolid. After 16 
Hours this is plated a 2nd time on 2 plates to culture antibiotic resistant strains. The sediment is then washed with 
0.1 M PBS and plated a 3rd time to culture antibiotic resistant bacteria which may have remained stuck to 
urothelial cells. Finally the sediment is treated with 150μl 0.01% Triton X-100 and plated a 4th time to culture both 
antibiotic resistant and intracellular bacteria. For each step 1 plate is placed in CO2 and 1 in anaerobic conditions 
and incubated at 37oC for 48 hours and 7 days, respectively. 
 
2.1.3.3 PURITY PLATING 
   At the end of the respective growth periods, plates were checked for growth and all 
colonies were identified by their appearance, counted and purity plated on chocolate 
agar. Purity plating was performed by inoculating individual colonies with a sterile 
inoculation loop (Better Equipped, Wrenbury, UK) and streak plated as in figure 2.3 
on fresh chocolate plates. The purity plates were allowed to grow in 37OC for a 
further 48 hours/7 days in their respective environments. Once pure plates were 
obtained for each isolate, the isolates were Gram stained (discussed next), and the 
remaining bacterial growth from the purity plates was placed in cryogenic storage at -
80OC in 1.5ml Nunc® CryoTubes (Sigma Aldrich, Gillingham, UK) containing Brain 
Heart infusion broth (Sigma Aldrich, Gillingham, UK) and 10% Glycerol (Sigma 
Aldrich, Gillingham, UK) to prevent cell lysis during freezing.   
1st          2nd   3rd            4th  
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2.1.3.4 GRAM STAINING 
 A Gram staining kit was obtained from Sigma Aldrich, Gillingham, UK. A thin 
emulsion of bacteria mixed with sterile dH2O was prepared on a microscope slide then fixed by passing over a flaming Bunsen burner. Gramǯs crystal violet solution 
(100%) was flooded over the microscope slide and left for 1 min. Crystal violet enters 
the peptidoglycan layer of bacteria, of which there is more in Gram-positive bacteria. 
Excess crystal violet was then rinsed off with tap water and then the slide flooded with Gramǯs iodine for ͳ min to trap crystal violet in the peptidoglycan. The iodine 
was rinsed off with tap water and a few drops of 50% acetone, 50% ethanol 
decolourisation solution added for 3-4 seconds to remove crystal violet and iodine 
from the thinner layers of peptidoglycan found in Gram-negative bacteria. A counter stain of Gramǯs safranin was flooded over the slide for 1 min to stain Gram-negative 
bacteria and rinsed off with tap water and allowed to dry. Slides were covered with 
immersion oil (Sigma Aldrich, Gillingham, UK Aldrich), then a cover slip and a second 
drop of immersion oil. Bacteria were identified as Gram-positive (violet) or -negative 
(pink) as well as their shape (e.g. bacillus, coccus) using a standard light microscope 
with a x100 oil objective 
    In cases where the Gram stain was questionable, bacteria were regrown from 
cryopreservation and a fresh stain performed. If bacteria were particularly small, 
x100 focus was not sufficient to determine the exact shape of the bacteria. The Gram stain result for these isolates was noted as Ǯ)nconclusiveǯ 
2.1.3.5 IDENTIFICATION OF ISOLATES BY 16S RRNA GENE SEQUENCING 
 Isolates were identified by sequencing of the 16s rRNA gene. Isolates were 
revived from cryogenic storage by replating on chocolate agar. A small scraping of 
frozen crybroth containing the cryogenically preserved bacteria was taken from the 
CryoTubes with an inoculation loop and streaked onto chocolate plates and incubated 
in 37OC for a 48 hours in the environment in which the isolates were originally 
discovered (5% CO2 or anaerobic). Any isolates that had contaminated or 
unsuccessful regrowth were noted and later replated using more of the 
cryopreserved broth and more of the chocolate plate.  The initially colony description 
was referred to in order to identify the correct isolate in cases of contaminated 
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regrowth.  Where it was not possible to resuscitate the isolate, ǮFailed regrowthǯ was 
noted. 
    )f resuscitated culture was pure, a ͳ μl inoculation of each isolate was suspended in ͳͲͲμl sterile nuclease free water ȋThermo Scientific, Paisley, UKȌ in a PCR reaction 
tube and lysed using an Eppendorf Mastercycler™ ȋEppendorf, Stevenage, UKȌ set to 
94OC for 5 mins to extract genomic DNA. A polymerase chain reaction was set up for each isolate in a sterile PCR reaction tube. Each tube contained ͷ μl genomic DNA 
(bacterial lysate of unknown concentration), ͳʹ.ͷ μl Qͷ Polymerase Mastermix ȋNew England Biolabs, (itchin, UKȌ, ͳ.ʹͷ μl forward primer ȋDG͹ͶFwd - ͷǯ-AGG AGC TGA 
TCC AAC CGC A-͵ǯȌ, ͳ.ʹͷ μl reverse primer ȋRDRͲͺͲRev - ͷǯ-AAC TGG AGG AAG GTG 
GGG AC-͵ǯȌ ȋEurofins, Ebersberg, GermanyȌ and ͷ μl sterile nuclease free water 
(Thermo Scientific, Paisley, UK). Primers were chosen based on their correspondence 
to highly conserved areas in pathogenic bacteria (220). The reaction was run on an 
Eppendorf Mastercycler™ at the following temperatures and times based on the 
primer and gene size: - 1) 98OC for 30 seconds (denature), 2) 98OC for 10 seconds 
(denature), 3) 55OC for 20 seconds (anneal), 4) 72OC for 20 seconds (extend) [Steps 
2-4 repeated 37 times], 5) 72OC for 2 mins (final extension). An extra reaction was prepared using ͷ μl sterile nuclease free water instead of ͷ μl bacterial lysate to act as 
a negative control and another reaction containing E.coli lysate, which had previously 
been successfully identified by 16s rRNA gene sequencing, to act as a positive control. 
Each PCR product was checked for reaction success and purity by loading on a 1% 
agarose gel containing ethidium bromide (Fisher Scientific, Loughborough, UK) and 
running at 120V for 90 mins alongside the negative control and a 50 basepair ladder 
to determine band size. Successful PCR reactions were identified based on the 
presence of a band at the correct size for the 16s rRNA gene which is around 300 
basepairs (figure 2.5). Any PCR products that did not show a band at the correct size 
based on the 50kb ladder or had no band at all had PCR performed again using an 
alternative reverse primer (RW01 - 5'-AACTGGAGGAAGGTGGGGAT-3)(taken from the 
PhD of Alberto Conterez-Sanz, supervised by Scott Wildman at The Royal Veterinary 




Figure 2.5: Example of a gel image of successful PCR products with a 50 base pair ladder. Ladder is used to 
determine the size of bands in PCR products. A negative control with no bacterial lysate indicates that there is no 
contamination in the PCR reaction mastermix. A positive control using E.coli lysate shows how bands should be 
seen in successful PCR reactions. 
 
   Successful PCR reactions were purified using a PCR Purification Kit (Qiagen, 
Manchester, UKȌ. The ͳͷ μl of PCR product remaining after the gel electrophoresis is 
mixed with ͹ͷμl Buffer PB and transferred into a Q)Aquick spin column insert ȋfigure 
2.6) and centrifuged at 13,000 RPM for 45 seconds. At this stage, the DNA binds to the white filter of the column.  The flowthrough was discarded and ͹ͷͲ μl Buffer PE was 
added and centrifuged at 13,000 RMP for 45 seconds. This contains ethanol and acts 
as a washing step which removed excess dNTPs, buffers, polymerase and magnesium 
salts but kept the DNA bound in the filter. A second centrifugation step ensured all the 
Buffer PE had been removed from the column and the column insert was then 
transferred to a labelled Eppendorf tube™.  ͷͲμl Buffer EB was added to the column 
insert and left for 1-2 mins to allow the DNA to elute from the filter. A final 




Figure 2.6: Image of QIAquick spin column used to purify DNA from successful PCR reactions. DNA is bound 
in the filter of the column insert when mixed with buffer PB. A wash step keeps DNA in the filter and removes 
excess buffers, polymerase, nucleotides and magnesium into the receptacle of the spin column. A final step adding 
buffer EB to the column insert elutes DNA from the filter into an Eppendorf. 
 
   The concentration of each product was recorded using a Nanodrop 2000 (Thermo Scientific, Paisley, UKȌ and adjusted to ͷ ng/μl using sterile nuclease free water.  The purified PCR product ȋͳͷ μl, ͷ ng/μlȌ was added to a MixʹSeq tube ȋEurofins, 
Ebersberg, Germany GenomicsȌ with ʹ μl ͳͲ pM forward primer ȋused for the original 
PCR reaction) and sent to Eurofins Genomics, Ebersburg, Germany for Sanger 
sequencing. If the returned sequence was very short, consisting of only 5-10 
nucleotides, or had no bases at all ȋshown as ǮNNNǯȌ, a BLAST could not be performed. 
In these cases, the purified PCR product was run again on a gel in order to check that 
there was indeed a band of the correct size. If no band was seen, a PCR was run again, 
checked using gel electrophoresis, purified and sent for sequencing. If a band was 
seen the sample was sent again for sequencing with no further modifications. Most 
often, the sequencing would generate a usable sequence which could be BLASTed to 
determine a species ID, however if the sequencing had failed twice those isolates were noted as ǮFailed sequencingǯ.  A microbe genomic BLAST ȋBasic Local Alignment 
Search Tool, NCBI) was performed on the returned sequences and the microbial 
identity with the highest percentage genetic match with the lowest indent was taken 





     It was important to compare the observed Gram stain/shape of the sequenced 
isolates with the true Gram stain/shape of the bacterium proposed by BLAST. If the 
Gram stains were not concordant these isolates were omitted from the final comparisons and noted as Ǯnon-concordantǯ. 
2.1.4 ASSAYS ON FROZEN URINE  
 A variety of assays were performed on patient urine to analyse nucleosides e.g. 
ATP and two particular cytokines of interest: - IL-8, and MCP-1 alongside creatinine 
to standardise all the assays. 
2.1.4.2 CREATININE ASSAY  
   Creatinine is a breakdown product of creatine phosphate in the muscles and is 
normally produced at a constant rate. It is excreted through glomerular filtration of 
the kidneys into the ultra-filtrate which forms urine. Since water is excreted and 
reabsorbed in the kidneys, the concentration of creatinine can vary depending upon 
the quantity of urine produced. It is therefore necessary to standardise all of our 
assays to creatinine levels. A creatinine assay (R&D Systems, Abingdon, UK) was 
performed on all samples (each patient was done in duplicate) before the ELISA 
assays and luciferin/luciferase assay. In order to measure the creatinine 
concentration in urine, the samples first had to be defrosted and required a 20-fold 
dilution in dH2O. Following this, mixing 2.5 ml of NaOH with 12.5 ml of picric acid 
made an alkaline picrate solution. A standard of 100 mg/dl creatinine was initially 
diluted 1 in 5 to 20 mg/dl in dH2O then serially diluted 1 in 2 to 10 mg/dl, 5 mg/dl, ʹ.ͷ mg/dl, ͳ.ʹͷ mg/dl, Ͳ.͸ʹ mg/dl and Ͳ.͵ͳ mg/dl. ͷͲ μl of standard, control ȋd(2O onlyȌ, and prepared urine was plated out in triplicate. ͳͲͲ μl of the alkaline picrate 
solution was added to all wells and incubated for 35 mins at room temperature.  The 
light absorbance was measured on an Infinite M200 Pro set at 490 nm using Tecan i-
control software. Graphpad Prism 5.0a was used to create a standard curve 
constrained to go through zero (figure 2.7) and the concentration of creatinine 













Figure 2.7: Example of standard curve for creatinine. Standard curves were created in GraphPad Prism and 
then used to extrapolate concentrations of creatinine in urine samples from.  
 
2.1.4.2 LUCIFERIN/LUCIFERASE ASSAY  
 An adenosine ͷǯ-triphosphate (ATP) Bioluminescent Assay kit was purchased 
from Sigma Aldrich, Gillingham, UK. Standards of ATP were prepared by performing a 
10 fold serial dilution of stock 10-2 M of ATP to give 10-3, 10-4, 10-5, 10-6, 10-7, 10-8 M. )nto a white ͻ͸ well plate ͷͲμl of Ͳ.ͲͳM PBS was added into each of the required wells. ͳ μl of the ͳͲ-3 M standard was added into the first 3 wells. This gave a 
concentration of 2x10-5 M. The same was performed for the other standards as shown 
in figure 2.8 below and a negative control of just 0.01M PBS was included at the bottom. ͳμl of urine was added into the other wells in triplicate.  ATP is rapidly 
degraded by freeze-thaw cycles and therefore these were avoided for all urine 
samples.  
 




















Figure 2.8: Diagram of ATP standard concentrations in Luciferin/luciferase assay. Areas where standards 
were added to a white 96 well plate in triplicate and the respective concentrations at the side (RED) and the wells 
used for measuring the concentration of ATP in patient urine samples (BLUE) 
 
   The ATP Assay Mix (FLAAM) and ATP Assay Mix Diluent (FLAAB) were mixed fresh 
for each assay. Firstly, the required volume for the total number of wells was 
calculated; - FLAAB and FLAAM were added together in a ratio of ʹͷ:ͳ therefore ͸Ͳ μl FLAAM was added to ͳͶͶͲ μl FLAAB. The reaction mixture was protected from light 
pollution since luciferin is rapidly degraded by light. The final mixture ȋͷͲ μlȌ was 
added to each well and the luminescence was read immediately on a BioTek Plate 
Reader with Gen 5 software. Graphpad prism 5.0a was used to create a standard 
curve (figure 2.9) and the concentration of ATP extrapolated for each patient urine 
sample. These values were divided by the creatinine concentration for each patient in 








Figure 2.9: Example of standard curve for ATP. Standard curves were created in GraphPad Prism and then used 
to extrapolate concentrations of creatinine in urine samples from.  





















2.1.4.3 ELISA ASSAYS  
 ELISA assays were performed on samples of urine from individuals with OAB 
and asymptomatic controls to measure the concentration of IL-8 and MCP-1 in the 
urine.  
    For the IL-8 ELISA (Invitrogen, Paisley, UK), the standard was first reconstituted to 
10 ng/ml with standard diluent buffer which was then diluted 10-fold in standard 
diluent buffer to create an initial standard concentration of 1000 pg/ml. This was 
followed with 2-fold serial dilutions in standard diluent buffer to generate 
concentrations of 500 pg/ml, 250 pg/ml, 125 pg/ml, 62.5 pg/ml, 31.2 pg/ml and 15.6 
pg/ml.  Standard diluent buffer with no IL-8 standard added acted as a negative 
control.  Urine samples were defrosted from -20oC storage and ͷͲ μl was added to the 
relevant wells. The IL-ͺ standards ȋͷͲ μlȌ were also added to the relevant wells. )L-8 
binds to anti-IL-8 antibodies bound to the bottom of the wells. This was followed by ͷͲ μl of biotinylated anti-IL-8 solution and then left at room temperature for 90 mins. 
The anti-IL-8 solution contains anti-IL-8 antibodies that bind to the IL-8 in a 
sandwich (figure 2.10). After the incubation time, all the liquid was decanted from the 
wells and washed 4 times with working wash buffer (25x wash buffer diluted 25-fold 
in dH2O). Any unbound anti-IL-8 solution was discarded in this step.  After washing ͳͲͲ μl of streptavidin-horse radish peroxidase ȋ(RPȌ working solution ȋͳͲ μl of ͳͲͲx 
concentrated solution with 1 ml streptavidin-HRP diluent) was added to each well 
and incubated at room temperature for 30 mins. In this step, the presence of anti-IL-8 
antibodies allowed the streptavidin to bind to it, which only occurs in the presence of 
IL-8. Post-incubation, the wells were decanted and washed 4 times as previous. The final step was to add ͳͲͲ μl of stabilised chromogen to each well. Chromogen turns 
blue in the presence of HRP. With higher concentrations of IL-8, there was a higher 
concentrations of HRP and therefore a deeper blue colour. After ͵Ͳ mins, ͳͲͲ μl of 
stop solution was added to each well. This turns the blue solution to yellow. The light 
absorbance of the wells was measured using a BioTek Plate Reader set at 450nm with 
Gen 5 software. Prism 5.0a was used to create a standard curve (figure 2.10) and the 
concentration of IL-8 extrapolated using Graphpad prism for each patient urine 
sample. These values were divided by the creatinine concentration for each patient in 
order to standardise the results. 
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   For the MCP-1 ELISA (Life Technologies, Paisley, UK), the standard was first 
reconstituted to 10,000 pg/ml with standard diluent buffer which was then diluted 
10-fold in standard diluent buffer to create an initial standard concentration of 1000 
pg/ml. This was followed by a 2-fold serial dilution using standard diluent buffer to 
generate working concentrations of 500 pg/ml, 250 pg/ml, 125 pg/ml, 62.5 pg/ml, 
31.2 pg/ml and 15.6 pg/ml.  Standard diluent buffer with no MCP-1 standard added 
acted as a negative control. Samples were defrosted and diluted 4-fold in standard diluent buffer ȋͷͲ μl urine in ͳͷͲ μl bufferȌ. )ncubation buffer ȋͷͲ μlȌ was added to all required wells followed by ͷͲ μl of standard and prepared samples in triplicate. On top of this ͷͲ μl of human MCP-1 biotin conjugate was added to each well except to 
the chromogen blanks. The plate was left to incubate at room temperature for 2 
hours. MCP-1 binds to anti-MCP-1 antibodies bound to the bottom of the wells. The 
MCP-1 biotin conjugate solution contained anti-MCP-1 antibodies that bind to the 
MCP-1 in a sandwich (figure 2.10). After the incubation time, all the liquid was 
decanted from the wells and washed 4 times with working wash buffer (25x wash 
buffer diluted 25-fold in dH2O). Any unbound MCP-1 biotin conjugate solution is discarded in this step.  After washing ͳͲͲ μl of streptavidin-horse radish peroxidase ȋ(RPȌ working solution ȋͳͲ μl of ͳͲͲx concentrated solution with ͳml streptavidin-
HRP diluent) was added to each well except the chromogen blanks and incubated at 
room temperature for 30 mins. In this step, the presence of MCP-1 biotin antibodies 
allows the streptavidin to bind to it, which will only occur in the presence of MCP-1. 
Post-incubation, the wells were decanted and washed 4 times as previous. The final 
step was to add ͳͲͲμl of stabilised chromogen to each well and incubated for 30 mins 
at room temperature in the dark. Chromogen turns blue in the presence of HRP. With 
higher concentrations of MCP-1, there will be higher concentrations of HRP and therefore a deeper blue colour. After ͵Ͳ mins, ͳͲͲ μl of stop solution is added to each 
well. This turns the blue solution to yellow. The light absorbance of the wells was 
measured using a BioTek Plate Reader set at 450 nm with Gen 5 software. Graphpad 
prism 5.0a was used to create a standard curve (figure 2.10) and the concentration of 
MCP-1 extrapolated using Graphpad prism for each patient urine sample. These 
values were divided by the creatinine concentration for each patient in order to 











Figure 2.10: Example of standard curve for IL-8 and MCP-1. Standard curves were created in GraphPad Prism 
and then used to extrapolate concentrations of creatinine in urine samples from.  
 
2.1.5 BLADDER BIOPSIES  
 Bladder biopsies were taken from patients with pure OAB as diagnosed by the 
ICIQ-FLUTS long form (appendix 1.3) attending the Sunderland Day Care Centre at 
Medway Maritime Hospital for a cystodistension clinical trial (214). The patients 
were asked if they would be willing to provide a CSU sample and biopsies of bladder 
for research purposes during their cystodistension. Patients were given a general 
anaesthetic and the samples taken prior to the cystodistention. A total of 4 biopsies 
were taken per patient; 2 were sent to hospital pathology for clinical diagnosis and 2 
were provided to the university for either bacterial culture or electron microscopy, 
the details of which are described in the following sections. Biopsies were collected from the hospital and transported back to the university in Eppendorf tubes™ 
containing a sterile saline solution provided by the hospital on ice.  
2.1.5.1 BACTERIAL CULTURE FROM BLADDER BIOPSIES 
 The antibiotic protection assay was performed on the biopsies as discussed 
previously, however prior to this the biopsies had to be broken up. The Eppendorf tubes™ containing the biopsies were shaken and gently vortexed to detach bacteria 
and urothelial cells then the protocol for the antibiotic protection assay was followed 
(details in section 2.1.3.2 – Antibiotic Protection Assay), followed by purity plating, 



















Gram staining and identification of isolates by 16s rRNA gene sequencing as 
discussed in section 2.1.3.5 - Identification of isolates by 16s rRNA gene sequencing. 
2.1.5.2 ELECTRON MICROSCOPY ON BLADDER BIOPSIES 
 Some biopsies were used for imaging using TEM to look for intracellular 
bacteria (111). The biopsies were immediately placed in gluteraldehyde overnight to 
fix them. They were then washed 3 times in 0.01M PBS to remove the gluteraldehyde. 
Each biopsy was transferred into a 7 ml glass vial and submerged in a 4% stock 
osmium tetroxide (OsO4, Sigma Aldrich, Gillingham, UK) in water (4 ml H2O, 2 ml 
OsO4, 4 ml 2x PBS) and left for 1 hour at room temperature in order to stain the 
biopsies to provide contrast for imaging. After this incubation time, the OsO4 was 
washed off with dH2O (x2) for 5-10 mins each time. Then the biopsies were further 
fixed by incubation at room temperature in a series of increasing concentrations of 
ethanol:- 30% for 10 mins, 50% for 10 mins, 70% overnight, 100% for 10 mins (x2). 
The biopsies were next transferred to propylene oxide (Sigma Aldrich, Gillingham, 
UK) for 15 mins (x2) to further dehydrate them then a 50:50 solution of propylene 
oxide mixed with epoxy embedding medium (Sigma Aldrich, Gillingham, UK) for 30 
mins to gradually infiltrate the embedding medium. This was then followed by 30 
mins in pure epoxy embedding medium (x2) assuming orientation of the biopsy 
within. The embedded biopsies were transferred to foil embedding capsules to retain 
the shape and stored in a 60OC oven for 24 hours to harden the resin. 
   )n order to cut the embedded biopsy into Ͳ.ͷ μm thin slices, a glass knife was 
prepared by cutting a fine edge into a small square of glass. The edge was then used 
to form a boat with silver tape (figure 2.11A). The sample was placed in a chuck of a 
microtome slicer and the resin was then trimmed to size before thin Ͳ.ͷμm slices 
were captured in the boat of the glass slicer and transferred to a coverslip. Each slice 
was then air dried and stained with 1% toluidine blue to stain for individual 
structures in the cells. These slices were then transferred to gold holders (figure 
2.11B) to be inserted into the electron microscope. Images were obtained of potential 





Figure 2.11: Diagram of microtome used to slice biopsy and holders used to mount slices for TEM.  A) 
Diagram showing how glass cut at a 45o angle is used to cut resin bound bladder biopsies. The biopsy is held in the chuck of a microtome which moves downwards cutting Ͳ.ͷμm thick slices on the glass. The slices are collected in a 
boat created by looping silver tape around the glass block. B) An example of the 3mm diameter gold holders used 
to mount the toluidine blue stained slices for imaging in the electron microscope. 
 
2.2 BLADDER PERICYTE OBSERVATION AND FUNCTIONAL EXPERIMENTS  
2.2.1 TISSUE PREPARATION 
 Physiological saline solution (PSS) was prepared fresh prior to each 
experiment containing: - 100mM NaCl, 5mM KCl, 0.24mM NaH2PO4, 0.96mM 
Na2HPO4, 10mM Na acetate, 1mM CaCl2, 1.2mM MgSO4, 5mM glucose, 25mM NaHCO3, 
and 5mM Na pyruvate (all Sigma Aldrich, Gillingham, UK) as suggested by Crawford et 
al for ex vivo observations of kidney slices (52). This was bubbled with 95% O2/5% 
CO2 to conserve tissue viability. pH was adjusted to 7.4 with 10M NaOH and 
maintained via the bicarbonate buffering system by presence of HCO3, H2CO3 and CO2. 
    9 week old male JAX C57/Black 6 mice of an average weight of 21-26 g (Charles 
River UK Ltd, Kent, UK) were culled by cervical dislocation in accordance with the 
Animals Scientific Procedures Act of 1986. The bladder was immediately removed 
and placed in PSS bubbled with 95% O2/5% CO2. The bladder was then transferred to 
a petri dish containing fresh PSS, also being bubbled with 95% O2/5% CO2, under a 
dissection scope and the urothelium was carefully removed using forceps, tweezers 
A)          B) 
84 
 
and a fine bristle brush. The urothelium was either used for functional experiments, 
or stained with fluorescent antibodies for tissue viability and pericyte location 
(described in the respective sections below). 
2.2.2 TISSUE VIABILITY 
 Live mouse urothelium was prepared as described in previous section and 
placed in Nunc® tissues culture dishes (Fisher Scientific, Loughborough, UK) before 
being treated with propidium iodide (Thermo Fisher, Paisley, UK) and DAPI for dead 
cells and all cells, respectively as performed by Crawford et al on rat kidney slices 
(52). The bladder urothelium was cut into four sections and incubated in PSS being 
aerated with 95% O2/5% CO2 before being stained for cell viability for each of the 
following time points: - 15 mins, 30 mins, 1 hour and 2 hours. Post incubation, the tissue was stained with ͷ μM propidium iodide (PI) (Sigma Aldrich, Gillingham, UK 
Aldrich) for 15 mins. PI is taken up by cells with compromised cell membranes and is 
therefore used to stain for nuclei of dead cells. 3 x 10 min washing steps with PSS 
followed to remove excess PI then a 15 min fixing step using 4% v/w 
paraformaldehyde (PFA) made up in 0.4M PBS. After this step, oxygenated PSS was 
no longer required. 3 more washing steps followed using PBS to remove excess PFA.  
The fixed tissue was then mounted on to microscope slides with Vectasheild 
mounting medium containing DAPI (Vector Laboratories, Peterborough, UK) to stain 
for nuclei of all cells, both live and dead and covered with a coverslip. Slides were 
analysed using an x40 air objective on a Nikon eclipse 50i fluorescent microscope. 
DAPI was excited with a mercury bulb at 350nm and emission visualised via a DAPI 
emission filter at 470nm (blue). PI was excited at 536nm and emission visualised via 
a Texas Red emission filter at 617nm (red). Separate images were taken using both 
filters and then overlapped using Image J software. Cells were counted manually per 
image using the Image J cell counter plug-in. By counting the number of DAPI stained 
cells (figure 2.12A) and PI stained cells ȋfigure ʹ.ͳʹBȌ in a field per view ȋʹʹͲ μm x ͳ͸ͷ μmȌ it was possible to obtain a ratio of live to dead cells for each time point by 
the following equation: - 






Figure 2.12: Cell counting method for staining with DAPI and propidium iodide. A) DAPI cell count example 
for tissue left in physiological saline for 15 mins indicates 218 total cells. B) Propidium iodide cell count example 
for tissue left in physiological saline for 15 mins indicates 179 dead cells. Therefore (218-179/218) x 100% = 
17.9% live cells. 
 
2.2.3 IMMUNOHISTOCHEMISTRY NG2/IB4 
 Mouse urothelium was prepared as previously described and placed in Nunc® tissues culture dishes ȋFisher Scientific, Loughborough, UKȌ with ͵ͲͲ μl PSS. All subsequent incubations were performed at a volume of ͵ͲͲμl. Each slice was pre-
incubated at room temperature for 4 h with 10 ng/ml TNF-Ƚ, ͳͲ ng/ml of )L-ͳȾ or 
50ng/ml of LPS (R&D Systems, Abingdon, UK) or PSS alone (to act as a control) in 
order to stimulate pericytes prior to immunohistochemistry (52). After the 4 h incubation ͷͲμg/ml Alexa-488 conjugated isolectin B4 (IB4) was added to the wells to 
stain for perivascular cells, made up in PSS for 45 mins. After this initial staining, the 
tissue was washed by incubating slices in normal PSS bubbles in a chamber with 95% 
O2/5% CO2 for 15 mins. Tissue was then fixed with 4% paraformaldehyde prepared 
in 0.4 M PBS by incubating for 15 mins. After this step, oxygenated PSS is no longer 
required. Paraformaldehyde is washed off in PBS 3 times for 10 mins each time. Next 
the tissue is permeabilised using 0.1% Triton X-100 (in 0.1M PBS) for 10 mins on a 
rocker table at room temperature. Tissue was then blocked with 10% serum made in 
0.1% triton X-100 solution for 2 hours on the rocker table at room temperature. 
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Blocking prevents non-specific binding of donkey-raised secondary antibodies added 
later. The primary antibody was rabbit anti-neuro-glial 2 (NG2), to stain for pericytes, 
made up to 1mg/ml in 10% donkey serum/0.1% Triton X-100. Tissue was incubated 
in the fridge overnight with this antibody mixture. The following day, after 3x 10 min 
washes in 0.1M PBS, the donkey anti-rabbit Alexa 555 (secondary antibody) was 
prepared in 10% Donkey serum/0.1% Triton X-100 and the tissue incubated in the 
solution for 2 hours. 3 final wash steps with PBS followed and then using Citifluor 
AF1 (Agar Scientific) tissue was mounted on glass slides and sealed with coverslips 
and nail varnish.  
   The tissue was analysed using an upright Nikon eclipse 50i fluorescent microscope 
with x40 air objective.  Alexa-488 was excited with a mercury bulb at 488nm and 
emission was captured using a XXX emission filter at 520nm (green). Alexa-555 was 
excited with a mercury bulb at 555nm and emission was captured using a XXX 
emission filter at 580nm (red). Multiple images were taken and later analysed using 
Image J software. The distance between pericytes was measured in control 
urothelium and compared to those in urothelium pre-treated with cytokines and LPS. 
The mean number of pericytes on a length of capillary was calculated and compared 
to that of urothelium pre-treated with cytokines and LPS.  
2.2.4 DIC IMAGING OF LIVE TISSUE 
 For experiments in which pericyte-mediate changes in capillary diameter were 
recorded in response to chemical stimuli (52), bladder urothelium was dissected as 
discussed in section 2.2.1 – Tissue preparation. The urothelium was mounted with the 
superficial urothelium facing upwards on a bath and secured with a harp made of 
platinum and nylon threads (figure 2.13A). This assembly was then transferred to the 
stage of an upright Olympus BX51WI microscope and continually superfused with 
oxygenated PSS using a Watson Marlow 120S peristaltic pump at a rate of ~2.5 ml 
min-1 (1.5 ml dish volume) (figure 2.13B). Capillaries with both pericyte and non-
pericyte sites were identified and DIC images were captured using an Olympus x60 
water immersion objective, an attached Rolera XR CCD camera (QImaging, Surrey, 
Canada) and Image Pro Plus 7.0 software (Media Cybernetics, Cambridge, UK). 
Multiple DIC images were taken at 1 frame per second for a total of 1200 frames to 





Figure 2.13: Images of mouse bladder urothelium under harp during DIC imaging. A) Half a mouse bladder 
urothelial layer held in place in a bath with a platinum and nylon harp, B) The urothelium in the bath with the 
harp placed under a x60 water objective being superfused with PSS oxygenated with 95% O2/5% CO2. Vasoactive 
drugs were also superfused across the tissue using this set up. 
 
     A number of experiments were performed using a range of vasoactive drugs, at 
varying concentrations, to determine pericyte activity in the bladder. In each case, 
baseline images were taken during superfusion with PSS and then the drug was 
added and the changes recorded in video format. The following drugs were used to 
evoke vasoconstriction: 1 nM, 10 nM and 100 nM angiotensin-II (Ang-II), and 10 mM 
and 1 mM ATP. The following drugs were used to evoke vasodilation: NO donor, 100 μM S-nitro-N-acetyl-D, L-penicillamine ȋSNAPȌ, ͳͲͲ μM and ͳͲ μM sodium 
nitroprusside (SNP) and 100 nM, 50 nM, 10 nM and 1 nM Bradykinin.  All drugs were 
purchased from Sigma Aldrich, Gillingham, UK and prepared into stock aliquots as per 
the data sheets provided. When required, working concentrations were prepared in 
oxygenated PSS.  
    Analysis of video images was performed offline using Image J software. Straight-
line measurements were taken from one side of the inner capillary wall to the other 
at both pericyte and non-pericyte sites for each experiment. The length of these lines was measured in pixels and translated into μm ȋͶ͹ pixels converts to ͳͲμmȌ, and 
repeated every 5 frames for the duration of the video. Resting baseline measurements 
were taken at the start of each experiment for approximately 100 seconds. These 
A)            B) 
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measurements acted as the baseline diameter for each capillary; expressed as 100% 
diameter. All subsequent measurements were calculated and expressed as a 
percentage change from this baseline value as seen in the equations below. Data were 
compared using a paired Student T-test and unpaired T-test where applicable. 
 





 A chi-squared test was used to compare incidence of one species of bacteria, 
incidence of intracellular bacteria, incidence of Gram negative bacteria, or incidence 
of positive culture between disease state and controls in each of the studies. This was 
done by first creating a 2x2 contingency table of incidence of bacteria versus no 
incidence. For example, if 45 of disease state patients (n=60) and 20 of control 
patients (n=50) cultured positive for Staphylococcus the contingency table below 
would be generated (table 2.1). From this a chi-squared test is performed by 
inputting the data into GraphPad prism to determine a p value for the difference in 





Table 2.1 Example of 2x2 contingency table for Chi squared test.  
 
   An unpaired Studentǯs T test (or a one way ANOVA where applicable) was 
performed to compare ages, BMIs, mean number of species, pH and concentrations of 
ATP and IL-8, between disease state and controls. This test was also used to compare 
the distance between pericytes post-incubation with drugs in immunohistochemistry 
experiments. 
    A paired Studentǯs T test was performed to compare capillary distance pre- and 
post- drug application in DIC imaging experiments.  
    P<0.05 was considered as statistically significant for all tests. Sample size (n) 
represents 1 patient (unless otherwise stated as 1 sample in the case of multiple 
samples per patient) or 1 pericyte in 1 mouse. 
 
 Staphylococcus No Staphylococcus  
Disease state 45 15 60 
Control 20 30 50 
 65 45  
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CHAPTER 3 – RESULTS 1: 
PREDICTING RUTIS POST-RENAL TRANSPLANT 
3.1 INTRODUCTION 
 As discussed in the General Introduction, renal transplant recipients are 
particularly predisposed to rUTI due to their post-transplant care management 
scheme, which includes immunosuppresants and antibiotics, which allows for 
opportunistic infections and antibiotic resistant species to thrive. In this chapter, we 
will investigate the species of interest in our cohort of patients and whether 
intracellular bacteria could be a niche for rUTIs in RTRs in order to better understand 
how a bacterial infection manifests itself and how these patients develop recurrent 
infections despite being on antibiotics. 
3.1.1 SPECIES OF INTEREST IN UTI IN RENAL TRANSPLANTATION 
Reported prevalence of UTI incidence in RTR varies greatly between 23% and 
75% depending on the study, but this is most likely due to the variation in criterion 
for diagnosing infection and intensity of antibiotic and immunosuppressant 
treatment. The largest study to date analysed medical reports from the US Renal Data 
System database where Medicare were the primary source of medical insurance for 
renal transplants; a total of 23,924 RTR records were analysed (120). It emerged that 
within the first year post-transplant 17% of both men and women developed a UTI, 
increasing to 60% of women and 47% of men within 3 years (120). A later study by 
Pelle et al in 2007 found 75.1 % of RTRs (n=177) develop an early UTI within the first 
6 months and 18.7% develop acute pyelonephritis (APN) (122). This is significantly 
higher than the previous study, however does highlight that UTI can be extremely 
common in RTRs. Also from the Pelle study it was found that the highest prevalence 
of first UTI was caused by E.coli (28.4%) followed by Enterococcus spp. (23.6%) then 
Pseudomonas aeruginosa (14.9%) and Staphylococcus non-aureus (11.5%)(122). 
Other studies, (summarised in Table 3.1), have found very different percentages of 
causative species of UTI. For example, one study by Valera et al found that 71% of 
infections were caused by E.coli (222), whereas the study by Chuang et al found only 
29% of infections to be caused by this pathogen (223). It can be seen however that 
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the predominant species across all studies are E.coli, Enterococcus, Pseudomonas 
aeruginosa, and Klebsiella (table 3.1). A systematic review on this area by 
Parasuraman et al has cumulated the percentages from Chuang, Pelle, Memikoglu and 
Di Cocco to determine an overall view of the microbiology of UTIs in RTRs 
summarised at the bottom of table 3.1 (121). 
 
Table 3.1: Studies characterizing predominant species causing UTI in renal transplant recipients (RTR): 
Each study has similar patient numbers ranging from 136 to 500 RTRs however there are significant differences 
between the predominant species causing UTIs in each study. E.coli has been found in one study to be the cause of 
71% of UTIs (Valera et al) but only 29% in another (Chuang et al). Overall, the four main causes of UTI in RTRs are 
E.coli, Enterococcus, Pseudomonas aeruginosa, and Klebsiella. 
 
3.1.2 PREDISPOSING FACTORS FOR UTI POST-RENAL TRANSPLANT Pelleǯs ʹͲͲ͹ study also analysed correlations between UT) and APN incidence and 
a number of other clinical features to identify predisposing factors for infection in 
RTRs (discussed next) (122). They found that the risk of developing APN was higher 
in women (64%) than men (36%) and correlated strongly with frequency of episodes 
of acute rejection. Furthermore, they suggested that the intensity of immunotherapy 
may be a cause for rapid onset of APN, although other investigations have concluded 
Study Patient 
numbers 
Majority Taxa of UTIs in RTRs 
Chuang et al, 2005 (223) n = 500 
29% E.coli, 
24% Enterococcus 
Valera et al, 2006 (222) n = 161 
71% Enterococcus, 
10% Pseudomonas aeruginosa 
Dantas et al, 2006 (224) n = 163 
30.4% Enterobacter, 
13.4 % Pseudomonas aeruginosa 
Pelle et al, 2006 (122) n = 177 
28.4% E.coli,  
23.6 % Enterococcus spp. 
Memikoglu et al, 2007 (225) n = 136 
59.1% E.coli,  
16.9% Klebsiella spp. 
Di Cocco et al, 2008 (226) n = 218 
66.3% E.coli, 
10.1% Enterococcus Gołębiewska et al, 2014 (227) n = 209 58% E.coli, 
36% Enterococcus spp. 
Parasuraman et al 2013 (121) 
(Systemic review of Chuang, Pelle, 
Memikoglu, and Di Cocco) 
n = 1,519 
34.5% E.coli, 
19.5% Enterococcus 
12.5% Pseudomonas aeruginosa 
9.5% Staphylococcus spp. 
9% Klebsiella spp. 
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dose is not a relevant factor in UTI incidence (122). Together these strong 
correlations suggest that there is no direct precursor for increased incidence of rUTI 
in RTRs but rather there could be a multitude of risk factors of varying influence. The 
fore mentioned systematic review by Parasuraman also generated odds ratios (OR) 
for various risk factors where ORs of greater than 1 represent true risk (121) Risk 
factors for UTI and their ORs which are notably greater than 1 were being female (OR 
5.8), obtaining a kidney from a deceased donor (OR 3.64), and increased 
immunosuppression dose (OR 17.04). Increased immunosuppression dose is 
proposed here as the main determinant of UTI incidence and is calculated from a 
review of 7 publications in the field and is therefore likely to be more reliable than 
individual studies. Interestingly, risk factors for UTI and their ORs also found women 
to be at greater risk (OR 5.14) and those with increased frequency of acute rejection episodes ȋOR ͵.ͺͶȌ, which correlates with Pelleǯs finding (122). Other factors include 
inclusion of stents post-operation, which increases the likelihood of biofilm formation 
(discussed in section 1.5.4 Bacteriuria in overactive bladder), since stents offer an 
ideal growth surface for biofilm forming bacteria such as Proteus and UPEC. For this 
reason they are removed as soon as possible, after 6 weeks. Fayek et al reported that 
presence of a stent increased incidence of UTI to 14.2% compared to incidence with 
no stent at only 7.9% (228). Furthermore, there are insensitivities with the other 
tests involved in monitoring RTRs discussed in the next section, 
3.1.3 UNREPORTED ROUTINE URINALYSIS 
As mentioned in the section 1.5.3 Diagnosis of UTIs, many diagnostic 
laboratories diagnose UTIs when a patient has 104-5 colony forming units (CFU) of a 
single organism or 105 CFU/ml mixed growth with one predominant organism when 
plating midstream urine (128). Despite the Infectious Diseases Society of America 
(IDSA) and the European Association of Urology (EAU) revising the guidelines to 
include a cut-off of 102 CFU/ml for the diagnosis of bacterial cystitis (229), most 
laboratories still follow Kassǯs criterion interpreting urine culture with <ͳͲ5 CFU/ml 
as probable absence of infection (129). For this reason, many potentially dangerous 
opportunistic infections could go unreported in RTRs. By reducing the threshold, risk 
of rejection can be minimised by catching opportunistic infections early before they 
cause physical damage and stimulation of immune attack of the graft. 
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   Another difficulty with current urinalysis techniques is that they often miss the low-
grade inflammation associated with low-level bacteriuria. Even though dipstick 
leukocyte esterase has been validated against the higher threshold of 105 CFU/ml, the 
readings can very often be incorrect. Leukocyte esterase is released from neutrophils 
during localised inflammation whereby a positive result would indicate pyuria 
associated with an infection. Unfortunately, false positive results can occur in women 
when samples are contaminated with vaginal discharge. Elevated glucose or oxalic 
acid in the urine may also reduce efficacy of the dipstick reading (230). Furthermore, 
in the clinical laboratory, counting the numbers of white blood cells (WBC) in unspun 
urine either by automated cell counting or my microscopic methods has been 
discredited as a marker for UTI since WBCs die rapidly post-voidance and positive 
results do not always correlated with infection (215). Since pyuria is used in many 
hospital pathology labs to determine if a patient has a possible UTI, many infections 
could be going unreported if culture is not performed on samples due to negative 
pyuria and no symptoms. 
   Many quiescent bacteria also go unreported as they are often classified as 
contaminants at low-level when detected in a mixed culture (129). The concept of a 
bladder microbiome introduces the idea that opportunistic bacteria may already be 
residing in the bladder and use of immunosuppressants and antibiotics allows them 
to develop into infections. Antibiotics can target particular genus of bacteria and not 
others allowing the non-susceptible species to grow opportunistically and the use of 
immunosuppresants reduces the immune systemǯs efficacy at dealing with alterations 
in bacterial growths (i.e. infections). Furthermore, certain quiescent bacteria living in 
the bladder urothelium may be able to form intracellular bacterial communities, 
which can make identifying potential infections harder (as discussed in section 1.5.2.4 
- Intracellular bacterial communities in OAB) (111, 144, 145, 153). 
3.1.4 INTRACELLULAR BACTERIAL COMMUNITIES POST-RENAL TRANSPLANT 
Kelley et al have previously discovered that 44% of MSU samples taken from 
53 RTRs within the first 2-4 weeks post-transplantation and before stent removal 
presented with intracellular bacteria within shed urothelial cells (153). However, 
only one of these patients was diagnosed with a UTI by routine microbiological 
culture (see Appendix 1.2 - MSU and CSU culture interpretation, EKHU NHS Foundation 
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Trust, 2015). This suggests that intracellular bacteria may be an underlying cause for 
rUTIs since their life cycles involve invasion and replication followed by efflux to 
naïve nearby host cells. This cycle creates a niche of bacteria that are able to evade 
antibiotics and immune responses and may be responsible for the recurrence 
observed in these patients (111, 144). From this discovery, a grant proposal was 
drafted by Medway School of Pharmacy Urinary System Physiology Unit in 
collaboration with Canterbury and East Kent NHS Renal Unit and accepted by Kidney 
Research UK. The grant was based on the hypothesis that quiescent bacteria residing 
intracellularly in the bladder urothelium are responsible for the rUTI and sub-clinical 
UTIs experienced by patients post-renal transplant. The following chapter is based on 
the data generated from the aims and methods outlined within that grant proposal. 
3.2 HYPOTHESIS AND AIMS 
We hypothesise that intracellular bacteria in the bladder urothelium are responsible 
for many of the rUTI experienced by patients post-renal transplant. 
In order to begin to test these hypotheses the following objectives will be to:- 
1. Investigate alterations in bladder bacterial species of interest over a period 
of 6 months post-transplant compared to baseline controls. 
2. Observe intracellular bacteria in shed urothelial cells and compare to 
incidence of low-level infection to determine whether intracellular bacteria 
could be a predictor for rUTI. 
3. Analyse and compare all clinical and biological information from RTRs and 
controls to determine if there is any potential for development of improved 





 Renal transplants were performed at Guyǯs (ospital London, UK. Collection of 
clinical data, including patient age, BMI, form completion and urine collection was 
performed by clinical staff and clinicians at Kent and Canterbury Hospital, Kent, UK. 
Dipstick urinalysis and Sternheimer-Malbin analysis was performed by myself and 
the research nurses at Kent and Canterbury Hospital. Hospital pathology was 
performed by clinical staff in the pathology department at William Harvey Hospital, 
Ashford, UK. University culture, sequencing and analysis was performed by myself. 
3.3.2 ETHICS 
 Ethical approval for this research was granted by NHS Health Research 
Authority committee for South East Coast, Kent. All participants were over the age of 
18, fully briefed and consented before being recruited into the study.  
3.3.3 PATIENT SAMPLE COLLECTION 
 This was a prospective cohort study, which analysed mid-stream urine 
samples obtained one month, three months, and six months after transplantation 
from RTRs.  Most patients received renal transplant surgery at Guyǯs (ospital, London 
and attended the renal outpatients department of Kent and Canterbury Hospital for 
monitoring. All patients were prescribed co-trimoxazole 80/400 mg tablets (80 mg 
Trimethoprim and 400 mg Sulfamethoxazole) for 12 months post-transplant as a 
prophylactic for opportunistic infections. Upon being consented, patients were 
invited to provide 3 mid-stream samples of urine at each time point after 
transplantation; 1 month, 3 months and 6 months. On each visit they also completed a 
questionnaire designed by East Kent Hospital University to obtain a symptoms score 
and determine impact on life (see Appendix 1.1 – Diagnosing urine infection in kidney 
transplant patients, EKHFT, 2015). Mid-stream urine samples were also taken from 
the kidney donors before donation, which acted as the control group. This study was 
blinded by non-disclosure of the origin of each sample until after the isolated bacteria 
were identified.  
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3.3.4 ROUTINE URINALYSIS AND NHS MICROBIOLOGY  
 Fresh midstream samples were taken from patients upon visiting the renal 
outpatients clinic and immediately analysed with an automated cell counter and 
automated dipstick urinalysis for epithelial cells, white blood cells, red blood cells, 
leukocyte esterase, nitrites, protein, pH, specific gravity, ketones and glucose as per standard hospital protocol. To compare with the automated systems, a ͳͲμL sample of urine was mixed with ͳͲμL Sternheimer-Malbin stain (Fisher) and loaded onto a 
standard haemocytometer within 2 hours of sample collection. Shed urothelial cells, white blood cells and red blood cells were counted per μL and multiplied by a dilution 
factor of 2 to account for the 1:1 dilution with Sternheimer-Malbin.  
   Urine samples were sent to hospital pathology for routine culturing and biochemical 
testing of cultures (see Appendix 1.2 – MSU and CSU culture interpretation, EKHU, 
2015). Results of these were compared with our own. In total, 329 samples were 
collected from 72 patients. Of these, 36 were donors, which provided up to 2 samples, 
the remaining 36 were RTRs providing samples at various time points post-
transplant. All 329 samples underwent routine hospital culture, automated cell 
counting, dipstick analysis, microscopic cell counting and DAPI staining.   
3.3.4 UNIVERSITY CULTURE  
 In some cases, multiple samples per patient were collected per time point due 
to additional patient monitoring, however only 1 sample per time point per patient 
was also cultured using expanded culture methods at the university (university 
culture) in order to reduce cost and workload. Therefore, 145 RTR samples and 18 
donor samples were frozen at -20oC (for later culture if required). As such 127 RTR 
samples and 39 donor samples of urine were used to perform university culture as 
per the methods discussed in the General Methodology, section 2.1.3 - Processing of 
fresh urine samples (figure 3.1). The results of both university and hospital culture 




Figure 3.1: Number of samples cultured by hospital and university culture.  A total of 329 samples from 72 
patients were collected. Of these 57 samples were from 36 donors pre-donation and 272 samples were from 36 
RTR patients at various time points from 1 week to 6 months post-transplant. All samples underwent hospital 
culture, hospital dipstick and cell counting and DAPI analysis. Due to time restraints on sample processing, 18 
donor samples and 145 RTR samples were frozen and therefore university culture was not performed on these 
samples. All remaining samples were cultured by university methods. 
 
3.3.5 UNBLINDING THE STUDY 
 Until all sequencing was completed, Kent and Canterbury Hospital renal 
research staff blinded this study from the university. Post-sequencing the details of whether the sample had come from a donor or recipient, the patientsǯ gender, age, 
prophylactic and immunosuppressant treatment programme and whether the patient 
had been treated for a UTI at any stage were released for analysis.  
   Analysis was performed by two notably different means – one method comparing 
individual samples to compare the presence of specific biomarkers and determine the 
efficacy of hospital testing on a sample by sample basis, the results of which are 
discussed in section 3.4.3 – Incidence of UTIs, 3.4.4 – Trends associated with UTIs and 
rUTIs (culture), 3.4.5 – Hospital biomarkers for UTIs and 3.4.7 - Changes in the bladder 
microbiome post-RT. The second method involved comparing patients; at any one 
time point and over the series of time points, the results of which are discussed in 
sections, 3.4.4 – Trends associated with UTIs and rUTIs (age, sex and recurrence), and 
3.4.6 Alternative biomarkers to predict UTIs and rUTIs. 
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3.3.6 SPECIFICITY AND SENSITIVITY TESTING 
 In cases where it was necessary to test the specificity and sensitivity of 
hospital tests, culture and biomarkers, a 2x2 contingency table was created. On the 
left was the gold standard test or presence of infection and on the top was the 
biomarker or test being scrutinised (table 3.2). Where both the gold standard and test 
are positive (a) or negative (d) this is classified as a true positive or true negative, 
respectively. In cases where the gold standard is positive but the test is negative (c), 
this is classified as a false negative.  In cases where the gold standard is negative but 
the test is positive (b), this is classified as a false positive.  Sensitivity and specificity 
are calculated as follows: - 
Sensitivity of biomarker = 
܉܉+܊  Specificity of biomarker = ܌܋+܌ 
Confidence intervals were calculated using the Clopper-Pearson method. Tests or 



















Table 3.2: Example of 2x2 contingency tables used for the calculation of sensitivity and specificity of tests.  
Sensitivity is calculated as number of samples with a true positive/(number of samples with a true positive + 
number of samples with a false positive). Specificity is calculated as the number of samples with a true 







3.4.1 ISOLATES OMITTED FROM ANALYSIS  )n ͵Ͳ cases it was not possible to resuscitate the isolate therefore ǮFailed regrowthǯ was noted ȋn=͵Ͳ/ͳͶͻʹ, ʹ.Ͳͳ%, table 3.3). 28 isolates were contaminated 
with E.coli, probably from contaminated cryobroth. Due to the rapid growth rate of 
E.coli it was not possible to isolate the slower growing original isolates from beneath 
the E.coli and these samples were noted as ǮContaminated cryobrothǯ ȋn=ʹͺ/ͳͶͻʹ, 
1.88%, table 3.3). 80 isolates had failed PCR using both sets of primers the isolate was noted as ǮFailed PCRǯ ȋn=ͺͲ/ͳͶͻʹ, ͷ.͵͸%, table 3.3). 30 isolates were not able to be 
sequenced on two separate occasions and therefore these isolates were noted as ǮFailed sequencingǯ (n=30/1492, 2.01%. table 3.3). In 29 cases it was not possible to 
identify the Gram stain of an isolate due to mixed staining, or if bacterium were 
particularly small and 100x focus was not sufficient to determine the exact shape of 
the bacterium, the Gram stain result for these isolates was noted as Ǯ)nconclusive 
Gram stainǯ ȋn=͵ʹ/ͳͶͻʹ, ʹ.ͳͶ%, table ͵.͵). 
  Therefore, of a total 1492 cultured isolates from 230 samples, 1140 (76.41%) were 
successfully sequenced. For 153 isolates the originally recorded Gram stain was not 
concordant with the Gram stain of the BLASTed sequenced and these isolates were 
omitted from the final comparisons (n=168/1140, 11.26%, table 3.3). 
 
Total isolates 
Percentage of total 
isolates 
# of Isolates identified 1492 100% 
Failed regrowth 30 2.01% 
Contaminated cryobroth 28 1.88% 
Failed PCR 80 5.36% 
Failed sequencing 30 2.01% 
Inconclusive Gram stains 32 2.14% 
Non-concordant Gram stains 168 11.26% 
Table 3.3: Total number of isolates from each cohort missing or omitted from analysis: Total of 1492 isolates 
collected from all samples. 2.01% of total isolates failed to regrow upon resuscitation. 1.88% of total isolates were 
too contaminated to perform PCR. 5.36% of total isolates failed PCR twice with different primers on each occasion. 
2.14% of total isolates could not be identified by the Gram stain. 11.26% of total isolate BLAST results indicated a 





3.4.2 DEMOGRAPHICS OF PATIENT COHORTS 
 A total of 329 MSU samples of urine were collected from 72 patients; 57 from 
36 control patients and 272 from 36 RTRs, with 22 controls patients providing 2 
samples, and RTRs providing between 1 and 10 samples each over a period of 3 to 
241 days post RT with most patients providing between 2 and 4 samples each. All 
samples underwent hospital culture. 39 control samples and 127 of the RTR samples 
were cultured in our laboratory (university culture) as per the methods discussed in 
the General Methodology, section 2.1.3 - Processing of fresh urine samples. The 
remaining samples were frozen for further investigation at a later date if necessary 
(figure 3.1). 
3.4.3 INCIDENCE OF UTIS 
 In order to identify the percentage incidence of UTI in RTRs and controls, the 
number of patients who presented with a UTI at any time point was calculated. Of the 
samples which were sent for hospital microbiological culture. 2 control patients (2 
samples, 5.5%, n=36) and 12 RTRs (17 samples, 33.3%, n=36) were reported to have 
positive culture >104 CFU/ml and therefore presented with a clinical UTI at any time 
point (figure 3.2A). These are statistically different by a Chi squared test (p=0.0074). 
   Of the total 72 patients, 59 patients (166 samples) were also cultured by university 
culture methods in our laboratory; 26 donor patients (39 samples) and 33 RTRs (127 
samples), where a CFU count of >103 CFU/ml identified positive Ǯlow-level infectionsǯ.  
From the 59 patients cultured at the university, 4 donors (5 samples, 15.4%, n=26) 
and 12 RTRs (28 samples, 35.3%, n=33) were reported to have positive culture >103 





Figure 3.2: Culture results of samples cultured by hospital and university culture. A) A total of 72 patients 
provided 329 samples. 36 donors provided 57 samples and 36 renal transplant recipients (RTR) provided 272 
samples. All of these samples were cultured by hospital methods and it was found that 2 samples from 2 different 
donor patients (5.7%) and 17 samples from 12 different RTRs (33.3%) were positive for UTI. B) Of the total 329 
samples, 166 samples from 59 patients were cultured by university methods also.  From these, 5 samples from 4 
different donor patients (15.4%) and 28 samples from 12 different RTRs (35.3%) were found to have low-level 
bacteriuria by university methods.  
 
   In order to compare the effectiveness and reliability of university culture, the 
incidence of positive hospital culture and incidence of positive university culture was 
compared in a contingency table where hospital culture is the gold standard. All 
samples were compared in the same calculation. The percentage confidence, 
discrepancy, sensitivity and specificity was calculated as discussed in Section 3.3.6 
Sensitivity and sensitivity testing. A total of 8 true positives and 125 true negatives 
were found leaving 8 false negatives and 25 false positives, which is an 80.1% 
concordance between the two culture methods. The sensitivity is calculated as 50% 




















Concordance  = 80.1 % 
Discrepancy = 19.9 % 
Sensitivity = 50.0 % 
Specificity = 83.3 % 






Table 3.4: Sensitivity and specificity of university culture compared to hospital culture. Hospital culture is 
taken here as the gold standard of testing for UTI in RTRs. University culture has a concordance of 80.1% with 
hospital culture. There are 25/166 false positives and 8/166 false negatives, a sensitivity of 50.0% and a 
specificity of 83.3%.  
 Another means of analysing reliability of hospital and university culture was 
to compare incidence of UTI with symptom score. A positive symptom score is taken 
as a score of 1 or more to the questionnaire found at Appendix 1.1 – Diagnosing urine 
infection in kidney transplant patients, EKHFT, 2015. Symptom score was compared 
against hospital culture (n=272 samples, table 3.5A) and university culture (n=127 
samples, table 3.5B). The resulting % concordance of symptom score to hospital 
culture is low at 54.8% for hospital culture; sensitivity of this test of infection is 
58.8% and specificity is 54.5% (table 3.5A). The resulting % concordance of symptom 
score to university culture is lower still at 42.5% for university culture; sensitivity of 
this test of infection is 33.3% and specificity is 45.4% (table 3.5B). 
     
A) Hospital culture and symptom score 
      n=272 samples 
 B) University culture and symptom score 










































Concordance  = 54.8 % 
Discrepancy = 45.2  % 
Sensitivity =  58.8% 
Specificity =  54.5% 
  Concordance  = 42.5 %  
Discrepancy = 57.5 % 
Sensitivity =  33.3% 
Specificity =  45.4% 
Table 3.5: Positive culture compared with positive symptom score. Symptom score of 1 or more to the 
questionnaire found at Appendix 1.1 – Diagnosing urine infection in kidney transplant patients, EKHFT, 2015 
compared with culture result. A) Concordance of symptom score and hospital culture is 54.8%. The sensitivity of 
this as a test of infection is 58.8% and specificity is 54.5%. B) Concordance of symptom score and university 
culture is 42.5%. The sensitivity of this as a test of infection is 33.3% and specificity is 45.4%. 
103 
 
3.4.4 TRENDS ASSOCIATED WITH UTIS AND RUTIS 
   Numerous studies have shown that UTI occurrence is higher in women, and data 
from this study shows that this is the true for both those identified by hospital culture 
and university culture. Of the control patients included in the study (n=36), 52.8% 
were female and 47.2% male. Of the RTR patients (n=36), 55.5% were female and 
44.5% male (p>0.05, figure 3.3A). The age of donors (n=36) and RTR patients (n=36) 
follows a normal distribution ranging from 22 to 69 years for donors and 18 to 77 
years for RTRs. Both have a mode age of 41 to 50 years (fig 3.3B). Upon observing the 
sex of those RTRs with positive hospital culture (n=12) and positive university 
culture (n=12), 66.6% were female and 33.3% male in both cases (p>0.05, figure 
3.3C). These differences are not considered to be significant by Chi squared test as 
p>0.05. The age of RTRs with positive culture shifts towards the higher ages however 






Figure 3.3: Sex and age of control and RTR patients and RTR patients with positive hospital and university 
culture. A) Sex of donors (n=36) are 52.8% female and 47.2% male, and sex of RTR patients (n=36) are 55.5% 
female and 44.5% male. B) Age of donors ranges from 22 to 69 years with a mode age of 41-50 years. Age of RTR 
patients ranges from 18-77 with a mode age of 41-50 years. C) Sex of RTR patients with infections are 66.6% 
female and 33.3% male for both methods of infection identification. D) Age of RTR patients with infections trends 
to be higher than in fig 3.3B however still has a mode age of 41to 50 years. 
 
   Incidence of UTI post-transplantation reportedly increases with time post-
transplant. From this study, incidence of UTI does increase slightly from 11.1% of 
RTRs having a hospital grade UTI within the first month (>1month, n=27) to 13.4% 
after one month (n=23), then 25% after 3 months (n=24) (figure 3.4A). After 6 
months this drops slightly to 20% (n=20). By analysing the percentage of RTRs with 
low count bacteriuria by university culture methods, an increase is also observed 
overtime from <1 month at 18.5% to 21.7% after 1 month, and then further to 25% 
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after 3 and 6 months (figure 3.4A). These data are not significant by a one-way 
ANOVA (p<0.05).  
    A sample from each patient for each time point was not possible in all cases and 4 
patients only gave 1 sample due to time restraints on the study. From the remaining 
33 patients it was possible to determine the percentage of RTRs who had incidence of 
rUTIs; that is ≥ʹ UT)s within ͸ months post-transplant. From the 33 RTRs, 4 were 
diagnosed with a UTI more than twice or more within the 6-month period post-
transplant by hospital culture (12.1%, n=33) (figure 3.4B). By university culture, 7 
RTRs had low count bacteriuria more than twice within the 6 month period post-
transplant (21.2%, n=33) (figure 3.4B). These are not significant by a Chi squared test 
(p=0.5). Interestingly, only 2 patients of the 4 patients with rUTIs diagnosed by 
hospital culture had rUTIs by university culture also (data not shown). 
 
Figure 3.4: Trends of UTIs identified by hospital and university culture. A) Incidence of UTI increases slightly 
with time post-transplant. At less than one month, 11.1% of all RTRs were diagnosed with a hospital grade a UTI 
(n=27), and this increases to 13% at 1 month (n=23), then to 25% at 3 months (n=24) and drops slightly to 20% at 
6 months (n=20). With university culture these percentages are expectedly higher at 18.5% (1 month), 21.7% (1 
month), and 25% (3 and 6 months) (p<0.05 by ANOVA). B) Of 33 patients who supplied more than one sample 
post-transplantation, 4 (12.5%) were diagnosed with rUT) ȋ≥ʹ UT) in less than ͸ monthsȌ by hospital culture and 




    If samples grown by hospital culture were found to have >104 CFU/ml of pure 
growth then species identification was performed by culturing on a range of growth 
media, which select for particular types of bacteria. For 6/17 (35.3%) positive 
hospital cultures the causative species was identified as E.coli and 1/17 (5.8%) of 
infections were caused by Klebsiella, 1/17 by Enterococcus, 1/17 by Citrobacter, and 
1/17 by Staphylococcus (figure 3.5A). If >104 CFU/ml mixed growth was found then 
this was reported as mixed growth, likely due to contamination, and the individual 
species were not identified. This was the case for the remaining 7/17 infections 
identified by hospital culture, therefore, the species were not identified for a large 
percentage of positive samples, but it could be determined by looking at the species of 
bacteria identified by 16s rRNA sequencing and number of CFUs of bacteria grown by 
university culture. Of the 7 samples identified by hospital culture as mixed growth, 
only one had positive university culture which could be used to identify possible 
causative species. In this single sample, >103 CFU/ml of Lactobacillus and 
Streptococcus were identified, which may have been the reason for the hospital 
observing mixed culture (data not shown).  
   By identifying the species of all culturable isolates which grew at >103 CFU/ml by 
university culture by performing 16s rRNA sequencing it is possible to get a wider 
view of the species which could be causing UTI in RTRs. The most common species 
growing at >103 CFU/ml in urine of RTRs (n=29) is identified by 16s rRNA 
sequencing as Lactobacillus (34.5%), followed by E.coli (24.2%), Corynebacterium 
(13.8%), Atopobium (10.3%), Streptococcus, Gardnerella, and Bifidobacterium (8.3%) 




Figure 3.5: Trends in UTI from positive hospital cultures and university cultures. A) Infections identified by 
hospital culture (grey bars) were mainly identified as mixed cultures, which are classified as contaminated 
samples, followed by 35.3% caused by E.coli. B) Infections identified by university culture (black bars) were 
mainly identified as Lactobacillus (34.5%), which is generally classified as a probiotic species and non-pathogenic, 
followed by 24.2% caused by E.coli, then 13.8% by Corynebacterium and 10.3% by Atopobium. 
3.4.5 HOSPITAL BIOMARKERS FOR UTIS 
   Many UTIs are pre-detected by hospital markers such as dipstick analysis and WBC 
count, therefore in order to determine if pyuria or nitrites can be effectively used as a 
surrogate biomarker for infection in these samples, the positive infections were 
correlated with incidence of positive leukocyte esterase (a dipstick marker for 
leukocytes), nitrites (a dipstick marker for bacterial growth), and positive WBC count 
performed by automated and manual methods. In this case, individual samples were 
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analysed rather than patients. The sensitivities and specificities were calculated for 
each biomarker with both hospital culture (table 3.6A) and university culture (table 
3.6B) as the gold standard in the contingency tables. 
 Leukocyte esterase is highly specific (99.2% to 99.7%) but not very sensitive (6.06% 
to 10.5%) when compared with either hospital culture or university culture (table 
3.6A and B). Manual WBC count is also highly specific (96.9% to 97.7%) but not very 
sensitive (0.0% to 21.05%) when compared with either hospital culture or university 
culture. Automated WBC count is much more sensitive when compared with manual 
WBC count with a sensitivity of 68.4% in hospital culture and 57.6% with university 
culture.  Automated WBC count does not have as high a specificity as leukocyte 
esterase of manual WBC count however, at only (48.4% to 67.7%). 
     
A) Biomarkers with hospital culture 
      n= 329 samples (RTR and donor patients) 
    B) Biomarkers with university culture 
      n= 166 samples (RTR and donor patients) 
 
Sensitivity  Specificity   Sensitivity Specificity 
Nitrites 42.1% 77.5%  Nitrites 45.4% 56.9% 
Leukocyte 
esterase 
















Table 3.6: Sensitivity and specificity of common biomarkers of infection compared to hospital and 
university culture. A) LE in the most specific biomarker when used with hospital culture (99.7%) however it is 
not very sensitive (10.5%). Manual WBC is also specific (97.7%) but not sensitive (21.05%). Automated WBC 
count in the most sensitive biomarker test at 68.4%. B) LE in the most specific biomarker when used with 
university culture (99.2%) however it is not very sensitive (6.06%). Manual WBC is also specific (96.9%) but not 





3.4.6 ALTERNATIVE BIOMARKERS TO PREDICT UTIS AND RUTIS 
Since automated cell counting for pyuria is the most accurate method of 
detecting pyuria (table 3.6) and has the strongest correlation with positive culture, it 
can be hypothesised that positive pyuria could be used to predict an infection before 
it becomes sufficiently established to be detected. By looking at patient clinical 
history, the number of patients with previous positive pyuria prior to an infection 
was determined. The number of patients with a hospital detected infection (n=10) 
who had previously high pyuria was only 1 (figure 3.6A). Applying this same method 
to patients who had infection detected by university culture methods (n=13), the 
number of patients with previous positive pyuria was also only 1.  
  Another hypothesis could be that by reducing the threshold of CFU count to 103 
CFU/ml, an infection could be detected before is has become established enough to be 
detected by hospital culture. By looking back at patient university culture history, the 
number of patients with previous positive culture detected by university culture prior 
to an infection was counted. The number of patients with a hospital detected infection 
(n=12) who had previously positive university culture was only 1 (figure 3.6A). This 
suggests that high CFU count infections establish rapidly and unless more frequent 
culture testing is performed then this method cannot be used to predict an infection. 
Applying this same method to patients who had infection detected by university 
culture methods (n=12), the number of patients with previous positive university 
culture was 5.  
   Since IBCs have been of previous interest to UTI as they could protect bacteria from 
immune responses and antibiotics and allow for rUTI occurrence when bacteria re-
emerge from within urothelial cells. Using the same analysis theory as before, it was 
hypothesised that observance of Ǯclue cellsǯ ȋcells with closely associated bacteria 
detected by DAPI staining (General Methodology 2.1.3.1)) could be used to predict an 
infection. By looking back at clue cell observations in patients, the number of patients 
with previous clue cell observations prior to an infection was counted. The number of 
patients with a hospital detected infection (n=12) who had previously positive clue 
cell observation was 5 (figure 3.6A). Applying this same method to patients who had 
infection detected by university culture methods (n=12), the number of patients with 
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previous clue cell observations was 6, suggesting that clue cells could be used as an 
indicator of potential UTI.  
   Since clue cells show bacteria in close proximity to urothelial cells and could 
represent intracellular species, the samples with positive infection and clue cells 
observations were correlated to determine which species could be on the clue cells. It 
was found that of the 6 samples with positive university culture and clue cells, 4 
contained >103 CFU/ml Lactobacillus (66.6%), 2 out of 6 contained >103 CFU/ml 
Corynebacterium, and 1 out of 6 contained E.coli, Klebsiella, Atopobium, Streptococcus, 
and/or Gardnerella (figure 3.6B) 
 
 
Figure 3.6: History of positive biomarkers as a predictor of infection. A) Of RTRs who had an incidence of 
infection identified by hospital culture (grey bars, n=12) and RTRs who had infection identified by university 
culture (black bars, n=12), only 1 of each had previous positive pyuria suggesting pyuria likely only occurs once an 
infection has established and cannot be used to predict UTI. Of 12 RTR who had an incidence of infection identified 
by hospital culture, only 1 had incidence of previous positive university culture suggesting high level infection is 
spontaneous and establishes rapidly, therefore cannot be predicted unless sampling is more regular. 5/12 RTRs 
who had infection identified by university culture had previous positive infection so low-level infection is more 
stable than severe infection identified by hospital culture and may be caused by quiescent bacteria. Incidence of 
clue cells is more effective as a predictor of infection since 5/12 RTRs with positive hospital culture and 6/12 
RTRs with positive university culture were found to have previous observations of clue cells in the urine. B) Of 
patients with clue cells and infection identified by university culture (grey bars, n=6), 66.6% of infections were 
caused by Lactobacillus, a non-pathogen, followed by 13.5% by Corynebacterium. Of patients with clue cells and 
infection identified by hospital culture (black bars, n=6), 60% of infections were caused by mixed cultures 




3.4.7 CHANGES IN BLADDER MICROBIOME POST-RT 
 By looking at individual species of interest identified by 16s rRNA sequencing 
which are found in each patient at each time point it is possible to analyse the 
incidence of the most predominant species, not just those that are pathogenic or 
greater than 103 CFU/ml.  The donor patients acted as normal healthy controls and 
the species found in each RTR were pooled per time point; <1 month, 1 month, 3 
months and 6 months post-renal transplant. From figure 3.7A it can be seen that 
Staphylococcus is the most common species in both controls (74.2%) and RTRs across 
all time points (59.1% to 80.95%) and therefore its incidence is not affected by co-
trimaxazole use. Streptococcus is the second most common genus in controls (61.8%), 
however incidence of Streptococcus is significantly reduced in RTRs at <1 month post 
transplantation (11.1%, p<0.0001***) and remains reduced across all time points 
(13.6% at 1 month to 27.8% at 6 months, p<0.01* to ***) (figure 3.7B).  
   Interestingly, similar trends can be found for Streptococcus, Corynebacterium, 
Peptoniphilus and Actinomyces whereby incidence reduces from controls within the 
first month but increases again after 3 months. As previous mentioned, Streptococcus 
incidence reduces from 61.7% in controls to 11.1% in RTR within the first month 
11.1% (p<0.0001***), however the incidence increases to 33.3% after 3 months 
(p<0.05, figure 3.7B). Corynebacterium and Peptoniphilus incidence in controls was at 
47.1% and is reduced within the first month to 14.8% for both species (p=0.012*, 
figures 3.7C and 3.7D). By month 3, Corynebacterium has repopulated in RTRs to the 
47.6% again, similar to what was found in the controls (figure 3.7C). However, 
Peptinophilus remains significantly lower in RTR compared to controls (p<0.05*, 
figure 3.7E) 
   Actinomyces incidence is initially reduced in RTRs compared to controls from 35.3% 
to 7.4% (p=0.014*, figure 3.7E) within the first month post-transplant suggesting 
these genus are sensitive to co-trimaxazole In the following months, incidence of 
Actinomyces fluctuates however generally remains lower than in controls (4.7% to 
13.5%, figure 3.7E). These data suggest that Streptococcus and Actinomyces remains 
sensitive to co-trimaxazole whereas Corynebacterium and Peptoniphilus are able to 
develop resistance and repopulate the urinary tract. All other differences between 
bacteria in controls and RTRs at all time points are not significant.  
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Incidence of Enterococcus, Lactobacillus and E.coli remain unaltered in RTRs 
compared to controls (figure 3.7F-H). Incidence of Fusobacterium is reduced to 0% in 
RTR patients suggesting this species is sensitive to co-trimaxazole, however it can be 
pointed out the incidence in controls was not high initially (14.7% figure 3.7I). All p 
values are calculated by Chi squared tests comparing incidence at time point to 




Figure 3.7: Changes in the microbiome of renal transplant patients over time. Donor samples are used as 
controls (n=34) as they have not received any immunsuppressants or antibiotic treatment. Isolates from patients 
who provided more than one sample in any given time point are pooled and counted as n=1. The same control 
group is used for each bar chart. All p values are calculated by Chi squared tests comparing incidence at time point 
to incidence in controls. A) The most predominant species in controls is Staphylococcus, found in 81.0% of control 
patients and remains relatively unaffected in RTRs (59 to 80.9%, p>0.05). B) Incidence of Streptococcus in controls 
is 61.8%. Within one month, incidence drops significantly from to 11.1% post-transplant (P<0.001***). Incidence 
is still significantly lowered in RTRs at 30 days (13.6%, p=<0.001***), 3 months (33.3%, p<0.01*) and 6 months 
(27.8%, p<0.01*). C) Incidence of Corynebacterium in controls is 47.6%. Within one month the incidence of 
Corynebacterium drops significantly from 47.6% in controls to 14.8% (p= 0.012*). Interestingly, incidence 
increases again after 1 month (27.3%) and further increases after 3 months (47.6%). D) Incidence of Peptoniphilus 
in controls is 47.1%. This is reduced in the first month in RTRs to 9.1% and remains lowered across all time points 
(14.8 to 23.8%). E) Incidence of Actinomyces in controls is 35.3%. This is reduced in the first month in RTRs to 
7.4% and remains lowered across all time points (4.7 to 13.6%). F) Incidence of Enterococcus in controls is 28.6% 
and remains relatively unaffected in RTRs (28.6 to 45.4%, p>0.05). G) Incidence of Lactobacillus in controls is 
28.6% and remains relatively unaffected in RTRs (25.9 to 33.3%, p>0.05). H) Incidence of E.coli in controls is 
23.5% and remains relatively unaffected in RTRs (18.2 to 27.8%, p>0.05). I) Incidence of Fusobacterium in 
controls is 14.7% and this is reduced to 0% in RTRs. Taken together these data suggest that within the first month 
Streptococcus, Corynebacterium, Peptoniphilus, and Actinomyces are susceptible to antibiotic usage however 





 The aims of this chapter were to determine key bacterial species in rUTIs in 
RTRs, to investigate alternative biomarkers for rUTIs in RTRs, and to determine if 
there is an intracellular bacterial component to rUTIs in RTRs. Following 
investigation, the 5 main findings are: - i) hospital diagnosis of UTIs could be missing 
key low-level bacteriuria, ii) clue cells could be used as a prospective biomarker for 
rUTIs in RTRs, iii) there are significant reductions in Actinomyces, Corynebacterium 
and Peptoniphilus in RTRs. 
3.5.1 INCIDENCE OF INFECTION IN RTRS REFLECTS PUBLISHED DATA 
 Our data has shown that the incidence of infection in RTRs reflects that of data 
published by others. The age of our cohort is similar to that of other reports of the 
average age of patients receiving renal transplants. From the US Renal Data System 
database sturdy where a total of 23,924 RTR records were analysed, 17,358 of these 
were men (60% and the remainder were women (40%) (120). Our data had a higher 
percentage of female recipients (55.5%). This could be due to the fact that the US 
study has a very large n number. Our data was however in keeping with this study in 
that the more female RTRs (40%) developed UTIs than men (22.2%, figure 3.3). In the 
large US study 38.2% of recruited males had had a UTI and 47% of females had had a 
UTI. These figures are slightly higher than ours, but this could be due to the fact that 
the patients recruited in our study had only recently had a RT. Finally, our data 
reflects the systemic review by Parasuraman et al (121) in that E.coli is the most 
prevalent pathogen causing UTIs in RTRs (figure 3.5). 
3.5.2 HOSPITAL CULTURE AND IDENTIFICATION IS LIMITING  
 The percentage of infections identified from 272 samples sent for hospital 
culture was 6.2% (figure 3.2), whereas the percentage of infections identified by 
university culture out of 127 patients was 22% (figure 3.2). This is nearly a four-fold 
increase in the percentage of infections detected, indicating that the university 
culture method is able to detect low-level infections due to the lowered threshold of 
CFU count. It would therefore be expected that all positive hospital cultures would 
also be positive university culture methods, however this was only the case in 5.7% of 
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samples. University and hospital positive culture had an 80.1% concordance, a 
sensitivity of 50% and a specificity of 83.3% suggesting that some infections could 
also be being missed by university culture methods and therefore they may need 
reconsideration. 
  By performing 16s rRNA sequencing our method was more effective at identifying a greater range of species of pathogenic bacteria which could be causing UT)ǯs in RTRs; 
identifying particular species such as Atopobium, Corynebacterium, Streptococcus, 
Gardnerella, and Bifidobacterium (figure 3.5). These species are not the same as those identified by Parasuramanǯs systemic review, which identified the highest prevalence 
of first UTI to be caused by E.coli (34.5%), Enterococcus (19.5%), Pseudomonas 
aeruginosa (12.5%), Staphylococcus spp. (9.5%), and Klebsiella spp. (9%), however 
their study cumulated results from 1,517 RTRs whereas we were only able to recruit 
36 in the time of this study, which could be a reason for the differences in the types of 
species found (121). The species of interest from this study are not usually identified 
by hospital culture since they are generally not considered to be pathogenic, however 
they are notable emerging pathogens that have been associated with UTIs and should 
therefore not be dismissed from further investigation (231).  Furthermore, university 
culture methods also do not prejudice for multiple growths greater than 104 CFU/ml 
from the same sample, which hospital culture regards as contamination.   Therefore, 
although some positive infections by hospital culture were missed by university 
culture methods, the university method was over all better at detecting a range of 
bacterial species and was not prejudice for single cultures. Taken together this 
indicates that UTIs can best be identified by the reduced threshold of 103 CFU/ml 
since more infections can be identified. 
3.5.3 HOSPITAL BIOMARKERS FOR INFECTION ARE LIMITING  
 Often, an infection is accompanied by symptoms of increased frequency of 
micturition, pain and nocturia. In some cases, this in itself can be a marker of 
infection, however our data shows that symptom score and hospital culture only has 
a concordance rate of 54.5%, a sensitivity of 58.8% and a specificity of 54.8%, 
therefore other biomarkers of infection must be used to identify infection.  
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 Hospital automated cell counting appeared the best test for detecting pyuria 
compared to counting using a haemocytometer, since it had the best combined 
sensitivity (68.4%) and specificity (67.7%, figure 3.6A). Manual WBC count and 
nitrite dipstick had excellent specificities (>90%) however had very low sensitivities 
(<11%) Interestingly, the protocol for hospital culture must take into consideration 
positive pyuria by automated cell counting, however our analysis has shown that 
42.4% of low-level infections identified by university culture did not have 
accompanying positive pyuria suggesting that pyuria does not always accompany 
low-level infection (data not shown). Our results do reflect the conclusions made by 
Malone-Lee et al they discredit the use of microscopic pyuria and LE as biomarkers 
for infection (215). 
3.5.4 USING UNIVERSITY CULTURE AND CLUE CELLS AS BIOMARKERS FOR INFECTION  
 By analysing patient clinical history it was possible to identify whether 
previous incidence of pyuria, low-level infection, or clue cell observation could be 
used to predict an infection. The number of patients with positive pyuria prior to 
detecting either low-level or clinical UTI was only 1 suggesting that positive pyuria 
con only be detected once an infection has become established and cannot be used to 
predict an infection.  It was found that 69.2% of patients with a low-level infection 
(n=13) and 40% of patients with a clinical grade infection (n=10) had had previous 
low-level infections, indicating that low-level infections can be pre-determinant for 
clinical UTI (figure 3.5A). Therefore, by reducing the threshold of CFU/ml count, 
hospitals could put patients with low-level infections under more intense monitoring 
in order to catch any hospital grade infections sooner.  
Presence of clue cells were observed in 17 out of 36 RTR patients at any particular 
time point and 9 of these developed a low-level infection by university culture (53%) 
and 6 developed a hospital grade infection (35%) (figure 3.5B). By looking at the 
samples containing clue cells and the species which were identified at >103 CFU/ml it 
was found that most of the samples with a positive infection containing clue cells 
were caused by Lactobacillus, which is generally regarded as a non-pathogenic, 
probiotic species in the urogenitary tract. Other species such as E.coli, 
Corynebacterium and Klebsiella were also identified however, and are regarded as 
pathogenic. Although these numbers are low, this is still a promising finding and 
117 
 
could be easily improved upon and adapted into hospital pathology methods in order 
to use clue cell observations as an indicator of potential UTI (discussed in more detail 
in section 3.5.7 –Future work and ideas). 
3.5.5 SPECIES OF INTEREST IN RTRS 
 By pooling the species found in each patient at each time point it was possible 
to determine the percentage incidence of each species at any time point. Interestingly, 
the incidence of E.coli remained relatively the same at each of the four time points 
compared to controls, signifying that although this species is the most common cause 
of UTI in RTR, the numbers of UT)ǯs recorded were not high enough to alter the 
difference in incidence of this species between controls and RTRs (figure 3.7H).  
  There is a reduction in the incidence of Corynebacterium, Streptococcus, 
Peptoniphilus and Actinomyces (figure 3.7B-E) at all time points, which could be due 
to high susceptibility of these genus to co-trimaxazole.  By consulting James McCormackǯs antibiotic sensitivity chart it is possible to see the range of bacteria that 
are susceptible to co-trimaxazole, which includes Staphylococcus aureus, some 
Streptococcus spp. and Gram negative bacilli except Pseudomonas aeruginosa (232). 
Co-trimaxazole is generally used a prophylactic against pneumonia, which in renal 
transplant patients is most often caused by Staphylococcus aureus, Streptococcus 
pneumoniae, and Gram-negative bacilli, and therefore rationalises the use of co-
trimaxazole (233). The use of this particular antibiotic does not explain however the 
observed reduction in Corynebacterium, Peptoniphilus or Actinomyces, since these 
genus are not expected to be affected by co-trimaxazole (232). The fact that 
Staphylococcus incidence remains the same, despite use antibiotics, can be explained 
by the fact that S.aureus but not S.epidermidis are susceptible to co-trimaxazole. 
Corynebacterium, Peptoniphilus or Actinomyces are not generally recognised as 
probiotic or protective, but rather as emerging pathogens, however reduced 
incidence of these species may allow for other opportunistic pathogens to grow. First, 
susceptibility of these genus to co-trimaxazole needs to be determined to begin to 
confirm this theory, followed by co-culture. Antibiotic susceptibility testing could also 
explain increased incidence of Corynebacterium and Actinomyces 3 to 6 months post-
transplantation which suggest repopulation, perhaps due to antibiotic resistance. 
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   The incidence of clue cell observations was compared with positive university 
culture to determine if the species of bacteria associated to urothelial cells could be 
identified this way. Many of the samples positive for both clue cells and low-level 
infection were found to be caused by Lactobacillus, which is renowned for its 
probiotic properties in the genitourinary tract (234). If clue cells were to be used for 
predicting infections, it would have to be taken into consideration therefore that 
many observations might not be pathogenic. Fortunately, Lactobacillus cultures are 
easily identifiable on chocolate culture plates as small, green, dry colonies with mild 
beta-haemolysis. Therefore, positive clue cell observations followed by observations 
of these colony types could be regarded as normal healthy growth. 
 
3.5.6 METHODOLOGY ERRORS AND LIMITATIONS 
  Due to the slower than expected rate of RTRs coming through Kent and 
Canterbury Hospital and the time constraints of this doctorate, it was not possible to 
collect the complete number of samples and patients suggested in the grant for this 
study. All of the observations made in this study would benefit from increased patient 
numbers in order to better support the findings and conclusions. 
    An issue with the university method of determining low level infections appeared 
when comparing the samples with positive hospital infections with those identified 
by culture. One would expect positive hospital infections to also be positive by 
university culture since the threshold for CFU/ml is lower (figure 3.2A). It can 
therefore be concluded that university culture is able to detect more infections but 
still miss others. This could be due to bacteria dying in the fridge or in transit 
between sample collection and plating. Alternatively, the use of selective media in 
hospital culture allows for certain species to grow better than on the chocolate agar 
utilised in university culture.  
    A limitation of observing clue cells and correlating it with identified infections by 
expanded culture is that one is assuming that the bacteria on the clue cells are the 
same as those identified by university culture. Furthermore, clue cells do not indicate 
that bacteria are intracellular. In order to ascertain if these are the same species and 
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if they are intracellular it would be essential to perform an antibiotic protection assay 
(137). This technique uses non-penetrable antibiotics to kill susceptible planktonic 
bacteria on urothelial cells, and is followed by a lysing and culture step to grow any 
intracellular bacteria which can then be identified by 16s rRNA sequencing. For 
future studies, this protocol should be performed to determine with certainty that 
infections are caused by species observed on clue cells. 
   The purpose behind this study was inform the next study on OAB in the following 
chapter. As discussed in the introduction, OAB is not considered an infection, 
however there have been recent advances in clinical research which suggest that 
alterations in the microbiome may be a cause for this syndrome (138, 193, 195, 235, 
236).  Alterations in the microbiome are most evident when taking antibiotics since 
they can reduce incidence of probiotics and allow for opportunistic infections. Hence, 
RTRs were used to represent high-risk patients in a preliminary study.  The idea 
being that any potential changes in the microbiome leading to urinary tract 
symptoms is more likely to occur in those receiving a renal transplant due to risk of 
opportunistic infections. The data from this study on RTR patients who are all taking 
prescribed antibiotics and immunosuppresants is that significant reductions in certain bacteria is evident however this doesnǯt correlate with incidence of infection 
(data not shown). This suggests that the microbiome can be manipulated but it does 
not suggest that it is a cause for infection in this subset of patients. This suggests that 
any differences which may be seen in the following OAB study ought to be more 
rigorously investigated. Furthermore, inclusion of an antibiotic protection assay in 
the next study could further inform of the identification of intracellular species. 
3.5.7 FUTURE WORK AND IDEAS 
  It was concluded that university culture methods were able to detect low-level 
infections which are not regarded as UTIs by hospital culture. This is likely due to the 
reduced threshold of CFU/ml count utilised by the university. Also observed was the 
fact that low-level infections were found in 40% of patients prior to diagnosis of a 
clinical grade UTI. Therefore, a large scale study aiming to better determine types of 
infection in RTRs could inform hospitals of ways they could introduce lower 
threshold CFU count as a means to monitor patients post-transplant. In cases where 
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low-level UTIs are diagnosed, these patients could then be put under more frequent 
monitoring in order to catch any potential complicated infections sooner.  
   Also observed was an increased range of bacterial species identified by university 
culture methods, some of which are notable emerging uropathogens. Many of these 
species could be being missed by hospital culture due to the restricted protocol for 
identifying pathogenic species. Expanded culture methods cannot easily be adapted 
in to hospital culture methods due to the cost and time implications of performing 
16s rRNA sequencing, other than reducing the threshold of CFU/ml to 103 CFU/ml 
and extending growing times. However, some hospitals have recently begun using 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI 
TOF-MS) to identify infections that cannot be identified by culturing on species-
specific agar (237). Although expensive to install, this system can be used as a service 
by the entire hospital and, in some hospitals in the UK where it has already been 
implemented, has allowed for significantly faster, more effective, and more accurate 
patient diagnosis and treatment. 
    It was previously mentioned that the presence of clue cells does not infer 
intracellular bacteria. There are various methods which can be used to determine 
whether bacteria are intracellular upon detection of clue cells in a sample; i) an 
acridine orange and crystal violet stain on Cytospun urine to visualise intracellular 
bacteria, and ii) culturing bacteria obtained from within urothelial cells by 
performing an antibiotic protection assay. The second of these methods is more 
informative as it also allows for genetic identification by 16s rRNA sequencing post 
culture. This method will be adapted from Khasriya et al (137) for future 
investigations in this thesis. 
    Although this study has identified some species of interest that appear to be 
significantly reduced post-transplant, it is not known if these species are reduced due 
to antibiotic sensitivity or other means. There is very little literature on the effects of 
co-trimaxazole and co-trimaxazole resistance in Corynebacterium, Actinomyces and 
Peptinophilus, therefore determining the sensitivity of these genus to this antibiotic 
would be of great value. This can be done by performing a spread culture on 
chocolate agar then placing paper disks soaked in co-trimaxazole on the surface. If 
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these genus are sensitive to co-trimaxazole, an area of no growth would appear 
around the paper disk. Determining co-trimaxazole sensitivity would answer the 
question of whether the reduced observation is due to antibiotic use and therefore, if 






1. Percentage incidence of hospital diagnosed UTI in RTRs was 33.3%, in keeping 
with many studies. 
2. University culture is able to detect more infections and has a high sensitivity, 
however this method of testing has a low specificity and misses some 
infections.  
3. Automated WBC counting is the most effective way of detecting pyuria, 
however pyuria and infection do not always correlate and cannot therefore be 
used to diagnose infection without culture as well. 
4. Species of bacteria identified by 16s rRNA sequencing differ from the 
cumulated findings of 4 similar studies, notably we have identified some 
emerging pathogens including Atopobium, Corynebacterium, Streptococcus, 
Gardnerella, and Bifidobacterium. 
5. Reductions in Actinomyces, Corynebacterium and Peptoniphilus in RTRs could 
be due to antibiotic susceptibility and reduced incidence may be a cause for 
infection.  
6. Clue cells could be used to predict future infections, however most clue cell 
observations were associated with high Lactobacillus growth, which is not a 
pathogen, but a probiotic species.  
7. The methods used in the next study need to include antibiotic protection 
assay, include more rigorous measurements of changes in the microbiome and 




CHAPTER 4 - RESULTS  2: 
THE BLADDER MICROBIOME IN OVERACTIVE 
BLADDER 
4.1 INTRODUCTION 
 Numerous studies have highlighted that the current criterion for diagnosing 
UTI is flawed and that by reducing the threshold of CFU/ml of a single species from 
105 to 103 can reveal infection where it may have previously been missed (129, 134, 
136). Application of this to OAB has indicated that there may be a possible Ǯlow count bacteriuriaǯ in OAB that could be causing the symptoms of OAB (134, 136, 137, 219). 
Positive results from a preliminary, small scale abstract by Malone-Lee et al have 
shown that treating OAB with antibiotics can reduce the symptoms of this syndrome 
(104). Interestingly, most UTIs are caused by the following species: - UPEC, 
Enterococcus faecalis, Proteus mirabilis, Klebsiella pneumoniae, Pseudomonas 
aerogenosa, and Serritia marcenscens (107, 108). However, there are some studies 
which have performed EQUC and culture-independent 16s rRNA sequencing; the 
most advanced methods of exploring the microbiome to date, that have not reported 
these species to be significantly increased in OAB compared to controls (138, 194, 
195, 197). They have however found increased incidence of species such as 
Gardnerella, Actinobaculum, Actinomyces, Aerococcus, Arthrobacter, Cornybacterium, 
or Oligella (138, 197). 
   In recent years, the research groups that have applied these advanced techniques 
have moved away from the theory of a low-level infection and have proposed the 
concept of an imbalance in a bladder microbiome that is unique to every individual. 
Due to the proximity to the anus and vagina in women, this is more than feasible, and what with the capability of so many of the species identified in the Ǯbladder microbiomeǯ to form biofilms and intracellular communities, the likelihood of bladder 
colonisation is strengthened. One investigation has proposed that the microbiome 
changes over time (236) and another, in concordance, stated that each individual 
should therefore act as their own control (236). Interestingly, Gram-positive UT)ǯs 
such as those caused by Aerococcus, Corynebacterium, Actinobaculum, and 
124 
 
Gardnerella, are more prevalent in the elderly and are often over-looked as 
uropathogens (138, 231, 238, 239). Aerococcus is often misclassified or regarded as a 
contaminant in microbial culture (240), and therefore 16s rRNA sequencing could 
confirm species ID and increase awareness of this uropathogen. Corynebacterium and 
Actinobaculum are very slow growing species on blood agar and are therefore also 
occasionally regarded as contaminants (231). Gardnerella is better known as the 
causative species of bacterial vaginosis, however this species is slowly becoming 
recognised as a uropathogen as well (231). Once again this species requires extended 
culture of 48-72 hours. Taken together it could be hypothesised that microbiome 
imbalances may allow for increased levels of emerging pathogens and could play a 
part in OAB if less limiting culture assays are used to diagnose infection.  
   Other studies have proposed an intracellular component to OAB (17, 153, 241), 
whereby bacteria reside within the urothelium stimulating low level inflammation, 
which may in turn lead to detrusor muscle contractions. Furthermore, re-emerging 
bacteria from IBC may cause recurrent UTIs, which could be missed if they are at low 
level. There have been no published investigations which have been able to identify a 
spectrum of the exact species which are capable of forming IBC in the bladder. This 
chapter will investigate the microbiome of individuals with OAB by identifying all 
species of bacteria cultured from urine and comparing the microbiome to those of 
controls. Furthermore, by sequencing all species following an antibiotic protection 
assay it will give us insight into any intracellular species and determine if there is a 
role for intracellular bacteria in OAB aetiology. Along with the clinical data obtained 
from the hospital, this project aims to identify potential biomarkers of OAB with an 








4.2 HYPOTHESIS AND AIMS 
 We hypothesise that the microbiome, including incidence of intracellular 
bacteria colonies, changes with age, predisposing (in this case) women to OAB. 
   In order to begin to test these hypotheses the following objectives will be to:- 
1. Investigate the differences in the microbiota in the MSU and CSU sample 
urine between patients with OAB and controls in various age groups 
irrespective of CFU/ml. 
2. Determine whether there is an intracellular bacteria component to OAB 
and, if so, which species are most prevalent. 
3. Correlate incidence of species of interest and differences in clinical data in 
order to determine any potential biomarkers for OAB. 
4.3 METHODOLOGY 
4.3.1 DISCLAIMER 
 The collection of clinical data, including patient age, parity (number of 
children), BMI, and patient diagnosis was performed by clinical staff and clinicians at 
Medway Maritime Hospital, Kent, UK. ICIQ form completion, urine collection, dipstick 
urinalysis and Sternhiemer-Malbin analysis was performed by myself and the 
clinicians at Medway Maritime Hospital. Hospital pathology was performed by clinical 
staff in the pathology department at Medway Maritime Hospital. University culture 
and sequencing was performed predominantly by myelf with assistance from 
clinicians from Medway Maritime Hospital. All analysis was performed by myself. 
4.3.2 ETHICS 
 Ethical approval was obtained from the NHS Health Research Authority (NRES 






4.3.3 PATIENT SAMPLE COLLECTION 
 Midstream (MSU) and catheterised (CSU) samples were taken from patients 
who fitted a specific description of OAB dictated by International Validated Questions 
from the International Consultation on Incontinence Modular Questionnaire – Female 
Lower Urinary Tract Symptoms Long Form (ICIQ-FLUTS-LF) (see Appendix 1.3).  
Patients were clinically diagnosed with OAB following assessment of history and 
examination. All patients also indicated a positive response to Question 3a of the 
ICIQ-FLUTS-LF (Do you have a sudden need to rush to a toilet to urinate?). All 
patients were female aged 18 and over and suffered moderate to severe OAB with 
urgency, frequency and nocturia. Any patients with symptomatic urinary tract 
infections, interstitial cystitis, predominant stress incontinence symptoms, or 
previous pelvic radiation were excluded from the cohort. Control samples were also 
taken from women visiting out-patient clinics for non-urinary problems, who were 
asked to participate in the study and scored 0 on the International Consultation on 
Incontinence Modular Questionnaire – Female Lower Urinary Tract Symptoms Short 
Form (ICIQ-FLUTS-SF) to ensure that they did not suffer with any OAB symptoms. All 
sampling methods met the ethical approval and each patient gave consent on each 
occasion before providing a sample.  
   OAB MSU samples were collected from a weekly clinic held on Wednesday mornings 
run by Professor Jonathan Duckett at the department of Obstetrics and Gynaecology 
at Medway Maritime Hospital, Kent, UK. Control MSU samples were collected from a 
clinic on Monday mornings run by Dr. Peri Krishna-Moorthy, for women with non-
urinary gynaecological queries at Medway Maritime Hospital, Kent, UK.  
   OAB CSU samples were collected from patients undergoing a clinical trial for 
cystodistension to treat OAB symptoms. Control CSU samples were collected from 
patients undergoing surgeries such as hysterectomy, myomectomy or laparoscopy. 
All samples were collected under general anaesthetic in a sterile operating theatre 
prior to the scheduled operation. Urine was analysed by dipstick once surgery was 
completed. Some of the urine was placed in boric acid and sent for hospital pathology 
The remaining urine was kept in a fridge until collected or delivered to the university 
within 4 hours after collection, where it was analysed as discussed in Section 2.1.3 - 
Processing of fresh urine samples.. 
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   Patients with OAB who provided a CSU sample before their cystodistension also 
provided two biopsies of bladder tissue. These biopsies were taken via a cystoscopy 
(telescopic examination of the inside of the bladder) and were placed in sterile saline 
to be processed as according to the protocols for microbial culturing, electron 
microscopy or ATP assay discussed in Section 2.1.5 - Bladder biopsies.  
   For age related analysis, patients were split into groups by age. The first age group, 
20-44, is the average age at which women are between puberty and pre-menopause. 
The second age group, 45-60 is the average age at which women are post-menopause 
and pre-elderly and the final age group 65+ is the average age at which women reach 
elderly age. 
4.4 RESULTS  
4.4.1 DEMOGRAPHICS OF PATIENT COHORTS 
 Four main cohorts of patients were derived from collections from clinics and 
day surgeries; MSU samples from patients with OAB (OAB MSU, n=69), MSU samples 
from controls (control MSU, n=84), CSU samples from patients with OAB (OAB CSU, 
n=60), and CSU samples from controls (control CSU, n=14)(table 4.1). Descriptive 
statistics were used to describe the features of the individual cohorts when possible; 
age and BMI from hospital records; leukocyte esterase, nitrites, and pH from dipstick 
results, epithelial and white blood cell count from hospital pathology; UTI diagnosis 
from hospital pathology; epithelial and white blood cell count from Sternheimer staining; and incidence of observed Ǯclue cellsǯ in DAP) stained urine ȋurothelial cells 
with closely associated bacteria). Not all data was able to be recorded for all samples 
due to clinician oversight in cases of age and BMI, difficulty accessing facilities after 
surgery and not performing a CFU count for the primary samples collected. The total 
n numbers for each data set is summarised in table 4.1 
 Most OAB and control CSU samples were not dipsticked or cell counted in the 
hospital due to difficult access to facilities after theatre collection (table 4.1).  Control 
MSUs and CSUs were not sent for pathology as these individuals were not suspected 




 OAB MSU Control MSU OAB CSU Control CSU 
Total samples collected n=69 n=84 n=60 n=14 
Age  n=65 n=79 n=54 n=12 
BMI  n=43 n=73 n=52 n=12 
Dipstick analysis  n=66 n=68 N/A§ N/A§ 
Hospital pathology  n=59 N/A§§ n=53 N/A§§ 
University culture n=60 n=82 n=42 n=14 
University culture with CFU count  n=28 n=25 n=26 n=12 
Sternheimer-Malbin  n=65 n=47 n=28 n=12 
DAPI stain  n=69 n=80 n=48 n=12 
Table 4.1: n numbers for clinical and biological data sets for each group of patients. A total number of 69 
OAB MSU samples, 84 Control MSU samples, 60 OAB CSU samples, and 14 Control CSU samples were collected for 
this study. In each case, incomplete data was collected for the various data sets. This table summarises the n 
numbers for each of the following data sets: - patient age, patient BMI, urinary dipstick analysis, hospital 
pathology, university CFU count, Sternheimer-Malbin staining, and DAPI staining.  
§ = OAB and control CSU samples were not dipsticked in the hospital due to difficult access to facilities after theatre 
collection. §§ = Control MSUs and CSUs were not sent for pathology as these individuals were not suspected of an 
infection and therefore the costs incurred were not justified. 
 
4.4.1.1 AGE AND BMI 
   For the OAB MSU group, age ranged from 14 to 87 with a mean age of 59.9 (n=65) 
(figure 4.1A). In some cases patients BMI was not recorded due to clinician oversight, so for this reason only Ͷ͵ patients BM)ǯs are included in the statistics. BM) ranged 
from 17.3 to 45.6 with a mean of 29.4 (n=43) (figure 4.1B).  Of the control MSU 
samples were collected, age ranged from 17 to 83 with a mean age of 39.6 (n=79) 
(figure 4.1C). BMI ranged from 15.5 to 41.1 with a mean of 26.3 (n=73) (figure 4.1D). 
Of the OAB CSU samples collected, age ranged from 17 to 83 with a mean age of 56.5 
(n=54) (figure 4.1E). BMI ranged from 16.5 to 45.7 with a mean BMI of 29.6 (n=52) 
(figure 4.1F). Of the control CSUs were collected, age ranged from 22 to 79 with a 
mean age of 36.3 (n=12) (figure 4.1G). BMI ranged from 18.6 to 31.0 with a mean BMI 





Figure 4.1: Demographics of age and BMI of OAB MSU, Control MSU, OAB CSU and Control CSU cohorts. A) 
69 OAB MSU samples were collected from patients with OAB attending day clinics. Age of this cohort ranged from 
14 to 87, mean age of 59.9 (n=65). B) BMI ranged from 17.3 to 45.6, mean of 29.4 (n=43). C) 84 Control MSU 
samples were collected from control patients attending day clinics for non-urinary gynecological queries. Age of 
this cohort ranged from 17 to 83 years, mean age 39.6 years (n=79). D) BMI ranged from 15.5 to 41.1, mean BMI 
of 26.3 (n=43). E) 60 OAB CSU samples were collected from patients with OAB undergoing cystodistension clinical 
trial in day theatre. Age of this cohort ranged from 17 to 83 years, mean age 56.5 years (n=54). F) BMI ranged 
from 16.5 to 45.7, mean BMI of 29.6 (n=52). G) 14 Control CSU samples were collected from control patients 
undergoing non-urinary gynaecological surgery in day theatre. Age of this cohort ranged from 22 to 79 years, 




4.4.1.2 DIPSTICK ANALYSIS  
 From the OAB MSU group, dipstick results, leukocyte esterase was 
predominantly negative (50.0%, n=66), with 24.2% presenting with a trace reading 
and the remainder with +1, +2, or +3 (figure 4.2A). The mode (non-continuous data) result for nitrites was Ǯnegativeǯ with ͻ͵.ͻͶ% of patients having this result (n=66) 
(figure 4.2B). pH of urine ranged from 5.0 to 8.5 with a mode pH of 6.0 and a mean of 
6.1 (n=66) (figure 4.2C). 
   From the control MSU samples collected, dipstick results, leukocyte esterase was 
predominantly negative (64.7%, n=68), with 2 the remainder with +1 (10.3%), +2 
(8.8%), or +3 (13.2%) (figure 4.2DȌ. The mode result for nitrites was Ǯnegativeǯ with 
97.06% of patients having this result (n=68) (figure 4.2E). pH of urine ranged from 
5.0 to 8.5 with a mode of pH 5.0 (41.2%) and a mean of pH 6.0 (n=68) (figure 4.2F). 
   Many OAB and control CSU samples were not dipsticked or cell counted due to 
difficult access to facilities after theatre collection.  
 
Figure 4.2: Demographics of dipstick analysis of OAB MSU and Control MSU cohorts. CSU samples were not 
able to be dipsticked due to difficult access to facilities after theatre collection. A) For the OAB MSU cohort, 
leukocyte esterase was predominantly negative (50.0%, n=66), with 24.2% presenting with a trace reading and 
the remainder with +1, +2, or +3. B) Nitrites were predominantly negative (93.94%, n=66).  C) pH ranged from 5.0 
to 8.5, mean pH 6.1, mode pH 6.0 (39.4%, n=66). D) For the Control MSU cohort, leukocyte esterase was 
predominantly negative (64.7%, n=68). E) Nitrites were predominantly negative (97.1%, n=68). F) pH ranged 
from 5.0 to 8.5, mean pH 6.0, mode pH 5.0 (41.2%, n=68). 
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4.4.1.3 HOSPITAL PATHOLOGY 
 In some cases, it was not possible to send samples for pathology due to the 
small volumes obtained. Also, in cases where patients were already diagnosed with 
idiopathic OAB and showed no symptoms of UTI, a pathology test was not required. 
Of the samples sent for pathology (n=59), 8.47% (n=5) of OAB MSUs were diagnosed 
as having a UTI by hospital pathology (figure 4.3A). These individuals were removed 
from further analysis as their diagnosis was no longer Ǯpureǯ OAB. The mode result for 
WBC count from hospital pathology was 101 to 102, with 76.3% of patients showing 
low numbers compared with only 1.7% having more than 103 (figure 4.3B). Hospital 
pathology reported ͹͸.͵% of patients ȋn=ͷͻȌ to have Ǯ+ͳǯ epithelial cells, ͳͳ.ͻ% with none and the remainder with Ǯ+ʹǯ or Ǯ+͵ǯ ȋfigure Ͷ.͵C). 
   Of the 60 OAB CSU samples collected, 5.66% (n=3/53) of patients were diagnosed 
with a UTI from hospital pathology (figure 4.3D). These individuals were removed 
from further analysis as their diagnosis was no longer pure OAB. The mode result for 
WBC count from pathology was 1 to 10, with 67.9% of patients showing low numbers 
compared with only 1.9% having more than 103 (figure 4.3D). Hospital pathology reported ͺͳ.ͳ% of patients ȋn=ͷ͵Ȍ to have Ǯ+ͳǯ epithelial cells, ͳͷ.ͳ% with none and 
the remainder with Ǯ+ʹǯ or Ǯ+͵ǯ ȋfigure Ͷ.͵E). 
   Control MSUs and CSUs were not sent for pathology as these individuals were not 





Figure 4.3: Demographics of hospital pathology of OAB MSU and OAB CSU cohorts. Control MSUs and CSUs 
were not sent for pathology as these individuals were not suspected of an infection.  A) 8.5% of patients in the 
OAB MSU cohort (n=59) were diagnosed with infection by hospital pathology and removed from further analysis. 
B) Mode result for WBC count performed by hospital pathology was 1 to 10 cells/ml (%, n=59). C) Mode result for 
epithelial cell count performed by hospital pathology was Ǯ+ͳǯ ȋ͹͸.͵%, n=ͷͻȌ. D) 5.66% of patients in the OAB CSU 
cohort (n=53) were diagnosed with infection by hospital pathology and removed from further analysis. E) Mode 
result for WBC count performed by hospital pathology was 1 to 10 cells/ml (67.9%, n=53). F) Mode result for 
epithelial cell count performed by hospital pathology was Ǯ+ͳǯ ȋͺͳ.ͳ%, n=ͷ͵Ȍ. 
 
4.4.1.4 UNIVERSITY PATHOLOGY 
 For the OAB MSU group a total of 69 samples were collected. By decreasing the 
threshold of bacteria to 103, the number of infections identified by university culture 
performed in the laboratory was 21.4% (n=28) (figure 4.4A). The range of epithelial 
cells identified by Sternheimer staining and counting using a haemocytometer was 0 
to 20 cells with a mode of 0 cells and a mean of 3.1 cells (n=65) (figure 4.4B). WBC 
count from this method ranged from 0 to 100 cells with a mode of 0 cells and a mean 
of 80 cells (n=65) (figure 4.4C). Staining cytospun urine with DAPI showed that the 
majority of samples contained either clean cast cells (shed urothelial cells with no 
associated bacteria, 31.9%) or clue cells only (39.1%, n=69) (figure 4.4D). 
A total of 84 control MSU samples were collected. By decreasing the threshold of 
bacteria to 103, the number of infections identified by university culture performed in 
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the laboratory was 36.0% (n=25) (figure 4.4E). The range of epithelial cells identified 
by Sternheimer staining and counting using a haemocytometer was 0 to 30 cells with 
a mode of 0 cells (46.2%) and a mean of 3.6 cells (n=47) (figure 4.4F). WBC count 
from this method ranged from 0 to 100 cells with a mode of 0 cells (78.4%) and a 
mean of 3.5 cells (n=47) (figure 4.4G). DAPI observations on cytospun urine showed 
that 32.5% of samples contained clean cast cells (n=80), 23.8% contained clue cells 
only and 20.0% contained clue cells and polymorphonuclear cells (PMNs) (figure 
4.4H). 
A total of 60 OAB CSU samples were collected. The number of infections identified by 
university culture is 11.34% (n=26) (figure 4.4I). The range of epithelial cells 
identified by Sternheimer staining and counting using a haemocytometer was 0 to 15 
cells with a mode of 0 cells (85.7%) and a mean of 0.9 cells (n=28) (figure 4.4J). WBC 
count from this method ranged from 0 to 500 cells with a mode of 0 cells (78.4%) and 
a mean of 18.7 cells (n=28) (figure 4.4K). DAPI observations on cytospun urine 
showed that 50.0% of samples contained clean cast cells (n=48) and 37.5% contained 
no cells (figure 4.4L) 
A total of 14 control CSUs were collected. The number of infections identified by 
university culture is 18.2% (n=12) (figure 4.4M). The mode number of epithelial cells 
identified by Sternheimer staining and counting using a haemocytometer was 0 cells 
with 91.7% (n=12) and only 1 sample with 2 epithelial cells/ml (figure 4.4N). All 
samples (n=12) contained 0 WBC by Sternheimer staining (figure 4.4O). DAPI 
observations on cytospun urine showed that 33.3% of samples contained clean cast 







Figure 4.4: Demographics of university testing of OAB MSU and OAB CSU cohorts. A) 21.4% of OAB MSU 
cohort (n=25) were identified with potential infection by reduced threshold of 103 CFU/ml and expanded culture. 
B) Range of epithelial cell count performed by Sternheimer staining and haemocytometer from 0 cells/ml to 20 
cells/ml with a mode result of 0 cells/ml (46.2%) and mean result 3.1 cells/ml (n=65) C) Range of WBC count 
performed by Sternheimer staining and haemocytometer from 0 cells/ml to 100 cells/ml with a mode result of 0 
cells/ml (78.5%) and mean result 80 cells/ml (n=65) D) DAPI observations on cytospun urine shows 31.9% of 
samples contain clean casts and 39.1% contain clue cells (n=69). E) 36.0% of Control MSU cohort (n=25) were 
identified with potential infection by reduced threshold of 103 CFU/ml and expanded culture. F) Range of 
epithelial cell count performed by Sternheimer staining and haemocytometer from 0 cells/ml to 30 cells/ml with a 
mode result of 0 cells/ml (46.2%) and mean result 3.6 cells/ml (n=47). G) Range of WBC count performed by 
Sternheimer staining and haemocytometer from 0 cells/ml to 100 cells/ml with a mode result of 0 cells/ml 
(78.4%) and mean result 3.5 cells/ml (n=47). H) DAPI observations on cytospun urine show 32.5% samples 
contain clean cast cells and 43.7% contain either clue cells or clue cells with PMNs (n=80). I) 11.34% of the OAB 
CSU cohort (n=26) were identified with potential infection by reduced threshold of 103 CFU/ml and university 
culture. J) Range of epithelial cell count performed by Sternheimer staining and haemocytometer from 0 cells/ml 
to 15 cells/ml with a mode result of 0 cells/ml (85.7%) and mean result 0.9 cells/ml (n=28).  K) Range of WBC 
count performed by Sternheimer staining and haemocytometer from 0 cells/ml to 500 cells/ml with a mode result 
of 0 cells/ml (74.2%) and mean result 18.7 cells/ml (n=28). L) DAPI observations on cytospun urine shows 50.0% 
of samples contain cast cells and much of the remainder contain nothing (37.5%, n=48). M) 18.2% of the Control 
CSU cohort (n=12) were identified with potential infection by reduced threshold of 103 CFU/ml and university 
culture. N) Range of epithelial cell count performed by Sternheimer staining and haemocytometer from 0 cells/ml 
to 2 cells/ml with a mode result of 0 cells/ml (91.7%) and mean result 0.1 cells/ml (n=12). O) Mode result for 
WBC count performed by performed by Sternheimer staining and haemocytometer was 0 cells/ml (100%, n=12). 
P) DAPI observations on cytospun urine shows 33.3% of samples contain clean cast cells and 66.7% contained no 
cells (n=12).  
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4.4.2 ISOLATES OMITTED FROM ANALYSIS  
A total of 577 isolates isolated and cryopreserved from OAB MSU, 801 from 
Control MSU, 63 from OAB CSU and 38 from Control CSU giving a total number of 
1479 isolates collected (table 4.2).  
   Of a total 1479 cultured isolates from 227 samples across all cohorts, 1354 (91.54%, 
n=1479) were successfully sequenced, 40 had failed regrowth (2.7%, n=1479), 18 
failed PCR (1.2%, n=1479), 43 failed sequencing (2.9%, n=1479). 87 inconclusive 
Gram stains (5.8%, n=1479). Of the successfully sequenced isolates, 87 had 
inconclusive Gram stains and therefore could not be confirmed by Gram stain 
concordance (6.4%, n=1479), and 221 had non-concordant Gram stains (14.9%, 
n=1479) (table 4.2). 
In three cases, a successful sequence was generated however there was no 





















# of Isolates identified 577 801 63 38 1479 100% 
Failed regrowth 17 22 0 1 40 2.7% 
Contaminated regrowth 10 8 0 0 18 1.2% 
Failed PCR 4 11 0 0 15 1.0% 
Failed sequencing 14 24 2 3 43 2.9% 
Inconclusive Gram stains 37 40 10 0 87 5.8% 
Non-concordant Gram stains 96 125 0 0 221 14.9% 
Table 4.2: Total number of isolates from each cohort missing or omitted from analysis. A total of 577 
isolates collected from OAB MSU, 801 from Control MSU, 63 from OAB CSU and 38 from Control CSU giving a total 
number of 1479 isolates collected. 2.7% of total isolates failed to regrow upon resuscitation. 1.2% of total isolates 
were too contaminated to perform PCR. 1.0% of total isolates failed PCR twice with different primers on each 
occasion. 5.8% of total isolates could not be identified by their Gram stain. 14.9% of total isolate BLAST results 
indicated a species that were not in concordance with the original Gram stain noted. 
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4.4.3 HOSPITAL TEST ACCURACY  
 Since the threshold of bacteria is set to 105 CFU for hospital pathology, many 
possible infections could be missed. By reducing this threshold to 103 CFU, it is 
possible to determine any possible low-level infections from each sample. Results 
show that by decreasing the threshold of bacteria to 103, the number of infections 
identified in OAB MSU is increased from 8.47% by hospital culture (n=59, table 4.3) 
to 21.43% by university culture (n=28, table 4.4). This is more than a two-fold 
increase. A two-fold increase is also identified in OAB CSU from 5.66% to 11.53%. 
Interestingly, although control samples were not sent for hospital culture, data shows 
that university culture identifies 35.0% of control MSU samples to have a low level 
infection, higher than in OAB (21.43%)(table 4.4).  
   Hospital test accuracy was determined by comparing dipstick analysis with 
traditional methods of cell counting and identification of infection by both hospital 
methods and university culture. Since control MSUs were not sent for pathology and 
there were restrictions on tests which could be performed on OAB CSUs in theatre, 
only OAB MSU were used for comparison of hospital culture, and only control MSU 
and OAB MSU were used for university culture.  Leukocyte esterase dipstick results 
were positive in 4/5 cases of positive infection by hospital culture in OAB MSU 
samples (table 4.3). Interestingly, of infections identified by reduced threshold of 
bacteria in OAB MSU (n=6), only 1 of these samples had positive leukocyte esterase, 
suggesting higher bacterial presence is required to have measurable leukocyte 
esterase.  These positive leukocyte esterase incidences do not however correlate with 
positive leukocyte count. Furthermore, many positive leukocyte esterase results do 
not correlate with infection (n=17/66) (data not shown).  
   Nitrite dipstick results are also used to indicate an infection by presence of bacteria. 
From both hospital culture and university culture methods, positive nitrites do not 
correlate with positive infection with 0.0% of all identified infections having positive 
nitrites (table 4.3 & 4.4). In fact, of all samples tested with a dipstick (n=134), only 6 





 Control MSU OAB MSU OAB CSU 
Infections identified by hospital culture N/A 5/59 (8.47%) 3/53 (5.66%) 
Infections with +ve leukocyte esterase N/A 4/5 (80.0%) N/A 
Infection with +ve nitrites N/A 0/5 (0.0%) N/A 
Infections with +ve leukocyte cell count N/A 0/5 (0.0%) N/A 
Table 4.3: Infections identified by hospital culture and respective dipstick findings. Control MSU samples 
were not sent for hospital pathology as they were not suspected of having an infection. Of 59 OAB MSU samples 
sent for hospital pathology, 5 (8.47%) were identified as having an infection and withdrawn from further analysis. 
Of the 5 samples which were positively identified as having an infection, 4/5 (80.0%) had positive leukocyte 
esterase however 0.0% had a positive leukocyte cell count (>10/mL) or positive nitrites. Of 53 OAB CSU samples 
sent for hospital pathology, 3 (5.66%) were identified as having an infection and withdrawn from further analysis. 
OAB CSU samples were not able to be dipsticked so this data is not available. 
 
 Control MSU OAB MSU OAB CSU 
Infections identified by university culture 9/25 (36.0%) 6/28 (21.4%) 3/26 (11.5%) 
Infections with +ve leukocyte esterase 1/9 (11.11%) 1/6 (16.67%) N/A 
Infection with +ve nitrites 0/9 (0.0%) 0/6 (0.0%) N/A 
Infections with +ve leukocyte cell count 1/9 (11.11%) 0/6 (0.0%) N/A 
Table 4.4: Infections identified by university culture and respective dipstick findings. Of 25 Control MSU 
samples cultured in the laboratory, 9 (36.0%) were identified as having a potential infection by reducing the 
threshold to 103 CFU/ml. Of the 9 samples that were positively identified as having an infection, 1/9/ (11.1%) had 
positive leukocyte esterase and a positive leukocyte cell count (>10/mL) however 0/9 (0%) had positive nitrites. 
Of 28 OAB MSU samples cultured in the laboratory, 6 (21.43%) were identified as having a potential infection. Of 
the 6 samples that were positively identified as having an infection, only 1/6 (16.7%) had positive leukocyte 
esterase however 0.0% had a positive leukocyte cell count (>10/mL) or positive nitrites. Of 26 OAB CSU samples 
cultured in the laboratory, 6 (21.43%) were identified as having a potential infection. OAB CSU samples were not 
able to be dipsticked so this data is not available. 
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4.4.4 CULTURED ISOLATES FROM URINE SAMPLES 
 By identifying the species of all culturable isolates by 16s rRNA sequencing it 
was possible to map the differences in the microbiome of patients with OAB 
compared to controls to identify any potential species of interest. Percentage 
incidence of all species was compared between OAB MSU (n=60) and Control MSU 
(n=82). Species with non-concordant Gram stains, and individuals with confirmed 
UTI by hospital pathology (n=5) were excluded. Figure 4.5 shows decreased incidence 
of Staphylococcus from 65.9% in controls to 50.0% in OAB (p=0.084), Lactobacillus 
from 54.9% to 18.3% (p<0.0001****), Peptoniphilus from 26.8% to 20.0% (p=0.456), 
and Fusobacterium from 25.6% to 13.3% (p=0.114). Also observed is increased 
incidence of Escherichia coli from 11.0% in control to 30.0% in OAB (p=0.008**), 
Bifidobacterium from 7.3% to 15.0% (p=0.232), Actinobaculum from 2.4% to 11.7% 
(p=0.104), Proteus from 2.4% to 20.0% (p=0.001**) and Clostridium from 1.2% to 
8.3% (p=0.097). Statistical significance on incidences of bacterial presence was 
calculated using chi-squared test for all species (figure 4.5). 
   From the introduction, it was mentioned that species such as Aerococcus, 
Arthrobacter, Corynebacterium and Gardnerella are underreported Gram-positive 
uropathogens more prevalent in the elderly. From this data there is no major 
difference between the incidence of Corynebacterium (36.6% in Control and 33.3% in 
OAB) or Gardnerella (18.3% in Control and 11.7% in OAB). There is a slight increase 
in incidence of Aerococcus (from 1.2% in controls to 3.3% in OAB) however frequency 
is still extremely low (figure 4.5).  
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Figure 4.5: Percentage of patients with incidence of genus grown from OAB and Control MSU samples of urine. A total of 970 isolates cultured from MSU samples grown from 
82 Control MSU samples and 60 OAB MSU samples were successfully identified by sequencing of the 16s rRNA gene. Incidence of each species is expressed as a percentage of samples 
with genus from the total number of samples. Decreased incidence from controls to OAB can be seen with Staphylococcus from 65.9% to 50.0% (p>0.05), Lactobacillus from 54.9% to 
18.3% (p<0.0001***), Peptoniphilus from 26.8% to 20.0% (p>0.05), and Fusobacterium from 25.6% to 13.3% (p>0.05). Increased incidence from controls to OAB can be seen with 
Escherichia coli from 11.0% to 30.0% (p<0.01**), Bifidobacterium from 7.3% to 15.0% (p>0.05), Actinobaculum from 2.4% to 11.7% (p>0.05), Proteus from 2.4% to 20.0% (p<0.01**), 
and Clostridium from 1.2% to 8.3% (p>0.05). 
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   By comparing the total number of species per patient it can be observed that the 
mean number of species is significantly greater in both Control MSU (n=82) (4.61 
species per patient) and OAB MSU (n=60) (4.32 species per patient) than Control CSU 
(n=14) (1.79 species per patient) and OAB CSU (n=42) (0.95 species per patient) 
(p<0.0001*** by T test) (figure 4.6A).  
   By comparing Control CSU (n=14) and OAB CSU (n=42), again omitting non-
concordant Gram stains, it can be seen that there are some differences between the 
species of bacteria from each cohort. There is a decreased incidence of Lactobacillus 
(28.6% to 14.3%, p=0.378), Acidovorax (21.4% to 7.1%, p=0.318), Serratia (21.4% to 
0.0%, p=0.016*), Staphylococcus (14.3% to 4.8%, p=0.549), and Gardnerella (14.3% 
to 4.8%, p=0.549) from Control to OAB (figure 4.6). There is also an increased 
incidence of Streptococcus (7.1% to 14.3%, p=0.816) and Escherichia coli (0.0% to 
11.9%, p=0.417). Of these differences, only that of Serratia is significant (p=0.017*). 
Statistical significance on incidences of bacterial presence was calculated using chi-
squared test for all species (figure 4.6B). All p values for incidence of bacteria 
calculated using Chi squared test. 
   Analysing CSU data for underreported emerging Gram-positive uropathogens, there 
is again no significant increase in OAB of any of the species of interest in the data, but 
rather incidence is lower in OAB than controls. Gardnerella incidence is reduced from 
Controls (14.3%) to OAB (4.8%) (p=0.549), as is Corynebacterium (from 7.1% to 
2.4%, p=0.405), Arthrobacter (from 7.1% to 0.0%, p=0.56) and Aerococcus (from 




Figure 4.6: Frequency and percentage incidence of bacteria cultured from OAB and Control CSU samples of 
urine. A) The mean number of species successfully identified from Control MSU samples (n=82) and OAB MSU 
samples (n=60) are 4.61 and 4.32 respectively.  Significantly fewer species were identified per sample from 
Control CSU (n=14) and OAB CSU (n=42) at a mean of 1.79 and 0.95 species per patient respectively (p<0.0001*** 
by T test). This indicates MSU samples are contaminated with perineal bacteria. B) A total of 85 isolates cultured 
from MSU samples grown from 14 Control CSU samples and 42 OAB CSU samples were successfully identified by 
sequencing of the 16s rRNA gene. Incidence of each species is expressed as a percentage of samples with genus 
from the total number of samples. Decreased incidence from controls to OAB can be seen with Lactobacillus from 
28.6% to 14.3% (p>0.05), Acidovorax from 21.4% to 7.1% (p>0.05), Serratia from 21.4% to 0.0% (p<0.01*), 
Staphylococcus from 14.3% to 4.8% (p>0.05), and Gardnerella from 14.3% to 4.8% (p>0.05). Increased incidence 
from controls to OAB can be seen with Streptococcus from 7.1% to 14.3% (p>0.05), and Escherichia coli from 0.0% 
to 11.9% (p>0.05).  
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 By collating data on the incidence of bacterial presence for all MSU, CSU, 
Control and OAB samples, it can be more easily compared. Figure 4.7 takes the 12 
most commonly found species from this study and compares the incidence between 
the patient cohorts. Staphylococcus is found in high percentages (50% to 65.5%) in 
both control and OAB MSU samples but in low percentages in both control and OAB 
CSU samples (4.8% to 14.3%, p=0.00001***)(figure 4.7A). Lactobacillus is found in 
high percentages in MSU (54.88%) and CSU controls (28.6%) but in low percentages 
in MSU (18.3%) and CSU OAB (14.3%, p=0.00001***)(figure 4.7B). Streptococcus is 
found in high percentages (50% to 53.3%) in both control and OAB MSU samples but 
in low percentages in both control and OAB CSU samples (7.1% to 14.3%, 
p=0.000***)( figure 4.7C). Corynebacterium is found in relatively high percentages 
(33.3% to 36.6%44) in both control and OAB MSU samples but in low percentages in 
both control and OAB CSU samples (0% to 7.1%, p=0.0001***)(figure 4.7D).  
Peptoniphilus is found in relatively high percentages (20% to 26.8%) in both control 
and OAB MSU samples but in low percentages in both control and OAB CSU samples 
(0% to 2.4%, p=0.0427*)(figure 4.7E). Enterobacter is found in relatively high 
percentages (1316.6% to 20.7%) in both control and OAB MSU samples but is not 
present at all in control and OAB CSU samples (p=0.0265*, figure 4.7F).  Acidovorax is 
not found in MSU samples but can be found in 21.4% of control CSU samples and 
14.3% of OAB CSU samples (p=0.00016***, figure 4.7G).  Serratia is found in few 
control and OAB MSU samples (3.7% to 10%), however it was found in 21.4% of 
control CSU samples and 0% OAB CSU samples (p=0.03316*, figure 4.7H). E.coli was 
found in few control MSU samples (11%) and no control CSU samples, however it was 








Figure 4.7: Incidence of bacterial presence in samples by patient cohort. A) Staphylococcus is found in high 
percentages (50% to 65.5%) in both control and OAB MSU samples but in low percentages in both control and 
OAB CSU samples (4.8% to 14.3%)(p=0.00001***). B) Lactobacillus is found in high percentages in MSU (54.88%) 
and CSU controls (28.6%) but in low percentages in MSU (18.3%) and CSU OAB (14.3%)(p=0.00001***). C) 
Streptococcus is found in high percentages (50% to 53.3%) in both control and OAB MSU samples but in low 
percentages in both control and OAB CSU samples (7.1% to 14.3%)(p=0.00044***). D) Corynebacterium is found 
in relatively high percentages (33.3% to 36.6%) in both control and OAB MSU samples but in low percentages in 
both control and OAB CSU samples (0% to 7.1%)(p=0.0001***).  E) Peptoniphilus is found in relatively high 
percentages (20% to 26.8%) in both control and OAB MSU samples but in low percentages in both control and 
OAB CSU samples (0% to 2.4%)(p=0.0427*). F) Enterobacter is found in relatively high percentages (1316.6% to 
20.7%) in both control and OAB MSU samples but is not present at all in control and OAB CSU samples 
(p=0.0265*). G) Acidovorax is not found in MSU samples but can be found in 21.4% of control CSU samples and 
14.3% of OAB CSU samples (p=0.00016***). H) Serratia is found in few control and OAB MSU samples (3.7% to 
10%), however it was found in 21.4% of control CSU samples and 0% OAB CSU samples (p=0.03316*). I) E.coli 
was found in few control MSU samples (11%) and no control CSU samples, however it was present in 30% OAB 
MSU samples and 11.9% OAB CSU samples (p=0.00797***). All P values calculated using a 2x4 Chi squared test. 
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4.4.5 IDENTIFYING INTRACELLULAR BACTERIA 
 Intracellular bacteria were identified by deduction of CFU count post-wash 
from CFU count post Triton X-100 during the antibiotic protection assay. Total 
percentage of patients with intracellular bacteria identified from OAB MSU (n=31) 
was 58.1% compared with 56.7% from Control MSU (n=30, p>0.05 by chi squared 
test) (figure 4.8A).  
   The species of intracellular bacteria from each group are shown in figure 4.8 and 
show reduced incidence of Staphylococcus 36.7% in control to 23.3% in OAB, as well 
as reduced Arthrobacter (10.0% to 0.0%, p=0.236), and Peptoniphilus (10.0% to 0.0%, 
p=0.236). Increased incidence of Streptococcus (0.0% to 10.0%, p=0.236) and Serratia 
(0.0% to 6.7%, p=0.472) are also observed. Statistical significance on incidences of 
bacterial presence was calculated using chi-squared test for all species (figure 4.8B). 
 
 
Figure 4.8: Frequency and percentage incidence of intracellular bacteria cultured from OAB and Control 
MSU samples of urine. A) The percentage of patients from Control MSU samples (n=30) and OAB MSU samples 
(n=30) from which intracellular bacteria were cultured are 58.1% and 56.7% respectively, which is not 
statistically significant (p>0.05). This indicates intracellular bacteria are not unique to OAB. B) A total of 60 
isolates from 30 Control CSU samples and 30 OAB CSU samples were identified as intracellular by antibiotic 
protection assay followed by sequencing of the 16s rRNA gene. Decreased incidence from controls to OAB can be 
seen with Staphylococcus from 36.7% to 23.3% (p>0.05), Arthrobacter from 10.0% to 0.0% (p>0.05), and 
Peptoniphilus from 10.0% to 0.0% (p>0.05), Increased incidence from controls to OAB can be seen with 




4.4.6 USING BLADDER BIOPSIES TO IDENTIFY INTRACELLULAR BACTERIA 
Hultgren et al have previously identified intracellular bacteria from bladder 
biopsies taken from individuals with UTI (figure 4.9). By the EM images of bladder 
biopsies from individuals with OAB, it can be seen that many autophagosomes were 
observed (figure 4.10A). Furthermore, we found in one sample a particular blood 
vessel with an infiltrating neutrophil (figure 4.10B).  
 
 
Figure 4.9: Example of transmission electron microscopy images of intracellular bacteria in bladder 
urothelial cells, adapted from Anderson et al (144). Large white round biopods containing dark elongated 
intracellular bacteria identified by white arrows. Images taken of bladder urothelial cells infected with 




Figure 4.10: - Transmission electron microscopy (TEM) images of autophagosomes in bladder biopsies 
from patients with OAB. A) Autophagosomes are seen in all samples processed for TEM (n=6). Multivesicular 
bodies (MVBs) are probably late endosomes (autophagosomes) associated with autophagy. Programmed cell 
death and/or intracellular bacteria can cause autophagy. B) Extravasating neutrophil seen in 1 of 6 samples 
processed for TEM suggests possible infection.  
    
Bladder biopsies were also used for culture, allowing potentially more insight into 
intracellular bacteria and those closely associated to the urothelium. Of 24 biopsies 
taken, only 5 cultured bacteria, which leave 79.2% of samples with no growth. From 
figure 4.7 it can be seen that the percentage of MSU samples with no growth from 
OAB is 40.5%. Of the biopsies where there was positive culture, species identified are 
Staphylococcus (n=2), Peptoniphilus (n=2), Haemophilus (n=1) and Acidovorax (n=1) 




4.4.7 FACTORS AFFECTING THE BLADDER MICROBIOME 
 It has been recognised that factors such as age, hormones, and diet can affect 
other human microbiomes such as the gut. From the groups obtained, the mean age of 
OAB MSU and OAB CSU combined (n=111) is 57.8 years (SD=15.9 years), whereas the 
mean age of control MSU and CSU combined (n=91) is 39.1 years (SD=14.7 years) 
(p<0.0001*** by T test) (figure 4.11A). The mean BMI of the OAB MSU (n=39) cohort 
was significantly higher (29.1, SD=5.8) than that of the control MSU group (26.4, 
SD=5.3) (p=0.008**). This significance carries into the CSU cohorts also with the 
mean BMI of the OAB CSU cohort of 29.7 (SD=6.0) compared with 23.7 (SD=4.2) for 
controls (p=0.005**) (figure 4.11B). 
 
 
Figure 4.11: Mean AGE and BMI of OAB and control MSU and CSU samples of urine. A) The mean ages of both 
control MSU (39.6 years, n=79) and control CSU (36.3 years, n=11) differ significantly (P<0.0001***) from the ages 
of both OAB MSU (59.1 years, n=58) and OAB CSU (56.2 years, n=11) suggesting OAB is more prevalent in older 
women. B) The mean BMI of both control MSU (26.4, n=73) and control CSU (23.7, n=11) differ significantly 
(P<0.001**) from the BMI of both OAB MSU (29.1, n=39) and OAB CSU (29.7, n=49) suggesting individuals with 
OAB are generally heavier than controls. Statistical significance calculated using a Studentǯs T-test. 
149 
 
   By grouping patients by age for MSU samples, it is possible to identify trends with 
increasing age from controls that can be compared to OAB. Control MSU samples 
were split into three age groups for analysis; 20 to 44 (n=53), 45 to 64 (n=18), over 
65 (n=5). Staphylococcus incidence remains relatively equivalent between OAB and 
controls across the age groups although incidence decreases in both cohorts with age 
(figure 4.12A). Lactobacillus incidence is much lower in OAB than controls in ages 20-
64 years however no control patients over 65 years had Lactobacillus in their 
samples (figure 4.12B). Streptococcus incidence remains relatively equivalent 
between OAB and controls in ages 20-64 years, however in 65+ years, there are more 
OAB patients with Streptococcus than controls (figure 4.12C). Corynebacterium 
incidence remains relatively equivalent between OAB and controls across the age 
groups and ages (figure 4.12E). Peptoniphilus incidence remains relatively equivalent 
between OAB and controls in ages 20-64 years, however in 65+ years, there are more 
control patients with Peptoniphilus than OAB (figure 4.12E). Fusobacterium incidence 
remains relatively equivalent between OAB and controls in ages 20-64 years, 
however no control patients over 65 years had Fusobacterium in their samples (figure 
4.12F). Enterococcus incidence remains relatively equivalent between OAB and 
controls across the age groups and ages (figure 4.12G). Gardnerella incidence 
increases with age in controls however is reduced in patients with OAB over 65 years 
(figure 4.12H). Anaerococcus incidence is reduced in patients with OAB with 
increased age, however control patients over 65 years have Anaerococcus (figure 
4.12I). 
   From this it can be deduced that in OAB there are a few differences in trends with 
age; i) incidence of Staphylococcus, Corynebacterium, and Enterococcus remain 
relatively unaffected by diseases state or age., ii) post 65 years, incidence of 
Lactobacillus, Streptococcus and Fusobacterium increases in OAB but decreases in 
controls, iii) post 65 years, incidence of Peptoniphilus, Gardnerella and Anaerococcus 
decreases in OAB but increases in controls. 
   Statistics were not performed for this data due to the fact that the samples sizes for 
the older cohort of control and the younger cohort of OAB were very small and 
therefore rendered Chi squared tests invalid. However, trends were identified, which 




Figure 4.12: Percentage incidence of bacteria cultured from OAB and Control MSU samples of urine by age.  
Control samples (n=82) are split into age groups of 20-44 (n=53), 45-64 (n=18) and 65+ (n=5). OAB MSU samples 
(n=60) are split into age groups of 20-44 (n=11), 45-64 (n=24) and 65+ (n=23). A) Incidence of Staphylococcus 
remains relatively unaffected by diseases state or age. B) Post 65 years, incidence of Lactobacillus increases in 
OAB but decreases in controls. C) Post 65 years, incidence of Streptococcus increases in OAB but decreases in 
controls. D) Incidence of Corynebacterium remains relatively unaffected by diseases state or age. E) Post 65 years, 
incidence of Peptoniphilus decreases in OAB but increases in controls. F) Post 65 years, incidence of Fusobacterium 
increases in OAB but decreases in controls. G) Incidence of Enterococcus remains relatively unaffected by diseases 
state or age. H) Post 65 years, incidence of Gardnerella decreases in OAB but increases in controls. I) Post 65 
years, incidence of Anaerococcus decreases in OAB but increases in controls. Statistics were not performed for this 























































































































































































































































































































































































































A)	 	 						 	 																							B)	 	 	 	 	 										C) 	 		
D)	 	 						 	 																		 	E)	 	 	 	 	 											F) 	 		
G)	 	 						 	 																		 	H)	 	 	 	 																					I) 	 		
KEY:-	 Control		 20-44	yrs	 n	=	53	 OAB	 20-44	yrs	 n	=	11	
45-64	yrs	 n	=	18	 45-64	yrs	 n	=	24	
65+	yrs	 n=	5	 65+	yrs	 n	=	23	
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 By comparing various factors of the bladder environment, it is possible to see if the 
bladder environment differs between OAB and controls. There is no significant 
difference between the pH of OAB (mean pH 6.0, n=62) or control groups (pH 6.2, 
n=68) (p=0.35) (figure 4.13A). The mean concentration of ATP/creatinine for 
controls was found to be 3.75x10-11 nM/mg/dL (SD=3.41x10-11 nM/mg/dL), slightly 
higher than that of controls at 2.92x10-11 nM/mg/dL (SD=2.13x10-11 nM/mg/dL), 
however not significantly so (p=0.19) (figure 4.13B). Contrary to expectations, IL-8 
tends to be higher in controls (0.86pg/ml, SD=1.14pg/ml) than OAB (0.58pg/ml, 
SD=0.95pg/ml), however this is also not significant (p=0.23) (figure 4.13C).  
Statistical significance of means of cohorts was calculated using an unpaired two 
tailed t-test. 
 
Figure 4.13: Mean pH, ATP and IL-8 concentration of OAB and Control MSU samples of urine. A) Mean pH of 
OAB MSU samples (pH 6.0, n=62) does not differ significantly from that of control MSU samples (pH 6.2, n=68) 
(p>0.05). B) Mean concentration of ATP/creatinine of OAB MSU samples (2.92x10-11 nM/mg/dL, n=41) does not 
differ significantly from that of control MSU samples (3.75x10-11 nM/mg/dL, n=39) (p>0.05). C) Mean 
concentration of IL-8/creatinine of OAB MSU samples (0.58pg/ml, n=41) does not differ significantly from that of 
control MSU samples (0.86pg/ml, n=39) (p>0.05). 
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4.4.8 GRAM NEGATIVE SPECIES  
 As opposed to looking at how factors may affect the microbiome, it is just as 
likely that the increased incidence of Gram negative bacteria in the microbiome could 
affect the bladder environment. Gram negative species are taken here as; Bordetella, 
Campylobacter, Dialister, E.coli, Fusobacterium, Haemophilus, Klebsiella, Olligella, 
Prevotella, Proteus, Pseudomonas, Serratia, Shigella, Sneathea, and Viellonella.  Taken 
together there is a 73.4% incidence of Gram negative bacteria in OAB MSU (n=60) 
compared to 54.2% in control MSU (n=82) (p=0.027* with chi squared test) (figure 
4.14). 
 
   Downstream signalling from LPS stimulation of PRRs are release of cytokines and 
increased ATP release, therefore by comparing Gram negative bacteria with the 
concentration of IL-8 and ATP it may be possible to determine if the presence of Gram 
negative bacteria is affecting the bladder environment. OAB MSU samples were 
separated into those with Gram negative species in their urine (n=28) and those 
without (n=11), and control samples also separated into those with Gram negative 
species (n=20) and those without (n=21). The mean concentration of IL-8 for OAB 
MSU with Gram negative species is 0.67 pg/mL, SD=1.08 pg/mL, slightly higher than 
that of OAB MSU samples without Gram negative species, 0.36 pg/mL, SD=0.44 
pg/mL. This is in keeping with the theory that Gram negative species increases IL-8 
concentration however is not statistically significant by a T test (P=0.37) (figure 
4.15A). Interestingly however, the concentration of IL-8 is higher in controls without 
Figure 4.14: Frequency of Gram negative 
bacteria cultured from OAB and Control MSU 
samples of urine. Gram negative bacteria 
included are Bordetella, Campylobacter, Dialister, 
E.coli, Fusobacterium, Haemophilus, Klebsiella, 
Olligella, Prevotella, Proteus, Pseudomonas, 
Serratia, Shigella, Sneathea, and Viellonella. 
Incidence of Gram negative bacteria is 
significantly higher in OAB MSU (73.4%, n=60) 




Gram negative species (0.93 pg/ml, SD=1.42 pg/ml) than those with (0.80 pg/ml, 
SD=0.78 pg/ml) which is contradictory, however this is again not a statistically 
significant difference (figure 4.15A).  The mean concentration of ATP for OAB MSU 
with Gram negative species is 3.41x10-11 nM/mg/dL, (SD=3.57x10-11 nM/mg/dL), 
slightly lower than that of OAB MSU samples without Gram negative species, 4.60x10-
11 nM/mg/dL (SD=2.93x10-11 nM/mg/dL) (figure 4.14B), however is not statistically 
significant by a T test (P=0.37). The concentration of ATP is relatively similar in both 
groups of controls with a mean concentration of 2.77x10-11 nM/mg/dL (SD=2.05x10-
11 nM/mg/dL) ATP in those with Gram negative species and 3.05x10-11 nM/mg/dL 
(SD=2.25x10-11 nM/mg/dL) ATP in those without, and the overall concentration ATP 
is lower in controls than OAB combined however this is not statistically significant by 
a T test (p=0.19) (figure 4.15B). 
 
Figure 4.15: Mean concentration of Interleukin-8 and ATP for OAB and control cohorts with and without 
Gram negative species. On 41 control MSU and 39 OAB MSU samples, a luciferin/luciferase assay and IL-8 ELISA 
was performed on frozen urine samples. Results were divided by creatinine to standardise them. Of the 41 control 
MSU samples assayed, 20 cultured Gram negative species and 21 did not. Of the 39 OAB MSU assayed, 28 cultured 
Gram negative species and 11 did not. A) Mean concentration of IL-8 for OAB MSU with Gram negative species 
(n=28) is 0.67 pg/mL, SD=1.08 pg/mL, higher than that of OAB MSU samples without Gram negative species 
(n=11)(0.36 pg/mL, SD=0.44 pg/mL, P>0.05) however the opposite is observed in the Control cohort; mean 
concentration of IL-8 is higher for those without Gram negative species (n=21)(0.93 pg/ml, SD=1.42 pg/ml) than 
with Gram negative species (0.80 pg/ml, SD=0.78 pg/ml). B) Mean concentration of ATP for OAB MSU without 
Gram negative species (n=11) is 4.60x10-11 nM/mg/dL (SD=2.93x10-11 nM/mg/dL), higher than that of OAB MSU 
samples with Gram negative species (n=28) (3.41x10-11 nM/mg/dL, SD=3.57x10-11 nM/mg/dL) (P>0.05). This is 
higher still in control cohort with mean ATP measured at 2.77x10-11 nM/mg/dL (SD=2.05x10-11 nM/mg/dL) in 
those with Gram negative bacteria (n=20) and even higher in the control group without Gram negative bacteria 
(n=21) (3.05x10-11 nM/mg/dL, SD=2.25x10-11 nM/mg/dL) (p>0.05). 
154 
 
4.4.9 REDUCED FREQUENCY OF LACTOBACILLUS IN OAB  
 From MSU (figure 4.5) and CSU data (figure 4.6B), it was observed that there 
was a significantly reduced incidence of Lactobacillus in OAB compared to controls By 
reanalysing the exact species of Lactobacillus found in MSU samples, it is possible to 
determine the exact species present in healthy controls which may be missing in 
those with OAB and may be protective to the bladder. From control MSU (n=82), ʹͲ.͹% of individualsǯ samples grew L.gasseri and L.psittaci, whereas these 
frequencies are reduced to 11.7% and 8.3% respectively in the OAB cohort (n=60). 
7.3% of controls grew L.iners, L.crispatus and L.hominis (figure 4.16), all of which are 
reduced in OAB. Across all species of Lactobacillus, there is a reduced incidence, 
except with L.casei and L.plantarium, however these exist in only 1.7% of OAB MSU. 
Of particular interest is the complete lack of L.crispatus, L.hominis, and L.acidophilus 
in OAB (figure 4.16). None of the differences are statistically significant by Chi 
squared test (p>0.05). 
 
Figure 4.16: Percentage incidence of Lactobacillus species cultured from OAB and Control MSU samples of 
urine. A total of 75 Lactobacillus isolates cultured from MSU samples grown from 82 Control CSU samples and 60 
OAB CSU samples were successfully identified by sequencing of the 16s rRNA gene. Incidence of each species is 
expressed as a percentage of samples with genus from the total number of samples. Decreased incidence from 
controls to OAB can be seen with all species of Lactobacillus particularly L.gasseri from 20.7% to 11.7% (p>0.05), 
L.psittaci from 20.7% to 8.3% (p>0.05), and L.iners, L.crispatus and L.hominis from 7.3% to 0.0% (p>0.05). 
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   As mentioned, Lactobacillus has probiotic capabilities particularly against Gram 
negative species. By comparing incidence of Lactobacillus with Gram negative species 
it can be observed that in control MSU (n=82), there are fewer individuals with Gram 
negative species only, 24.4%, compared to OAB (n=60) at 60.7% (figure 4.17A). 
Furthermore, the percentage of patients with Lactobacillus only is 21.9% in controls, 
lower than that of OAB at only 8.2%.  
   Since Lactobacillus frequency is significantly reduced in OAB groups, and Gram 
negative species are significantly increased, these differences could affect observed 
pH or ATP levels in the bladder. The mean pH of individuals with Lactobacillus is pH 
6.0 for OAB MSU (n=61) and pH 6.2 for control MSU (n=67), however the difference 
between the means is greater between individuals with OAB without Lactobacillus 
(pH 6.2) and controls without Lactobacillus (pH 5.8) (figure 4.17B). These results are 
not statistically significant by performing a one-way ANOVA dependent on both 
Lactobacillus status and OAB status (p>0.5) and was confirmed with a Mann-Whitney 
U (p=0.694) due to non-normal distribution of the pH demographics.  
 
 
Figure 4.17: Gram negative bacteria incidence and pH of urine in combination with Lactobacillus incidence 
from OAB and Control MSU samples of urine. A) In controls (n=82) the percentage of individuals with Gram 
negative species only (24.4%) is relatively similar to that of those with Lactobacillus only (22.0%) with slightly 
more (33.0%) growing both. In OAB (n=60), 66.7% cultured Gram negative species only and only 8.2% grew 
Lactobacillus only, suggesting a lack of Lactobacillus may be allowing Gram negative species to grow in this cohort. 
B) The mean pH is slightly lower in those with Lactobacillus (pH 6.0) (n=11) than without Lactobacillus (pH 6.2) 
(n=49) in the OAB cohort (n=60), however not significantly by ANOVA (p>0.05). This is not seen in controls 




    The aims of this chapter were to determine key bacterial species in OAB, to 
investigate alternative biomarkers for OAB, and to determine if there is an 
intracellular bacterial component to OAB. Following investigation, the main findings 
are: - i) low-level infections (103 CFU/ml as determined by university culture) does 
not correlate with symptoms of OAB, ii) incidence of emerging (i.e. recently 
hypothesised) Gram positive uropathogens (e.g. Aerococcus, Arthrobacter, 
Corynebacterium and Gardnerella) are not increased in patients with OAB, iii) there is 
an increase in the incidence of Gram negative species (e.g. E.coli, Proteus and Serratia) 
in patients with OAB, iv) intracellular bacteria are equally present in control and OAB 
samples, and as such likely a normal part of the bladder microbiome, v) alterations in 
the microbiome over time (i.e. with increasing age) may predispose women to OAB 
rather than any particular bacterial infection, vi) Lactobacillus is significantly reduced 
in patients with OAB and correlates with increased incidence of Gram negative 
uropathogens and may be developed into a possible biomarker for OAB. 
4.5.1 GRAM-NEGATIVE UROPATHOGENS IN OAB 
 Gram negative species are the leading cause of UTI and of particular interest 
following the recent discovery of low-level bacteriuria in OAB suggesting UTI may be 
a cause of OAB. As expected, by reducing the threshold of infection to 103 CFU/ml, the 
percentage of patients with urinary infections increases two fold in both MSU and 
CSU samples. However, the percentage of control MSU samples with low-level 
infections is 35.0%, higher than in OAB MSU, which is 21.43%, suggesting that not all 
species at 103 CFU/ml or more may be detrimental as previously suggested (134-
136). On the other hand it could be proposed that mere incidence is more relevant 
that colony count or that changes in an individualǯs microbiome over time 
predisposes OAB. 
   Our data has shown however that Gram negative species are found in increased 
incidence in OAB compared to controls. Of particular interest are those species which 
were increased significantly; E.coli and Proteus. The more recent investigations using 
ECUQ and culture-independent 16s rRNA sequencing have not noted these species to 
be of particular interest. This could be due to the rapid growth rates of E.coli and 
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Proteus, which swarm and outgrow other bacterial species and hence, supports the 
use of culture-independent methods for further investigation.  
   Looking at incidence of other Gram negative species of interest, it was seen that 
Acidovorax, was only found only in CSU samples which highlights the highly adhesive properties of the genus and itǯs ability to form biofilms in the bladder (figure 4.7G). 
Enterococcus, on the other hand, was not found in any CSU samples (figure 4.7F). This 
could suggest that once in the bladder, is much more intracellular, which has been 
supported by evidence showing this to be a highly intracellular species (152). Serratia 
was found to be highest in control MSU samples, which, considering the high 
pathogenicity and highly adhesive properties of this species, can only be explained as 
a data anomaly.  
   Our data were inconclusive in determining how Gram negative species may alter the 
environment since comparisons with Gram negative incidence and IL-8 and ATP 
concentration were not significantly different in either OAB MSU or control MSU but 
also IL-8 was higher in controls without Gram negative species. The concentration of 
ATP tended to be higher in OAB than in controls however this does not appear to be 
due to the presence of Gram negative bacteria. Taken together this contradicts the 
theory that Gram negative species leads to downstream pro-inflammatory cytokines 
and ATP release. 
    A possible continuation from this would be to perform an endotoxin assay to 
quantify the concentration of LPS in urine, which will hopefully show a more realistic 
correlation between LPS and cytokine production in OAB than has previously been 
shown using cells in tissue culture. Furthermore, there are no mentions in the 
literature of measuring LPS concentrations directly and this could provide insight 
into a possible biomarker for OAB for the future.  
4.5.2 GRAM-POSITIVE UROPATHOGENS IN OAB 
 Figure 4.7 highlighted that many of the key species in the bladder are Gram 
positive. Furthermore, it showed that most of the more prevalent Gram positive 
species are found in much higher incidence in MSU samples than CSU samples, 
irrespective of disease state. This generally reflects the less-capable adherence and 
colonisation of Gram positive bacteria compared to Gram negative bacteria.  
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 From the introduction to this chapter, it was mentioned that species such as 
Aerococcus, Arthrobacter, Corynebacterium and Gardnerella are underreported Gram-
positive uropathogens more prevalent in the elderly and that the advanced studies 
undertaken by Pearce et al have found these species to be of particular interest in 
OAB (138, 197). Our data has not found these species to be significant in either MSU 
or CSU samples. Unfortunately, due to the difficult accessibility to control CSU 
samples, the low numbers of patients in this cohort will significantly skew the data 
for CSU. Furthermore, our investigations have used restricted culture methods that 
may have missed out many incidences of these species.  
4.5.3 INTRACELLULAR BACTERIA MAY NOT BE RELEVANT  
 Malone-Leeǯs ʹͲͳ͵ study on the antibiotic protection assay was the first of its 
kind to look at culturing lysed urothelial cells and they identified much the same 
species as those found in the work of Hultgren on IBCs in UTI; i.e. E.coli., E.faecalis, 
and P.mirabilis (111, 137). As previously mentioned these are all Gram-negative 
bacteria with the ability to invade host cells and form IBCs. Much of the work in IBCs 
has, up until recently, focused mainly on E.coli however with the recent contribution 
from Malone-Lee revealing a more invasive capability from E.faecalis, our data was an 
interesting addition. We have shown that there are Gram positive species of bacteria 
capable of being intracellular in the bladder, notably, Staphylococcus, 
Corynebacterium, Arthrobacter, Peptoniphilus and Streptococcus, however no 
individual species stands out as significantly more predominant in OAB compared to 
controls. The observation of increased intracellular Serratia in OAB contradicts the 
reduced Serratia seen in CSU samples. This could be due to low numbers of Control 
CSU patients. Increased Streptococcus is consistent in both CSU and intracellular data 
suggesting this may be a potential species of interest in the bladder. Interestingly 
however, Corynebacterium and Arthrobacter have been noted to be underreported 
Gram-positive uropathogens, therefore this is exciting additional information for the 
pathogenicity of these species in UTI, particularly in reference to the previous 
chapter. 
   Hultgren refers in one of his publications to work done in 1985 on biopsies from 
patients with UTIs (242). The authors of this paper showed that half of patients (8 out 
of 16) who had negative urine cultures grew bacteria from bladder biopsies 
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indicating that urine culture may not reflect the true bacteriological status of the 
bladder. Interestingly, our research group has noted the opposite by using the 
antibiotic protection assay followed by 16s rRNA gene sequencing methods to 
identify intracellular bacteria cultured from biopsies taken from patients with 
idiopathic DO. Very few biopsies cultured bacteria when CSU samples taken from the 
same patients on the same day did grow bacteria. The biopsies were vigorously 
broken up with a combination of shaking and vortexing before spreading on 
chocolate agar. Furthermore, the application of triton X-100 at the lysing stage of the 
antibiotic protection assay should theoretically have released further intracellular 
bacteria however this was not the case. It can therefore be concluded that using 
biopsies for culture of IBC is not as effective as urine culture. 
   Hultgren et al have also previously identified IBC from bladder biopsies taken from 
individuals with UTI (figure 4.8). By taking EM images of bladder biopsies from 
individuals with OAB, we aimed to observe and image IBC present in OAB. Although 
no IBC were seen from the biopsies, there were many autophagosomes observed 
(figure 4.9A). Hultgren et al have described autophagosomes as being similar in 
morphology to IBCs but notably absent of bacteria (20). Interestingly, 
autophagosomes tend to occur when a cell is undergoing apoptosis triggered by 
activation of PRRs and is important in eliminating intracellular bacteria (21). Despite 
the fact intracellular bacteria have not been identified, the presence of 
autophagosomes in urothelial cells of OAB patients is in itself an exciting finding.  
   All species identified by the antibiotic protection assay have the capability to form 
IBCs suggesting our data are not wrong but rather that the prevalence of IBC in OAB 
and healthy controls is simply not that high or perhaps our methods are not as 
effective as others used. Alternatively, it suggests that intracellular bacteria may not 
be unique to OAB but may in fact also be part of the normal microbiome.  
4.5.4 ALTERATIONS IN THE MICROBIOME OVER TIME 
 Our data has shown that a low-level infection can often be asymptomatic since 
35% of the control MSU samples presented with an infection based on 103 CFU/ml. It 
could be said that only women who present with symptoms are likely to require 
microbiological urine culture however it does highlight concern for misdiagnosis. It 
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has also been shown that intracellular bacteria may be a normal part of the human 
bladder microbiome since no particular species stood out as being more prevalent in 
OAB compared to controls.  Furthermore, the emerging uropathogens we would have 
expected to see in higher numbers in OAB were not significantly different to those of 
controls.  Cumulatively, these data indicate that infection may not be a cause for OAB 
but it does not take away from the fact that bacteria may be important. As discussed 
in the General Introduction, the human microbiome is tolerated by the immune 
system and works in synergy to maintain health. Therefore, it could be hypothesised 
that changes in ones microbiome over time is a more likely cause for OAB than a 
hospital grade or low-level infection. This can be supported by the fact that incidence 
of OAB increases with age and BMI. Hormones changing with menopause, metabolites 
from our diet and stress are all factors that can alter a microbiome.  
 
   This thesis attempted to look at how age and the onset of menopause could be 
altering the microbiome. Although data on menopausal status was not available, the 
cohorts of patients were sub-categorised based on the average age of menopause 
onset (45 years). There are no obvious differences between the incidence of any 
species of interest between the age groups in either control or OAB however this 
could be due to the inaccuracy of the sub-grouping based on menopausal status since 
status was not known only assumed. Since the exact menopause status could not be 
determined, this restricts the value of the data, therefore no firm conclusions can be 
made regarding the changes in microbiome with age. 
 
    Another consideration for alterations in the bladder microbiome is BMI and diet. 
The food we eat and the breakdown products from digestion can act as Ǯprebioticsǯ for 
our microbiome. Prebiotics act as a nutrient source and support the growth of 
microorganisms particularly in the gut, therefore what we eat is key to our gut health. 
With the right nutrients, probiotic species tend to thrive, e.g. plant protein and 
unsaturated fat increase Lactobacillus and Bifidobacterium growth, whereas animal 
protein and saturated fat decrease these genera and increase risk of opportunistic 
infections and/or development of Crohnǯs disease, ulcerative colitis and inflammatory 
bowel disease (243). The onset of menopause reduces many hormones including 
oestrogen and leptin, both of which suppress appetite when reduced. Therefore, 
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investigating diet, in particular the consumption of high-fibre foods, in correlation 
with leptin levels and OAB incidence could highlight whether diet not only affects the 
gut microbiome but can extend to the bladder microbiome also (due to colonisation 
from rectum to urethra).  
 
   Unfortunately, the fine balance of the bladder microbiome is far from being well-
understood but it can be assumed that as one species becomes compromised, 
another/numerous others take its place. However, since every individual microbiome 
and synergistic relationship with the immune system is unique, every patient would 
need to act as their own control. This is a much more difficult study to perform, since 
predicting OAB is impossible and many participants will be required in order to 
obtain a minimum number of women who will develop OAB. However, with the 
remarkable reduction in Lactobacillus, a known probiotic, this species may be key in 
microbiome alterations and susceptibility to OAB. Investigation is required to better 
understand the environment in which this species is best established and how it 
interacts with other species in the bladder. 
4.5.5 CO-CULTURE OF LACTOBACILLUS WITH UROPATHOGENS 
 Our results have shown that the percentage of patient with OAB that grew 
Lactobacillus is significantly lower than that of controls, which is in keeping with 
findings from all other studies looking at the microbiome in OAB (137, 138, 197). 
From our results, this is the only genus of bacterium where there is a significantly 
reduced incidence in OAB. Furthermore, we have shown that incidence of 
Lactobacillus has a negative correlation with incidence of Gram negative species. This 
suggests Lactobacilli may have a protective, even probiotic potential in the bladder 
and may be key in alterations of the bladder microbiome, predisposing women to 
OAB. How this species grows and interacts with other species in the bladder requires 
further examination. Interestingly, in 2013, Abdulwahab et al assessed the ability of 
cultured Lactobacillus, taken from asymptomatic women, to inhibit growth of UPEC 
taken from women with UTI. Three strains of Lactobacillus; L.acidophilus, 
L.fermentum and L.delburekii were isolated as the most common species in 
asymptomatic women and were used in co-culture with UPEC. All three species were 
able to inhibit the growth of UPEC. Unfortunately, the species identified here do not 
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correlate with the most common Lactobacillus species normally found in 
premenopausal asymptomatic women as noted by Vasquez et al in Sweden and 
Antonio et al in the USA (203, 244). It is worth noting however, that this study was 
performed in and took sample swabs from women in Egypt. Differences in 
Lactobacilli colonization between these North African and Caucasian women has been 
investigated and supported by Fourney and Foster (245), supporting the notion that 
every microbiome is unique between individuals and cultures. In light of our results 
indicating a complete absence of L.crispatus in OAB, it would be interesting to know 
the capability of L.crispatus to inhibit UPEC growth in culture as well as other known 
pathogens such as Proteus mirabilis, Serratia and Clostridium, which were all 
significantly higher in OAB from our data. 
4.5.6 LACTOBACILLUS AS A PROPHYLACTIC AGAINST UROPATHOGENS   
 Lactobacilli are so called due to their capacity to ferment sugars into either 
lactic acid (homofermentative) or lactic acid or alcohol (heterofermentative), 
depending upon the species. Lactic acid reduces the pH of the surrounding 
environment and acts as an antibacterial by breaking down cell walls of pathogenic 
bacteria leading to leakage and cell death (246). Many Lactobacilli species also 
produce bacteriocins and hydrogen peroxide (H2O2). L.crispatus produces the highest 
levels of H2O2 of all the Lactobacillus species, seconded by L.jensenii (203, 204). 
Interestingly, our data shows a complete lack of L.crispatus from the OAB cohort, 
which is also noted by Pearce et al (138).  
      Unfortunately, there have been no publications on the diversity of Lactobacillus 
species in the bladder, only the vagina; however, due to the proximity of the vagina to 
the urethra and the fact that urogenital colonisation is usually from the gut, it can be 
assumed the vaginal colonisation will be fairly representative of bladder colonisation 
in individuals.  The four most common species identified in the vagina are L.iners, L. 
crispatus, L.gasseri and L.jenesenii followed by L.acidophilus, L.gasseri, L.fermentum, 
L.oris, L.reuteri, L.ruminis, and L.vaginalis (203, 244), which is closely representative 
of the species found in our data, apart from the inclusion of L.psittaci. Lactobacillus 
has been widely researched as a probiotic in the gut, the oral cavity, the vagina and 
less so in the bladder however, using Lactobacillus as a prophylactic against UTI is not 
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a novel concept. Two studies of particular interest have generated optimistic results 
for this as a prospective prophylactic for UTI.  
   The first of these studies gave oral L.rhamnosus and L.reuteri or trimethoprim-
sulfmethoxazole as prophylatics against UTI to 252 postmenopausal women and 
assessed incidence of UTI over 12 months in a randomised control trial. On average women in the antibiotic group had ͹ UT)ǯs per year prior to antibiotics. This was 
reduced to 2.9 with antibiotics. Similar figures were seen with Lactobacillus 
probiotics; 6.8 in the first year before treatment and 3.3 during. All data are 
significant suggesting oral Lactobacillus had a similar prophylactic effect on UTI 
compared to antibiotics (126).  
  Another group led by Stamm, has performed a phase 1 and phase 2 controlled trial, 
again looking at the role of Lactobacillus as a prospective prophylactic for UTI. These 
investigations have used L.crispatus as a vaginal suppository due to its ability to 
produce high levels of H2O2. A vaginal suppository would theoretically lead to higher 
rates of colonisation compared to oral probiotics due to the proximity of the urethra 
to the vagina, but also since oral probiotics can be significantly depleted by the 
gastrointestinal tract before reaching the anus. Results showed a reduction of roughly 
half incidence of UTI compared to placebo with minimal side effects (247, 248). 
   Taken together these studies and their results show that Lactobacillus, in particular 
Lactobacillus crispatus, can provide an effective prophylactic effect on UTI, in 
particular on UPEC.  A randomised trial examining the effects of probiotics on OAB 
would be exciting since our results have clearly indicated reduced incidence of 
Lactobacillus in these patients. Furthermore, investigating the possible role of 
Lactobacillus metabolites on bladder function might highlight how a loss of this genus 
could lead to the symptoms of OAB.  
4.5.7 POTENTIAL BIOMARKERS FOR OAB 
 Our data suggests that leukocyte esterase and nitrites are unreliable for 
identifying infection even at the higher threshold of 105 used by hospital pathology. 
Furthermore, there were many false positives in our data, which has been noted and 
explained by others (215). Therefore, dipstick analysis cannot be used to identify a 
possible UTI particularly if it is a low-level infection. By reducing the threshold of 
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bacteria to 103 the incidence of infection is not greatly increased, therefore a low-
level infection is not likely to be the cause of OAB from our cohorts despite 
suggestions by other groups. Age does appear to be a predisposing factor for OAB as 
incidence increases rapidly with age, however our cohort has seen patients as young 
as 14 with idiopathic OAB therefore this cannot be used as an indicator for OAB. Our 
ATP and IL-8 results were not statistically different between OAB and controls 
despite others reporting ATP to be a potential biomarker for OAB. There were 
significantly higher number of patients presenting with positive culture for 
uropathogens E.coli and Proteus, therefore these individuals may be experiencing 
low-level rUTI which is leading to their symptoms. Unfortunately, despite being 
significant, the low numbers of individuals with these particular uropathogens does 
not qualify their incidence to be used a biomarker. The reduced incidence of 
Lactobacillus on the other hand could be used as a potential biomarker for OAB, 
particularly when combined with incidence of Gram negative species as 60% of 
patients with OAB grew Gram negative species with a lack of Lactobacillus. Further 
work is required to determine if this reduced incidence of Lactobacillus is found in 
other LUTS such as IC and rUTI before it can be considered as a biomarker.  Also, due 
to the small, slow growing colony size of Lactobacillus, a Lactobacillus specific agar 
such as deMan Rogosa Sharp (MRS) could be used to promote this genus over others 
to easier determine its presence in urine samples.  
4.5.8 IMPROVING OUTPUT OF 16S RRNA SEQUENCING 
 The percentage of non-concordant Gram stains from the total number of 
isolates was 14.47%. This is remarkably high and suggests that 16s rRNA sequencing 
may not be accurate. The original primers used (DG74 and RDR080) are taken from 
Griesen et alǯs ͳͻͻͶ study on PCR primers for pathogenic bacteria and isolate the 
1170-1540 region in E.coli. This publication quotes however "RDR080, and DG74 
correspond to regions of the 16S rRNA gene which are highly conserved among 
divergent groups of eubacteria and therefore would be expected to amplify DNA from 
most pathogenic bacteria. The primer locations were chosen to be relatively specific 
for eubacterial genes;" but then later refers to these primers as Universal Primers 
(220). As mentioned, the location for the primers is 1170-1540bp in E.coli, which 
suggests this is in the V9/VT region for E.coli (249). V9 and V3 regions are most 
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variable however are not the most suitable to species ID. A study by Chakravorty et al 
identified V2 and V3 are most effective for identifying species to genus level however 
not for closely related Enterobacteriacae. They also indicate that using the V9 region 
does not provide complete data and do not include it in the remainder of their 
analysis (250). With more time, it would be advantageous to go back to isolates with a 
non-concordant Gram stain and re-perform PCR with primers designed for the V2 or 
V3 regions instead. Fortunately, despite the lack of evidence supporting the V9 region 
in 16s rRNA sequencing, the hypervariability of this region has allowed us to generate 
results very similar to those of almost all previous studies investigating the 
microbiome in OAB. 
4.5.9 IMPROVING CULTURE METHODS 
 Since the start of this investigation, alternative methods have come to light 
that improve the culture of many uncultured species. The following chapter discusses 
how improved methods were developed in our laboratory for further studies 





1. Hospital methods of dipstick should not be relied upon to diagnose infection 
and are even poorer at diagnosing low-level infection in OAB. 
2. By reducing the threshold of CFU/ml to 103 more potential infections can be 
identified, however there are more low-level infections in controls than in 
patients with OAB suggesting low-level infection does not always correlate 
with incidence of OAB. 
3. Intracellular bacteria appear to be a normal part of the bladder microbiome. 
4. Individually, Gram negative species are found to be more predominant in CSU 
samples and Gram positive species are found to be more predominant in MSU 
samples. 
5. Cumulatively, Gram negative bacteria are found in significantly higher 
frequency in OAB than controls.  
6. Lactobacillus is found to be significantly lower in patients with OAB and this 
correlates with increased Gram negative bacteria indicating that OAB may be 
due to a lack of protective pro-biotic bacteria. 
7. There do not appear to be any strikingly significant differences in the 
microbiome with increased age supporting the idea that patients act as their 
own controls as the microbiome changes.  
8. Culture methods need to be expanded to include other conditions and 




CHAPTER 5 – RESULTS 3:  
IMPROVED METHODOLOGY FOR URINE CULTURE 
5.1 INTRODUCTION 
  Since the start of this project, various published studies have highlighted 
potential weaknesses in performing sediment culture and growing bacteria in only 
basic conditions such as 5% CO2 and anaerobic at a single temperature. Twelve most 
apposite studies have recently employed 2 different methodologies to investigate the 
non-cultivated species in urine samples of males, females, healthy individuals, and 
those with LUTSs (138, 189-196, 235, 236, 251). The first of these methods is culture 
of urine on a larger variety of agars in a variety of gas mixes and temperatures 
enhance quantitative urine culture (EQUC). The second method is culture-
independent quantitative PCR whereby bacterial DNA is extracted directly from the 
urine samples followed by next generation sequencing and bioinformatics. One 
particular study has adopted both methods in order to compare them against each 
other concluding that even EQUC misses uncultured species and thus culture-
independent methods are preferred (195). The details of each of these methods and 
the results from the studies using them shall be discussed in the following section, 
before going on to investigate how these can be adapted into our current 
methodology with in the capabilities of our laboratory facilities.  
5.1.1 CURRENT METHODS 
 The UK Health Protection Agency suggests growth on cysteine lactose 
electrolyte deficient (CLED) and chromogenic agars for as the most efficient method 
for quantification of bacteria in urine (252).  In CLED agar the presence of cysteine 
supports the growth of bacteria that require this amino acid; the presence of lactose 
and bromothymol blue act as an indicator for lactose and non-lactose fermenting 
microbes; and a lack of electrolytes prevents the swarming growth of Proteus species 
which can contaminate other colonies (252). Chromogenic agars contain various 
substrates which can identify particular species by the colour of the colonies. For 
example; primary UTI chromogenic agar contains ß-galactose, ß-glucose and 
tryptophan which turns enterococci blue, E.coli pink and Proteus brown based on the 
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presence of ß-galactosidase, ß-glucosidase and tryptophan deaminase activity, 
respectively (252). The UK (ealth Protection Agency references Kassǯs ≥ͳͲ5 CFU/ml 
rule as indicative of an infection and anything less than this as contamination (252). 
This basic method misses out approximately 47% of possible urinary genera in 
females (n=70 genera) and 63% in males (n=46 genera) highlighted by Lewis et al 
(2013) who identified bacteria from MSU samples by culture-independent 
quantitative PCR methods (236). 
   The methods for culturing urine described in the General Methodology (Section 2.3) 
were adapted from Khasriya et alǯs ʹͲͳ͵ study (137). Their method was to perform sediment culture by plating ͷ μl spun urine on blood agar and fastidious anaerobic 
agar and growing in 5% CO2 and anaerobic conditions, respectively, at a single 
temperature of 37oC. Previous work in our laboratory (unpublished data) determined 
that blood agar and chocolate grew similar cultures, however chocolate agar can 
support growth of Haemophilus species which is a known uropathogen (253). 
Therefore, chocolate agar was chosen as a preferred agar for the clinical studies at the 
start of this thesis (Chapters 3-4). Subsequent clinical studies by our group required 
us to update our methods in order to keep up with recent advances in urine culture. 
The aim was therefore to adapt our urine culture methods to potentially include 
culture-independent molecular PCR and/or EQUC.  
5.1.2 CULTURE-INDEPENDENT MOLECULAR PCR 
 This method removes the need to culture bacteria and therefore eliminates the 
risk of missing non-cultivated species. 16s rRNA sequencing is still performed in 
order to identify species, however the DNA is extracted directly from the bacteria in 
the urine samples and the more advanced technique of next generation sequencing 
(NGS) is used rather than Sanger sequencing. This requires enzymatic lysis of bacteria 
with lysozyme followed by mechanical breakdown with lysing matrix B tubes. The 
DNA is then extracted from the lysate with a phenol chloroform alcohol extraction 
and ethanol precipitation. Upon obtaining bacterial DNA, a PCR reaction is prepared 
with primers barcoded for multiplexing (performing multiple PCR reactions at once). 
After the PCR has run, the amplicons are pooled and sent for NGS. NGS is a high-
output method of sequencing which can read thousands of different DNA sequences 
per sample. This can allow a pool or library of different sequences to be created per 
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sample/multiple samples. The use of barcoded primers, allows for demultiplexing 
whereby each sequence is separated into individual FASTA files for each barcode, 
which requires specialised software. From these FASTA files a taxa can be allocated 
and from this the number of any particular taxa in each sample based on the number 
of amplicons related to that taxa.  
    One study which has adapted/utilised these methods identified 45 bladder species 
of which 20 could not be routinely cultivated (193). And a later, wider study, found 94 
bladder genera, of which 63 could not be routinely cultivated (236) suggesting 
culture-independant methods are much more sensitive than culture-dependant 
methods. However, later studies with EQUC have shown that many of these are 
cultivatable with inclusion of extended culture (138, 195), and thus cheaper options 
may still be employed to identify the majority of species found in the urinary 
microbiome. Furthermore, these methods are complex and would require much 
practice before perfecting in the lab. Fortunately, NGS services are available which 
can perform the DNA extraction, prepare the DNA for NGS, and perform the NGS for 
you, as well as delivering a bioinformatics report detailing the results of your reads as 
a further option (e.g. Eurofins Genomics and Source BioScience).  
5.1.3 ENHANCED QUANTITATIVE URINE CULTURE 
Hilt et al (2014) published the first data using EQUC as a method for isolating 
various non-cultured bacteria from urine (n=260 isolates) (195). They inoculated 100 μl of unspun urine onto blood agar plates ȋBAPȌ, chocolate agar, and colistin and 
nalidixic acid agar (CNA) plates and incubated them for 48 hours at 35oC in 5% CO2. 
They also inoculated ͳͲͲ μl of unspun urine onto BAP for incubation in aerobic 
conditions at two temperatures, 30oC and 35oC, for 48 hours each. And finally they inoculated ͳͲͲ μl of unspun urine onto fastidious anaerobic agar ȋFAAȌ for culture in 
anaerobic and campygas (5% O2, 10% CO2, 85% N) conditions, both at 35oC for 48 
hours. This generated a total of 5 different conditions summarised in the table below 
(table 5.1). Interestingly, Hilt et al used matrix-assisted laser desorption/ionization 
time-of-flight (MALDI-TOF) mass spectrometry (MS) to identify species instead of 16s 
rRNA gene sequencing. This newly emerging technique for identifying species is 




     (iltǯs tabulated results indicate which species grew in each condition and can 
therefore be used to identify species missed from other studies. The original 
methodology for this thesis (Chapter 3-4) was adapted from Khasriya et alǯs study, 
which also listed all species identified by their methodology. From the published data 
of both these studies, missed cultured species from Khasriya et al, and therefore this 
study, can be extrapolated; of 93 individual species identified by EQUC, 15 of them 
(16.1%) were cultured from conditions not included by Khasriya et al, that is, aerobic 
at 30oC and 35oC, and Campygas. Furthermore, Khasriya et al plated spun urine which 
contains concentrated urothelial cells. This method is essential if the initial plating is 
followed by an antibiotic protection assay to determine intracellular bacteria 
(detailed in section 2.3.2), but is not necessary for determining planktonic species 
only and can in fact generate data which is bias for species capable of attachment to 
urothelial cells. The differences between spun and unspun urine has been shown by 
the differences in reported species by Khasriya and Hilt. Furthermore, by plating only ͷ μl, any species present at levels lower than ͳͲ2 CFU/ml are at risk of being missed, 
therefore plating ͳͲͲ μl is more effective for culturing low numbers of bacteria. )n 
2014, Pearce et al, recognised that even with EQUC some species are still missed, 
therefore they combined the methods of culture-independent sequencing of the 16s 
rRNA gene and EQUC and MALDI-TOF MS to obtain the most complete description of 
bladder bacterial species (138). They noted a high-level of overlap in species 
suggesting that both methods are effective, however EQUC was not able to identify 
many incidences of Atopobium and high-throughput sequencing missed Trueperella. 
Table 5.1 Types of agars and conditions used in by Hilt et al (195) for culturing urine by the enhanced 
quantitative urine culture method (EQUC). For example, urine was cultured on blood agar plates (BAP), 
chocolate plates and colistin and nalidixic acid agar (CNA) in 5% CO2 at 35OC for 48 hours. 
Agar Conditions Temperature Time 
BAP/Chocolate/CNA 5% CO2 35oC 48 hours 
BAP Aerobic 35oC 48 hours 
BAP Aerobic 30oC 48 hours 
FAA Anaerobic 35oC 48 hours 
FAA Campygas 35oC 48 hours 
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   As mentioned, Hilt and Pearce used MALDI-TOF-MS to identify the species found in 
their studies. Although this new technique is effective at determining bacteria to a 
species level with up to 85% accuracy, it is dependent upon known species peptides 
being included in the spectral database (254).  Much the same as when a BLAST 
search is performed, discovered peptides are matched to a database of known 
peptides from known species. The use of MALDI-TOF-MS as a method of identifying 
species has previously been compared with 16s rRNA in regards to vaginal 
Lactobacilli by Anderson et al in their 2014 publication (255). They collected 77 
samples of vaginal Lactobacilli of 15 different species including L.iners, L.crispatus, L. 
jensenii and L.gasseri.  It was discovered that MALDI-TOF-MS analysis was able to 
identify 97.4% of the samples in concordance with 16s rRNA, however in some cases 
MALDI-TOF-MS was only able to identify isolates to genus level. This publication 
confirmed that MALDI-TOF-MS relies on a developed spectral database and as a new 
method, this has yet to be extended and fully established. Therefore, 16s rRNA 
sequencing appears to remain the most effective method for identifying bacteria to 
species level, confirmed by the highly concordant results from MALDI-TOF-MS. The 
results from the previous chapter of this thesis has identified exciting results for 
Lactobacillus, however there could be some discrepancies about the accuracy of 16s 
rRNA sequencing based on the choice of primers used. As mentioned in the discussion 
of the previous chapter (Section 4.5.1), the location for the original primers is 1170-
1540bp in E.coli, which suggests this is in the V9/VT region for E.coli (249).  V9 and 
V3 regions are most variable however are not the most suitable to species 
ID. Therefore it was concluded that a more selective set of primers should be used to 
better identify Lactobacilli isolates to species level.   
5.1.4 CURRENT RESEARCH QUESTIONS 
It is clear that the basic culture methods advised by the UK Health Protection 
Agency and those performed by Khasriya et al are likely not culturing and identifying 
all species of bacteria in urine samples. EQUC can improve this by culturing in extra 
conditions such as aerobic and campygas, and at a lowered temperature of 30oC, 
however even then many species are missed. Culture-independent molecular PCR can 
remove the need to culture bacteria at all and with the use of next generation 
sequencing methods the results can still be quantifiable. We wanted to determine if 
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our method of culturing urine, which was adapted from Khasriya et al, could be 
improved and yet remain cost efficient and within the capabilities of our laboratory 
facilities. Since the methods for culture-independent PCR are complex and would 
require considerable comprehension to perfect, various NGS service suppliers were 
investigated to perform the full service on our behalf. Also, we wanted to confirm that 
the Lactobacillus species found in our study were reliably identified. Therefore, we 
chose to repeat the 16s rRNA sequencing on these isolates using the same primers as 
those used by Anderson et al for comparing 16s rRNA sequencing with MALDI-TOF-
MS for vaginal Lactobacillus (255). 
5.2 HYPOTHESIS AND AIMS 
We hypothesise that the EQUC and culture-independent 16s rRNA sequencing will 
show more variation in species per patient sample than the basic method adapted 
from Khasriya et al. 
In order to begin to test this hypothesis the following objectives will be to:- 
1. Compare culture growth using the original method with EQUC to 
determine how many species could be being missed in our studies. 
2. Determine the cost and efficiency of an external NGS service to reduce 
work-load. 
3. Compare results from NGS service with original culture method and 









 All work performed in this chapter was a joint effort by Miss Tash Curtiss and 
myself. 
5.3.2 SELECTING PATIENTS 
Three control samples of catheter specimen urine were obtained from patients 
attending Sunderland Day Case Clinic at Medway Maritime Hospital, Gillingham, Kent 
for non-bladder surgeries such as hysterectomy, myomectomy and laparoscopy. All 
samples were collected under general anaesthetic in a sterile operating theatre prior 
to the scheduled operation. All patients scored 0 on the International Consultation on 
Incontinence Modular Questionnaire – Female Lower Urinary Tract Symptoms Short 
Form (ICIQ-FLUTS-SF) and gave written consent prior to surgery. 
5.3.3 SEDIMENT CULTURE 
 5 ml of fresh urine was centrifuged in a 15 ml falcon tube at 800 RPM for 5 minutes. The sediment was resuspended in ͳͲͲ μl Ͳ.ͳM PBS and ͷ μl was plated on 
two chocolate agar plates per patient sample (E&O Labs) with a sterile single-use plastic ͷ μl inoculation loop ȋBetter EquippedȌ. One plate was placed in ͷ% COʹ at ͵͹-
oC for 48 hours and one was placed in a 2.5 L anaerobic jar with anaeogen (Fisher) 
and anaerobic indicator, resazurin (Fisher) and kept at 37oC for 7 days. Anaerobic 
bacterial growth is slower than in bacterial growth in 5% CO2 therefore the plates in 
anaerobic jars were left for longer to ensure growth was optimised.   At the end of the 
respective growth periods, plates were checked for growth and all colonies were 
identified by their appearance, described and purity plated on chocolate agar. Purity 
plating was performed by inoculating individual colonies with a sterile inoculation 
loop (Better equipped) and streak plating on fresh chocolate plates. The purity plates 
were allowed to grow in 37OC for a further 48 hours/7 days in their respective 
environments. Once pure plates were obtained for each isolate, the isolates were 
Gram stained, and the remaining bacterial growth from the purity plates was frozen 
at -80OC in 1.5 mL Nunc® CryoTubes (Sigma) containing Brain Heart infusion broth 
(Sigma) containing 10% Glycerol (Sigma) to prevent cell lysis during freezing.  
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5.3.4 ENHANCED QUANTITATIVE URINE CULTURE 
 Seven conditions were chosen for the EQUC for which ͳͲͲ μl of unspun urine 
was plated onto each of the following; i) Columbia blood agar (CBA), ii) chocolate 
agar, and iii) colistin and nalidixic acid agar (CNA) each incubated for 48 hours at 
37oC in 5% CO2, iv) CBA for incubation in aerobic conditions at two temperatures, 
30oC, and v) 37oC, for 48 hours each, and vi) fastidious anaerobic agar (FAA) for 
culture in anaerobic, and vii) campygas (5% O2, 10% CO2, 85% N) conditions, both at 
37oC for 48 hours. A colony count was performed on each unique species and the 
number multiplied by 10x to calculate the CFU/ml. In order to compare EQUC to the 
original methodology used in chapter 3 and 4, urine was also cultured as discussed in 
Section 2.1.3.2 Streak plating and antibiotic protection assay by plating ͷ μl of 
centrifuged urine on two chocolate plates and incubating for 48 hours at 37oC in 5% 
CO2 and 37oC in anaerobic conditions. For these plates, the CFU/ml was calculated by 
multiplying the CFU count by 40x due to the centrifugation step concentrating the 5 
ml of urine. 
   Purity plating was performed by inoculating individual colonies with a sterile 
inoculation loop (Better equipped) and streak plating on fresh chocolate plates. The 
purity plates were allowed to grow in in their respective environments. Once pure 
plates were obtained for each isolate, the isolates were Gram stained, and the 
remaining bacterial growth from the purity plates was frozen at -80OC in 1.5mL 
Nunc® CryoTubes (Sigma) containing Brain Heart infusion broth (Sigma) containing 
10% Glycerol (Sigma) to prevent cell lysis during freezing. 
5.3.5 16S rRNA GENE SEQUENCING  
Isolates were identified by sequencing of the 16s rRNA gene as discussed in 
the General Methodology; samples were revived by regrowing on agar in their 
respective environments, lysed in H2O at 94oC, the 16s rRNA gene isolated by PCR, gel 
electrophoresis to check for the correct band size, purification, nanodropping to 
determine the final concentration on DNA, and sequencing by Eurofins Mix2Seq. 
Three methods for submitting samples for sequencing to Eurofins Genomics 
are available; Mix2Seq service, Value Read service and Service à la Carte. Mix2Seq 
costs £3.18* per read where primers and sample are submitted in the same vial. 
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Value read service is £4.75*/reaction where primer and template can be sent 
separately allowing repeated reactions if no read is generated due to technical issues. 
Service à la Carte costs £6.80* per reaction and offers a quality check prior to read, 
DNA concentration adjustment, a free one time repetition and heterozygote analysis. 
Due to the number of isolates which may be generated in the future it was necessary 
to choose the first option of the Mix2Seq service to keep costs down.  
5.3.6 SELECTING A NEXT GENERATION SEQUENCING SERVICE 
 Three companies were contacted regarding their 16S metagenomics profiling 
services; Eurofins Genomics, Germany; Beckman Coulter Genomics, USA; and Source 
BioScience, UK. The easiest, most efficient and cheapest service was selected from 
these three. 
   Eurofins Genomics offer an NGS service called Ǯͳ͸s rRNA microbiome profiling MiSeqǯ which offered a quality check of each sample, amplicon generation of the 
genes region of interest, pooling and normalization of amplicons, sequencing of the 
amplicon on an Illumina MiSeq with 2 paired-end reads of 300bp. This was followed 
by bioinformatics analysis provided on a disk or paper format. The cost of this service 
is £175*/sample with a minimum of 6 samples per submission. This cost would be 
reduced to £128*/sample for greater than 48 samples.  
   Beckman Coulter offer an NGS service called ǮMetagenomic Sequencingǯ. This service 
was not able to provide DNA extraction or PCR services therefore this would have to 
be performed beforehand. Submitted PCR product would be cleaned up, quantified 
and pooled and then read on a Roche-NGS. Each sample in a pool needs a different 
primer with a MID tag on it so that it is possible to demultiplex the data later.  The 
same primer sets can be used again in separate pools but the primer costs still needed 
to be factored into the project. The price per pool would be £2,257* and therefore the 
price per sample would be dependent on how many samples were submitted to the 
pool. Metagenomic analysis would be a further £36* per sample or £1,582* per 
project. 
 Source BioScience offer an NGS service called ǮMetagenomic sequencingǯ which consisted of a quality check of each sample, amplicon generation of the geneǯs region 
of interest, pooling and normalization of amplicons, sequencing of the amplicon on an 
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Illumina MiSeq with 2 paired-end reads of 300bp. This was followed by 
bioinformatics analysis provided on a disk or paper format. The cost of this service is 
£350*/sample to perform the quality check and prepare for sequencing then £1900* 
to create a pool.  
    After communication with sales representatives from all the above companies it 
was agreed that Eurofins would be most efficient as this allowed simple sample 
submission (discussed next) with the lowest cost 
5.3.7 NEXT GENERATION SEQUENCING SAMPLE SUBMISSION 
 As discussed, Eurofins Genomics was selected to run the test samples for 
metagenomics sequencing. Due to the cost reduction for larger sample submission 
(£128*/sample for 48+ samples), any future sample submission would have to be on 
frozen samples to allow for collection and storage until a large batch could be 
submitted at once. For this reason the samples were frozen prior to submission in 
order to reproduce future submission.  Since a minimum of 6 samples was required 
for submission, 5 ml of each of the 3 CSU samples was filtered prior to freezing and 5 
ml was frozen without filtering to determine the most effective method of capturing 
bacteria.  Each CSU sample (5 ml) was frozen for 2 weeks at -20oC and 5 ml of each 
CSU sample was passed through a Ͳ.ʹʹ μm Millipore filter to capture any bacteria, 
and then frozen for 2 weeks at -20oC. Within 14 days the samples and filters were 
wrapped in tin foil, placed in labelled plastic bags and sent to Eurofins in Germany via 
recorded DHL delivery. 
 
*All prices correct as of November 2015 
5.3.8 CREATING A LACTOBACILLUS PHYLOGENETIC TREE 
 All species which were initially identified as Lactobacillus from the OAB study 
(Chapter 4) were resuscitated in their original conditions and 16s rRNA gene 
sequencing performed on each as discussed in the General Methodology (Section 
2.1.3.5Ȍ. The PCR was set up with new primers taken from Andersonǯs study which 
confirmed 16s rRNA to be more accurate at differentiating between vaginal 
Lactobacillus species than MALDI-TOF-MS (255): - Forward 5'-
177 
 
GAGAAGAACGTGCGTGAGAG-3' and Reverse 5'-ATGTGAAAGCCTTCGGCTTA-3'. 
Another PCR was set up with new primers taken from Herlemann et al who used 
DegePrime to design a broad-taxonomic-range primer pair that targets the bacterial 
V3-V4 region (256)- Forward ͷǯ- CCTACGGGRSGCAGCAG-͵ǯ and Reverse ͷ'-
GACTACHVGGGTATCTAATCC -3'. 
    From each set of primers, a phylogenetic tree was created from the sequencing 
results using CLC Genomics Viewer 7, which can be used to join species to each other 
by sequence similarity. The sequences were extracted as FASTA files and open in CLC 
Genomics Viewer 7. Failed sequences and any anomalies in sequencing were 
removed. Sequences were renamed with their respective BLAST result species 
identity. When aligning sequences there are three parameters which must be 
considered; i) the gap open cost which is the price for introducing gaps in an 
alignment where nucleotides are missing, ii) the gap extension cost which is the price 
for every extension past the initial gap, and iii) the end gap cost which is the price of 
gaps at the beginning or the end of the alignment. These sequences were aligned and 
the costs optimised to a gap open cost of 10.0 and gap extension cost of 10.0. By 
making these values the same and as high as possible, the best alignments were generated. The End gap cost was set to ǮAs any otherǯ so that gaps at the ends of 
sequences are treated like gaps in any other place in the sequences. Once aligned, a 
phylogenetic tree was created using the Unweighted Pair Group Method with 
Arithmetic Mean (UPGMA) tree construction method, which assumes a constant rate 
of evolution, compared to the Neighbour Joining method which assumes varying rates 
of evolution. The Jukes-Cantor substitution method was selected for the nucleotide 
distance measure, which assumes equal base frequencies and equal substitution 
rates, compared to the Kimura 80 Method which assumes equal base frequencies but 
distinguishes between transitions and transversions. Once generated, the tree layout 





5.4.1 EUROFINS 16S RRNA MICROBIOME PROFILING MISSES ISOLATES 
Eurofins Genomics performed the bacterial DNA-isolation and qPCR on 16s 
rRNA genes with bacteria-specific primers was used for quantification. The results of 
the 16s rRNA genomic profiling were returned by email. Relating to the bacterial 
standards of known concentration, lower than required DNA-concentrations were 
detected; approximately 0.001 ng/µl DNA per sample compared to the required 10 
ng/µl (Table 5.2). Eurofins tried to amplify the target-region, but no PCR-product 
could be detected. They also performed some supplementary tests in order to verify 
whether human DNA can be detected in the samples. Two of the urine samples 
contained low amounts of human DNA, suggesting that DNA was present but bacteria 
were not. 
     Eurofins discussed the results within their team and proposed two reasons for the 
low bacterial DNA concentrations; i) the samples were taken from clinically healthy 
persons, having neither a bladder infection, or a tumour, ii) the samples were not the 
first void of the day nor were they MSU samples. Both of these suggestions can be 
argued against since recent investigations have proved that urine is not sterile even 
in healthy persons. It was therefore not possible to obtain any results from the NGS 
sequencing and this method had to be dismissed as an option for analysing urine 
samples for bacterial DNA content. 
 
Sample name DNA concentration per sample [ng/µl] 
Control CSU sample 1 Filter 0.0013275 
Control CSU sample 2 Filter 0.00115 
Control CSU sample 3 Filter 0.00116 
Control CSU sample 1 Urine 0.00121 
Control CSU sample 2 Urine 0.000963 
Control CSU sample 3 Urine 0.001154 
Table 5.2 Concentrations of DNA obtained from Eurofins Next Generation Sequencing service for three 
control CSU samples. Samples were either filtered through a Ͳ.ʹʹ μm Millipore filter to capture any bacteria and 
frozen for 2 weeks at -20oC, or the frozen urine was sent unfiltered. Eurofins require a minimum of 10 ng/µl DNA, 
therefore for all samples, concentrations of bacterial DNA were too low for Eurofins to perform next generation 




5.4.2 EQUC COMPARED TO SEDIMENT CULTURE 
 Control sample-1 did not grow any colonies across all conditions in both EQUC 
and sediment culture (data not shown). These were left for a further 48 hours which 
also did not result in growth suggesting very low level bacteria in the sample. 
Focusing therefore on control samples-2 and -3, and considering only the differences 
between plating 5 μl spun urine and 100 μl unspun urine with the original conditions 
of 5% CO2 and anaerobic, there are many inconsistencies when comparing the 
CFU/ml of individual species. In the case of Lactobacillus iners growth in control 
sample-2, 1000 CFU/ml grew in CO2 37OC when plating 5 μl spun urine however no 
colonies grew when plating 100 μl spun urine but were seen in the anaerobic 
conditions (figure 5.3A). Also in sample-2, Alloscardovia omnicolens grew at 80 
CFU/ml when plated with 5 μl spun urine but only 10 CFU/ml with 100 μl unspun 
urine. A further discrepancy can be seen in sample-3 in the case of Lactobacillus 
hominis which was found to grow at 320 CFU/ml with 5 μl spun urine but did not 
grow when plating 100 μl unspun urine ȋfigure ͷ.͵BȌ. Despite the discrepancies in 
CFU/ml on some bacteria, the 100 μl unspun urine was able to grow ʹ extra bacterial species which were not seen in ͷ μl unspun urine; Anaerococcus lactolyticus and 
Finegoldia magna. Also, sample-3 was shown to culture an extra 3 species with 100 μl 
unspun urine compared to 5 μl spun urine; Actinobaculum massilae, Olligella 
ureolytica and Peptoniphilus timonensis 
   When looking at the new conditions and agars introduced with EQUC since with 
sediment culture for control sample-2 a further 2 species were identified; 
Paenibacillus wynii and a species of unknown identity (table 5.3A). Similar was seen 
in control sample-3 whereby EQUC was able to culture a further 4 species of bacteria; 
Actinomyces suimastitidis, Corynebacterium tuscaniense, Lactobacillus acidophilus and 







A) Control sample 2 
 
 
CFU/ml from  
ͷ μl spun  
urine 
CFU/ml from  





CFU/ml from  
EQUC 

































- - 80 70  
- 
- - - 
Alloscardovia 
omnicolens 
160 80 500 10  
- 
70 - 40 
Anaerococcus 
lactolyticus 
- - - 20  
- 
- - - 
Finegoldia 
magna 
- - - 10  
- 
- - - 
Lactobacillus 
iners 
- 1000 250 -  
60 
10 - - 
Paenibacillus 
wynii 
- - - -  
- 
- - 10 
Unknown 
species 
- - - -  
- 
- 100 - 
 
B) Control sample 3 
Actinobaculum 
massilae 




























































- - - 150  - 
- 
- - 
Table 5.3 Species identified by sediment culture and expanded quantitative urine culture (EQUC). A) 
Results for control sample 2, B) results for control sample 3. Species identified in the first column were found to 
be present in the various conditions signified by CFU. Sediment culture included two conditions (5% CO2 and 
anaerobic at 37OC) whereas EQUC included 2 extra conditions and an extra temperature (Campygas at 37OC, and 
aerobic at 37OC). Two extra types of agar were used: Columbia blood agar (CBA) and colistin and nalidixic acid 
agar (CNA). Fastidious anaerobic agar (FAA) was used for campygas and CBA was used for aerobic conditions. 
Blank cells signify species did not grow under that condition.  
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  By looking across the table of EQUC findings, it can be seen that CNA plates, Aerobic 
and Campygas conditions were able to select for previously uncultured species in the 
standard sediment culture used in chapters 3-4. Looking again at control sample-2, 
culture on CBA and CNA did not contribute any further species than culture on 
chocolate. In fact, chocolate grew more colonies across all species found in CO2 
conditions (table 5.3A). This was not the case with control sample 3 however (table 
5.3B). From this sample, CNA was able to grow Lactobacillus acidophilus and 
Lactobacillus psittaci, and CBA was able to grow Lactobacillus psittaci and 
Lactobacillus ultunensis, whereas chocolate agar did not.  
   Campygas conditions cultured 1 unique species not found in any other conditions 
for control sample 2 (table 5.3A). This was not possible to identify due to sequencing 
failing twice for this isolate. Looking therefore at control sample-3 it was possible to 
see that Campygas conditions were able to isolate Corynebacterium tuscanense where 
this isolate did not grow in other conditions (table 5.3B).  
    Aerobic conditions at 37OC identified Paenibacillus wynii from control sample-2 
where other conditions did not grow this species (table 5.3A). From control sample-3, 
this condition also identified a unique species, Actinomyces suimastitidis (table 5.3.B). 
Growth in aerobic conditions at 30OC was not performed due to restricted access to 
incubators that could be altered for temperature and used for bacterial growth.  
   Looking at the exact CFU/ml from individual Lactobacillus species there are some 
more discrepancies across the conditions in EQUC. For example, for control sample-2, 
250 CFU/ml of Lactobacillus iners were identified on chocolate agar however only 60 
CFU/ml on CBA and 10 CFU/ml on CNA (table 5.3A). The same is the case for 
Lactobacillus psittaci from control sample-3, which grew with 100 CFU/ml on CBA 
and CNA but with 1000 CFU/ml in Campygas (table 5.3B). This could suggest either 
that 16s rRNA sequencing has not been accurate in identifying the exact species from 
each condition, or that certain Lactobacillus spp. grow better in other conditions. This 




5.4.3 LACTOBACILLUS CONCORDANCE 
A total of 45 isolates from this study which were previously identified as 
Lactobacillus were re-suspended for repeated PCR with two sets of PCR reactions, one 
with primer set 1 from Anderson et al (255) and one with primer set 2 from 
Herlemann et al (256) to make a total of 90 PCR reactions. Upon BLASTing the newly 
generated sequences, concordance with the original species identification was 
recorded. Where sequencing failed, these isolates were removed from the 
calculations. Percentage concordance was calculated as follows:  
(�ݑܾ݉݁ݎ ݋݂ ܿ݋݊ܿ݋ݎ݀ܽ݊ݐ ݏ݌݁ܿ�݁ݏ�݋ݐ݈ܽ ݊ݑܾ݉݁ݎ ݋݂ ݏ݌݁ܿ�݁ݏ ) × ͳͲͲ 
 
   It was found that from 19 that were initially identified as L.psittaci, 0% were 
identified as this species with both sets of new primers (table 5.4). All (100%) 
of successful sequences identified these isolates as L.jensenii with the new primers 
(n=17).  There is also a 0% concordance for L.hominis which was identified as 
L.gasseri with both sets of new primers (n=4). There is however a 100% 
concordance for isolates first identified as L.iners (n=7) and L.crispatus (n=2). There is 
82% concordance of successful sequences for isolates first identified as L.gasseri 
(n=8). Therefore, an amended version of figure 4.25: Percentage incidence of 
Lactobacillus species cultured from OAB and Control MSU samples of urine found in 
chapter 4 for the Lactobacillus spp. in OAB versus asymptomatic controls based on these results has been created and new statistics performed using Fisherǯs exact test 
(figure 5.1). 
The inclusion of a phylogenetic tree checks the evolutionary distances 
between species based on their genetic sequences. The tree created from the 33 
Lactobacillus isolates indicates that all species identified as L.jensenii are closely 
related with little evolutionary difference between sequences (between approx. 






Figure 5.1: Percentage incidence of Lactobacillus species cultured from OAB and Control MSU samples of 
urine (amended version from Section 4.4.9 Reduced incidence of Lactobacillus). A total of 75 Lactobacillus 
isolates cultured from MSU samples grown from 82 Control CSU samples and 60 OAB CSU samples were 
successfully identified by sequencing of the 16s rRNA gene. Incidence of each species is expressed as a percentage 
of samples with genus from the total number of samples. Decreased incidence from controls to OAB can be seen 
with all species of Lactobacillus particularly L.gasseri from 20.7% to 11.7% (p=0.02*), L.jensenii from 20.7% to 
8.3% (p>0.05), L.iners, from 7.3% to 3.3% (p>0.05) and L.crispatus 7.3% to 0.0% (p=0.04*).  All P values were calculated using Fisherǯs exact test.  
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1 1 50% 
Lactobacillus crispatus 
(100%) 
Table 5.4: Percentage concordance of Lactobacillus species identified by original primers and new primer 
subsets. The original primers used in Chapter 4 of this thesis identify Lactobacillus species as L.psittaci (n=19), 
L.gasseri (n=10), L.iners (n=7), L.hominis (n=4) and L.crispatus (n=2). Alternative primers derived from Anderson 
et al (255) and Herlemann et al (256) are used to compare species ID of the Lactobacillus isolates. The number of 
concordant isolates by species ID are listed beneath the alternative primer sets used and relative percentage 
concordance calculated next to them. In cases where there is a 0% concordance, the correct species is listed. E.g. 
0% of isolates originally identified as L.psittaci are identified as L.psittaci with the new primers. 100% of these 





Figure 5.2: Phylogenetic tree of Lactobacillus species cultured from OAB and Control MSU samples of 
urine. An alignment was performed followed by the creation of a phylogenetic tree on sequences generated from 
33 Lactobacillus isolates cultured from MSU samples obtained from asymptomatic individuals and those with OAB. 
This tree shows the evolutionary distances of Lactobacillus species from each other and confirms that all the 
sequences bar one are likely to be correct. Scale represents the number of differences between sequences (0.030 
means 0.3% differences between two sequences. Junction values represent the % support for the nodes. 
 
5.5 DISCUSSION 
    The aims of this chapter were to determine a cost-effective method to better 
investigate the bladder microbiome based on the capabilities of our laboratory. 
Following investigation, the main findings are: - i) Eurofins Genomics offers the most 
cost effective 16s metagenomics service compared to Source BioScience and Beckman 
Coulter Genomics, ii) Eurofins Genomics 16s metagenomics service was unable to 
detect bacterial DNA in the three CSU samples sent, iii) two of these three urine 
samples were not sterile, iv) inclusion of CNA agar, campygas and aerobic conditions 
increased the diversity of species found in the two non-sterile samples, v) 
centrifuging urine samples is bias for species closely associated to urothelial cells. 
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5.5.1 DISREGARDING EUROFINS 16S rRNA MICROBIOME PROFILING 
 Since the NGS service was not able to identify sufficient bacterial DNA in order 
to perform NGS, this option was discarded as a future improved methodology.  A 
restriction with the methodology used for NGS was that CSU samples were sent. 
Although this type of sample was intentionally chosen since CSU samples provide a 
more accurate insight into the exact bacteria within the bladder (129), this has likely 
reduced the yield of bacterial DNA from extraction compared to using MSU samples. 
These results have shown that even species at 103 CFU/ml are not being captured by 
Eurofins method of DNA extraction (table 5.3A). Since it has been shown that 103 
CFU/ml is sufficient to be considered low-level bacteriuria (134-136), if species are 
being missed at this level then even by sending MSU samples it could be predicted 
that key species would not be represented. 
   The quantity of DNA detected, even after amplification, was 10,000-fold lower than 
the required concentration in all 3 samples, however two samples grew bacteria even 
with the sediment culture method. This suggests that the Eurofins method for 
extracting DNA is not appropriate for CSU samples. The studies discussed in Section 
1.6 The bladder microbiome which used culture-independent sequencing had the 
ability to adapt and amend methods to increase the yield of bacterial DNA from urine 
samples. Two principal methods were employed by the investigating teams using NGS 
to extract bacterial DNA from urine. The first method is more laborious, using 
centrifugation, enzymatic digestion with lysozyme, and physical fragmentation using 
beads, to break up cells in the first instance. This is then followed by DNA extraction 
using phenol chloroform isogamy and then alcohol precipitation to precipitate DNA 
(213, 236, 251). The second method uses Triton X-100 and lysozyme as well as 
vortexing to break up cells followed by DNA extraction using a Qiagen DNeasy DNA 
extraction kit, which uses a silica-based membrane containing chaotropic salt to 
remove water and contaminants from DNA (190-192, 194, 195). The latter method 
removes the need to use phenol extraction and alcohol precipitation, which can 
introduce human error. Eurofins Genomics used a method nwhich has been 
optimised for capturing bacteria from a wide range of starting materials including 
wastewater, marine water, food and faeces. Upon contacting Eurofins regarding the 
exact method used to extract DNA, they disclosed that filters were treated with lysis 
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buffer and the supernatant entered the extraction procedure using Maxwell 16 FFS 
nucleic acid extraction kit. This suggests that the inclusion of vortexing or bead 
beating would be necessary for better DNA extraction in our samples. 
5.5.2 EQUC INCREASES DIVERSITY OF CULTURED SPECIES 
 EQUC has clearly shown that many species may have been missed from the 
sediment culture used in the previous two chapters; the number of species from both 
samples was more than two-fold greater using EQUC compared to sediment culture. 
The inclusion of Campygas cultured Corynebacterium tuscaniense, which did not grow 
in other conditions. Interestingly however, this species has been identified in many 
samples in the previous two chapters which did not employ the use of Campygas as a 
condition. It could indicate that this species prefers Campygas conditions, may have 
been missed in a number of samples in the previous chapters, and therefore actual 
incidence may in fact be higher than reported. Inclusion of aerobic conditions has 
cultured Paenibacillus wynii and Actinomyces suimastitidis, both of which are 
previously unreported in this thesis. Therefore, further investigations ought to 
include both of these conditions. The use of CNA and CBA was not effective in 
culturing extra species for one of the samples, however it was with the other sample 
whereby CBA and CNA were unique in culturing Lactobacillus acidophilus and 
Lactobacillus ultunensis, respectively. 
   Due to restricted access to incubators, it was not possible to use 30OC as a condition. 
It would have been interesting to incorporate this condition as it has been shown to 
increase diversity to include species such as Actinomyces naeslundii, Gemella 
haemolysans, Gamella sanguinis, and Kocuria rhizophila, all of which are previously 
unreported in this thesis (195).  
  Despite EQUC showing increased diversity, there were multiple discrepancies in the 
CFU count between sediment culture and EQUC suggesting that centrifuging urine 
skews data and does not give a true representation of the species in the urine. As 
mentioned in Hilt et alǯs study; centrifuging urine increases the yield of bacteria 
which are attached to urothelial cells (195). Unless culture is to be followed with an 
antibiotic protection assay, the sediment culture method should not be used to 
quantify planktonic bacteria in urine samples.  
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  This was a small study including only 3 samples, of which only 2 had positive 
culture. This is a very small sample size for comparing methodologies however it was 
adequate for our laboratory to determine the effectiveness of EQUC compared to NGS 
and sediment culture. Therefore, for future studies within our laboratory, the 
following conditions will be used; i) chocolate agar incubated for 48 hours at 37oC in 
5% CO2 and ii) 48 hours at 37oC in aerobic conditions, iii) fastidious anaerobic agar 
(FAA) for culture in anaerobic and iv) campygas (5% O2, 10% CO2, 85% N) conditions, 
both at 37oC for 48 hours.  
5.5.3 SELECTING DIFFERENT PRIMERS 
 The results from the Lactobacillus concordance study showed that the original 
primers used in Chapters 3 and 4 were not identifying all Lactobacillus species 
correctly. Where L.psittaci was identified with the original primers, these isolates 
should have been L.jensenii as identified by the new primers. This is also the case with 
L.hominis, which should have been identified as L.gasseri. By amending isolates 
originally identified as L.psittaci and L.hominis to L.jensenii and L.gasseri, respectively, 
the Lactobacillus isolates from asymptomatic controls (figure 5.1) correlate better 
with findings from other studies showing that the most common Lactobacillus species 
are L.iners, L. crispatus, L.gasseri and L.jenesenii, where L.hominis is not included (203, 
244). This could be due to the fact that the original primers are designed to select for 
the V9 region of the 16s rRNA gene which is not the most suitable for species 
identification, but is the most highly variable region. Both sets of new primers appear 
to be more accurate since the species ID from both of these primers are concordant 
with each other and correlate more accurately with results from other studies. Since Ǯprimer set ͳǯ were Lactobacillus specific yet Ǯprimer set ʹǯ generated the same species 
identity but are genus wide, the latter primers were preferred for future 16s rRNA 
sequencing on isolates captured from EQUC.  
5.5.4 A PHYLOGENETIC TREE CONFIRMS CORRECT IDENTIFICATION 
The inclusion of a phylogenetic tree has further confirmed that the sequences 
generated are correct since the BLAST result for each isolate correlates with the 
groupings seen in the tree e.g. all the L.jensenii, L gasseri and L.iners are grouped 




1. Methods for detecting bacteria in urine adopted by Eurofins Genomics are 
not sensitive enough to detect very low CFU/ml and therefore this method 
is not best suited to future projects. 
2. Inclusion of aerobic and campygas conditions and the use of fastidious 
anaerobic agar for anaerobic conditions should be included in the culture 
methods of future studies.  
3. Spun urine creates bias for cell-associated bacteria and therefore unspun 
urine should be used for culture in future projects. 
4. Alternative universal primers are better able to identify species to a 
species level than those used in Chapter 3 and 4. 
5. Despite the use of less-efficient primers, our data from Chapter 3 and 4 still 
qualifies since these primers were able to identify bacteria to genus level. 
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CHAPTER 6 - RESULTS 4 
THE ROLE OF PERICYTES IN BLADDER INFECTION 
6.1 INTRODUCTION 
6.1.1 PERICYTES AND MYOFIBROBLASTS 
As has been discussed in the general introduction, pericytes are present in the 
lamina propria of the bladder, shown through immunohistochemistry staining with Ƚ-SMA, NG2, c-kit and PDGFRȾ in mouse bladder (50). They have been shown to 
transdifferentiate into myofibroblasts (46), which contribute to collagen deposition, 
scarring and tissue remodelling, all of which have been observed in OAB (44). This 
chapter focuses on how a low level bladder infection could be leading to the 
symptoms of OAB by stimulation of pericytes. Pericytes have not only been shown to 
respond to vasoactive compounds, but also LPS and cytokines, which is discussed in 
more detail in the following section and provides a sound basis for our hypothesis. 
6.1.2 ROLE OF PERICYTES IN INFECTION IN OTHER ORGANS 
 Pericytes have been shown to express TLR4 (257), the principal receptor for 
LPS, in both the lung and the brain and a number of studies have investigated the 
effects of LPS on pericytes and associated downstream signalling, cytokine 
production and contractile abilities of pericytes (54, 257-269). 
6.1.2.1 PERICYTES RESPOND TO LPS BY RELEASING CYTOKINES AND COX-2 
   Stimulation of rat lung pericytes in vitro with 10-100ng/mL LPS leads to increased 
expression of the pro-inflammatory transcription factor NF-κB and )L-ͳȽ, )L-ͳȾ and 
TNF-Ƚ mRNA measured by reverse transcriptase PCR ȋRT-PCR) of pericyte cytoplasm 
and immunoblotting of supernatant (257, 259). A similar study on isolated TLR4+ 
brain pericytes measured 23 cytokines and chemokines by ELISA (263). Expression 
of the following cytokines and chemokines was increased post stimulation with LPS: - 
IL-3, IL-10, IL-13, MCP-1, GM-CSF and CXCL10, CCL20, CXCL1, CCL2 and CCL5 
respectively (figure 6.1A). Another study has performed a similar experiment on 
brain pericytes with LPS and found that LPS increased pericyte production of IL-ͳȽ, 
TNF-Ƚ, )L-3, IL-9 and IL-13 (265). These two studies highlight the diversity of 
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downstream cytokines released from pericytes and the importance of pericytes 
during infection for upregulating chemokines necessary for migration of monocytes, 
neutrophils and other immune cells. Furthermore, it has been shown that 
downstream signalling from LPS to pro-inflammatory cytokines is TLR-4 and NF-κB 
dependant in brain pericytes (263).  
6.1.2.2 LPS RELAXES PERICYTES AND INDUCES APOPTOSIS 
   Three very different studies have indicated that LPS has a relaxatory effect on lung 
pericytes (261, 264, 267). One of these studies investigated the contractile ability of 
isolated lung pericytes on collagen lattices in culture (261). After incubation with LPS 
the percentage contraction of these lattices was significantly reduced. This contractile 
reduction was not altered with the addition of various inhibitors of iNOS indicating 
that LPS relaxation of pericytes occurs in an iNOS independent mechanism (261). The 
second of these studies showed through patch clamping experiments that LPS leads 
to the opening of pericyte K+ channels, which in turn could be causing relaxation in 
the pericyte cells (264). Finally, a recent study in 2015 by Zeng et al showed that by 
injecting mice with LPS and then staining sections of lung tissue with NG2 (pericytes) 
and isolectin 4 (vasculature), it was possible to quantify pericyte loss and 
pericyte/capillary coverage (267). Mice injected with LPS had significantly reduced 
pericyte density along microvessels in their lungs (267). LPS has also been shown to 
induce pericyte apoptosis by activating caspase-3 shown by increased p11 and p17, 
which may explain the reduced pericyte density in the previous study (268). 
   The resulting effect of LPS relaxing pericytes might increase vascular permeability 
to innate leukocytes migrating to the site of infection. One particularly interesting 
publication has highlighted that pericytes stimulated with LPS upregulate ICAM-1, a 
protein essential for innate leukocyte extravasation. Furthermore, this study 
indicates that not only do pericytes facilitate in extravasation by increasing vascular 
permeability, but they also instruct leukocyte migration and cell survival by providing 
essential signals (270). 
6.1.2.3 PERICYTES RESPOND TO TNF-Ƚ AND IL-1Ⱦ    
   Interestingly, two of the afore mentioned downstream cytokines, IL-ͳȾ and TNF-Ƚ, 
have also been investigated on their specific role on pericytes in both the lung and 
brain (262, 266, 269). One study has shown that TNF-Ƚ can induce further cytokine 
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production particularly MIP-ͳȽ, )L-6 and IL-ͳȾ (266), which can induce acute phase 
response, macrophage activation, pericyte relaxation and leukocytosis (figure 6.1B, 
table 6.1). Another study by Pieper et al showed that presence of TNF-Ƚ and )L-ͳȾ led 
to pericyte phagocytosis, and increased iNOS mRNA and COX-2 mRNA production in 
pericytes (269). iNOS leads to nitric oxide synthesis and COX-2 leads to vasodilation 
and activation of prostaglandins, both of which are essential in pro-inflammatory 
responses (figure 6.1A, table 6.1). Another exciting study by Kerkar et al, who in 2005 
investigated the role the downstream cytokines IL-ͳȾ and TNF-Ƚ on lung pericyte 
function, showed that TNF-Ƚ stimulation of lung pericytes leads to capillary leak and 
influx of immune cells (262). IL-ͳȾ and TNF-Ƚ also induced an iNOS mRNA increase in 
turn leading to RONS production, increased expression on ICAM-1 (essential for 
immune cell infiltration), and increased production on IL-ͳȾ, )L-6, G-CSF and CCL5 
(figure 6.2B, table 6.1). Taken together these studies suggest that pericytes respond 
in similar ways to IL-ͳȾ and TNF-Ƚ irrespective of the resident tissue.  
     To summarise, LPS and the downstream pro-inflammatory cytokines IL-ͳȾ and 
TNF-Ƚ can lead to the production of a variety of pro-inflammatory cytokines (262, 
263, 265, 266) via activation and translocation of NF-κB to the nucleus (263), 
production of chemokines(54, 263, 266)leading to immune cell infiltration to the site 
of infection (54, 262), activation of COX-2 leading to vasodilation (269), as well as 
phagocytosis (269), apoptosis (268), and pericyte loss (267). Taken together these 
studies suggest that pericytes are instrumental to the development of localised 
inflammation but may be able to dissociate from endothelial cells and migrate 






Figure 6.1: Schematic of downstream effects of LPS binding to TLR-4 on pericytes and TNFȽ and IL-1Ⱦ 
stimulation of pericytes. A) LPS from Gram-negative bacteria binds to TLR-4 on pericytes and leads to nitric 
oxide and COX-2 production (263), as well upregulation of the transcription factor NF-κB (263) leading to 
production of a multitude of cytokines and chemokines, in particular IL-1Ƚ, TNFȽ, )L-6 and IL-8 (54, 263, 265). LPS 
stimulation also leads to pericytes becoming phagocytic (269) and pericyte loss (267). B) TNFȽ and IL-1Ⱦ 
stimulation of pericytes acts in a positive feedback loop to produce more pro-inflammatory cytokines such as IL-
1Ƚ and )L-6 (262, 266), and upregulates ICAM-1 facilitating extravasation of leukocytes (262). RONS and mRNA 




Table 6.1: Function of downstream compounds released by pericytes. Pro-inflammatory cytokines such as Il-
6, IL-ͳȾ and TNFȽ lead to acute phase response, leukocytosis and pericyte relaxation, which, along with IL-8 and 
MCP-ͳǯs chemotactic properties and vasodilation caused by COX-2, will lead to influx of immune cells to the site of 
infection. Inducible nitric oxide synthase synthesises nitric oxide which acts as a defence mechanism against 
pathogens. COX-2 further acts to breakdown arachidonic acid into prostaglandins and thromboxane A2, which can 
stimulate smooth muscle contraction or dilation. 
Downstream Function 
Pro-inflammatory 
cytokines:- IL-6, TNF-Ƚ, )L-ͳȽ and )L-ͳȾ Acute phase response (C-reactive protein, serum amyloid A, fibrinogen, mannose binding protein, complement). Macrophage activation. 
Pericyte relaxation. 
VEGF 
Leukocytosis (increased production on white blood cells) 
Prostaglandins → fever. 
IL-8 Neutrophil chemotactic factor. 
COX-2 Vasodilation 
COX-2 inhibitors 
Prostaglandin-E2, thromboxane A2. 
iNOS Nitric oxide synthesis. 
IL-12 and IFN-ɀ Activation of Type 1 T-helper cells → Adaptive immunity 





6.1.3 VASOACTIVE COMPOUNDS ACTING ON PERICYTES 
As mentioned in the main introduction, pericytes are able to control blood 
flow by responding to various vasoactive compounds. These compounds may be 
endogenous to the body or a pharmaceutical drug. In order to form a better 
understanding of the role of pericytes in the bladder it is essential to determine which 
vasoactive compounds pericytes are able to respond to and to what extent by creating 
experiments where responses can be measured and quantified. The responsiveness of 
perictyes to various vasoactive agents such as angiotensin II, noradrenaline, 
endothelin, indomethacin, and ATP, and vasodilatory agents such as prostaglandin 
E2, NO, bradykinin, and carbachol has been described in the vasa recta of rat kidney 
by Crawford et al (52). Each of these compounds is endogenous in most tissues, 
although the mechanisms by which they lead to mediated change in vessel diameter 
in pericytes differs by the signalling pathways they induce. The principle technique 
used by Crawford et al in the kidney was using DIC imaging to acquire images of 
pericytes in live kidney slices and measuring capillary diameter changes at pericyte 
sites when tissue is superfused with vasoactive compounds. By adapting this 
technique it is possible to create a model to investigate the function of pericytes 
regulating blood flow in the bladder. This can then be expanded upon to investigate 
the role of IL-ͳȾ, TNFȽ and LPS in regulation of pericytes, which has not yet been 




6.2 AIMS AND HYPOTHESIS 
 We hypothesis that pericytes can react to pro-inflammatory components 
generated during an immune response to the presence of bacteria in the bladder. We 
also hypothesise that the pericytes will respond in a measurable contractile manner 
to control blood flow and, in chronic cases, pericyte loss will occur.   
 
    In order to begin to test these hypotheses the following objectives will be to 
investigate:- 
1. Identify whether pericytes are in proximity to the vasculature in 
murine bladder urothelium by immunohistochemistry. 
2. Use DIC imaging to investigate pericyte function by superfusing known 
vasoactive compounds over isolated murine bladder urothelium and 
visualising pericyte mediated changes in vessel diameter. . 
3. Use the above model to investigate the acute effect of TNFȽ on murine 
bladder pericytes and vessel diameter. 
4. Determine how prolonged exposure (4 hours) of bladder tissue to LPS, TNFȽ and )L-ͳȾ can affect pericyte density in the murine bladder.  
6.3 METHODOLOGY 
6.3.1 DISCLAIMER 
 All experiments were performed by myself. 
6.3.2 ETHICS 
 All culls were performed by trained personnel by cervical dislocation in 
accordance with the Animals Scientific Procedures Act of 1986.  
6.3.3 OPTIMISING DISSECTION FOR DIC IMAGING  
 The methods for dissection in Section 2.2.1 Tissue preparation and set up of 
tissue in Section 2.2.4 DIC imaging of live tissue for DIC imaging are optimised. Various 
challenges were met when trying to obtain DIC images of live bladder urothelium. 
Initially, rat bladder was used (n=8, data not used) but due to the structure of the 
bladder in this species, the detrusor muscle could not be removed properly, and much 
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of the muscle tissue would be left behind. This meant the detrusor continually 
contracted under the objective making imaging impossible. Therefore, the tissue was 
pinned out with insect pins onto Sylgard® 184 (figure 6.2). Even in cases where an 
attempt was made to remove the detrusor (n=5), pinning out did not reduce the 
movement of the tissue making imaging impossible. Upon discussions with 
collaborators, it was learnt that mouse bladder is easier to dissect and the detrusor 
could be peeled off in one piece. This meant that pinning out was no longer required 
and only a harp was necessary to hold the tissue in place under the objective (figure ʹ.ͳ͵AȌ. Similar effects on the detrusor were observed with SNP at ͳͲͲμM ȋn=ͳȌ and ͳͲμM ȋn=ͳȌ. )n these experiments, the tissue was not pinned out. Therefore, mice 
were used for all experiments in this chapter as per the methods discussed in Section 




Figure 6.2: Image of DIC set up optimised for rat bladder imaging.  Rat bladder detrusor was difficult to 
remove from the urothelium therefore the tissue contracted under the objective. In an attempt to combat this the 
rat bladder was pinned down with insect pins into Sylgard® 184 with a harp placed over the top. This set up was 
then placed on the microscope stage and superfused with physiological saline solution. This set up was not able to 





6.3.4 CALCULATING PERICYTE DENSITY  
   Four mice were included in the experiment; urothelium was removed from the 
bladder, and cut into 3 or 4 strips (dependant on bladder size) and pre-incubated with LPS, TNFȽ, and )L-ͳȾ in PSS and a control of just PSS by leaving tissue strips in 
Nunc wells with the respective cytokines at the concentrations discussed in the 
General Methodology Section 2.2.3 Immunohistochemistry NG2/IB4 for four hours 
prior to staining. This generated a total of n=4 controls, n=3 LPS, n=3 IL-ͳȾ and n=͵ TNFȽ. Three images were taken per urothelium strip where staining was clearest. 
Distances between branch pericytes along vessels was measured in Image J. Pericyte 
density was calculated per strip and given as a mean distance between pericytes per field of view ȋ͵ͻͲ μm2Ȍ, per mouse, per condition ȋcontrol, LPS TNFȽ, or )L-ͳȾȌ. By 
comparing the pericyte number and density across individual mice it was possible to 
observe variability in pericyte density between conditions in each animal. By 
comparing across all mice it was possible to determine if differences in pericyte 
density between conditions were due to chance or were statistically relevant. 




6.4.1 OBSERVATION OF PERICYTES IN THE MURINE BLADDER 
By staining murine urothelium with anti-IB4 (vasculature, green) and anti-
NG2 (pericytes, red), it was possible to see where pericytes lay in the vasculature and determine average pericyte cell count per ͳͲͲμm2 and pericyte density at vessel 
branch points. Since C-fibres are also IB4 positive, vessels were identified due to their 
thick network structure and since SMC can also be NG2 positive, pericytes were 
identified due to their bulbous structure. It can be observed that pericytes tend to be 
densely populated in the vasculature and tend to be present at all branch points, 
where they are able to control directional blood flow (figure 6.3A and B). Vessel 
pericytes are more spaced out along the vessel (figure 6.3C-E). 
 
Figure 6.3: Isolectin B4 (IB4) and Neuroglial 2 (NG2) staining of mouse bladder urothelium. IB4 (conjugated 
with Alexa 488 green) staining for vasculature and anti-NG2 (probed with Alexa 555 conjugate 2o antibody, red) 
staining for perivascular pericytes in the bladder urothelium of adult male mice shows vast winding capillary 
network with many pericytes at both branch points and along branches. A-B) Network of microvasculature highly 
populated with pericytes at branch points. C-E) Branches of microvasculature are also populated with pericytes 
periodically spaced along the length. 
A)	 	 	 	 	 															B) 	 	 	 	
	 		
		C) 	 	 	 				D) 	 	 																			E)	 	 	





6.4.2 CALCULATING PERICYTE DENSITY PRE- AND POST-INCUBATION WITH LPS, 
TNFȽ AND IL-1Ⱦ 
LPS acts as a potent activator of innate pro-inflammatory responses in many cells including pericytes. TNFȽ and )L-ͳȾ are examples of two cytokines released 
during these innate pro-inflammatory response which have been shown to act in a 
paracrine manner to further stimulate pericytes (figure 6.1B). By incubating bladder urothelium for Ͷ hours in either LPS, TNFȽ, or )L-ͳȾ in PSS prior to staining, it was 
possible to investigate pericyte responses to Gram negative bacteria and associated 
downstream cytokines which may be found in the bladder during an infection with a 
Gram negative species such as UPEC.  
   Mean number of branch pericytes per field of view ȋ͵ͻͲ μm2) in control ȋn=ͶȌ is ͺ.ͳ͹ per field of view ȋ͵ͻͲ μm2) (figure 6.4). This is slightly lower in urothelium pre-incubated with LPS for Ͷ hours in PSS ȋ͹ pericytes per field of view ȋ͵ͻͲ μm2), p= Ͳ.ͷͲͳ͵Ȍ. The number of pericytes per field of view ȋ͵ͻͲ μm2) is significantly reduced when tissue is pre-incubated with TNFȽ to ͷ cells ȋp=Ͳ.ͲͶ*Ȍ and further reduced when pre-incubated with )L-ͳȾ to 3.78 cells (p= 0.007**) indicating that these 
cytokines could be leading to pericyte cell death (figure 6.4). All statistical differences 
were calculated using an unpaired student T-test. 
    From mouse 1, the strip incubated with IL-ͳȾ had a significantly greater mean distance between pericytes ȋͷ.ͻμmȌ compared to controls ȋ͵.Ͳ͵μm, p=Ͳ.ͲͲ͸**Ȍ, 
whereas only a slight increase is observed with the strips incubated in LPS ȋ͵.͸ͷμm, p=Ͳ.ͷ͹Ȍ and TNFȽ ȋ͵.ͺͷμm, p=Ͳ.ʹ͹Ȍ ȋfigure ͸.ͷAȌ. From mouse ʹ, the strip incubated with LPS had a slightly greater mean distance between pericytes ȋ͵.ͻͺμmȌ compared to controls ȋ͵.ͷʹμm, p=Ͳ.Ͷ͹Ȍ, whereas a decrease in mean distance is observed with the strip incubated with TNFȽ ȋp=Ͳ.ʹ͵Ȍ ȋfigure ͸.ͷBȌ. From mouse ͵, mean distance between pericytes remained relatively similar across control ȋʹ.͹ͷμmȌ, )L-ͳȾ ȋ͵.ͳμmȌ, and TNFȽ ȋʹ.͹͹μmȌȋall p>Ͳ.ͲͷȌ ȋfigure ͸.ͷCȌ. From mouse Ͷ, the strip 




   Comparing all mice cumulatively, there is a significantly greater mean distance between pericytes in strips incubated in only PSS ȋ͵.Ͳʹμm, n=ͶȌ and those incubated 
in IL-ͳȾ ȋ͵.͹͸μm, n=͵Ȍȋp=Ͳ.ͲͳͶ*Ȍ and LPS ȋ͵.͹ͺμm, n=͵Ȍȋp=Ͳ.Ͳ͵ͳ*Ȍ. Mean distance 
between pericytes is not significantly greater in strips incubated with TNFȽ ȋ͵.Ͳ͸μmȌ 
but it is slightly greater than that of controls (p=0.91, figure 6.5E). 
 
 
Figure ͸.Ͷ: Mean number of branch pericytes per ͵9Ͳ μm2 in mouse bladder urothelium post-incubation 
with LPS, IL-ͳȾ and TNFȽ. Mean number of branch pericytes in control (n=4) is 8.17 per field of view. This is 
lower but not significantly lower in urothelium pre-incubated with LPS for 4 hours in PSS (7 pericytes per field of 
view, p= 0.5013). The number of pericytes per field of view is significantly reduced when tissue is pre-incubated with TNFȽ to ͷ cells ȋp=Ͳ.ͲͶ*Ȍ and further reduced when pre-incubated with IL-ͳȾ to 3.78 cells (p= 0.007**) 
indicating that these cytokines could be leading to pericyte cell death. Statistical significance noted as * = p<0.05, 





Figure ͸.ͷ: Mean distance between branch pericytes per ͵9Ͳ μm2 in mouse bladder urothelium post-
incubation with LPS, IL-ͳȾ and TNFȽ. Mean distance between branch pericytes in controls varies from 2.75 to ͵.ͷʹμm with a mean on ͵.Ͳʹμm ȋn=ͶȌ. When pre-incubated for 4 hours with LPS the mean distance increases slightly in all mice and significantly increases to ͵.͹ͺμm when data is pooled ȋn=͵, p=Ͳ.ͲͳͶ*Ȍ. When pre-incubated 
for 4 hours with IL-ͳȾ the mean distance increases slightly in two mice and increases significantly in one mouse from ͵.Ͳʹμm in control to ͷ.ͻͳμm in )L-ͳȾ. When data is pooled for all mice, mean distance increases significantly 
from control to IL-ͳȾ ȋ͵.͹͸μm, n=͵Ȍȋp=Ͳ.Ͳ͵ͳ*Ȍ. Mean distance between pericytes pre-incubated with TNFȽ is not 
significant however trends to be slightly increased.  Statistical significance noted as * = p<0.05, ** p<0.01 
calculated with an unpaired student T test. 
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6.4.3 PERICYTE FUNCTIONAL RESPONSES TO ANGIOTENSIN II 
 Angiotensin II is one of the most potent vasoconstrictor compounds found 
endogenously throughout tissues. It is a member of the renin-angiotensin system and 
is produced by cleavage of angiotensin I by angiotensin-converting enzyme. It plays a 
role in vasoconstriction and increased blood pressure throughout the body, and in the 
bladder it has been shown to increase smooth muscle cell growth and hyperplasia, as 
well as increased collagen deposition (271). 
    DIC imaging of live bladder urothelial preparation with addition of angiotensin II 
showed that at concentrations of 100 nM 10 nM and 1 nM, vessels constricted in 
response to the drug with varied response rates (table 6.2). Responses to angiotensin 
were highest (100%) with an intermediate concentration of angiotensin of 10 nM 
(n=3) (table 6.2) reducing to 50% with 100 nM (n=10) and 33.3% with 1 nm (n=6). 
Where there was a notable percentage response rate, pericyte sites were clearly 
visible as the areas of maximal constriction (figure 6.6E).  In responsive tissues, 
higher concentrations of angiotensin II induced a more rapid constriction; on average 
within 76.6 seconds after the drug is added to the tissue (n=3) compared to 122.75 
seconds with 10 nM (n=3) and 157.5 seconds with 1 nM (n=2) (table 6.2, figure 6.6A). 
Tissues responding to higher concentrations angiotensin II also reached maximal 
constriction faster, 98.3 seconds with 100 nM (n=5) compared to 218.25 seconds 
with 10 nM (n=3) and 395 seconds with 1 nM (n=2). The maximal constriction of the 
vessels was not concentration dependant. An overall maximal constriction of Δ͹ͺ.ͳͷ% of original vessel diameter was reached using ͳͲ nM (p=0.05*) angiotensin )), however this was only Δͺͳ.ͳͻ% with ͳͲͲ nM (p=0.004**) and Δͺ͵.ʹͻ% with ͳ nM 
(P=0.03*) (figure 6.6D). These differences are considered significant by a paired 





Table 6.2: Drug response rate, the time taken for Angiotensin II to induce constriction, reach maximal 
constriction and become desensitised.  Time to induce constriction post application of Ang II increases from a 
mean 76.6 seconds (n=5) with 100 nM Ang II to a mean 157.5 seconds with 1 nM (n=2).  Time to maximal 
constriction also increases as concentration increases. In experiments performed with 100 nM Ang II the tissue 
desensitizes (vessel diameter returns to normal before drug is removed) in only 100 seconds post-application. As 
the concentration is lowered, the tissue desensitizes slower and with 1 nM does not desensitize. Overall maximal 
vessel constriction is obtained by application of 10 nM Ang II (78.15% original diameter)(n=3). % diameter of 
original diameter at the end of the video indicates that application of higher concentrations allows vessels to 
return to original diameter (95.98%), likely due to desensitisation, compared to lower concentrations such as 1 
nM which remain at 80.43% constriction. 
 
   In all responding tissues at 100 nM and 10 nM, cells become desensitised to the 
drug allowing the vessel diameter to begin to return normal diameter before the drug 
is removed. (figure 6.6A-B). Time to desensitisation is measured from the point 
where constriction is reversed and the vessel begins to return to normal diameter. On 
average, desensitisation takes 100.0 seconds from when the drug is first added and 
23.3 seconds since constriction begins with 100 nM angiotensin (n=3) (table 6.3, 
figure 6.6A). This time is slower with a lower concentration of 10 nM (224.5 seconds 
from when the drug is added). At the lower concentration of 10 nM, angiotensin II 
vessel constriction takes longer to respond (figure 6.6B), however constricts more 
than with 100 nm. When the drug is removed the vessel diameter does not return to 
normal as with 100 nM (figure 6.6B). Furthermore, since there is more constriction at 
pericyte sites, non-pericyte sites are also affected so that the difference between the 




















% of Δ 
diameter 
at end of 
video 
100 nM 5/10 50% 76.6 s 98.3 s 81.19% 100 s 95.98% 
10 nM 3/3 100% 122.75 s 218.25 s 78.15% 224.5 s 88.29% 





Figure 6.6: Effect of vasoactive compound Angiotensin II on diameter of bladder urothelium 
microvasculature. Superfusion of Angiotensin II (Ang II) over live mouse bladder urothelium. A) 100 nM Ang II 
induces a rapid response constricting the capillary which returns to baseline before Ang II is removed indicating 
drug desensitisation at higher concentration. B) 10 nM Ang II induces a delayed response constricting the 
capillary which reverses when Ang II is removed but does not return to baseline. C) 1 nM Ang II induces a delayed 
response constricting the capillary which stops constricting when Ang II is removed but does not reverse. D) 
Maximal constriction is obtained by application of 10 nM Ang II (-16.71%, n=3) (p=0.05*), however this 
concentration also affects non-pericyte sites more than other concentrations. The most significant change in 
diameter was with the higher concentration of 100 nM (p=0.004**). Statistical significance noted as * = p<0.05, ** 
p<0.01 calculated with a paired student T test. E) Example of DIC images of capillary i) pre- and ii) post- 10 nM 
Ang II addition. Pericytes are indicated by red dotted circles, white dotted lines indicate where maximal 




6.4.4 PERICYTE FUNCTIONAL RESPONSES TO ATP 
 Not only is ATP an important signalling molecule in normal bladder function 
but it has also been shown by many studies to be increased in patients with 
overactive bladder (17, 18, 72, 272). ATP binds to P2 receptors on afferent nerves, 
myofibroblasts, smooth muscle cells, and urothelial cells with in the bladder and can 
induce constriction in pericytes (52), and is therefore of particular interest to this 
study. DIC imaging of live bladder urothelial preparation with addition of ATP 
showed that at concentrations of 1 mM and 0.1 mM, vessels constricted in response to 
the drug with response rates of 33.3% and 25%, respectively (table 6.4). Responses 
to ATP were highest (33.3%) with a higher concentration of ATP of 1 mM (n=9), 
reducing to 25.0% with 0.1 mM (n=8). Where tissues responded, pericyte sites were 
clearly visible as the areas of maximal constriction (figure 6.7D).  
  In responsive tissues, the higher concentration of ATP induced a more rapid 
constriction; on average within 73.3 seconds after 1 mM is added to the tissue (n=3) 
compared to 252 seconds with 0.1 mM (n=2)(table 6.4, figure 6.7A-B). Furthermore, 
in the higher concentration of 1 mM, constriction reaches a maximum faster; 685 
seconds compared to 757 seconds with 0.1 mM ATP (table 6.4). (table 6.4, figure 
6.7A-B). Tissues responding to the higher concentration of ATP also reached maximal 
constriction faster, 685 seconds with 1 mM (n=3) compared to 757 seconds with 0.1 
mM (n=2). The maximal constriction of the vessels was concentration dependant. An overall maximal constriction of Δͺʹ.ʹͺ% of original vessel diameter was reached 
using 1 mM ATP (p=0.0006***), however this was slightly lower at Δͺ͸.ͶͲ% with Ͳ.ͳ 
mM (p= 0.1294, figure 6.4C). Significance is determined by a paired Student T test. 
  In 4 of the 5 responding tissues at 1 mM (n=2) and 0.1 mM (n=2), pericytes continue 
to constrict once the ATP has been removed (figure 6.7B). For this reason, in these 
tissues the maximal constriction is the same as the % constriction at the end of the 
video. In the one remaining video, cells become desensitised to the drug (1 mM) 
allowing the vessel diameter to begin to return normal before the drug is removed 
(figure 6.7A). Since only one of five experiments shows desensitisation, the time to 






Table 6.3: Drug response rate, the time taken for ATP to induce constriction and reach maximal 
constriction.  Time to induce constriction post application of ATP increases from a mean 73.3 seconds (n=3) with 
1 mM ATP to a mean 252 seconds with 0.1 mM (n=2).  Time to maximal constriction also increases as 
concentration increases. In 2/3 experiments performed with 1 mM ATP and 2/2 with 0.1 mM ATP the tissue 
continues to constrict once the drug has been removed (vessel diameter returns to normal before drug is 
removed) in only 100 seconds post-application Overall maximal vessel constriction is obtained by application of 1 
mM ATP (82.28% original diameter)(n=3). % diameter of original diameter at the end of the video indicates that 


















% of Δ 
diameter 
at end of 
video 
1 mM 3/9 33.3% 73.3 s 685 s 82.28% N/A 85.41 % 




Figure 6.7: Effect of vasoactive compound ATP on diameter of bladder urothelium microvasculature. 
Superfusion of ATP over live mouse bladder urothelium. A) 1 mM ATP induces a rapid response constricting the 
capillary which begins returns to baseline before ATP is removed indicating drug desensitisation at this 
concentration. B) In 2/3 experiments performed with 1 mM ATP and 2/2 with 0.1 mM, ATP induces a delayed 
response constricting the capillary which does not stop constricting when ATP is removed and does not reverse. 
C) Maximal constriction is obtained by application of 1 mM ATP (-17.72%, n=3) (p=0.0006***), however this 
concentration also affects non-pericyte sites more than other concentrations. Statistical significance noted as *** = 
p<0.001 calculated with a paired student T test.  D) Example of DIC images of capillary i) pre- and ii) post- 0.1 mM 
ATP addition. Pericytes are indicated by red dotted semi-circles, white dotted lines indicate where maximal 
constriction occurs (1200 frames) at pericyte sites, and yellow dotted lines indicate non-pericyte region of the 









6.4.5 PERICYTE FUNCTIONAL RESPONSES TO BRADYKININ 
 As well as using vasoconstrictor drugs to determine whether bladder pericytes 
constrict in same way as kidney ones, it is necessary to perform experiments using 
vasodilators. Bradykinin is a member of the kinin system and plays a role in blood 
pressure regulation by causing vasodilation and increasing vascular permeability 
(reviewed in (273)). Bradykinin also causes contraction of non-vascular smooth 
muscle in the gut and lung of most animals (274).  
   DIC experiments with bradykinin were challenging since this drug appeared to have 
contractile effects upon the detrusor muscle as well as the vessels. Despite peeling the 
urothelium away from the detrusor during dissection, small muscle fibres still 
remained attached to the lamina propria. Upon addition of bradykinin, the tissue 
appeared to be pulled towards and moved from focus making imaging impossible ȋfigure ͸.ͺȌ. )nitially, bradykinin was used at a concentration of ͳμM ȋn=ͳȌ, to which 
the smooth muscle responded very rapidly, contracting within 8 seconds (table 6.4). The concentration of bradykinin was reduced to Ͳ.ͷμM ȋn=ͳȌ, ͳͲͲnM ȋn=ͳȌ, ͳͲnM 
(n=1) and then further to 1nM (n=2) but even at the reduced concentrations, the 
effect was the same, however the muscle took longer to respond as concentration 
reduced, with exception to the single responding experiment with 1nM which can be 
taken as an anomaly (table 6.4). Despite other functional experiments with 
angiotensin II, ATP and SNP not requiring pinning out on Sylgard® 184 (figure 6.2), 
this method was revised for bradykinin for 100nM (n=2), 10nM (n=1) and 1nM (n=1) 
but did not offer sufficient prevention of tissue movement in order to measure any 
changes in vessel diameter. In two of the three experiments using 1nM bradykinin 
there was no effect on the muscle fibres but also none on the vessel, suggesting the 
tissue may have died by being over stretched or that this concentration was 











Average time to 
induce constriction 
post-drug ͳ μM 1/1 (100%) 8 seconds Ͳ.ͷ μM 1/1 (100%) 25 seconds 
100 nM 3/3 (100%) 40 seconds 
10 nM 2/2 (100%) 65 seconds 
1 nM 1/3 (33%) 35 seconds 
 
Table 6.4: Bradykinin response rate, the time taken for the drug to induce muscle constriction. Smooth 
muscle attached to the mouse urothelium contracted with the addition of bradykinin. With the highest dose used of ͳ μM the average time to constriction was 8 seconds. As the dose was reduced the average time to constriction 
increased in a dose dependant manner. Even at concentrations of 10 nM the smooth muscle still contracted too 
much to maintain focus on the tissue. At the lowest dose used of 1 nM the response rate reduced to 33.3% (n=3), 
however in the two non-responding videos there was also no response in the vessels.  
 
 
Figure 6.8: Image showing smooth muscle contraction upon addition of 1 nM Bradykinin. Singular images 
from DIC experiments pre and post drug application by superfusion. A) Snapshot of bladder urothelium at frame 1 
pre-drug application. B) Snapshot of bladder urothelium at frame 1 pre-drug application with red dotted areas 
indicating pericyte location. C) Snapshot of bladder urothelium 45 seconds post-drug application. White arrows 
indicate direction of muscle contraction. D) Snapshot of bladder urothelium 60 seconds post-drug application. 




6.4.6 PERICYTE FUNCTIONAL RESPONSES TO NO 
Nitric oxide signalling plays a valuable role in bladder function as a 
neurotransmitter stimulating myofibroblasts and afferent nerves during bladder 
filling, however it is unstable and only exists as a gas in standard conditions; 
therefore, it is necessary to use NO donors to experiment with this compound. 
Sodium nitroprusside (SNP) is one such NO donor. SNP also appeared to have 
contractile effects upon the detrusor muscle as well as the vessels, as was seen with 
bradykinin. Even at very small concentrations such as ͳͲ μM SNP has a very strong 
affect on the smooth muscle in the bladder, which means that unless the entirety of 
the muscle is removed, the response of pericytes to SNP cannot be measured (figure 
6.9). It can be seen in figure 6.9A and B that pericytes can be clearly observed (red 
dotted areas, figure 6.9B), which become harder to observe post SNP application 
(figure 6.9C-D) as the detrusor muscle contracts and the tissue moves out of focus 
(figure 6.9B), which cannot be regained by refocusing the microscope. According to 
the literature SNP relaxes smooth muscle (275), however the videos taken here 
appear to show contraction. 
    S-Nitroso-N-acetyl-DL-penicillamine (SNAP) is another example of an NO donor 
used in physiological experiments. Interestingly, SNAP, did not have the same muscle 
contractile effect on the detrusor muscle. A 0% response rate was observed on both 
vascular smooth muscle and detrusor smooth muscle when tissue was superfused 
with ͳͲͲ μM SNAP (n=9, data not shown). Therefore, the structure of SNP or how this 







Figure 6.9: Images showing smooth muscle contraction upon addition of 10 μM SNP. Singular images from 
DIC experiments pre- and post-application of NO donor sodium nitropruside (SNP) by superfusion. A) Snapshot of 
bladder urothelium at frame 1 pre-drug application. B) Snapshot of bladder urothelium at frame 1 pre-drug 
application with red dotted areas indicating pericyte location. C) Snapshot of bladder urothelium 280 seconds 
post-drug application. White arrows indicate direction of muscle contraction. D) Snapshot of bladder urothelium 




6.4.7 PERICYTE FUNCTIONAL RESPONSES TO TNF-Ƚ 
 TNFȽ is a potent activator of pro-inflammatory responses and is produced in 
response to presence of pathogens. It has previously been shown to act on pericytes 
in other organs to induce production of COX2, RONS and other pro-inflammatory 
cytokines (262, 266, 269). Application of TNF-Ƚ to murine urothelium will hopefully 
give an indication to how pericytes respond to TNF-Ƚ acutely and in turn provide 
insight into pro-inflammatory cytokinesǯ effect on blood flow during infection. 
   DIC imaging of live bladder urothelial preparation with addition of TNF-Ƚ showed that at a concentration of ͳͲ ng/μL, vessels constricted at pericyte sites in response to 
the drug. TNF-Ƚ had a ͳͲͲ% success rate ȋn=͵Ȍ with tissues responding on average 
38.8 seconds after the drug is added to the tissue (n=3)(table 6.5, figure 6.10).  
   Responding tissues reached maximal constriction on average 115 seconds post-application and an overall maximal constriction of ΔͻͲ.ͷͷ% of original vessel 
diameter was reached, which remained relatively the same even once the drug had been removed, until the end of the video ȋΔͻͳ.Ͳͷ%, n=͵Ȍ (p=0.0715, figure 6.10C). 
This difference is not considered significant by a paired Student T test. 
 
Table 6.5: Drug response rate, the time taken for TNF-Ƚ to induce constriction and reach maximal 
constriction.  Time to induce constriction post application of TNF-Ƚ is a mean ͵ͺ.͵ seconds ȋn=͵Ȍ.  Time to 
maximal constriction is 115 seconds and the maximal constriction is 90.55% of the initial diameter. % diameter of 
original diameter at the end of the video indicates that maximal diameter remains similar (91.05%) until the end 
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Figure 6.10: Effect of pro-inflammatory cytokine TNFȽ on diameter of bladder urothelium 
microvasculature. Superfusion of TNFȽ over live mouse bladder urothelium. A) 10 ng/μl TNFȽ induces a rapid 
response constricting the capillary which reverses slightly before TNFȽ is removed indicating a desensitisation of 
response at this concentration. B) 10 ng/μl TNFȽ induces a rapid response constricting the capillary which 
continues to contstrict even once TNFȽ is removed. C) Mean maximal constriction obtained by application of 10 ng/μM TNFȽ is -9.95% (n=3, p=0.07), however this concentration also affects non-pericyte sites. Statistical 
significance calculated with a paired student T test. D) Example of DIC images of capillary pre- and post- 10 ng/μl 
TNFȽ addition. Pericytes are indicated by red dotted semi-circles, white dotted lines indicate where maximal 





6.4.8 MURINE BLADDER UROTHELIUM CELL VIABILITY 
 As relatively low response rates were observed in DIC experiments with 
Angiotensin II, ATP and SNAP, a tissue viability stain was performed to determine the 
% cell viability after times of 0 mins, 30 mins, 1 hour and 2 hours of tissue being in 
PSS. Since the staining with PI required incubating with PI in PSS for 15mins 
therefore the times were amended to 15 mins, 45 mins, 1h 15min and 2h 15mins. PI 
is taken up by cells with compromised cell membranes and is therefore used to stain 
for nuclei of dead cells. A counter stain of DAPI stains for DNA in all cells. Therefore 
the cell viability was calculated as follows: - 
% cell viability = ቆሺTotal DAP�ሻ − ሺTotal P�ሻTotal DAP� ቇ  � ͳͲͲ% 
 
 Image J was used to manually count cells assisted by the application of a grid set to 
30,000 pixels so only cells on the lines of two sides of a square are counted 
avoiding counting cells twice.  Cells from the image taken under the 350nm filter (for 
DAPI, figure 6.11A) were counted first, followed by a manual cell count from the 
image aquired using a 536nm filter (for PI, figure 6.11B). Areas where blue live cells 
can be seen under the 350 nm filter (figure 6.11A) but are absent under the 536 nm 
filter are indicated by white dotted areas. Overlaying these two images into a 
composite image shows purple cells where cells are dead and blue cells were cells are 
alive (figure 6.11C). All urothelial strips were imaged in 3 different areas selected at 
random. Total manual cell count of both DAPI and PI are found in table 6.6, where it 
can be seen that even at 15mins incubation in PSS, all cells in one urothelial strip are 
dead and only 13.7% alive in the other. This viability is reduced to 0% and 8.62% 
(figure 6.11D) after 45 mins and then 0% for all strips after 1 h 15 mins (figure 6.11E) 
and 2 h 15 mins (figure 6.11F). These data suggest that tissue is dying rapidly in the 
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(all cells) 
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Table 6.6: Cell viability staining with DAPI and propidium iodide cell counts. Tissue left in physiological 
saline (PSS) for 15 mins (n=2), 45 mins (n=2), 1h 15 mins (n=2) and 2h mins (n=1) followed by staining with DAPI 
(blue) for all cells and propidium iodide (PI, red) for dead cells to determine cell viability. 3 images taken per piece 
of tissue, excited at 350nm (DAPI, blue) and 530nm (PI, red) and cell count performed manually in Image J for 





Figure 6.11: Cell viability staining of mouse bladder urothelium with DAPI and propidium iodide. Tissue 
left in physiological saline (PSS) for 15 mins (n=2), 45 mins (n=2), 1h 15 mins (n=2) and 2h mins (n=1) followed 
by staining with DAPI (blue) for all cells and propidium iodide (PI, red) for dead cells to determine cell viability. 3 
images taken per piece of tissue, excited at 350nm (DAPI, blue) and 530nm (PI, red). A) an image of all cells 
labeled with DAPI at time point 15 mins indicates 218 total cells. B) an image of cells labeled with PI at time point 
15 mins indicates 179 dead cells. C) an image of all cells labeled with DAPI and PI at time point 15 mins indicates 
179 dead cells (=17.9% total cells). Total 6 images from n=2 15mins incubations gave total cell viability of 0% and 
13.7%. D) an image of all cells labeled with DAPI and PI at time point 45 mins with 21.9% live cells (indicated by 
white dotted areas). Total 6 images from n=2 45 mins incubations gave total cell viability of 0% and 8.62%. E) an 
image of all cells labeled with DAPI and PI at time point 1h 15 mins with 0% live cells (indicated by white dotted 
areas). Total 6 images from n=2 1h 15mins incubations gave total cell viability of 0% and 0%. F) an image of all 
cells labeled with DAPI and PI at time point 2 h 15 mins with 0% live cells. Total 6 images from n=1 2h 15mins 




6.5.1 BLADDER PERICYTES RESPOND TO VASOACTIVE COMPOUNDS 
 By staining mouse bladder urothelium with anti-NG2 (pericytes, red) as well 
as IB4 (vasculature, green), it has been possible to show that pericytes are widely 
expressed throughout the bladder and are predominantly found at branch sites 
indicating that they are essential for controlling blood flow direction (figure 6.3). 
There are fewer pericytes along vessels than are branch pericytes (data not shown), 
and it is these pericytes that were most responsive to ATP, angiotensin II and TNF-Ƚ. 
This suggests that blood pressure is controlled along branches rather than at branch 
junctions within the bladder.  
   Data in this chapter indicate that in the bladder, angiotensin II functions directly at 
pericytes to induce constriction of blood vessels (figure 6.6). With higher 
concentrations of angiotensin the pericytes respond faster, both in terms of starting 
constriction and reaching a maximal constriction. At higher concentrations of 
angiotensin II the pericytes also become desensitised faster and the vessels begin to 
return to a relaxed state. With the lower concentration of angiotensin 1 nM, 
desensitisation does not occur and the vessels continue to constrict even once the 
drug has been removed. As mentioned in the introduction to this chapter, it has been 
shown that increased OAB has been linked to increased collagen deposition in the 
bladder (271). Since our data show that pericytes can respond acutely to angiotensin 
II and even continue to respond after this vasoactive compound has been removed, it 
opens up the question of whether pericytes can respond to angiotensin II by 
transdifferentiating into fibrosis producing cells. This requires further investigation 
outwith the time restraints of this project, however it could be an exciting line of 
research to support the theory that pericytes are a key cell in bladder fibrosis (46). 
   Data in this chapter also indicate that in the bladder, ATP functions directly at 
pericytes to induce constriction of blood vessels (figure 6.7). With higher 
concentrations of ATP the pericytes respond faster, both in terms of starting 
constriction and reaching a maximal constriction. At higher concentrations of 1 mM 
ATP the pericytes also become desensitised faster and the vessels begin to return to a 
relaxed state. With the lower concentration of 0.1 mM ATP, desensitisation does not 
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occur and the vessels continue to constrict even once the drug has been removed. As 
mentioned in Section 1.5.6 Activator signalling and bacteriuria, increased 
concentration of ATP in the urine correlates with OAB incidence and symptom score 
(75, 181-183). Furthermore, ATP is produced by both UPEC and by urothelial cells in 
response to UPEC infection in the bladder (75, 184, 185) (figure 6.12). Data from 
Chapter 4 – Results 2: The Bladder Microbiome of Patients with Overactive Bladder 
have shown that incidence of Gram negative bacteria is higher in patients with OAB 
than asymptomatic controls. Data in this chapter prove that pericytes respond acutely 
to ATP and continue to respond after this vasoactive compound has been removed, 
showing that ATP also acts upon this cell type in the bladder. What has not been 
deduced from this research is the type of receptors present on bladder pericytes. 
Different receptors have a different sensitivities/selectivity for range of nucleotides 
and nucleosides. By investigating the responses to each metabolite, one can deduce 
the receptors responsible for signalling in that cell type. The types of P2 receptors on 
pericytes has been investigated in other organs including the retina and the vasa 
recta of the kidney; the principal receptor on pericytes in the retina is the P2X7 
receptor (276), and in the kidney, P2X1, P2X7 and P2Y4 (277). Further investigation 
is required to determine the receptors responsible for pericyte-mediated 
vasoconstriction in the bladder. However, considering the two afore mentioned 
studies have both found P2X7 on pericytes, it could be theorised that this could also 
be present on bladder pericytes. This particular P2X receptor is known to require 
high levels of ATP in order to respond but continued exposure does not desensitise 
the receptor but instead causes a channel to pore formation (277), which is in 
keeping with our results. Additionally P2X7 has a role in immune response. Taken 
together these results support the theory that bacteriuria may lead to pericyte 
responses via induced neurotransmitter production, providing a pathophysiological 
explanation behind OAB (figure 6.12). 
    Unfortunately, the response rates for DIC imaging throughout this project were low 
and therefore n numbers for both angiotensin and ATP experiments were low. 
Furthermore, superfusion with bradykinin and SNP led to smooth muscle contraction, 
which meant it was not possible to investigate the effects of vasodilators on pericytes 
218 
 
in the bladder. The following section discusses this in more detail and suggests 
reasons why response rates may not have been as good as expected. 
6.5.2 MODEL FOR INVESTIGATING BLADDER PERICYTE RESPONSES TO VASOACTIVE 
COMPOUNDS NEEDS IMPROVEMENT 
 In general the model of investigating pericyte function by DIC imaging has not 
been as sensitive as anticipated. Response rates to superfusion with low 
concentrations of ATP and angiotensin II were very low with only 25-33% of 
experiments having measurable responses. This meant that 9-12 mice were used to 
obtain n=3. These n numbers are relatively low; although they have provided 
provisional insight into the function of pericytes in response to these vasoactive 
compounds, these results can be improved upon.  
   One particular reason that may explain low response rates can be seen from the 
results of the cell-viability staining which indicated that much of the tissue is dead 
after only 30 minute. It is therefore essential to even more gentle during the 
dissection process and to use the tissue immediately. Due to the size of murine 
bladders, it is possible to obtain 3-4 pieces that are practically sized for staining and 
2-3 pieces that are appropriate for DIC imaging. It could be suggested that by cutting 
the tissue smaller for staining experiments causes more damage than one single cut 
to half the bladder for DIC experiments and that one or two experiments per animal 
would be more effective although if less ethical.  
    An alternative reason which may explain low response rates to ATP is that small 
nucleotide polymorphisms in the P2X7 gene exist in C57BL/6 mice(278), which 
means that higher concentrations of ATP are required to evoke responses in these 
strains than in other strains or species. This includes the concentrations used in the 
rat model designed by Crawford et al from where the concentrations used in this 
thesis were obtained (52). With hindsight it would be worth increasing the 
concentration of ATP in the DIC imaging experiments to amend for this, or use rat 
bladder, which is harder to dissect but does also increase the number of experiments 
possible per animal.   
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    Strangely, NO donors generally act as smooth muscle relaxants and have even been 
shown to act upon urethral muscles in a relaxatory manner (275).  Both SNP and 
SNAP were used in the DIC experiments as NO donors, which would theoretically 
evoke vasodilation, however SNP induced smooth muscle contraction, which made it 
impossible to visualise and measure vessel diameter. This is believed to be due to the 
contractile nature of SNP rather than the donation of NO from this chemical. 
Switching to SNAP this effect was no longer a problem however the vessels were non-
responsive. Alternatives to bradykinin and SNP could be used in order to determine 
the extent to which vasodilatory compounds increase capillary diameter and the 
concentrations at which they are most effective, including prostaglandin-E2, 
epinephrine and carbochol (52). SNAP may have provided this information however 
there were no responses from any of the experiments performed which may be due 
to the fact that this drug is extremely light sensitive. Furthermore, despite the fact 
that NO has been shown to be dilatory in renal pericytes, this does not suggest that an 
NO system exists within bladder pericytes. No published data has been found to 
prove or disprove this theory.  
    Bradykinin was also shown to induce smooth muscle contraction in DIC imaging 
experiments, however this result is less surprising. Bradykinin is known to cause 
smooth muscle contraction in the bronchia and the small intestine (279), and has 
been shown to induce contraction of the bladder detrusor in rats and guinea pigs 
(274). One particular study of interest has observed that by blocking bradykinin 
receptor 1 in rats with spinal injury induced OAB, the symptoms are reduced 
indicating that bradykinin may play a role in OAB (280). Interestingly, LPS has been 
shown to increase bradykinin 1 receptors in the mouse bladder, which could be an 
exciting lead for further investigations (281). During bacterial cystitis, spontaneous 
contraction is increased, as is the sudden need to urinate. This could be due to 
increased responses to bradykinin induced by presence of LPS, which could be 
investigated by staining for bradykinin 1 receptor in human bladder biopsies from 
UTIs, OAB and controls.  
6.5.3 TNF CAUSES ACUTE PERICYTE-SITE CONSTRICTION 
 Data indicates that TNF-Ƚ functions directly on bladder pericytes to induce 
constriction of blood vessels and even once TNF-Ƚ has been removed, the vessels do 
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not return to normal diameter (figure 6.10). Despite the low response rates to 
vasoactive compounds investigated, and inconclusive and incomplete data for 
vasodilators, the data from TNF-Ƚ was exciting and promising since this is one of the 
cytokines that is a downstream compound of LPS stimulation (figure 6.12), is known 
to be released from pericytes (54, 263, 265), and acts in a paracrine and autocrine 
manner to further stimulate pericytes (262, 266). Our data have shown that TNF-Ƚ 
leads to acute vasoconstriction at pericyte sites, which at ͳͲ ng/μM evokes a variety 
of responses; both desensitisation can occur, as well as extended contraction once the 
drug has been removed. This suggests that TNF-Ƚ has a very acute and a slightly 
prolonged effect on pericytes in the bladder as seen from the DIC experiments. TNF-Ƚ 
was also seen to affect pericytes in a chronic manner from IB4/NG2 staining, whereby 
prolonged exposure (4 hours) of bladder urothelium to TNF-Ƚ showed a significant 
reduction in the number of pericytes but not the distance between pericytes 
suggesting that this cytokine leads to rapid pericyte cell death. This suggests that a 
bladder infection, particularly with Gram negative species, could lead to downstream 
pericyte mortality and pericyte loss. 
    Due to the time restraints of this study it was not possible to investigate the role of 
other cytokines or LPS on the acute function of pericytes by DIC imaging. With 
hindsight it would have been exciting to include DIC imaging with LPS, IL-8, IL-ͳȾ, 
COX-2 and PGE-2 since these are notable cytokines and compounds produced 
downstream of LPS stimulation of pericytes (54, 263, 265) (figure 6.1). It could be 
hypothesised that LPS does not directly lead to pericyte vasodilation or 
vasoconstriction but rather leads to cytokine production and cell 
death/transformation in pericytes, and in turn, the downstream cytokines and PGE-2 
would evoke vasodilation at pericyte sites. 
6.5.4 LPS AND PRO-INFLAMMATORY CYTOKINES LEAD TO PERICYTE LOSS 
 Prolonged exposure (4hours) of bladder urothelium to TNF-Ƚ and )L-ͳȾ leads 
to a significant decrease in pericyte numbers, which suggests that cell death may be 
occurring (figure 6.4). The reason why this may only occur for TNF-Ƚ and )L-ͳȾ but 
not LPS is because these are downstream signalling molecules whereare LPS is a 




   The distance between pericytes is only significantly different when exposed to LPS 
or IL-ͳȾ (figure 6.5E), suggesting that these compounds are either 
transdifferentiating or migrating whereby pericytes are moving away from the 
capillaries. In this case it would be exciting to confirm that this is indeed the case. 
Unfortunately, myofibroblasts, which can be derived from pericytes, express many of 
the same antigens as pericytes, which means identifying them is very difficult (47). 
Tracking experiments can be designed to work around this and are discussed in the 
next section. To summarise, these data show that pro-inflammatory cytokines have a 
significant effect on the number of pericytes in the bladder, which during an infection, 
would reduce controlled blood flow and potentially lead to bladder ischemia and 






Figure 6.12: Schematic of how bacteria can alter the physiological function of the bladder.  (By reviewing 
the schematic from the introduction, the points which have been proven in this thesis are discussed 
alongside areas for further research). A) ATP tends to be higher in OAB compared to controls however this is 
not significant (figure 4.22B) B) Pericytes do respond to ATP in an acute manner to constrict and reduce blood 
flow (figure 6.7). C) Gram negative bacteria were found to be higher in OAB compared to controls (figure 4.23) D) 
IL-8 production was measured and not found to be higher in OAB compared to controls (figure 4.22C) E) There is 
increased pyuria in OAB compared to controls (figure 4.3) F) No research was performed to support this, G) 
Cytokines and LPS were found to reduce the number and density of pericytes (figures 6.4 and 6.5) H) No research 





6.5.5 TRACKING PERICYTE TRANSDIFFERENTIATION IN THE BLADDER 
 A variety of recent studies have opened new doors to ways of fate tracking 
pericyte transdifferentiation into fibrotic cells such as myofibroblasts (33, 46, 61, 63, 
276-279). Transdifferentiation studies in the bladder would be relatively easy 
compared to many of the other tissues used as it is a mucosal surface therefore 
stimulants can be applied to the tissue in the live animal and later observed in 
comparison to controls. Fate tracking experiments can be performed, as has been 
shown in a variety of other tissues, by employing the Cre-Lox recombinase method of 
cell tracking to stimulate pericytes in vivo and observe their destinations (33, 46, 61, 
63, 282-285). This method takes two F0 generation mice, one with a Cre gene inserted 
into the genome and the other with two LoxP genes inserted around a target gene of 
interest, followed by a marker e.g. green fluorescent protein. These two F0 generation 
mice are bred and the result is an F1 generation mouse with both the Cre and the 
LoxP genes. The constitutively expressed Cre protein binds to the LoxP genes and 
disrupts the target gene, instead transcribing the reporter, GFP. Using this method it 
is possible to target genes that are constitutively expressed in pericytes (e.g. NG2, PDGFRȾ and ȽSMA in conjuction with collagen ȽͳȌ, and allows them to fluoresce 
enabling tracking.  
  Furthermore, studies have also highlighted that identification of the fibronexus of 
myofibroblasts by TEM can act as a unique way of recognising this cell type over 
others (table 1.1). By injecting stimulants, such as cytokines, bacteria or LPS, directly 
into the bladder of a live mouse and later counting the number of myofibroblasts by 
TEM compared to controls, it could be determined if these stimulants are increasing 
the number of myofibroblasts. Furthermore, it would be exciting to compare human 
bladder biopsies for numbers of myofibroblasts. Methods for performing TEM on 
human bladder biopsies have been described in the General Methodology section of 
this thesis. By comparing the numbers of myofibroblasts in healthy controls to those 
with rUTIs or OAB it could be determined if myofibroblasts may potentially be 
exacerbating symptoms in these disease states by leading to fibrosis and bladder wall 
thickening which has been observed in OAB.  
 Cumulatively, this chapter has highlighted that vasoactive compounds such as 
ATP and angiotensin II have direct effects on bladder pericytes causing constriction of 
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blood vessels which can reduce blood flow and in turn lead to ischemia.  ATP has 
continually been shown to be increased in OAB and during bladder infection. The 
effects of bradykinin on smooth muscle are also interesting, as they have highlighted 
another possible avenue for which the causes of OAB could be investigated further 
since this compound appears to cause rapid detrusor contraction and has been 
associated to OAB. 
   Furthermore, this chapter has shown that LPS and the pro-inflammatory cytokines 
TNF-Ƚ and )L-ͳȾ have very similar effects on bladder pericytes as has been shown in 
other organs. TNF-Ƚ evokes acute pericyte constriction, which will inevitably reduce 
blood flow, but many other constituents of the inflammatory response could be 
investigated to determine if acute inflammation induces vasodilation over 
vasoconstriction. The effects of these compounds on pericyte density have also been 
investigated and highlights that the cytokines lead to pericyte loss, and LPS and IL-ͳȾ 
lead to reduced pericyte density. Fate mapping techniques or TEM could be used to 
investigate the fate of these pericytes in mouse models. Furthermore, TEM on human 
biopsies could determine if fibrosis caused by increased myofibroblasts presence is a 
potential cause of OAB.  
6.6 CONCLUSIONS 
1. Pericytes are found in close proximity to bladder capillaries and venules 
and can be found in high numbers around vessel branches. 
2. ATP and Angiotensin II evoke bladder pericyte constriction of blood 
vessels. 
3. Bradykinin and NO donor SNP cause smooth muscle contraction. 
4. TNF-Ƚ evokes bladder pericytes constriction of blood vessels. 
5. TNF-Ƚ and )L-ͳȾ lead to reduced pericyte numbers and LPS and )L-ͳȾ lead 





CHAPTER 7 -  
GENERAL DISCUSSION 
 The recent discovery of a bladder microbiome has led to the development of a 
spectrum of bacteria known to colonise the bladder, including various recognised and 
emerging uropathogens. With the development of more up to date techniques, many 
species previously undetected have also been identified, and thus the spectrum can 
be reliably referred to (197). Comparisons between the bladder microbiomes of 
asymptomatic individuals and bladder disease states has highlighted that alterations 
in the microbiome or low level infections may be a cause for certain syndromes 
including rUTI in post-renal transplant (213), OAB (138, 194, 195), and cystitis (286). 
Unfortunately, due to the high threshold CFU count for UTIs, any low level infections 
can go underreported (127), and therefore alternative biomarkers ought to be 
determined for both predicting rUTI and for OAB. Furthermore, despite some 
investigations stressing a role for bacteria, the exact pathophysiology has not been 
explained or hypothesised. Pericytes are a perivascular cell type that has been found 
in multiple organs including the bladder and are capable of responding to a variety of 
neurotransmitters (52), which are essential in bladder function, and can lead to 
changes in capillary diameter (52), and pericyte transdifferentiation into fibrosis 
producing myofibroblasts (46). Although the exact role of pericytes in the bladder has 
not been widely investigated, one study by Hashitani et al made the following concluding remark: ǲthe pluripotency of pericytes may contribute to the remodelling of the bladder suburothelium that is commonly seen in an overactive bladderǳ (50). 
Bringing together the two fore mentioned hypotheses; i) that bacteriuria can lead to 
OAB, and ii) that pericyte transdiffentiation can lead to OAB, proposes the theory that 
bacteriuria may lead to pericyte transdifferentiation via induced neurotransmitter 
and cytokine production, providing a pathophysiological explanation behind this 
syndrome. 
    The aims of this thesis were to determine key bacterial species in rUTIs in RTRs and 
OAB, to investigate alternative biomarkers for rUTIs and OAB, and to determine 
whether bacteriuria affects pericytes, which may be a cause of fibrosis seen in 
patients with OAB. Following investigation, the 5 main findings are: - i) clue cells may 
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be used as an effective means to predict UTIs in RTRs since tests for WBCs such as 
leukocyte esterase and WBC counts do not always correlate with an infection, ii) 
three key species appear to be significantly reduced in RTRs at all time points, 
however these are not generally known to be affected by co-trimaxazole, iii) 
Lactobacillus is significantly reduced in patients with OAB and correlates with 
increased incidence of Gram negative uropathogens, iv) pericytes in the bladder 
respond to LPS and downstream pro-inflammatory cytokines both acutely and 
chronically. This supports the theory that bacteriuria may lead to pericyte 
transdifferentiation via induced neurotransmitter and cytokine production, providing 
a pathophysiological explanation behind this syndrome. 
7.1 SUMMARY OF FINDINGS  
 Urinary tract infections are generally diagnosed by dipstick, WBC count and 
bacterial culture however recent publications and data from this thesis have 
recognised that neither of these means are effective. Malone-Lee et al published data 
suggesting that both dipstick and microscopic WBC count were not effective for 
detecting pyuria but rather that automated WBC count was the preferred method 
(215). Results from chapter 3 of this thesis support this in that automated WBC count 
is able to detect pyuria in patients with a UTI better than the other two methods. 
However, with approximately 70% of patients with a hospital grade infection have 
accompanying pyuria (figure 3.4), WBC count cannot always be used to diagnose an 
infection and with the threshold of CFU count set high at 104 CFU/ml, many infections 
could be being missed.  
    Chapter 3 of this thesis attempts to cumulate all clinical and biological data for 
RTRs over a number of time points post-transplant in order to determine if rUTIs can 
in some way be predicted or prevented before manifestation. Clue cells are a key 
medical sign of bacterial vaginosis (BV), which is caused by Gardnerella vaginalis, and 
their presence in vaginal swabs has been used as a means for diagnosing BV since 
their discovery in 1955 (287). This thesis is the first study to look at using clue cells 
as a biomarker for UTI in RTRs. Since these patients are particularly predisposed to 
recurrent infections, clue cells indicate a potential reservoir of intracellular bacteria, 
which could be used to predict a UTI. Results show that previous incidence of clue cell 
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observation could indicate a possible UTI in approximately 69% of cases, however 
this was based on low n numbers (n=13, figure 3.5A). Although investigations have 
not been able to confirm intracellular bacteria in these patients, it has highlighted that 
clue cells could be used as a prospective biomarker in order to prevent infections 
becoming too manifested in these immunocompromised patients. Further 
investigation is required to determine whether intracellular bacteria are important in 
rUTIs in RTRs. An antibiotic protection assay would highlight key species, the exact 
percentage of patients with rUTIs who have intracellular bacteria, and whether 
intracellular bacterial presence correlates with recurrence. 
   By culturing and sequencing every species from RTRs, it was possible to see the rich 
diversity of bacterial species in the urine, further affirming that urine is not sterile, 
but rather that the bladder has its own microbiome.  Various recent studies have 
attempted to show the diversity of bacterial species in the bladder microbiome and 
compare that of healthy asymptomatic controls to those of disease states. Our data 
compares well to these studies, even those using more advanced methods. 
Interestingly, 3 key species were significantly reduced in RTRs at all time points 
indicating that a shift in the bladder microbiome may be a cause for concern in these 
patients. These species; Actinomyces, Corynebacterium and Peptoniphilus are not 
known to be affected by co-trimaxazole, therefore more investigation is required to 
determine how these species are reduced in RTRs.  
 
 The second results chapter of this thesis applied the same methodology of 16s 
rRNA sequencing to investigate the species of bacteria colonising the bladder of 
patients with OAB and comparing it to that of asymptomatic controls. It was observed 
that patients with OAB have significantly reduced Lactobacillus incidence suggesting 
that symptoms may be due to alterations in the microbiome rather than low-level 
infection as originally hypothesised. It was observed however that incidence of 
Lactobacillus correlated with increased incidence of Gram-negative uropathogens 
such as Proteus and E.coli. Although incidence of Gram-negative uropathogens is not 
significantly increased in OAB, these data suggest that a lack of Lactobacillus may 
have implications on other species of the bladder microbiome. Lactobacillus is a key 
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probiotic in both gut and vaginal health and could be implemented in bladder health 
also. Some studies have shown that Lactobacillus can be used as a prophylactic for 
UTI, however there have been no studies to date looking at this species as a 
prophylactic or treatment for OAB.  It is also interesting to note that Lactobacillus was 
not reduced in RTRs therefore even though RTRs are vulnerable and susceptible 
individuals, RTRs cannot be used to study or predict rUTIs and microbiome changes 
in OAB.  In other words, OAB is a unique syndrome, different from rUTIs.  
   The first results chapter of this thesis was not able to confirm intracellular bacteria 
from clue cell observation, therefore the methodology was adapted for the second 
chapter to include an antibiotic protection assay. This data was the first to describe 
the full spectrum of species that are capable of forming IBC in bladder urothelial cells. 
From the results, no particular species were any more prevalent in OAB than in 
asymptomatic controls indicating that intracellular bacteria may not be relevant in 
this particular bladder syndrome. Unfortunately, many CSU samples of urine were not 
rich enough in bacteria to have any growth on culture plates. Development of the 
methodology in the third results chapter included more conditions but also plated ͳͲͲ μL instead of ͷ μL. Using this method, various species were cultured which were 
previously missed, and therefore this method ought to be adapted for repeat on 
samples from both RTRs and patients with OAB.  
  
 The final results chapter of this thesis attempted to explain how an infection 
may lead to particular symptoms of OAB such as overactivity and fibrosis. Many 
studies have suggested that OAB may be caused by a low-level infection left 
unreported by hospital tests. However, explanations for the resulting symptoms of 
OAB have only been loosely hypothesised. One of the main indications of infection is 
the production of cytokines and inflammation. The pro-inflammatory cytokines most 
associated to UTI are TNF-Ƚ, )L-6 and IL-ͳȾ and have also been implemented in 
stimulating resident pericytes to increase vascular permeability, transdifferentiate 
and move away from their post along microvasculature.  The final results chapter 
aimed to test the theory that bladder pericytes also respond to these cytokines and 
some neurotransmitters in an attempt to provide a pathophysiological explanation 
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behind the symptoms of OAB. By exposing pericytes to LPS and the downstream 
cytokines produced during an infection, it was possible to determine how pericytes 
respond both acutely and chronically. Exposure to TNF-Ƚ showed rapid constriction 
of pericytes, which in vivo would cause reduced blood flow and increased blood 
pressure. Exposure to TNF-Ƚ and LPS over Ͷ hours led to reduced density of pericytes 
indicating they may be moving apart from each other, moving away from the capillary 
or transdifferentiating. This confirms that bladder pericytes are able to respond to 
bacterial components as well as pro-inflammatory agents. Further investigation is 
required to determine if pericytes are indeed transdifferentiating by performing fate 
tracking studies in loco as discussed in Section 6.5.5 - Tracking pericyte 
transdifferentiation in the bladder. Other cytokines, complement factors e.g. C3a and 
C5a, and other bacterial components need to be investigated in gain a wider 
knowledge of influences leading to pericyte changes. Furthermore, a study based on 
infecting germ free mice with known uropathogens would be more informative of the 
effect of whole bacterium in vivo discussed in Section 7.3.4 - The role of bladder 
pericytes in infection.  
7.2 METHODOLOGY ERRORS AND LIMITATIONS  
 Reflecting upon the methodology used for the RTR study, it is essential to 
include an antibiotic protection assay when culturing all samples in order to gain 
information on possible intracellular as well as planktonic bacteria. Although this was 
adapted for the OAB study, key information is missing from the renal study. Future 
studies should increase the volume of urine plated on agar in order to capture bacteria in very low numbers that would otherwise be missed if plating only ͷ μL. 
Furthermore, inclusion of Campygen and aerobic conditions for culture will help to 
obtain the maximum diversity of cultureable species.  
    A number of isolates were not able to be resuscitated from cryogenic storage in 
order to perform the PCR. Upon resuscitation and regrowth, isolates were replated on 
chocolate agar plates sectioned into 8 in the same conditions as they were initially 
discovered (i.e. 5% CO2 or anaerobic) which was not enough space to obtain an 
isolated colony. Any isolates that had contaminated or unsuccessful regrowth were 
replated using more of the cryopreserved broth and more of the chocolate plate. The 
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initially colony description was referred to in order to identify the correct isolate in 
cases of contaminated regrowth. In some cases however, contamination was too great 
or regrowth was too low to perform a PCR. Therefore, not all isolates were identified 
and may skew the accuracy of the data obtained. 
    It was essential to compare the observed Gram stain/shape of the sequenced 
isolates with the true Gram stain/shape of the bacterium proposed by BLAST. The 
reason for this is that Gram staining is more accurate than sequencing; despite using 
a high-fidelity polymerase, which ensures insertion of the correct nucleotide during 
PCR, an error rate still exists. Since the program used for the PCR in this project was 
set at 37 cycles per reaction and the average size of a 16s rRNA gene is 320bp this 
works out as roughly 0.26% PCR products with an error. In addition, the protocol for 
PCR purification included 4 centrifugations at 13,000RPM which can damage the 
DNA, removing small numbers of nucleotides from the end of the DNA fragment. 
Furthermore, due to the nature of Sanger sequencing, further errors are possible. 
Therefore, the sequences generated cannot be wholly relied upon even if the Gram 
stains are concordant.  
   The identity of a number of isolates was not able to be confirmed by concordant 
Gram stains since the Gram stain was not established. Some species of bacteria are 
both Gram positive and negative depending on the stage of growth, notably 
Gardnerella vaginalis and Arthrobacter. Determining Gram positive or negative could 
be difficult in many other cases if many bacteria were dead in which case they would 
show as Gram negative when their true form was Gram positive. Furthermore, if the 
microscope slide had been too heavily overloaded with bacteria prior to staining, the 
crystal violet stain would remain in between the bacteria showing Gram positive 
when the true nature should have been Gram negative.  
 The Mix2Seq service used to sequence the isolates does not offer a re-run service. 
That is, if the sequencing was unsuccessful the first time, Eurofins will not perform a 
free re-run of the sample but will instead send the sequence as it has been generated. 
Therefore, in some cases, samples would have to be resent for sequencing, incurring 
extra time and cost.   In three cases, a successful sequence was generated however 
there was no significance found upon BLASTing. These could have been new or 
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uncultured species however due to the slow nature of the evolution of 16s rRNA gene, 
it is unlikely that a similar match would not be suggested by the BLAST search. 
In three cases, a successful sequence was generated however there was no 
significance found upon BLASTing. These could have been new or uncultured species 
however due to the slow nature of the evolution of 16s rRNA gene, it is unlikely that a 
similar match would not be suggested by the BLAST search. 
7.3 APPLICATION AND SCOPE FOR FUTURE STUDIES  
7.3.1 INTRACELLULAR BACTERIA IN RTRS 
 As mentioned in the conclusions of the discussion of chapter 3, Section 3.5.5 
Methodology errors and limitations, intracellular bacteria may be a reservoir for 
reinfection and recurrence in RTRs however the methods used were not able to 
confirm intracellular bacteria in these samples. Since the strongest correlation with 
rUTI was observation of clue cells, and clue cells may indicate intracellular bacteria, 
more work is required on this to clarify this potential biomarker. Future studies could 
be used to identify patients with clue cells and put them under stricter observation by 
increasing sample collection to weekly and monitor clue cells with the inclusion of an 
antibiotic protection assay to determine whether clue cells are a reservoir for 
infection in RTRs.  
   If the results of such a study show the clue cells are indeed a reservoir for infection 
in RTRs, then the stricter monitoring could be used to predict rUTIs and preventative 
mechanisms can be put in place. For example, the identification of clue cells in a urine 
sample of a RTR, could instigate prescription of more advanced broad-spectrum, 
prokaryote-penetrating antibiotics which will target intracellular bacterial reservoirs. 
A reduction in rUTI incidence will inevitably reduce graft rejection and decrease 
patient mortality. 
7.3.2 LACTOBACILLUS AS A PROPHYLACTIC 
 This thesis in conjunction with other publications has shown that in 
differences in the bladder microbiome between patients with OAB and asymptomatic 
controls is only consistently significant in respect to incidence of Lactobacillus. As 
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mentioned in Section 4.5.7 Lactobacillus is a probiotic, this species has prophylactic 
capabilities and has been used in the gut, vagina and more recently as a prophylactic 
for UTIs.  As discussed in Section 4.5.6 Lactobacillus as a prophylactic against 
uropathogens, two studies of particular interest have generated optimistic results for 
use of Lactobacillus as a prospective prophylactic for UTI.  
  The first study performed a phase 1 and phase 2 controlled trial, again looking at the 
role of Lactobacillus as a prospective prophylactic for UTI. These investigations have 
used L.crispatus as a vaginal suppository due to its ability to produce high levels of 
H2O2. Results showed a reduction of roughly half incidence of UTI compared to 
placebo with minimal side effects (247, 248). The second study gave oral L.rhamnosus 
and L.reuteri or trimethoprim-sulfmethoxazole as prophylatics against UTI to 252 
postmenopausal women and assessed incidence of UTI over 12 months in a 
randomised control trial and showed that Lactobacillus had a similar prophylactic 
effect on UTI compared to antibiotics (126). This study also measured the rate of 
development of antibiotic resistant UPEC over 12 months in both groups. After 12 
months, 100% of UPEC isolated from UTIs in this study from the antibiotic group 
were resistant to trimethoprim and sulfmethoxazole compared to 0% in the 
Lactobacillus group. These data highlight just how rapidly antibiotic resistance can 
develop in the management of infection with antibiotics, which will inevitably lead to 
complicated rUTI over time. Given that the use of trimethoprim-sulfmethoxazole is 
used in renal transplant as a prophylactic for up to 6 months, if not more, this is a 
worrying indication as to the severity of the development of antibiotic resistance in 
these already vulnerable patients. Unfortunately, prophylactic Lactobacillus cannot be 
given as an alternative to co-trimoxazole as this antibiotic cocktail is specifically 
chosen due to its ability to prevent pneumonia, to which Lactobacillus cannot protect 
against. It could however be used in cooperation with immunosuppressants and 
antibiotics as a third protection for RTRs.  
    Taken together these studies and their results show that Lactobacillus, in particular 
Lactobacillus crispatus, can provide an effective prophylactic effect on UTI, in 
particular on UPEC. A randomised clinical trial examining the effects of probiotics on 
OAB would be exciting since our results have clearly indicated reduced incidence of 
Lactobacillus in these patients. Future studies could aim to monitor patient symptoms 
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in correlation with colonisation with Lactobacillus and perform various types of co-
culture with isolated uropathogens and Lactobacillus spp. to determine how well 
Lactobacillus acts as a probiotic.  
  If a clinical trial were to successfully show that Lactobacillus probiotics were helpful 
in suppressing symptoms of OAB then this could progress into Phase 2 clinical trial 
and even become a recommended treatment for OAB in some patients. Oral 
Lactobacillus therapy for womenǯs health is already a manufactured product and 
therefore there would be no major requirement for drug development in order to 
progress this to clinical trial and potential treatment. 
Furthermore, by investigating the possible role of Lactobacillus metabolites (e.g. 
hydrogen peroxide, lactic acid and bacteriocins) on bladder function this may 
highlight how a loss of this genus could lead to the symptoms of OAB. This could lead 
to research opportunities investigating alternative treatments for OAB which do not 
involve the use of live bacteria, reducing OAB symptoms as well as reducing the risk 
of infection and therefore the overall burden on the NHS. 
7.3.3 THE ROLE OF BLADDER PERICYTES IN INFECTION 
 As discussed previously in the general discussion, murine infection studies and 
transdifferentiation studies are essential to confirm the hypothesis that chronic 
bacteriuria can lead to fibrosis of the bladder. Germ free mice are born and kept in 
sterile conditions so that they never develop a microbiome. By infecting germ free 
mice with a known uropathogen, it would be possible to say with confidence that any 
differences in physiology are the result of the infection.  By comparing pericyte 
density or fibrosis in both of these mice, one could conclude the effects of bacteria on 
pericytes and their contribution to fibrosis.  Transdifferentiation studies utilise target 
genes in pericytes to insert fluorescent tags so that they can be tracked as they 
differentiate and migrate. By using Cre-Lox-GFP Germ free mice it could be possible 
to induce a bladder infection in germ-free mice and track pericytes as they respond to 
infection. 
Transdifferentiation studies cannot be performed in humans, however as discussed in 
section 6.5.5 Tracking pericyte transdifferentiation in the bladder, the measurement of 
fibrosis pre- and post-infection and in controls and OAB patients can be assessed by 
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observing the fibronexus of bladder biopsies by TEM. If the number of pericytes is 
decreased and the number of myofibroblasts is increased, one could conclude that 
this was due to pericyte transdifferentiation. By determining whether pericyte 
transdifferentiatinon is a potential cause for OAB, treatments could involve anti-TNF-
α therapy which could prevent potential increase in myofibroblasts and hence, reduce 
spontaneous contractions.  
7.4 FUTURE ADVANCES  
The main conclusion of this thesis is that bacteriuria may lead to pericyte 
transdifferentiation via induced neurotransmitter and cytokine production, providing 
a pathophysiological explanation behind OAB. There are other researching groups 
studying alternative but related concepts behind OAB and bacteriuria and the 
concluding findings of this thesis also support those theories. 
This section attempts to tie the results of this thesis with other recent 
advances in current research in order to develop new ideas. To do this a literature search was performed for key researchers in the field and ǮOAB in aging populationsǯ. 
Two key theories emerged from this that were of much interest. The first is that of Ǯinflammagingǯ a term first coined in ʹͲͲͲ derived from inflammation and aging 
whereby the body deteriorates due to increased inflammatory responses and age 
(288). The second suggests that complicated UTIs lead to alterations in the immune 
system transcriptome and future infections are more likely to develop into cystitis 
due to COX-2 dependant inflammation (289). These two theories support each other 
and, with future investigation, they could be used to explain the cause of OAB in the 
absence of infections.  
7.4.2 THE CONCEPT OF INFLAMMAGING 
Inflammaging is an emerging field of research which suggests that as one ages 
the immune system undergoes various changes including immunosenescence (age-
related deterioration of the adaptive immunity) and development of a chronic, low-
level, systemic innate and pro-inflammatory state (288). This phenomenon increases 
susceptibility to diseases such as Alzheimerǯs, type )) diabetes, atherosclerosis, 
arthritis and cancer.  The main theory behind the concept of inflammaging is that 
there is a build-up overtime of non-resolved inflammation caused by persistent and 
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recurring infections and injury. This persistence can lead to increased stress, 
increased cytokines, oxidation-inflammation, DNA damage and autophagy, each of 
which will contribute to activation of one or a combination of signalling pathways 
including NF-�B, Notch, TGF-�, sirtuin, Ras, RIG-1 and TOR; the downstream effects of 
all of which are pro-inflammatory (reviewed by Xia et al (290)). Furthermore, this 
will alter the transcriptome, increasing the mRNA transcribed for pro-inflammatory 
genes. Recent investigations have focused on the signalling pathways to better 
understand the process of inflammaging but also to potentially develop targets for 
age-related diseases. 
   There is consistency in reporting a correlation between age and OAB, which data in 
Chapter 4 of this thesis supports. One particular study by Tyagi et al in 2013 
hypothesised that OAB is a syndrome associated with inflammaging and thus 
measured the concentration of 8 cytokines and chemokines by MILLIPLEX of 140 
individuals with OAB to determine if age-related biochemical changes correlates with 
OAB severity (291). They found a positive age-associated elevation of NGF (p=0.001) 
and MCP-1 (p=0.07). As discussed in the general introduction, increased expression 
of NGF has previously been associated to OAB, and furthermore, to increased severity 
of symptoms. They go on to hypothesise that NGF increases may be a homeostatic 
response to nerve senescence in the bladder and MCP-1 may be related to increased 
adipocytes in the detrusor leading to bladder stiffness (291).  
    A recent study investigating vascular remodelling in mouse gut via up-regulation of 
Angiopoietin-2 found that the source of Angiopoietin-2 up-regulation was TNF-α 
produced by M2-like macrophages (292). These macrophages release TNF-α in 
response to changes in the microbiota and inflammaging. The consequences of this 
increased TNF-α is angiotensin-II-dependant vascular remodelling by reduced 
pericytes, reduced VE-cadherin and increased permeability. Our data supports this in 
that we have shown that TNF-α can directly affect pericytes and lead to pericyte loss.  
   This is a stimulating and credible theory since many individuals with OAB do not 
have bacteriuria however many have a history of UTIs. Furthermore, in respect to the 
newly discovered bladder microbiome, it could be proposed that changes in this 
microbiome could also stimulate immune responses which lead to increased cytokine 
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production, leukocytosis and transcriptome alterations. The study by Tyagi et al has 
not included some of the more potent pro-inflammatory cytokines mentioned in this 
thesis including TNF-α and IL-1β, however it would be interesting to see whether 
these cytokines are increased with age and OAB incidence since it has previously 
been shown that these cytokines have a strong effect on pericytes as a consequence of 
microbiome changes.  
   Taking the data from these two studies, a potential research proposal could be to i) 
investigate if there is an age-associated elevation of TNF-α, IL-1β and Angiopoietin-2 
in patients with OAB versus controls, ii) isolate macrophages from bladder biopsies 
taken from patients with OAB and characterise them to determine if there are any 
differences between their transcriptome/cytokine profiles, iii) incubate mouse 
bladder tissue with macrophages isolated from the bladder of patients with OAB to 
determine if there is a loss of pericytes as a consequence of TNF-α production, iv) a 
clinical trial to determine if  anti-TNF-α can suppress the symptoms of OAB. 
7.4.2 INFECTION HISTORY ALTERS SUSCEPTIBILITY TO RUTI 
A unique and exciting study by Hultgren et al, who led the investigations into 
IBC in UTI discussed in the general introduction, was published near the end of this 
thesis. This new development in current research has revealed that mice previously 
infected with UPEC, are significantly more likely to develop chronic bacterial cystitis 
upon second exposure if the primary infection did not resolve spontaneously 
(resolved mice), but rather developed into cystitis (sensitised mice) (289) (figure 
7.1).  This work follows on from a publication by the same team of researchers who, 
in 2010, highlighted that development of chronic cystitis relied upon severe acute 
inflammatory responses during early infection (293). 
   Their recent publication further describes how prior UPEC infection results in 
differences in the way the urothelium remodels itself depending on whether the 
mouse was sensitised or resolved(289). Both mice had significantly smaller 
superficial cells post-infection however these were particularly small in sensitised 
mice and did not appear to be terminally differentiated (figure 7.1). Remodelling from 
a prior infection did however protect from colonisation and IBC formation when re-
challenged with UPEC except in some sensitised mice.  
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   To explain some of these differences they investigated the transcriptome of whole 
bladders from sensitised and resolved mice; over 800 genes were significantly 
differentially expressed for pathways relating to cell development, proliferation and 
inflammation suggesting severe chronic inflammation leads to alterations which can 
protect against future infections (figure 7.1).  
   As mentioned, a subset of sensitised mice were not protected from future infections 
but were highly sensitive to severe acute or recurrent chronic cystitis upon rechallenge. (ultgrenǯs group investigated the expression of COX-2 in the bladders of 
both sensitised and resolved mice to explain how some sensitised bladders were not 
able to protect against rUTI despite significant remodelling. COX-2-dependent 
inflammation is leading to vasodilation, neutrophil influx and wounding. Findings 
indicated a significant reduction of COX-2 expression in resolved mice (figure 7.1).  
 
Figure 7.1 Flow diagram of resolution of secondary infection in mice dependent on resolution of primary 
infection. If a primary infection in mice is severe with early immune responses they will develop a chronic cystitis whereby the mice are ǮSensitisedǯ. ǮSensitisedǯ mice will have very small superficial cells which are not well 
differentiated. Furthermore, they will have an altered transcriptome ready for a secondary infection. Upon 
rechallenging, these mice will either be protected by the unique transcriptome or will develop a second severe 
chronic infection. Chronic infection in these mice is driven by COX-2 which was activated by the initial severe 
cystitis. If on the other hand a primary infection in mice is mild with spontaneous resolution they will be ǮResolvedǯ and have an unaltered transcriptome and better superficial cell differentiation that ǮSensitisedǯ mice. 
These mice will not activate COX-2 dependent inflammation and therefore will only develop a mild infection upon 
secondary infection. Diagram derived from results published by Hultgren et al, 2010 and 2016 (289, 293). 
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   Taken together, these findings suggest that severity of rUTIs are not only based on 
presence of bacteria or antibiotic resistance, but the means by which the immune 
system combats infection after infection. This also supports the theory of 
inflammaging whereby post infection, the transcriptome alters. Furthermore, it 
supports the theory that bacteriuria may lead to physiological changes induced by 
cytokine production providing a pathophysiological explanation for OAB.  
This suggests that COX-2 inhibition could be a potential suppressor of the symptoms 
of OAB. There have been some studies performed in rats using COX-2 inhibitors, 
which have shown positive results in reducing frequency. Studies in humans have 
only looked at the efficacy of non-selective COX inhibitors in LUTS and cystitis and 
rUTI. Therefore, a clinical study to explore the use of COX-2 specific inhibitors in 
patients with OAB only warrants investigation.  
 A potential research proposal based on the above theory could be to i) investigate 
whether RTRs suffering with rUTIs have an altered transcriptome to determine 
whether these patients are more at risk, ii) investigate whether treatment with COX-2 
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APPENDIX 1.1 DIAGNOSING URINE INFECTION IN KIDNEY TRANSPLANT PATIENTS 
 
 
Diagnosing urine infection in kidney transplant patients 
Questionnaire Version 1.0 
About Your Symptoms and their impact on quality of life (for use at visit 1) 
 Date ……../……../…….. 
 
 Please indicate whether you have had the following 
symptoms/problems in the past 24 hours and how severe they were: 
(please circle one number for each symptom) 
SYMPTOMS Did not have Mild Moderate Severe 
Frequency of Urination (going to 
the toilet very often) 
0 1 2 3 
Pain or burning when passing 
urine 
0 1 2 3 
Not being able to empty your 
bladder completely/ passing only 
small amounts of urine 
0 1 2 3 
Pain or uncomfortable pressure in 
the lower abdomen / pelvis area 
caused by your urinary tract 
infection 
0 1 2 3 
Low back pain caused by your 
urinary tract infection 
0 1 2 3 
Blood in your urine 0 1 2 3 





Please give an overall rating of the severity of your urinary tract infection symptoms 
as they are at the moment (please circle the number of your answer) 
 
0 No symptoms at all 
1 Mild 






 If you have experienced these symptoms/problems in the past 24 
hours, please indicate how bothersome they were: (please circle one 
number for each symptom)  
SYMPTOMS Not at all Not at all Not at all Not at all 
Frequency of Urination (going to 
the toilet very often) 
0 1 2 3 
Pain or burning when passing 
urine 
0 1 2 3 
Not being able to empty your 
bladder completely/ passing only 
small amounts of urine 
0 1 2 3 
Pain or uncomfortable pressure in 
the lower abdomen / pelvis area 
caused by your urinary tract 
infection 
0 1 2 3 
Low back pain caused by your 
urinary tract infection 
0 1 2 3 
Blood in your urine 0 1 2 3 
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Author:: R Arkley 
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WARNING: This document is only controlled if in 
authorised location 
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APPENDIX 1.2 MSU AND CSU CULTURE INTERPRETATION 




































= No significant growth 
Please send a repeat sample if still indicated 
NSG = No significant growth 
SG = Significant growth (>104) 
MX = Mixed growth of organisms 
MXC = Mixed growth of organisms - probable 
contaminants 
MXR = Mixed growth of organisms - Please send repeat 
MXR 
CCU 
= Mixed growth of organisms 





= No significant growth - please repeat 
Please send a repeat sample if still indicated 
Please send a clean catch urine 
MIN = Mixed growth including * 





NOT cultured except 
Leucocyte count 
 > 100/mm3 
Epithelial cells  
+ or less 
Epithelial cells  
++ or more 
< 104 orgs/ml 
NSG RPTSI 
> 104 orgs/ml 
Pure growth 
> 104 mixed growth 
Equal amounts of >2 
types of 
coliforms/enterococci 
< 104 orgs/ml 
<10 cols  
> 104 orgs/ml 
Pure growth 
> 104 mixed growth* Equal 
amounts of >2 types of 
coliforms/enterococci 
 
Identify and report 






Identify and report 







Identify and report 
with sensitivities 
UFAST 
If female or 
male ≥ 65 
UFASTM 
If male  
≤
Insufficient urine to dilute 
Boric acid in specimen 
Report as NSGR 
ONLY do Fastidious 
culture if leucs 
>100/mm3  after 








< 104 orgs/ml 
NSG 
> 104 mixed 
growth* MXC 
> 104 orgs/ml 
Pure growth I/S 
Document number: MIC-WI-674 
Author:: R Arkley 
Approved by: R.Arkley 
WARNING: This document is only controlled if in 
authorised location 
Page 2 of 2 






CSU CULTURE INTERPRETATION 
 






Report as Mixed growth 
OR 
Mixed growth with a 
predominant organism 
Report identification – 
sensitivities suppressed 
< 104 orgs/ml 
<=10 colonies 
Report  
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